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 Abstract 
There is a growing need to improve the efficacy and range of antifungal drugs. The increase in 
immunocompromisation among the general population due to old age, infection with 
imunnosuppressive diseases and immunosuppressive therapies has led to a global increase in fungal 
infections and invasive fungal diseases. Invasive mycoses are notoriously difficult to treat and are 
associated with high rates of mortality. The current suite of antifungal drugs are toxic, limited in their 
spectrum of activity, lacking in target selection and are becoming less effective due to antifungal 
resistance. For Cryptococcus, which causes debilitating disease and fatal meningo-encepthalitis, the 
most effective treatment is the combined use of amphotericin B (AMB) and flucytosine (5-FC). 
However, the toxicity of AMB and the cost of 5-FC makes this combination difficult to implement in 
resource poor countries where cryptococcosis is highest due to HIV/AIDS. Even in developed countries, 
resolution of cryptococcosis with AMB+5-FC is difficult and mortality remains high. Alternative anti-
cryptococcal therapies are therefore urgently required.  
Finding and developing new drugs is an expensive and time consuming process, and synergistic 
therapies that augment current drugs are an alternative approach. Drug synergy enhances the activity 
of antifungal drugs and improves the clearance of pathogens. It requires less drug, which decreases 
toxicity, and also slows the development of drug resistance. Iron is important for fungal virulence and 
pathogenicity and iron chelating agents have been used as antifungal synergents in salvage therapy. 
However, the mechanistic details of how iron chelators cause synergy are unknown. Advances in 
genome sequencing technologies and the rise of systems biology allow the cellular responses to 
antifungal treatments to be studied in detail. It is hypothesised that antifungal-chelator combinations 
are synergistic in Cryptococcus and that potential antifungal targets can be found by understanding the 
underlying mechanisms of synergy. This thesis aims to use a transcriptomic approach to understand 
the mechanistic detail of synergy to find potential antifungal targets. 
Chapter 3 begins with characterising the interactions of five widely used antifungal drugs (AMB, FLC, 
itraconazole (ITC), voriconazole (VRC) and caspofungin (CAS)) and a range of iron chelators (EDTA, 
lactoferrin (LF), ciclopirox olamine (CPO), deferoxamine (DFO), deferiprone (DFP) and deferasirox 
(DSX). This was performed in Cryptococcus neoformans var. grubii (genotypes VNI and VNII), 
Cryptococcus neoformans var. neoformans (genotype VNIV) and Cryptococcus gattii (genotype VGII) 
with a focus on strains with fully sequenced genomes. The S. cerevisiae reference strain S288C was 
also included to enable a detailed downstream transcriptome analysis. Antifungal-chelator interactions 
were tested using the CLSI protocol for checkerboard assays. Synergy was found for AMB+LF across all 
of the yeast strains tested, with LF causing a four- to sixteen-fold reduction in the AMB MIC. 
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Supplementation with iron abolished the antifungal activity of LF but did not change the activity of 
AMB+LF, suggesting that the potentiation of AMB by LF was not solely due to iron chelation. 
Antagonism was also observed between combinations of azole antifungals and EDTA, DFP and DSX, but 
this was only seen in C. neoformans var. grubii strains. The results of this chapter showed that diverse 
responses to antifungal-chelator combinations occur in different Cryptococcus strains and that caution 
is needed when considering the use of iron chelating agents as synergents for treating cryptococcosis.  
Transcriptomic analyses of AMB+LF synergy and VRC+EDTA antagonism are presented in Chapter 4. 
The transcriptomic response to AMB, LF and AMB+LF was first analysed in S. cerevisiae S288C. This 
provided a detailed platform of gene expression and interaction data for each treatment. Treatment 
with LF alone did not cause any changes in cellular functions, while AMB alone caused a shutdown of 
cellular growth processes, up-regulation of various stress responses and activation of the iron regulon 
via the iron regulating transcription factor Aft1. The addition of LF to AMB caused a down-regulation of 
stress responses and metal homeostasis, with stress-associated responses that are normally 
coordinated with zinc regulation via the transcription factor Zap1 dysregulated and the iron regulon 
shut down. AMB+LF also induced growth-related responses. Together, these data suggested that LF-
induced drug synergy was due to disruption of the cell͛s ability to mount an appropriate stress 
response.   
The mechanism of synergy differed in C. neoformans H99, where responses to AMB and AMB+LF were 
similar with an induction of stress responses and repression of cellular growth that were more 
pronounced in the combined treatment. This increased accumulation of stress following AMB+LF 
treatment, which resulted from the induction of ER stress, disruption of transmembrane transporter 
processes and increased metal dysregulation, likely overwhelmed the cell͛s capacity to cope with 
stress, resulting in accelerated cell death. Despite different underlying mechanisms of AMB+LF synergy 
in S288C and H99, the disruption of metal ion homeostasis appeared to underlie both processes.  This 
was validated by deleting iron- (Aft1, Cir1 and HapX) and zinc- (Zap1 and Zap104) regulating 
transcription factors, which resulted in increased AMB susceptibility. Deletion of upstream regulators 
of these transcription factors and their downstream targets involved in metal homeostasis did not 
increase AMB susceptibility, however, which suggested that the metal-regulating transcription factors 
were critical for synergy. Further analysis of drug-binding domains in Zap1 (in S. cerevisiae) and Zap104 
(in Cryptococcus) found these proteins to contain druggable sites, which suggested their potential as 
antifungal drug targets.  
The mechanistic basis for antagonism was analysed by comparing the transcriptomic responses of 
VRC+EDTA in C. neoformans H99 and in C. gattii strain 97/170, where this combination resulted in an 
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antagonistic and an additive response, respectively. In both species, VRC alone induced cellular 
responses typical for azoles, including stress responses and mitochondrial functions related to 
oxidation-reduction and energy generation. The addition of EDTA disrupted mitochondrial functions 
and this was accompanied by different cellular responses in the two species. In C. neoformans H99, 
this involved an up-regulation of drug efflux genes, suggesting a potential mechanism of antagonism 
by mediating the efflux of intracellular VRC. In contrast, in C. gattii 97/170 the alterations to 
mitochondrial function were accompanied by an absence of stress responses. The different 
interactions between VRC+EDTA in C. neoformans var. grubii and C. gattii highlight species-specific 
responses to drug combinations that remain to be understood.  
Overall, the results presented in this thesis show that metal regulation is important for resisting 
antifungal stress and that the dysregulation of metal ion homeostasis by some iron chelators, rather 
than metal chelation itself, can enhance the activity of antifungal drugs. Transcriptomic analysis of the 
cellular response suggests synergy may be mediated by disrupting stress responses in two ways: first, 
by over burdening the cell͛s adaptive stress response through increasing stress and cellular damage, 
and second, by incapacitating the stress response through the down-regulation of appropriate stress-
related pathways. Disrupting metal homeostasis provides a broad spectrum of activity through 
different stress-disrupting mechanisms and is a potential antifungal strategy. Potential targets of this 
strategy were metal controlling transcription factors, especially Zap1, which contains domains that can 
be inhibited by small molecules. 
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CHAPTER 1: Introduction 
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There is an urgent need to increase our options for treating fungal diseases. Globally, fungal infections, 
including invasive fungal diseases, are on the rise and are associated with changes to the host through 
immunosuppressive diseases such as HIV/AIDS, the increasing use of immunosuppressive therapies, 
the ageing population, and changes to the environment with global climate change and the increased 
occurrence of natural disasters changing our exposure to infective agents [1, 2]. Fungal infections are 
difficult to treat, and even with best current practice the mortality rates from invasive fungal diseases 
can be as high as 90% [3].  
Finding and developing new antifungal drugs incurs significant cost and time expenditures. An 
alternative approach that has gained increased interest is to enhance the activity of current antifungal 
drugs by combining them with agents that can synergise their activity. Synergistic drug combinations 
have improved survival outcomes in in vivo models of invasive fungal diseases [4, 5], suggesting they 
can be employed in human infections. However, despite their promise few studies have analysed the 
mechanisms underlying drug synergy [6, 7] and none have been done with the aim of harnessing this 
knowledge to find potential targets for antifungal drugs.  
This thesis focuses on understanding the mechanisms of drug synergy between antifungal drugs and 
iron chelating agents. Iron chelators were chosen as iron has a known role in fungal virulence and 
pathogenicity [8], and chelators have demonstrated synergising activity with antifungal drugs in 
pathogenic yeast and fungi [9, 10]. Cryptococcus was chosen as the study organism, as it is a major 
fungal pathogen and is also the focus of our laboratory; Saccharomyces was included as a model yeast, 
as it has the most curated, annotated and functionally characterised genome, along with a suite of 
useful resources including detailed protein interaction data and knock-out libraries. Drug-chelator 
interactions were explored using RNA-Seq-based transcriptomics. The outcome is a detailed picture of 
the surprisingly diverse cellular and molecular responses to synergy, additivity and antagonism by 
fungal cells.  
1.1. Cryptococcus  
Cryptococcus is a basidiomycetous yeast genus that encompasses over 37 different species, of which 
two are encapsulated and pathogenic in mammals. Cryptococcus neoformans (which includes varieties 
neoformans and grubii) and Cryptococcus gattii (formerly known as C. neoformans var. gattii) are the 
etiological agents of cryptococcosis, a disease that affects the immunosuppressed and 
immunocompetent, and is potentially fatal if presented in the meninges [11]. A new nomenclature for 
Cryptococcus was recently described by Hagen et al. (2015) which divides the two pathogens into 
seven species based on phylogenetic analysis [12]. However, as extensive genotypic and phenotypic 
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comparisons between these have not yet been undertaken and they can only be reliably separated 
using molecular techniques, this thesis will retain the established classification system of two species 
with different molecular genotypes. 
The two pathogenic Cryptococcus species are further classified into nine major molecular genotypes 
and five serotypes based on a variety of molecular analyses and the antigenic reactivity of their 
capsules, respectively. C. neoformans var. grubii includes genotypes VNI, VNII and VNB, which are all 
serotype A. C. neoformans var. neoformans is genotype VNIV and serotype D, and a hybrid between 
the two varieties of C. neoformans is serotype AD and genotype VNIII. C. gattii includes serotypes B 
and C and genotypes VGI to VGIV (Fig. 1.1) [13, 14]. Interspecies hybrids between C. neoformans and C. 
gattii have also been identified [15-17].  
C. neoformans and C. gattii are distinctly different in their natural habitat, epidemiology, genome 
sequence, phenotype, clinical presentation and response to antifungal treatment [18, 19]. Additionally, 
differences in pathogenicity and antifungal response have been observed among the genotypes of 
each species [20-22].  
 
 
Figure 1.1. The Cryptococcus species complex. C. neoformans and C. gattii are shown with their 
respective molecular genotypes and serotypes. Bolded lines linking serotype B and C to molecular 
types indicate the predominant genotypes associated with each serotype. Mya is millions of years ago. 
From Lin and Heitman (2006) [13]. 
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1.1.1. Cryptococcus neoformans  
C. neoformans is a cosmopolitan and opportunistic pathogen that can be isolated from soil and trees, 
but more commonly obtained from pigeon guano [23]. Before the 1980s, instances of cryptococcosis 
were limited to patients receiving immunosuppressive therapy [24]. It was not until the HIV/AIDS 
epidemic, where a significant number of the infected population presented with cryptococcosis, that 
C. neoformans became an AIDS-defining illness and an important pathogen [14].   
C. neoformans var. grubii causes the majority of cryptococcal infections in the HIV/AIDS community 
and is globally distributed. Within C. neoformans var. grubii, the VNI genotype is the most commonly 
isolated, followed by VNII. Small VNB populations, which were thought to be restricted to Southern 
Africa, have been found recently in different continents [22]. C. neoformans var. neoformans (VNIV) 
and the AD serotype hybrid (VNIII) are prevalent in Western Europe and South America [22, 25] (Fig. 
1.2). 
Since the introduction of highly active antiretroviral therapy (HAART) cryptococcal meningitis caused 
by C. neoformans has decreased substantially in developed countries, but it still remains a common 
cause of mortality in resource-limited countries like sub-Saharan African and Southeast Asia [14, 26]. In 
2009 the Centers for Disease Control and Prevention (CDC) estimated there were one million cases of 
cryptococcal meningitis per year amongst individuals with HIV/AIDS worldwide, causing nearly 625,000 
deaths [26]. This has substantially decreased with the greater use of antiretroviral therapy in Africa, 
however attributed mortality still remains high [27].  
1.1.2. Cryptococcus gattii  
Unlike C. neoformans, C. gattii is predominantly a primary pathogen with infection endemic in parts of 
Australia, Papua New Guinea and Africa [18, 28]. C. gattii can be biochemically distinguished from C. 
neoformans by growth on L-canavanine glycine bromothymol blue medium, which tests for the 
assimilation of glycine as a carbon source and in C. gattii strains turns the indicator in the medium blue 
[29]. C. gattii is generally less susceptible and more heteroresistant to azole antifungals than C. 
neoformans [30-32].  
C. gattii was first isolated from Eucalyptus trees by Ellis and Pfeifer in 1990 [33], and since then it has 
been isolated from more than 50 species of trees including Ficus and Terminalia, suggesting trees and 
decaying wood are its ecological niche [34]. It was formerly thought to be restricted to tropical and 
sub-tropical areas, however, an outbreak of C. gattii cryptococcosis in the temperate region of British 
Columbia Vancouver Island (Canada) was recognised in 1999. This outbreak remains ongoing and has 
extended to the Pacific Northwest of the United States [35-37]. A growing number of isolations from 
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temperate regions of Asia and Europe suggests this species may have a more global distribution than 
was previoulsy thought [34]. 
Each C. gattii genotype differs in distribution. VGI is the most prevalent genotype in Australia and 
Papua New Guinea [22], while large VGII populations are found in North and South America (Brazil, 
Columbia and Puerto Rico) and in some parts of Australia [22, 28]. VGIII is mainly detected in Central 
America and Southern California and has been isolated from HIV-infected patients [22, 28] while VGIV 
is most prevalent in South Africa and is identified in association with HIV/AIDS [28] (Fig. 1.2).  
 
 
Figure 1.2. Global distributions of environmental and clinical C. neoformans and C. gattii serotypes. 
Percentages are compiled from individual studies, reviewed by Antonio et al. (2013) [25].  
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1.2. Cryptococcosis  
Cryptococcal infection starts with the inhalation of the pathogen as desiccated yeast cells or spores 
from the environment. Initial infection in the lungs is typically asymptomatic and, with a normal 
immune response, can be either cleared or contained as a dormant latent infection. When a decline in 
the host͛s immunity occurs, the pathogen reactivates and can disseminate hematogenously with 
predilection for the brain, where the most common clinical manifestation of human cryptococcosis is 
meningoencephalitis [13] (Fig. 1.3).  
During meningeal involvement, symptoms of cryptococcosis can range from headache, fever, dyspnea, 
neck stiffness to altered mental status and seizures. While most attention has been focused on 
cryptococcal meningitis because it is life threatening, cryptococcosis can also affect other organs of the 
body, including the eyes, skin, prostate, bones and the urinary tract [14].  
The clinical presentation of cryptococcosis differs between C. neoformans and C. gattii. While C. 
neoformans infection is associated with presentation in the central nervous system as meningitis or 
meningoencephalitis, C. gattii infections are more aggressive and frequently present in the lungs and 
brain as cryptococcomas, which in the latter case is associated with neurological sequelae and 
prolonged antifungal therapy [23, 28]. AIDS patients undergoing HAART can also develop cryptococcal 
immune reconstitution inflammatory syndrome (IRIS), which is the over-reaction of an improved 
immune response to an underlying cryptococcus infection that results in clinical deterioration [38].  
1.3. Treatment   
1.3.1. Antifungal drug classes and cryptococcosis 
Although five classes of antifungal drugs are available for the treatment of mycotic infections, only 
three can be used to treat cryptococcosis. The classes of drugs that are effective include the polyenes 
and triazoles, which target the cell membrane, and nucleic acid and/or protein synthesis inhibitors (Fig. 
1.4). Examples of drugs within these classes are amphotericin B (AMB), fluconazole (FLC) and 5-
fluorocytosine (5-FC). Selected antifungal drugs and their modes of action will be discussed in more 
detail in Chapter 3.  
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Figure 1.3. Environmental sources of Cryptococcus and the process of infection from the lungs to the 
brain. From Lin and Heitman (2006) [13].  
 
 
 
Figure 1.4. Targets of antifungal therapy. From Kathiravan et al. (2012) [39].  
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1.3.2. Cryptococcosis management guidelines and problems with treatment  
In 2010, the Infectious Diseases Society of America updated the clinical practice guidelines for the 
management of cryptococcosis. Building from the previous edition published in 2000, this revision 
includes the management of cryptococcal meningoencephalitis in different populations, based on 
immune status, age, demographics, causative pathogen and clinical manifestation of disease. The 
major areas for management included the early recognition of disease, the use of lipid formulations of 
AMB, and therapy with the combined use of AMB with 5-FC, followed by maintenance with FLC [40].  
Combination therapy with AMB+5-FC has been shown clinically to be more effective in clearing the 
pathogen in the cerebrospinal fluid and to improve survival outcome compared to AMB or FLC 
monotherapy, or AMB+FLC combination therapy [41, 42]. However, AMB or FLC monotherapies, and 
combined AMB+FLC therapy, are often employed in resource-poor countries in sub-Sahara Africa and 
South East Asia where the availability of 5-FC and AMB is often limited. These limitations are 
associated with the cost, distribution and lack of registration of the drugs and pose significant 
challenges to cryptococcosis treatment, which underlie the high rates of morbidity and mortality in 
those countries [43, 44].  
Additionally, each drug is not without their problems. 5-FC is only used in combination with other 
drugs as resistance is easily acquired with monotherapy [45]. AMB, the most effective drug and 
considered the gold standard in mycotic therapy, is particularly toxic. Other formulations of AMB, such 
as liposomal AMB, are designed to exhibit less toxicity while retaining efficacy but are extremely 
expensive. The intravenous administration of AMB is also problematic in terms of patient care and 
compliance [43]. FLC has the least toxicity and the best bioavailability, however its use in monotherapy 
and as a prophylactic has lead to concerns of developing resistance, and there are reports detailing a 
decrease in susceptibility to FLC in the last few years. However, whether this is emerging FLC 
resistance or intrinsic resistance is not known [46, 47].   
1.3.3. Alternative antifungal and synergistic combination therapies for cryptococcosis 
As noted above, the repertoire of anti-cryptococcal drugs is limited and current treatments, which 
often use old and off-patent drugs [43], remain associated with high mortalities. Unfortunately, 
pharmaceutical companies are less inclined to invest in the licensing and improvement of off-patent 
drugs as these can be made generically, making them less profitable for the company, and improving 
the effect of the drug may not warrant a new patent [48]. Alternative therapies with new or novel 
drugs are desperately required, but investments in novel drugs can be protracted; for example it took 
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30 years from bench to bedside for echinocandin drugs [49]. Additionally, new and better drugs are 
marketed at prices that are often not affordable in poorer countries.  
Alternative approaches to antifungal therapies involve repurposing approved medical compounds and 
finding natural compounds that have antifungal activity. Repurposing approved medical compounds is 
advantageous in that their toxicology and pharmacology profiles are already known and can be used 
immediately to treat new diseases [50]. An example is 5-FC, which was originally an anti-tumour drug 
[45]. Compounds naturally produced by plants and microorganisms as defence mechanisms have long 
been investigated as a source for drug discovery [51]. Examples include AMB and caspofungin, which 
were originally derived from bacterial and fungal metabolites, respectively [52, 53]. Natural 
compounds and non-antifungal medicines have also been tested in combination with antifungal drugs 
as potential alternative therapies [54-56], and antifungal-iron chelating agents and antifungal-
immunotherapies combinations have been used as salvage and adjuvant therapies for mucormycosis 
and candidiasis, respectively [57-59]. However, routine use of these salvage and adjuvant therapies 
has not been implemented for clinical use.  
The practice of combining different antimicrobial agents is used in the treatment of many diseases. 
These include tuberculosis, leprosy, malaria, HIV/AIDs, and infections with antibiotic resistant bacteria, 
which are difficult to treat with monotherapies [60, 61]. The advantages of combination therapy 
coincide with many of the principles of its use, which aim to:   
- Increase antimicrobial activity with two agents that may not be accomplished with one agent 
and hence clear the pathogen faster 
- Enable the use of smaller drug dosages so that side effects and toxicity are diminished while 
maintaining drug efficacy  
- Delay the emergence of resistant mutants that may occur from the use of a single drug  
- Provide a broad spectrum of activity in seriously ill patients suspected of having either mixed 
infections or antimicrobial resistant infections [50, 62, 63]. 
Drug combinations can interact in different ways and the most desired interaction is synergy, which is 
where the therapeutic effect of the combined drugs or agents is significantly greater than their effects 
alone. Synergy satisfies the criteria for combination therapies and as it results in faster pathogen 
clearance and disease resolution, much attention has been given to finding synergistic drug 
combinations. One synergistic drug combination that is used clinically for bacterial infections is 
sulfamethoxazole and trimethoprim, otherwise known as co-trimoxoazole, which was first 
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implemented in the 1960s. Co-trimoxazole greatly reduces the MICs of sulfamethoxazole and 
trimethoprim compared to when these agents are used alone and is broadly synergistic by disrupting 
folate biosynthesis [64]. It is used for treating a range of infections, however an increasing incidence of 
resistance to co-trimoxazole is becoming an issue, especially in developing countries where it is widely 
used [65]. Another synergistic antimicrobial drug combination is ceftolozane and tazobactam, which 
was marketed as Zerbaxa® in 2014 for the treatment of intra-abdominal and urinary tract infections 
(https://www.merck.com/product/ usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf). Like co-trimoxazole, 
ceftlolzane + tazobactam has a broad spectrum of antibacterial activity, even against bacteria that 
commonly harbour antimicrobial resistance [66].  
Repurposed medicines and bioactive compounds have been screened to find agents that potentiate 
antifungal activity for improved cryptococcal therapy. In pioneering studies, combinations of FLC and 
caspofungin (CAS) with calcineurin inhibitors and target of rapamycin (TOR) inhibitors were found to 
be more effective against Cryptococcus in vitro than FLC and CAS alone [4]. A later study found 
treatment combinations of calcineurin inhibitors with either AMB or FLC improved the survival of 
organ transplant patients with cryptococcosis [67]. Other medicines such as the antibacterial drug 
rifampicin and antidepressant sertraline also exhibited synergy in Cryptococcus in vitro with AMB and 
FLC, respectively, and FLC and sertraline was further demonstrated to be more effective than FLC 
alone in a mouse model of systemic cryptococcosis [68, 69]. Natural phenolic compounds from plants 
can also synergise with antifungal drugs. Examples of these include dihydroxybenzaldehydes and its 
structural derivatives, thymol and cinnamic acid, which enhanced in vitro AMB, FLC and itraconazole 
(ITC) activity in Cryptococcus [70]. While natural compounds are thought to be relatively safe for 
human use as most of them are extracted from medicinal and edible plants, there is surprisingly a lack 
of in vivo studies that test their interactions with antifungal drugs.   
Some synergistic antifungal and non antifungal drug combinations in Cryptococcus are also synergistic 
in vitro in other fungal organisms, such as the calcineurin inhibitior FK-506 (Tacrolimus) with CAS in A. 
fumigatus and dihydroxybenzaldehydes with AMB in C. albicans [70, 71]. There are many drug 
combinations that are synergistic in fungal pathogens but have not yet been tested in Cryptococcus, 
for example antifungal drugs and iron chelating agents, where synergy has been reported in Candida 
and Aspergillus [9, 72]. Iron chelators have also been reported to potentiate antifungal activity and 
improve the survival of mice suffering from aspergillosis and mucormycosis [73, 74]. Based on the 
synergy seen in vito in fungal pathogens and the improved survival from fungal infections in vivo, iron 
chelation is a possible way of enhancing antifungal drugs in Cryptococcus.  
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1.4. Iron and its importance in biological systems 
Iron is an essential trace metal for living organisms. Its importance lies in the fact that it can exist in 
various oxidation states, of which the ferric (Fe3
+
) and ferrous (Fe
2+
) forms are most prevalent [75]. 
Due to this, iron serves as an important cofactor in enzymes that catalyse and participate in many 
redox reactions that are essential for maintaining metabolic functions in a cell. These functions involve 
(but are not limited to) DNA synthesis and repair, mitochondrial respiration and energy production, 
anti-oxidation and detoxification of foreign compounds, and protein and lipid biosynthesis [76, 77]. 
Additionally, iron is important for microbial virulence, with increased pathogenicity seen in the 
presence of extra iron [78].  
After aluminium, iron is the second most abundant element on Earth [75]. However, it mainly exists as 
ferric hydroxide in aerobic and pH neutral environments, which limits bioavailability as this compound 
is insoluble. To combat this, hosts and microbes have evolved mechanisms to scavenge iron. Hosts 
impose nutritional immunity through iron-binding glycoproteins like transferrin and lactoferrin to 
withhold iron and prevent its use by microbes [79]. Similarly, some microorganisms like Aspergillus 
secrete low molecular weight molecules called siderophores that bind highly to iron to sequester it for 
their own use [8].  
Within a biological system, iron is tightly controlled. Too much or too little iron can lead to detrimental 
consequences that in humans manifest as iron deficient and iron overload diseases, including sickle 
cell anaemia and Friedrich͛s ataxia, respectively [80].  
1.4.2. Iron regulation in Saccharomyces cerevisiae  
The regulation of iron is well characterised in the model yeast Saccharomyces. Here, the cellular iron 
response, otherwise known as the iron regulon, is controlled by the transcription factors Aft1, Aft2, 
and Yap5 [81]. Aft1 (Activator of Ferrous Transport) and its paralogue Aft2 are low-iron sensing 
transcription factors that regulate iron mainly through the activation of genes involved in iron uptake 
and release from cellular storage. Most of these proteins are present in the plasma membrane and the 
membranes of subcellular compartments. At the cell surface, these proteins include siderophore 
transporters (Sit1, Arn1, Taf1 and Enb1), metalloreductases to reduce ferric iron to its divalent form 
and cause its release from siderophores (Fre1 – 7), and ferroxidases that catalyse the oxidation of 
ferrous iron before cellular uptake (Fet3 and Ftr1). In addition, cell wall iron acquisition mannoproteins 
(Fit1 – 3) and a ferrous iron uptake protein (Fet4) have been identified. In the vacuole, which serves as 
an ion storage compartment, the release of iron into the cytosol is mediated by iron export (Fet5, Fth1 
and Smf3) and metalloreductase (Fre6) proteins. Under iron-limited conditions, the transcription of 
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iron uptake and storage genes is increased [82, 83]. A representation of the S. cerevisiae iron regulon is 
shown in Figure 1.5.  
Aft1 also induces regulators involved in the post-translational control of iron, mainly through Cth2 and 
to a lesser extent Cth1, which destabilise the AU-rich elements (ARE) within mRNAs from genes 
involved in iron-consuming pathways and cause their degradation. This results in the repression of 
non-essential but iron-dependent processes, such as Fe-S cluster and haem biosynthesis, and 
decreased storage of iron in the vacuole through the down-regulation of CCC1 [84, 85] (Fig. 1.5).  
The localisation of Aft1 is mediated by the iron pool within the mitochondria, which exists in the form 
of iron-sulphur (Fe-S) proteins and plays a role in optimal redox and respiratory functions [83, 86, 87]. 
Mitochondrial Fe-S clusters also regulate the activity of Yap5, a transcription factor involved in high-
iron sensing [88, 89], which in turn influences the activity of Aft1. It is not known how the cell senses a 
disruption in the synthesis of Fe-S clusters during iron deficiency, however, the suppression of Yap5 
leads to the down-regulation of GRX4 [90]. Grx4 is a glutathione that, together with its paralogue Grx3, 
binds to Aft1 and prevents it from entering the nucleus and activating the iron regulon [91].  
The regulation of iron through Aft1 appears to be unique to S. cerevisiae and a few closely related 
species, with orthologues only found to date in Candida glabrata and Kluyveromyces lactis. Other 
fungal species exert their regulation of iron through GATA-type and CCAAT-binding transcriptional 
repressors [92].  
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Figure 1.5. Regulation of the iron regulon in S. cerevisiae. Low-iron sensing transcription factors Aft1 
and Aft2 regulate genes involved in iron uptake, transport and storage (genes in black). Red spheres 
are Fe
3+
; orange spheres are Fe
2+
. Aft1 also controls the post-translational regulator Cth2, which down-
regulates non essential iron-dependant processes such as haem and biotin biosynthesis, and decreases 
vacuole storage of iron by down-regulating CCC1 (gene in gray) From Cyert and Philpott (2003) [93].  
 
1.4.3. Iron regulation in Cryptococcus  
The cryptococcal iron regulon shares orthologous iron mobilisation proteins with Saccharomyces, with 
ferroxidases (Cfo1 and Cfo2) and permeases (Cft1 and Cft2) that are orthologous to Fet3 and Ftr1 [94-
96]. Similarly, siderophore transporters (Sit1), a suit of ferric reductases (Fre1 – 7, Fre201) and 
mitochondrial iron related proteins (Frr1, Frr3 and Frr4) have also been identified [97-99]. Unlike 
Saccharomyces, however, Cryptococcus can use haem as an iron source through endocytosis that is 
mediated through the mannoprotein Cig1 and a component of the ESCRT complex Vsp23 [100, 101]. 
Melanin, which is synthesised by Lac1 and is present in the cryptococcal cell wall, has iron reducing 
properties [102]. Additionally, the homeostasis of iron in Cryptococcus is controlled by two regulators: 
the GATA-type transcription factor Cir1 (Cryptococcus Iron Regulator) and a bZIP transcription factor 
HapX [103, 104]. The regulation of iron in Cryptococcus is shown in Figure 1.6.  
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Figure 1.6. Iron regulation in Cryptococcus. Iron homeostasis is mainly regulated by Cir1 and HapX (in 
red). Other transcription factors also exert control on iron uptake genes while Gat201 regulates Cir1. 
Cfo2/Cft2 is thought to localise at the vacuole [105]. Low affinity uptake systems have yet to be 
characterised. Adapted from Ding et al. (2014) [106].  
 
Cir1 is similar in sequence to other fungal GATA-type iron regulators, such as Fep1 and Sre1 in 
Schizosaccharomyces and Aspergillus, respectively, but lacks one of the two zinc finger binding motifs. 
It exerts positive and negative regulation on genes encoding iron uptake and transport proteins (such 
as Cft1 and Cfo1), as well as other genes involved in different functions and cellular pathways like 
sterol and cell wall biosynthesis [104]. HapX is part of a protein complex that binds to CCAAT motifs. 
During iron limitation this complex up-regulates siderophore transport genes while repressing the 
expression of genes involved electron transport functions [103].  
This GATA and CCAAT-type iron regulating system in Cryptococcus differs from other fungal species in 
that HapX positively regulates Cir1 in both iron replete and limited conditions, and does not act as a 
repressor of iron response genes [92, 103]. This may be related to the constitutive transcription of 
CIR1, which does not change regardless of iron availability, suggesting it is post-translationally 
regulated. Based on protein expression in different iron status and reducing conditions, Jung et al. 
(2011) proposed a model for the regulation of Cir1, where the stability of Cir1 is controlled by the iron 
status of the cell and it acts as a repressor of target genes [107].  
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In addition to Cir1 and HapX, other regulators of iron such as Tup1, Nrg1, Sre1, and Rim101 have been 
identified that influence iron uptake, while Gat201 interacts directly with Cir1 [108-112] (Fig. 1.6).  
1.4.4. Iron and virulence in Cryptococcus  
Like all pathogens, Cryptococcus requires iron for virulence and pathogenicity. Iron limitation has been 
reported to decrease the synthesis of melanin and cause enlargement of the polysaccharide capsule, 
which are both important virulence attributes [113, 114]. In addition, iron uptake genes encoding the 
ferric reductases Fre2 and Fre3, and the ferroxidase Cfo1, have roles during infection. Fre2 is required 
for the utilisation of mammalian heme and transferrin as iron sources, while FRE3 expression was 
found to increase following serial passage of Cryptococcus through mice, which also increased their 
virulence [98, 115]. Finally, murine infections with cfo1Δ mutants were attenuated in virulence 
compared to a wild-type strain [104] and were more sensitive to antifungal drugs [116].  
Most strikingly, capsule and melanin production are regulated by Cir1, and cir1Δ mutants cannot grow 
at body temperature, which is essential for mammalian virulence, and are defective in mating [104, 
117]. The cryptococcal capsule is made primarily of the sugars glucuronoxylomannan (GXM) and 
galactoxylomannan (GalXM), and smaller amounts of mannoproteins. This polysaccharide matrix 
protects the cells from phagocytosis and can modulate the host immune response [118]. Melanin is an 
acid-resistant, solvent-insoluble, brown pigment that is synthesised and deposited in the cryptococcal 
cell wall. It has been shown to confer protection against oxygen-derived radicals, and increases 
tolerance to antifungal drugs such as AMB [119]. Mutants that lack capsule or melanin are avirulent in 
mouse infection models [120, 121]. Mutants deleted in other iron-regulating transcription factors such 
as HapX and Nrg1 also exhibit attenuated or avirulent phenotypes [103, 110]. Based on this, antifungal 
agents that disrupt iron homeostasis are being explored as alternative therapies for cryptococcosis 
[105].  
1.5. Systems biology 
1.5.1. Systems biology – a ͚holistic͛ approach to understanding how cells respond to change 
Systems biology can be described as the quantitative and high-throughput study of the interactions 
involved in biological organisation and processes as cells respond to changes in their environments 
[122]. It includes examining the variation of genotypes that can arise from a genome by the way genes 
are modified during expression, the population of RNA that may be translated to proteins, the 
population of proteins and the influence of post-translational modifications that contribute to 
phenotypic variation, and the changes in the chemical fingerprint of cells that arise from alterations in 
cellular processes. Systems biology integrates data from ͚omics͛ studies, such as genomics, proteomics, 
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transcriptomics and metabolomics, with the aim of undertanding and characterising a cell͛s biology in 
its whole entity as it is and as it responds to different stimuli. The approaches used in systems biology 
are interdisciplinary, integrating molecular biology with bioinformatics to quantify cellular 
constituents, model the biological system and predict an outcome from the reconstruction of an 
experimental situation [122-124].  
1.5.2. Transcriptomics and RNA-Seq 
Eukaryotic cells are complex biological systems that continually adapt and respond to external and 
internal stimuli by rewiring important cellular pathways, changing gene expression levels and changing 
gene and protein interactions. While genomics entails genetic potential from the structure and 
arrangement of a whole genome sequence, such as gene arrangements, chromosomal insertions and 
deletions, copy number variations and single nucleotide polymorphisms (SNPs), it is limited in that it 
does not reflect gene and protein expression or the post-transcriptional and post-translational changes 
that occur that alter protein functions. Proteomics enables the study of all expressed proteins, which is 
more beneficial than genomics in analysing biological systems as proteins are vital and have functional 
roles as structural elements and mediate signalling and catalysis in metabolic pathways. However, 
proteomics is disadvantaged by the inability to detect low-abundance proteins and membrane-bound 
accurately, and current protein extraction technologies have only enabled a subset of proteins within 
the cell to be isolated and studied [125]. Hence, proteomic data are invariably incomplete.  
Transcriptomics enables the simultaneous quantification and characterisation of the entire mRNA 
population within a cell, which is unique to a particular time in response to a particular environment 
[126, 127]. Although there is a non-linear correlation between mRNA transcripts and their translation 
into proteins [128], the study of RNA transcripts is beneficial as the global analysis of genes and their 
expression profiles allows a prediction of which proteins can be translated, even if they cannot be 
identified through proteomics. This technique has been useful in the identification of disease 
biomarkers, characterisation of the cellular fingerprint of diseases like cancer [129] and the 
development of new therapeutic strategies and vaccines [130].  
Various techniques have been developed to analyse the transcripts of a cell. These include DNA 
microarrays, cDNA amplified fragment length polymorphism (cDNA-AFLP), expressed sequence tag 
sequencing (ESTs), serial analysis of gene expression (SAGE) and massive parallel signature sequencing 
(MPSS) to name a few. However, each technique has issues such as background noise, sensitivity and 
laboriousness [127, 131, 132].  
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RNA-Seq, also known as whole transcriptome shotgun sequencing, is one of the latest next generation 
sequencing technologies. In this method, transcripts are converted into cDNA for massive parallel 
sequencing [127, 133]. It does not have the limitations of previous techniques, but current RNA-Seq 
technologies only permit transcripts to be sequenced in short cDNA fragments. Hence, reconstruction 
of the original transcripts either by de novo assembly or alignment to a reference genome requires 
many processing elements before analysis (to be discussed further in Chapter 4). Assembled RNA-Seq 
data can provide concise information on the levels of gene expressions and transcript structures, such 
as exon boundaries, transcriptional starting sites and the 5͛ and 3͛ ends of genes. Additionally, these 
data can provide information about alternative splicing and the diversity of splicing, and can reveal 
SNPs and novel transcribed regions [127, 131, 134]. 
Transcriptomics has been useful in investigating cellular responses to stimuli, such as to antifungal 
treatments, in order to understand their impact on the biology of fungal cells. Microarrays were used 
to understand the antifungal activity of the iron chelator ciclopirox olamine in C. albicans, at the 
molecular level, which had been poorly understood [135]. Transcriptomic investigations have been 
useful in understanding adaptive responses to drugs and drug resistance [136-138], and have been 
used to monitor the fungal response to chitosan in order to develop it as an antifungal drug [139]. 
Surprisingly, although there are many studies that have found synergistic drug combinations that 
enhance the antifungal activity, ͚omics͛ type studies of synergistic combinations, such as between 
antifungal drugs and iron chelators, are lacking. In addition to understanding antifungal drug 
responses, other recent applications of transcriptomics in fungi include investigating the antagonistic 
interactions between fungal plant pathogens and bacteria as an alternative to chemical treatments to 
control fungal infections [140], and using  transcriptomic comparison of a laboratory strain and its 
variants to investigate microevolution [141].  
1.6. Hypotheses and aims of this thesis 
The treatment of cryptococcosis is reliant on antifungal drugs that are associated with unacceptable 
rates of mortality even with current best treatment practice. New medicines are urgently needed but 
there are significant issues in their development. Enhancing the activities of current antifungal drugs is 
an attractive alternative to de novo drug development, and some repurposed drugs and natural 
products have been found to be synergistic with antifungals against Cryptococcus.  
Iron is important for virulence and pathogenicity, and disrupting iron homeostasis has been suggested 
as a potential antifungal target. Iron chelating agents have been found to synergise with antifungal 
drugs in medically important yeast and fungi, but the mechanistic basis of how these work has not 
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been explored. Antifungal-iron chelator interactions have not yet been investigated in Cryptococcus. 
The overall aim of this thesis was to find alternative therapies from understanding synergy between 
antifungal drugs and iron chelating agents.  
At the outset of this study it was hypothesised that synergistic antifungal-iron chelator interactions 
exist in Cryptococcus and that new antifungal therapies could be found through the transcriptomic 
analyses of these combinations. The well-characterised model Saccharomyces could be used to map 
and understand the transcriptomic profiles of synergistic combinations in detail, which would then be 
used to aid the analysis of synergy in Cryptococcus and find potential novel drug targets that could 
then be validated in this and other fungal pathogens. 
Therefore, the aims of this project were: 
1. To determine whether current antifungal drugs and various iron chelators produce synergy 
when used in combination against pathogenic Cryptococcus species and S. cerevisiae.  
2. To understand the mechanistic basis of synergy using the extensive genetic resources available 
for S. cerevisiae, allowing the transcriptomic profile of synergistic antifungal-iron chelator 
combinations to be mapped, analysed and validated.  
3. To use the data and resources generated in 1) and 2) to characterise the transcriptome of 
antifungal-iron chelator synergy in Cryptococcus and find potential targets for anti-
Cryptococcus therapy.  
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CHAPTER 2: General materials and methods   
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2.1. General materials 
2.1.1. Chemicals  
All chemicals and their suppliers are listed in Table 2.1. All chemicals used were of analytical grade.  
Table 2.1. Chemicals list  
Chemical Supplier 
1,2-Bis(2-Aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid 
(BAPTA) 
Sigma-Aldrich 
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone (deferiprone)  Sigma-Aldrich 
4-Morpholinepropanesulfonic acid (MOPS) Sigma-Aldrich 
Absolute ethanol Sigma-Aldrich 
Amphotericin B (solubilised) Sigma-Aldrich 
Ammonium sulphate APS FineChem 
Agar Difco 
Agarose (DNA grade)  Bioline 
β-Mecaptoethanol  BDH Biochemicals 
Blankaphor (Calcafluor white) Bayer Chemicals 
Boric acid APS FineChem 
Bromophenol blue Sigma-Aldrich 
Caffeine  Sigma-Aldrich 
Calcium chloride Unilab, Ajax FineChem 
Caspofungin  Merck Research Laboratories  
CloNAT (nourseothricin) Werner Bioagents 
Ciclopirox olamine Sigma-Aldrich 
Congo red Sigma-Aldrich 
Deferoxamine  Sigma-Aldrich 
Deferasirox Novartis 
Deoxynucleotide triphosphates (dNTPs) GeneWorks  
Deoxyribonucleic acid soldium salt from salmon testes Sigma-Aldrich 
D-glucose (anhydrous)  Univar APS Finechem 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
EDTA Sigma-Aldrich 
EDTA (Na2) Biochemicals 
Ferric chloride  Sigma-Aldrich 
Ferrous sulfate Fisons analytical reagent 
Fluconazole Sigma-Aldrich 
GelRed
TM
 Nucleic acid gel stain Biotum  
Glass beads (0.5 mm) Sapphire Bioscience 
Glycerol  Ajax Finechem 
Hydrogen peroxide solution (30% (w/w)) Sigma-Aldrich 
Hyperladder
TM
 I Bioline 
Isopropanol Sigma-Aldrich 
Itraconazole Sigma-Aldrich 
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Kanamycin  Sigma-Aldrich 
Lactoferrin  MP Biomedicals 
L-glutamine Sigma-Aldrich 
Lithium acetate Sigma-Aldrich 
LongAmp® Taq 2 X master mix New England BioLabs 
Peptone Amyl Media  
Phenol: Chloroform (5:1, Molecular grade) Sigma-Aldrich 
Phytosphingosine chloride  Sigma-Aldrich 
Polyethylene glycol (PEG) m.w. 3350 Sigma-Aldrich 
RPMI-1640 powder Life technologies 
SD-ura drop out media Sigma-Aldrich 
Sodium acetate anhydrous  Ajax FineChem  
Sodium chloride  Fisons Scientific Equipment 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium hydroxide (NaOH) Ajax FineChem Pty Ltd 
Sodium nitrite  Sigma-Aldrich 
Taq DNA Polymerase with standard Taq buffer  New Englands BioLabs 
Tris  Ajax FineChem 
Uracil Sigma-Aldrich 
Voriconazole Sigma-Aldrich 
Yeast nitrogen base (YNB) Becton, Dickonson and Company (BD)  
Zinc chloride Sigma-Aldrich 
 
 
2.1.2. Buffers and solutions 
Buffers and solutions and their components are outlined in Table 2.2.  
Table 2.2. Buffers and solutions 
Buffers and solutions Components 
20 X TBE 800 mL RO water  
215.6 g/L Tris base 
110 g/L Boric acid 
16.4 g/L Na2EDTA  
Adjusted to 1 L  
Blue juice 1 mg/mL Bromophenol blue  
20% glycerol 
DNA extraction buffer 50 mM Tris-HCl (pH 8) 
20 mM EDTA 
1% SDS 
Tris-EDTA (TE) buffer  1 mM Na2EDTA 
10 mM Tris-HCl (pH 8) 
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2.1.3. Media  
Media and their ingredients are shown in Table 2.3. All media were filter sterilised unless stated. 
Table 2.3. Media used 
Medium Components 
Roswell Park Memorial Institute (RPMI)-1640 (pH 
7.0) 
10.4 g/L RPMI-1640 powder 
34.53 g/L MOPS 
18 g/L D-glucose 
0.3 g/L L-glutamine 
Sabouraud dextrose agar (SDA).  
Autoclaved at 151 °C for 15 min. 
10 g/L peptone 
40 g/L D-glucose 
15 g/L agar 
Synthetic complete (SC) broth/agar (pH 4.5)  1.7 g/L YNB (no amino acids and ammonium sulphate) 
5 g/L ammonium sulphate 
1.92 g/L synthetic drop out media without uracil  
20 g/L D-glucose 
76 mg/L uracil 
20 g/L agar added for agar plates  
Yeast nitrogen base (YNB) broth (pH 7.0) 7 g/L YNB with amino acids and ammonium sulphate 
34.53g/L MOPS 
8 g/L glucose 
 
2.1.4. Equipment  
A list of equipment and software used is presented in Table 2.4.  
Table 2.4. List of equipment and software  
Equipment and software Supplier (country) 
BenchMixer
TM
  Benchmark (USA) 
Biochrom EZ Read 2000 Microplate Reader VWR International Pty Ltd (England) 
Centrifuge 5418 R Eppendorf (Germany) 
Centrifuge 5810 R Eppendorf (Germany) 
Dry block heater  Thermoline (Australia) 
Experion
TM
 automated electrophoresis system  Bio-Rad (USA) 
Experion
TM
 priming station Bio-Rad (USA) 
Experion
TM
 vortex II station  Bio-Rad (USA) 
Experion
TM
 software (Version 3.2)  Bio-Rad (USA) 
Galapagos Expert software (ver. 1.1.2.0) VWR International Pty Ltd (England) 
Haemocytometre  Neubauer (Germany)  
Minilys®   Sapphire Bioscience (France) 
NanoDrop 1000 spectrophotometer (ver. 3.6.0) Thermo Scientific (USA)  
Orbital mixer incubator Ratek (Australia) 
Qubit® 2.0 Fluorometer Invitrogen (USA) 
Veriti 96 well thermal cycler Applied Biosystems (Singapore) 
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2.1.5. Kits 
Commercial kits that were used for general methods are listed in Table 2.5. 
Table 2.5. Kits used  
Kits Supplier 
Experion
TM
 Std Sens RNA chips Bio-Rad 
Experion
TM
 RNA Std Sens reagents and supplies Bio-Rad 
Qiagen RNeasy mini kit Qiagen  
Qubit® RNA BR assay kit  Invitrogen  
Qubit® dsDNA HS assay kit  Invitrogen 
UltraClean® Microbial DNA Isolation kit MoBIO Laboratories, Inc. 
 
2.1.6. Yeast strains 
Yeast strains used in this project are listed in Table 2.6. 
Table 2.6. Yeast strains used 
Organism Strain name  Strain origin/source Genotype Comments  
C. gattii R265 Heitman Lab, Duke 
University  
VGIIa 
 
Genome sequenced 
(https://www.broadinstitute.
org/annotation/genome/cryp
tococcus_neoformans_b/Mult
iHome.html) [142] 
 R272 Heitman Lab, Duke 
University 
VGIIb Genome sequenced [143] 
 97/170 Heitman Lab, Duke 
University 
VGII Strain with high level of 
intrinsic FLC resistance [144] 
Sequenced in this study 
C. neoformans KNϵϵα Heitman Lab, Duke 
University 
VNI Genome sequenced 
Heitman Lab (unpublished)  
 H99 Heitman Lab, Duke 
University 
VNI  C. neoformans reference 
genome  
(http://www.broadinstitute.o
rg/annotation/genome/crypt
ococcus_neoformans/MultiHo
me.html)   
 WM148 
(CBS10085) 
Westmead hospital VNI  Genome sequenced 
(https://gold.jgi.doe.gov/proj
ect?id=38230) 
 WM626 
(MMRL 3150) 
(CBS10084) 
Westmead hospital VNII  Genome sequenced 
(https://gold.jgi.doe.gov/proj
ect?id=68032) 
 WM629 
(CBS10079) 
Westmead hospital VNIV  Genome sequenced 
(https://gold.jgi.doe.gov/proj
ect?id=38231) 
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 JECϮϭα Heitman Lab, Duke 
University 
VNIV Genome sequenced [145] 
S. cerevisiae S288C Wilkins Lab, 
University of New 
South Wales 
MATα SUC2 gal2 
mal2 mel flo1 flo8-1 
hap1 ho bio1 bio6 
Reference genome 
(www.yeastgenome.org/)  
Parent strain of BY4741 
 BY4741 Wilkins Lab, 
University of New 
South Wales 
MATa hisϯΔϬ 
leuϮΔϬ ŵetϭϱΔϬ 
uraϯΔϬ 
Daughter strain of S288C. 
Strain used for the Yeast 
deletion project  
C. parapsilosis ATCC 22019 ATCC collection Azole susceptible 
strain 
MIC reference strain 
C. krusei ATCC 6258 ATCC collection Azole resistance 
strain 
MIC reference strain 
 
2.2. General methods 
2.2.1. Growth 
All isolates used were streaked from glycerol stocks that were stored at -80 °C. Each isolate was grown 
on Sabouraud dextrose agar (SDA) and incubated at 30 °C for two days before use. Plated isolates that 
were more than one month old were discarded. 
2.2.2. Glycerol stock storage 
Glycerol stocks of yeast strains and mutants were made for long term storage. Two day old yeast 
cultures were grown on SDA, harvested and mixed with pre-sterilised 15 % glycerol and 0.15 % 
peptone. Stocks were flash frozen in liquid nitrogen and stored at -80 °C until further use.  
2.2.3. Preparation of drug stocks 
Antifungal drugs included amphotericin B (AMB), the azole drugs fluconazole (FLC), voriconazole (VRC) 
and itraconazole (ITC) and the echinocandin caspofungin (CAS). AMB and CAS were made to 1,600 
μg/ŵL in Milli Q water according to the drug͛s potency as outlined in the Clinical Laboratory Standards 
Institute (CLSI) guidelines [146]. FLC was dissolved in methanol (0.02%) and diluted to a stock 
concentration of 5,1ϮϬ μg/ŵL in Milli Q water, while ITC and VRC were dissolved in 100% DMSO to a 
final concentration of 1,600 μg/mL.  
Iron chelators tested were deferiprone (DFP), deferoxamine (DFO), deferasirox (DSX), ciclopirox 
olamine (CPO), EDTA and bovine lactoferrin (LF). DFP and DFO were made to stock concentrations of 
5,120 μg/mL in Milli Q water, while CPO was dissolved in water to 1,280 μg/mL. EDTA was also made 
to 5,120 µg/mL and adjusted to pH 7 by hydrochloric acid. DSX was made in 100 % dimethyl sulfoxide 
(DMSO) to 5,120 µg/mL. All stock solutions were filter sterilised and stored at -20 °C in 5 mL aliquots. 
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CHAPTER 3: Drug combination screening – 
assessing interactions between antifungal 
drugs and iron chelating agents 
 
This chapter begins the study of understanding synergistic drug combinations by establishing the drug 
interactions of commonly used antifungal drugs with a range of iron chelating agents. Two different 
methods of assessing drug interactions were used to find drug synergy.  
 
Chapter 3 of this thesis has been accepted for publication in the International Journal of Antimicrobial 
Agents owned by Elservier. The accepted work is under the following title:  
Yu-Wen Lai, Leona T. Campbell, Marc R. Wilkins, Chi Nam Ignatius Pang, Sharon Chen, Dee A. Carter. 
Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus. (doi: 
10.1016/j.ijantimicag.2016.06.012)  
 
Y. W. L. contributed to the design and data acquisition of the study and the drafting of the manuscript. 
C. N. I. P. contributed to the data acquisition and writing of the manuscript. L. T. C., M. R. W., S. C. and 
D. A. C. contributed to the design and analysis of the study and the drafting of the manuscript.  
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3.1 Introduction  
3.1.1. Combination therapy in fungal diseases 
The practice of combination therapy was introduced in the 1970s to treat cryptococcal meningitis 
[147] and it has been an important therapeutic resource in the treatment of fungal diseases. The use 
of combination therapy against fungi is mostly driven by the lack of effective antifungal drugs, unlike 
most combination therapies in bacterial infections that are implemented to slow drug resistance. A 
majority of antifungal drugs have a broad spectrum of activity and most cases of antifungal resistance 
are intrinsic rather than developing from drug exposure [148]. Combination therapies are commonly 
implemented in situations where infections are hard to treat; either because patients do not respond 
to standard therapy or the causative pathogen is multi-resistant [149].  
Combination therapy is favoured for invasive fungal diseases due to their significant morbidity and 
mortality levels [62, 150]. The search for synergents to increase the efficacy of antifungal drugs has 
seen the use of non-antifungal compounds (reviewed by Lupetti et al. (2003) [151]) with recent efforts 
focused on increasing the susceptibility of FLC with calcineurin and heat shock protein 90 inhibitors 
[152, 153]. Iron chelating agents have been used as salvage therapy for invasive mycoses in 
conjunction with polyenes, azoles and echinocandins with mixed outcomes [154], even though the 
treatment outcome of murine infections using similar drug combinations were favourable [74, 155, 
156].  
3.1.2. Drug interactions and their assessment  
While the basic inhibitory actions of antifungal drugs are known, their effects on fungal cells are 
complex, and predicting how drug combinations interact and affect a cell can be difficult. There are 
various models used for determining drug interactions, of which the most commonly used are Loewe͛s 
model of additivity and the Bliss independence model [157]. Based on the outcome of these analyses, 
drug combinations are commonly characterised into the following four of interaction types [63, 148, 
158]:  
- Additivity, where the effect of the combination is equal to the sum of the effects of each drug 
when used alone.  
- Synergism, when the combined effect of the drugs is significantly greater than their additive 
effect.  
- Indifference, when the combined effect is no greater than that of the more effective agent 
when used alone. 
27 
 
- Antagonism, when the combined effect of drugs is less than that of the more effective agent 
when used alone.  
3.1.2.1. Loewe͛s additivity 
Loewe͛s model of additivity uses the sum of the effects of drug A and drug B when used alone to 
determine their interactions when used in combination. This model assumes that the drugs used 
target the same biological site via the same mechanisms of action [159], and is represented by the 
equation:  = 1 where ai and bi refer to the inhibitory concentrations of drug a and drug b in 
combination and Ai and Bi are the inhibitory concentrations of the drugs by themselves. A value of 1 
indicates an additive drug interaction, while < 1 and > 1 indicate synergy and antagonism, respectively 
[157, 159].  
A widely used drug interaction method that uses this model is the fractional inhibitory concentration 
index (FICI), which is based on an extension of the CSLI microdilution broth susceptibility testing 
protocol used to measure the minimum inhibitory concentration (MIC) of drugs [160]. This assay is 
performed in the style of a checkerboard, in which serial dilutions of two drugs are dispensed 
horizontally and vertically such that different drug concentrations are combined in each well. The 
pattern of growth observed in checkerboard assays can determine the type of drug interaction, as 
Figure 3.1 illustrates.  
 
 
Figure 3.1. Representative patterns of types of drug interactions in a checkerboard assay. Black wells 
represent growth. From Kontoyiannis and Lewis (2004) [147].  
 
Based on Loewe͛s equation of additivity, the FICI for the combination of drugs A and B is FICI = FICA + 
FICB, i.e.,  
FICI =   
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The FICI value obtained for the combination determines the type drug interaction. While an FICI < 1 
and > 1 might be considered synergistic and antagonistic, respectively, the interpretation of 
interactions have varied across different drug combination studies [161]. For clarity, this project will 
follow the FICI definitions of drug interactions proposed by Odds (2003) [162] as follows:  
- FICI > 0.5 – 4: no interaction (either additivity or indifference).  
- FICI ч Ϭ.ϱ: synergy. 
- FICI > 4: antagonism.   
While Loewe͛s additivity is a simple and popular method for testing drug interactions, it has 
disadvantages. The serial dilution of drugs as shown in Figure 3.1 tests exponentially increasing drug 
concentrations, which results in not testing many combinations of drug concentrations between the 
ones tested, especially at higher drug concentrations. Additionally, there is no standard for reading the 
MIC of drug combinations, especially when cidal and static drugs that have different endpoints are 
tested together. These can affect how drug interactions are interpreted and can result in variation 
across different studies [161].  
3.1.2.2. Bliss independence 
The Bliss independence model, also known as the effect multiplication or the fractional product model, 
is based on the statistical probability of two drugs acting independently to affect growth [163]. It 
assumes that the drugs used are mutually non exclusive, meaning their modes of action, and possibly 
their sites of action, differ [159].  
This model looks at the maximal effect of drug A, drug B and the combination of drug A and B with an 
infinite amount of the drugs alone or in combination. The predicted drug effect is expressed as the 
fƌaĐtioŶal pƌoduĐt, usiŶg the eƋuatioŶ ƒAB = ƒAƒB, where ƒA aŶd ƒB are the effects of drug A and drug B, 
respectivelǇ, aŶd has the ǀalue Ϭ < ƒAB < ϭ. The dƌug iŶteƌaĐtioŶ is deteƌŵiŶed ďǇ the eƋuatioŶ ƒAB = ƒA + 
ƒB(1 – ƒA), where synergy is observed when the fractional product is more than the predicted drug 
effect, i.e. > 1, and conversely antagonism is when this is less than the fractional product, i.e. < 0. 
Values between 0 and 1 are considered additive [157, 159, 164].  
A method that uses this model is MacSynergy
TM
 II [165]. MacSynergy
TM
 II (ver 5.1) is analytical software 
program that describes and quantifies drug interactions as a three-dimensional dose response curve. It 
uses the standard deviation of the observed drug effects to determine statistical difference from the 
Bliss independence model [166]. The eƋuatioŶ ƒAB = ƒA + ƒB(1 – ƒA), is represented visually by a flat plane, 
and drug interactions cause synergistic peaks or antagonistic troughs on this plane. These are 
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sigŶifiĐaŶt if theiƌ iŶteƌaĐtioŶ ǀoluŵes aƌe > Ϯϱ μM2% and < -Ϯϱ μM2% for synergy and antagonism, 
respectively, at a 95% confidence interval [167].  
3.1.2. Current antifungal agents and cryptococcosis  
This thesis focuses on a set of antifungal drugs currently that are used to treat cryptococcosis. These 
are discussed below and their structures are shown in Figure 3.2.  
3.1.2.1. Amphotericin B (AMB) 
First discovered in 1953 [168], AMB is considered the gold standard for treatment of mycotic 
infections (Fig. 3.2). It is a polyene class drug produced by Streptomyces nodosus and binds strongly to 
ergosterol [52, 169]. This disrupts the integrity of the cell membrane and it was postulated that it 
caused cell death by creating open channels that allowed the leakage of cellular cytoplasmic contents 
[170]. Recent work, however, has demonstrated that just the binding of ergosterol is sufficient for the 
fungicidal activity of AMB, and that cellular leakage is a secondary mechanism [171].  
Polyene class antifungal drugs have been used in therapy for more than 50 years [170] and the 
development of drug resistance is low [172]. Most incidences of polyene resistance are either intrinsic 
to the fungal species (eg. Aspergillus terreus and Scedosporium prolificans) or arise from cross 
resistance to azoles [172-176]. Although AMB is the drug of choice for mycoses, it is quite toxic and 
there are also issues with patient compliance as its administration requires hospitalisation and 
monitoring of side effects [43]. Combination therapies with AMB in general have been seen to improve 
therapeutic outcome, as detailed below (Sections 3.1.2.2 – 3.1.2.4, 3.1.3.1 – 3.1.3.2 and 3.1.3.6).  
3.1.2.2. 5-Flucytosine (5-FC) 
5-FC (Fig. 3.2) is a fluorinated pyrimidine that was originally synthesised in 1957 as a potential 
anticancer drug. Its antifungal action is due to intracellular conversion to 5-fluorouracil (5-FU), which is 
either incorporated into RNA, thus affecting protein synthesis, or is further metabolised to 5-
fluorodeoxyuridylic acid, which inhibits DNA synthesis [45, 62, 177, 178]. Conversion requires cytosine 
deaminase, an enzyme that occurs only in fungal cells, however, high serum concentrations of 5-FC 
become toxic to the host [179].  
5-FC is used only in combination with other antifungal drugs such as polyenes and azoles, as 
monotherapy readily leads to the acquisition of 5-FC resistance. Resistance can be due to decreased 
uptake of the drug via mutations in cellular transport and uptake systems, or through defects in the 
enzymes that convert 5-FC to 5-FU/5-fluorodeoxyuridylic or incorporate these into nucleic acids [45, 
177].  
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3.1.2.3. Triazoles 
Fluconazole (FLC), voriconazole (VRC) and itraconazole (ITC) are triazoles used widely in the treatment 
of mycotic infections (Fig. 3.2). These compounds inhibit ergosterol biosynthesis by non-competitively 
binding to the haem component of lanosterol 14α-demethylase (Cyp51, encoded by ERG11) in the 
cytochrome P450 enzyme. This blocks the conversion of lanosterol to ergosterol, causing the 
accumulation of toxic sterol intermediates and depleting the membrane of ergosterol, which in turn 
leads to cell leakage and cell cycle arrest [170, 180]. Triazole drugs have different affinities for the 
target protein depending on how they interact with Cyp51 and are generally fungistatic, although ITC 
and VRC may be fungicidal in moulds like Aspergillus, Rhizopus and Fusarium [181-183].  
As triazoles are less toxic than polyenes and are easily administered, they are favoured for prophylaxis 
and the treatment of fungal infections [181]. However, their increased use has seen the development 
of resistance in some fungal pathogens. Resistance mechanisms include overexpression of ERG11, 
mutations in ERG11 that reduces the affinity between the drug and Cyp51, increasing efflux 
mechanisms, altering sterol biosynthesis and changing the structural integrity of the cell membrane 
[170]. All of these mechanisms can also enable cross-resistance to other triazole drugs. 
Heteroresistance can also occur, whereby a resistant subpopulation occurs in an otherwise susceptible 
strain [184]. In Cryptococcus, this appears to be caused by whole or segmented duplications of 
chromosomes, particularly chromosome 1 which contains ERG11 [185].  
FLC is a hydrophilic first generation triazole that was first approved as a treatment for vaginal 
candidiasis in 1994 [39]. It has the best bioavailability of the clinically approved azoles and achieves 
good penetration through the blood-brain barrier [186]. It also produces the least side effects in the 
host, and as such is widely used in treatment and as a prophylactic [39]. However, FLC has limited 
activity against moulds and filamentous fungi [181].  
As FLC is off-patent, inexpensive and well tolerated there is increased interest in combining it with 
other agents to enhance efficacy against Cryptococcus and other fungal pathogens [54, 152, 153]. In 
vitro combinations of FLC and AMB against Cryptococcus strains have shown mixed drug interactions, 
ranging from additive to antagonistic, depending on the strain tested [187, 188]. Theoretically, 
antagonism might be predicted as FLC depletes ergosterol that is required for binding by AMB, 
however, this combination was shown to be as effective as AMB monotherapy in clearing Cryptococcus 
in a murine infection model [188]. Combining FLC with 5-FC has been reported to produce additive and 
synergistic interactions in vitro [189], to reduce meningeal cryptococcal burden in mouse infections 
[190] and to more effectively clear Cryptococcus than FLC monotherapy in clinical trials [191].  
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ITC, like FLC, is a first generation triazole but it is lipophilic. It is used mainly against Aspergillus species, 
and it also exhibits in vivo and in vitro antifungal activity against Candida and Cryptococcus species 
[181]. The bioavailability of this drug varies as its absorption is affected by food, and more than 99% of 
the drug is bound to plasma proteins [192]. Although it can reach infections in tissues, ITC has poor 
penetration through the central nervous system and is for this reason it is not used in the treatment of 
meningeal cryptococcosis [181, 192].  
ITC has been noted to exhibit unfavourable interactions with other drugs [192], however in vitro 
combination with 5-FC has reportedly produced synergism and additivity against C. neoformans [188, 
193]. In a murine model of cryptococcosis, ITC combined with 5-FC did not improve treatment [194]. 
Another study also found ITC and 5-FC did not improve survival in a guinea pig model of 
cryptococcosis, however, this combination was later reported to improve survival in hamsters 
compared to ITC and 5-FC monotherapy [195, 196]. 
VRC is a second-generation azole derived from FLC, and was designed to improve the limitations of FLC 
against mould infections and to have a better pharmacokinetic profile than ITC [180]. It was first 
approved by the FDA in 2002 for the treatment of invasive aspergillosis [180, 186], and has a broad 
spectrum of activity against a range of yeast and mould species, exhibiting fungicidal activity against 
Aspergillus and fungistatic activity against Candida and Cryptococcus species [180, 181, 197].  
VRC has good penetration through the blood-brain barrier and high bioavailability [186, 197]. 
However, its absorption can be reduced by food co-intake and plasma binding [197]. Furthermore, 
bioavailability differs according to the ethnicity of patients due to genetic variability in CYP2C19, which 
is required to metabolise VRC [181, 186]. Careful monitoring of VRC therapy is required as the 
potential for unfavourable drug interactions with various co-administered drugs is high [197].  
VRC combined with AMB has shown to prolong the survival of immune-deficient mice challenged with 
Cryptococcus and to reduce fungal organ burden compared to AMB and VRC monotherapy [198, 199]. 
In a clinical case of HIV-associated cryptococcal meningitis, therapy with VRC combined with AMB and 
interferon gamma was reported to clear the pathogen [200].  
3.1.2.4. Caspofungin (CAS) 
Caspofungin belongs to the class of echinocandins drugs, which target the fungal cell wall (Fig. 3.2). 
This drug is a synthetically modified lipopeptide produced by Glarea lozoyensis. It inhibits 1,3- and 1,6-
D-glucan synthase, resulting in depletion of 1,3-β-D glucans that are responsible for most of the 
structural integrity and robustness of the fungal cell wall. Yeast cells that lack 1,3-β-glucan cease 
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growing, and eventually the cell becomes susceptible to osmotic pressure and lyses [53, 170, 180]. CAS 
also has secondary effects in reducing the ergosterol and lanosterol content of the cell [177].  
CAS and other echinocandins are only active against species that contain 1,3- and 1,6-D-glucans, which 
makes these drugs safe and well tolerated in humans [39]. CAS was approved for the treatment of 
invasive aspergillosis and is active against Candida species, but not against Cryptococcus even though 
the cryptococcal 1,3-β-glucan synthase is susceptible to echinocandins [39, 180, 201]. The intrinsic 
resistance of Cryptococcus to CAS may be due to efflux from the cell, degradation, or difficulty 
accessing the cell wall due to the cryptococcal capsule [53, 170]. Interestingly, combination therapy 
with CAS+FLC, AMB or the calcineurin inhibitor FK506 have produced synergy in vitro and in animals 
for C. neoformans [39, 53, 170]. However, there have been no follow up reports investigating how 
synergy occurs in these combinations.  
 
Figure 3.2. Chemical structures of AMB, FLC, CAS, ITC and VRC. From Vermes et al. (2000), Letscher-
Bru and Herbrecht (2003), and Carillo-Munoz et al. (2006) [45, 53, 178]. 
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3.1.3. Iron chelating agents  
In order to investigate how iron chelation affects antifungal activity a variety of synthetic and natural 
chelators as well as clinically used agents were selected for use. These are described below and a 
summary is presented in Table 3.1. 
3.1.3.1. Ethylenediaminetetraacetic acid (EDTA) 
EDTA is a substituted diamine compound that chelates divalent and trivalent heavy metal ions. It is 
widely used in many commercial products as a preservative and stabiliser in cosmetics, 
pharmaceuticals and cleaning agents. Some food products contain trace amounts of EDTA as an 
antioxidant to prevent spoilage [202, 203]. In the clinical setting, EDTA is used for the treatment of 
toxic heavy metal poisoning such as Pb
2+
 and Hg
2+
 [202]. It has also found use in the treatment of 
cardiovascular disease by chelating Ca
2+
 that causes atherosclerotic plaques, as well as chelating 
Fe
2+
/Fe
3+
 and Cu
2+
 to prevent free radical generation and lipid peroxidation [204, 205].  
EDTA complexes with metal ions in a one-to-one molar ratio, where its affinity to ferric iron (Fe
3+
) is 
the strongest [202, 206], followed by Pb
2+
, Cu
2+
, Zn
2+
, Co
2+
, Fe
2+
, Ca
2+
 and Na
2+
. It is only able to bind to 
free ferric iron and cannot extract the bound form from metallo-enzymes and other metal-containing 
proteins [206]. The side effects of EDTA are minimal and reversible, however reported ailments can 
include gastrointestinal upsets and musculoskeletal complaints, fever, leukopenia, thrombocytopenia, 
kidney damage, mineral depletion and hypocalcaemia [202, 204].  
EDTA has a broad spectrum of activity against microorganisms by binding to essential trace elements 
required for cell growth and repair [207-210]. Studies have reported activity against a variety of gram 
negative bacteria, Streptococcus species, Aspergillus niger, Candida albicans and tobacco rattle virus 
[203, 210-213]. However, EDTA is more commonly used as a ͚potentiator͛ of other antimicrobial agents 
as it can increase the effect of the agent by helping it gain access to the target cell [203, 207, 214, 215]. 
This activity has been investigated on biofilms in a variety of organisms including Staphylococcus, 
Pseudomonas and Candida [215, 216]. In Candida, EDTA was shown to impair the ability to form 
filaments, which is a prerequisite for creating biofilms [217].  
Other investigations on the potentiating effect of EDTA in fungi include its use as adjunctive therapy 
with liposomal AMB in a rodent model of invasive pulmonary aspergillosis where it improved the 
survival rate of rats compared to monotherapy [208]. It has also been reported to act synergistically 
with chitosan in killing Candida species [209].  
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3.1.3.2. Lactoferrin (LF)  
LF is a glycoprotein and a member of the transferrin family of iron-binding proteins. It is part of the 
mammalian innate immune response and is found mainly in mucosal secretions and in the secondary 
granules of neutrophils [218]. Each LF protein binds two ferric ions with high affinity. However, LF can 
also bind to other essential metal ions including cobalt, copper, zinc and aluminium, as well as non 
metal ions such as caboxylates, DNA, heparin, lipopolysaccharides and glycosaminoglycans [219]. LF is 
multifunctional, with immuno-modulatory, anti-inflammatory and antimicrobial properties [220].  
The spectrum of activity of LF is quite broad, inhibiting bacteria, viruses, yeasts and fungi, as well as 
protozoa [221]. LF can inhibit growth in some organisms by chelating iron and has shown to stop 
hyphal formation in Candida and Aspergillus [222, 223]. Both iron free (apo-lactoferrin) and iron 
saturated LF (hololactoferrin) have been shown to inhibit bacterial growth, with iron free LF exhibiting 
greater bacterial inhibition [224]. In yeast, however, only iron free LF has antifungal activity [225, 226]. 
Isolated LF peptides have been found to exert antimicrobial activity on the cell surface, with 
membrane interactions reported in bacteria, and effects on the cell wall in yeasts [227-230]. 
LF has been used in conjunction with antimicrobial drugs to eradicate biofilms formed by 
Pseudomonas aeruginosa and to treat keratitis associated with fungal pathogens [231, 232]. 
Combination therapies with LF have also been reported, with synergy with penicillin in the treatment 
of drug resistant microorganisms like multi-resistant Staphylococcus aureus [233]. In yeasts and fungi, 
synergistic combinations of LF with AMB and azoles have been reported [9, 234, 235]. No toxicity or 
side effects have been seen in the use of LF in humans and animals [236]; indeed LF is used to prevent 
bacterial sepsis in pre-term neonates [237]. 
3.1.3.3. Ciclopirox Olamine (CPO) 
Ciclopirox olamine is a hydropryidone derivative that has been used for three decades in the 
treatment of superficial and vaginal mycoses [238, 239]. It has a broad spectrum of activity that is not 
limited to the fungal kingdom, with activity against a range of gram positive and negative bacteria and 
Mycoplasma, and has been shown to be active against FLC-resistant strains of yeast [135, 240]. There 
have been suggestions of repurposing this drug as an antibiotic for drug resistant bacteria [241]. 
Pharmacological studies have shown CPO is non-toxic in animals and humans when orally 
administered [239].  
Susceptibility to CPO comes from its high binding affinity for trivalent metal ions, where the 
supplementation of Fe
3+
 ions to culture media reverses the inhibitory effect in a dose-dependent 
manner [242-244]. Studies of gene expression in C. albicans exposed to CPO reported an up-regulation 
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of genes involved in iron sequestration, transport and uptake, which are typical cellular responses to 
iron-limited conditions [135, 242, 243]. CPO has been found to be more active under aerobic 
conditions [243, 245].  
Studies investigating antifungal combination therapies with CPO have found synergy in vitro with 
ketaconazole against Aspergillus, and synergy with ITC and terbinafine against non-dermatophyte 
moulds including Scopulariopsis, Aspergillus, Onychocola, Scytalidium and Fusarium [9, 246].  
3.1.3.4. Deferoxamine (DFO) 
Deferoxamine, also known as deferrioxamine, has been used since the 1960s to relieve iron overload 
in haematological diseases such as beta thalassemia [247]. DFO is a bacterial siderophore produced by 
Streptomyces pilosus and it chelates iron ions in a 1:1 molar ratio [248]. DFO has a high affinity for iron 
but due to its molecular size and its hydrophilic properties, it is not able to readily penetrate cell 
membranes to chelate cytosolic iron [244, 248-250]. It is able to strip extracellular iron from ferritin 
and haemosiderin, but not from transferrin and lactoferrin [249-251]. Deferoxamine also binds Cu
2+
, 
Al
2+
, Mg
2+
, Ca
2+
 and Mn
2+
, but at a lower affinity than iron [252].  
DFO is antimicrobial against a range of bacteria including Staphylococcus, Neiserria and Proteus, and 
also has been reported to increase the rate of clearance of Plasmodium falciparum from patients with 
asymptomatic malaria [253-256]. DFO has antifungal activity against Pneumocystis but not other 
fungal species [257].  
The side effects from the administration of DFO involve auditory, ocular and neurological toxicity as 
well as musculoskeletal abnormalities [249, 258]. However, a major complication is the utilisation of 
DFO as a xenosiderophore, where it can provide iron to microbial pathogens and promote survival and 
infection in the host. Studies aimed at testing the inhibitory activity of DFO in fungi found that it could 
instead enhance Aspergillus and Rhizopus growth [9, 259].  
3.1.3.5. Deferiprone (DFP)  
Another iron chelating drug introduced in the 1990s, DFP is a synthetic oral bidentate chelator, where 
three molecules of DFP bind to one iron ion [260]. It is a favourable alternative to DFO in the 
treatment of iron overload diseases as it has better patient compliance due to less severe side effects 
(including zinc deficiency, joint and muscle pains and gastrointestinal upsets) that are reversible [247, 
261]. However, agranunolcytosis and neutropenia have been observed in some patients [247, 249, 
258, 262].  
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DFP is more lipophilic than DFO and is able to penetrate most tissues including the skin, lungs and the 
brain [249, 263]. In addition to being able to chelate intracellular iron, DFP can sequester ferric iron 
from haemosiderin, ferritin, transferrin and lactoferrin [264]. Compared to DFO, DFP has a lower 
affinity for Fe
3+
 ions and is less effective at lower concentrations as it has a tendency to dissociate from 
iron; however it is able to shuttle iron from transferrin to DFO molecules [252, 265]. DFP can also bind 
to other metal ions, with affinities after iron in the order of Cu
2+
>Al
2+
>Zn
2+
 at pH 7.4 [266]. Most 
importantly, DFP cannot be used as a xenosiderosphore. On iron poor media, proliferation of Yersinia 
enterolitica and staphylococcal growth occurred around a gradient disk of DFO but this was not seen 
around a disk of DFP [255, 267].  
DFP is active against a range of gram negative and positive bacteria, such as P. aeruginosa, Escherichia 
coli, Y. enterocolitica, Salmonella typhimurium and S. aureus. It also has anti-protozoan activity against 
Leishmania promastigotes and P. falciparum [268]. Aspergillus, Rhizopus and Candida are susceptible 
to DFP [9, 155, 269], and combination with ketaconazole or FLC was found to be synergistic against 
Aspergillus [9]. 
3.1.3.6. Deferasirox (DSX)  
Deferasirox is the most recently FDA-approved iron chelating agent. It is a tridentate oral iron chelator, 
with two molecules of DSX binding to one ferric ion [247, 260]. It belongs to the class of 
bishydroxyphenyltriazole chelators, and its binding affinity for iron compared with DFO and DFP is 
DFO>DSX>DFP [262, 263]. As with DFP, DSX does not act as a xenosiderophore and does not 
predispose patients to mucormycosis or yersiniosis. Side effects are reversible and mostly involve 
stomach upsets, skin rash and headaches [247, 261-263, 270]. Bacterial species Vibrio, KIebsiella and 
Aeromonas [270, 271], and a range of fungal species including Rhizopus, Mucor, Aspergillus, 
Cunninghamella and Pythium have been reported to be susceptible to DFP [73, 74, 272, 273], however 
it has no effect against Fusarium and Scedosporium [274]. 
There have been proposals to use DSX as an adjunctive therapy for invasive fungal infections [268], 
however results to date have been mixed. In vivo studies demonstrated DSX monotherapy prolonged 
the survival of diabetic mice with mucormycosis, and when combined with lipid AMB produced a 
higher rate of survival and lower fungal burden compared to AMB monotherapy or placebo treatment 
[73, 74, 156]. In addition, in two separate reports treating mostly diabetic patients with mucormycosis, 
the use of DSX combined with antifungal drugs cured the majority from fungal disease [57, 154]. 
However, a randomised, double blinded placebo controlled trial found patients on DSX combined with 
liposomal AMB had a higher mortality rate than those on liposomal AMB alone or the placebo [275]. 
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An additional case study involving a leukemic woman on triple antifungal therapy for zygomycosis 
reported the failure of DSX to resolve infection [58]. It is interesting to note that the studies detailing 
the successful use of DSX against mucormycosal infections involved subjects that were predisposed to 
some form of diabetic ailment, and Spellberg et al. (2012) proposed that the efficacy of DSX therapy 
may be related to the type of underlying disorder that made patients susceptible to murcomycosis 
[275].  
3.1.4. Aims and hypotheses of this chapter 
The overall aim of this thesis is to understand the mechanistic basis of synergy between antifungal 
drugs and iron chelating agents and to use this to discover and develop new antifungal therapies. Iron 
is an important trace element and many studies that disrupt iron homeostasis in Cryptococcus have 
shown its requirement for virulence and pathogenicity. Iron chelation has an antifungal effect and 
synergistic antifungal-chelator combinations have been observed in vitro in A. fumigatus, C. glabrata 
and C. albicans. Combinations of antifungal drugs and iron chelators have also been used as salvage 
therapy for the treatment of mucormycoses. However, MIC studies of iron chelating agents and their 
interaction with antifungal drugs have not been thoroughly explored in Cryptococcus. Given that iron is 
important and iron chelators have found to synergise with antifungals in other organisms, it was 
hypothesised that synergistic combinations of antifungal drugs and iron chelators would be found in 
Cryptococcus.  
As a range of interactions between antifungal drugs and iron chelators have been reported, this 
chapter aims to characterise the interactions between these agents in Cryptococcus and S. cerevisiae, 
with the latter included to facilitate subsequent transcriptome analysis. Iron chelators were selected to 
encompass a range of binding types and affinities, and were tested against the antifungals most 
commonly employed to treat cryptococcosis. It was hypothesised that various combinations would 
result in synergy, and that these could be used in transcriptome studies to identify common pathways 
and processes that could be targeted for disruption by new antifungal therapies.  
The aims specific to this chapter were therefore:  
1. To determine the susceptibility of a range of Cryptococcus strains and S. cerevisiae to 
antifungal agents AMB, CAS, FLC, ITC and VRC and iron chelating agents CPO, DFO, DFP, DXS, 
LF and EDTA by CLSI microdilution assay.  
2. To characterise pairwise combinations of the antifungals and iron chelators by checkerboard 
assay, FICI and MacSynergy
TM
 II, and find synergistic interactions for downstream 
transcriptome analyses.  
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Table 3.1. Structure, function, clinical use and reported antifungal activity of the iron chelating agents used in this study   
Iron chelator Structure Compound type and 
chelation 
Postulated mode of 
antifungal action 
Uses Observed Antifungal activity 
Lactoferrin 
(bovine) (LF) 
[221] 
 Iron binding 
glycoprotein  
 1 LF: 2 iron chelation 
[219] 
 Multifunctional 
protein with 
antimicrobial 
activity[220, 276] 
 Binds to cell surface 
and cell membrane 
[228, 277-279] 
 Given to neonates to 
prevent pre-term 
neonatal septic death 
[237, 280] 
 Synergistic against Aspergillus and 
Candida with antifungal drugs [72, 
222, 234, 235] 
 Biofilm disruptor [231, 232] 
 Antifungal activity against 
Aspergillus, Trichoderma, Sclerotinia, 
Sclerotium, Rhizotonia and Phoma, 
Cryptococcus, Dekkera, Pichia, 
Saccharomyces, Zygosaccharomyces 
species [225, 278, 281] 
EDTA  
 
 Substituted diamine  
 1:1 chelation with iron  
[202]  
 
 
 Divalent and trivalent 
metal ion chelator 
with high affinity for 
ferric iron [202] 
 Potentiator of other 
antimicrobial agents 
[203, 207, 214, 215] 
 Cosmetic preservative 
[202] 
 Toxic heavy metal 
chelation therapy [282] 
 Cardiovascular disease 
therapy [205] 
 Adjunct therapy for 
murine aspergillosis 
[208] 
 Disrupting agent against Candida and 
Cryptococcus biofilms [217, 283]  
 Antifungal activity against 
Saccharomyces, Candida and 
Aspergillus [203, 207, 210] 
 Synergistic with polyenes against 
Aspergillus [284], with polygodial on 
Saccharomcyes.  [207] Additive with 
chitosan against Candida [209] 
Ciclopirox 
olamine (CPO) 
 
[285] 
 Hydropyridone 
derivative [240] 
 3 CPO : 1 iron 
chelation [286] 
 Intracellular iron 
chelation  
 Binds to cell wall, 
membrane and 
organelles and inhibits 
function [244, 287]  
 Topical treatment of 
genital and superficial 
mycoses [238, 240, 288, 
289] 
 Suggestions of 
repurposing for 
antimicrobial and cancer 
therapy [241, 290] 
 Antifungal activity against 
Cryptococcus, Trichophyton, 
Microsporum, Epidermophyton, 
Candida, Malassezia [291, 292] 
 Combination with ketaconazole 
synergistic in Aspergillus [9] 
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Deferiprone 
(DFP) 
[263] 
 Α-ketohydroxy-
pyridine  [266] 
 3 DFP : 1 iron chelation 
[247] 
 Iron chelation  [155]  Clinical treatment of 
iron overload diseases  
[258] 
 Antifungal activity against 
Aspergillus, Rhizopus and Candida [9, 
155, 269] 
 Synergistic against Aspergillus with 
FLC  [9] 
 Synergistic against Cryptococcus with 
FLC [293] 
Deferasirox 
(DSX) 
 
[263] 
 Bishydroxy-
phenyltriazole [262] 
 2 DSX : 1 iron chelation 
[247] 
 Iron chelation [73, 
272] 
 
 Clinical treatment of 
iron overload diseases 
[258] 
 Adjunctive/salvage 
therapy against 
mucormycosis [57, 154, 
268] 
 Antifungal activity against Rhizopus, 
Mucor, Aspergillus, Cunninghamella 
and Pythium [73, 74, 272, 273] 
 Enhanced murine clearance of 
aspergillosis with liposomal AMB [74] 
 No activity against Fusarium and 
Scedosporium [274] 
Deferoxamine 
(DFO) 
 
[263] 
 Siderophore from 
Streptomyces pilosus   
 1:1 chelation with iron 
[248] 
 Intracellular iron 
chelation in 
Pneumocystis carinii 
[257] 
 Clinical treatment of 
iron overload diseases 
[258] 
 Promotes growth Aspergillus, 
Rhizopus, Cryptococcus and 
Saccharomyces [9, 155, 294-296] 
 Clearance of Pneumocystis  carinii 
infection in rats [257] 
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3.2. Materials and Methods  
3.2.1. Strains and growth media 
Strains with fully sequenced and annotated genes were used for initial MIC and checkerboard 
studies as these could be used in downstream studies to characterise the cellular response to 
synergistic combainations. These included C. neoformans KNϵϵα (molecular genotype VNI), C. gattii 
strains R265 (VGIIa), R272 (VGIIb), and strain 97/170 (VGII) which has an intrinsically high MIC to 
fluconazole (MIC 64 µg/mL [144]) and has been sequenced in our laboratory (unpublished), and S. 
cerevisiae reference strain S288C. Subsequent testing of drug-chelator pairs of interest were done 
on strains from major molecular genotypes in C. neoformans and included H99 and WM148 (C. 
neoformans var. grubii VNI), WM626 (C. neoformans var. grubii VNIIͿ, aŶd WMϲϮϵ aŶd JECϮϭα ;C. 
neoformans var. neoformans VNIV). Candida krusei (ATCC 6248) and C. parapsilosis (ATCC 22019) 
were quality control strains for in vitro susceptibility assays (Table 2.6). 
Cryptococcus strains were grown in yeast nitrogen broth (YNB; Becton, Dickinson and Company) 
buffered with 0.165 M MOPS (Sigma-Aldrich, Australia) and supplemented with 0.5% (W/V) D-
glucose. RPMI-1640 media (InVitro; Australia) buffered with 0.165 M MOPS supplemented with 
0.03% (W/V) L-glutamine and 2% (W/V) D-glucose was used as a growth medium for Candida and 
Saccharomyces as specified in the CLSI standards [146]. All media were adjusted to pH 7.0 and filter 
sterilised.  
3.2.2. Iron chelating agents and antifungal drugs  
Five different iron chelators were tested: EDTA, deferoxamine (DFO), deferiprone (DFP), ciclopirox 
olamine (CPO; all from Sigma-Aldrich, Australia) bovine lactoferrin (LF; MP Biomedical, Australia) and 
deferasirox (DSX; Novartis Pharma AG). Details of these, including their molecular structure, 
approval and current use are supplied in Table 3.1. Antifungal agents included amphotericin B 
(AMB), the azole drugs fluconazole (FLC), itraconazole (ITC), voriconazole (VRC) (Sigma-Aldrich, 
Australia) and caspofungin (CAS; Merck Research Laboratories). 
3.2.3. Minimum inhibitory concentration (MIC) testing by microdilution assay  
All MIC testing was performed according to the Clinical and Laboratory Standards Institute (CSLI) 
M27-A3 protocol for drug testing in yeasts [146]. All strains were subcultured onto Sabouraud 
dextrose agar (SDA) at 30 °C for 48 h prior to testing. Cells were standardised to a concentration of 1 
– 5 x 106 cells/mL with a haemocytometer before diluting  1:1000 in the appropriate medium to 
yield a final concentration of 0.5 – 2.5 x 103 cells/mL.  
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Following preliminary analyses, iron chelators were assayed using concentrations from 0.5 – 256 
µg/mL for EDTA, DFP, DFO, DSX and LF, and 0.03 – 32 µg/mL for CPO. Antifungals were assayed from 
0.015 – 16 µg/mL for AMB and CAS, 0.125 – 256 µg/mL for FLC and 0.008 – 16 µg/mL for ITC and 
VRC. A positive (no drug) growth control and negative (sterility) control were included in each test. 
Plates were incubated at 37 °C for 48 h for Saccharomyces and Candida control strains and for 72 h 
for Cryptococcus strains. The MICs for the fungicidal drugs AMB and CPO were read as the lowest 
drug concentration that inhibited 100% of growth. MICs for the remaining fungistatic drugs were 
read at the lowest concentration showing 80% inhibition of growth compared to the positive growth 
control. Based on preliminary MIC tests with EDTA and the study done by Kobayashi et al. (2011) for 
LF [72], EDTA and LF were read at 50% inhibition.  
The concentration and purity of the cell inocula were checked by back-plating onto SDA with 
iŶĐuďatioŶ at ϯϳ˚C foƌ ϰϴ to ϳϮ h. All assaǇs were tested in duplicate with each drug in a single 
experiment. At least two biological replicates were done on different days. All assays included the 
two Candida reference strains.  
3.2.4. Synergy testing by checkerboard assay 
Checkerboard assays were performed according to the CLSI checkerboard protocol [160]. 
Concentrations of antifungal drugs and iron chelating agents were selected to encompass the MICs 
determined for each strain, with the highest drug concentration beginning at 4x the MIC. Serial 2-
fold dilutions of the drug and chelating agent were made horizontally and vertically, respectively, in 
96 well microtitre plates. Fifty microlitres of each drug and chelator were aliquoted into the 
appropriate microtitre wells. Inoculations, incubation conditions, assay readings and back plating 
were performed as outlined above, according to the CLSI M27-A3 protocol [146]. Positive growth 
controls and negative sterility controls were included. At least two independent assays were 
performed for each yeast strain. Inhibition was read visually, and cell density was assessed by 
spectrometer for MacSynergy
TM 
II analysis [167]. 
3.2.5. Assessment of interactions by fractional inhibitory concentration index (FICI) and 
MacSynergy
TM 
II 
The fractional inhibitory concentration index (FICI) was calculated as FICI = FICA + FICB, where FIC = 
MIC of drug in combination/MIC dƌug aloŶe. FICI ǀalues of ч Ϭ.ϱ aƌe defiŶed as sǇŶeƌgistiĐ, > Ϭ.ϱ – 4 
are indifferent, and > 4 is considered antagonistic [162].  
MacSynergy
TM
II uses the Bliss independence algorithm to calculate synergy, which is defined by the 
equation ƒAB = ƒA + ƒB(1 – ƒA) where ƒAB is the additive effect of drugs A and B as predicted by their 
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individual effects (ƒA and ƒB) [167]. MacSynergyTMII is modelled in Excel and generates a three 
dimensional response curve of the synergy-antagonism landscape by representing the predicted 
indifferent effect as a flat plane. Peaks and troughs represent synergy and antagonism, and are 
significant if their interaction volumes are > Ϯϱ μM2% (log volume >2) or < -Ϯϱ μM2% (log volume <2), 
respectively, at a confidence interval of 95% [164, 165, 167].  
3.2.6. Iron rescue assays 
Iron rescue assays were performed to determine whether inhibition or synergy with AMB caused by 
LF was predominantly due to iron chelation.  Iron (III) chloride (Sigma-Aldrich, Australia) and iron (II) 
sulphate (Fisson, United Kingdom) were made to stock concentrations of 5,120 µg/mL in MilliQ 
water and filter sterilised. In brief, cultures of C. neoformans H99 and S. cerevisiae S288C were 
prepared as for MIC testing and 100 µL was dispensed into the test wells of a 96-well microtitre 
plate. AMB+LF was prepared at 4x the  concentration found to cause maximum synergy (defined as 
FIC = 0.06 µg/mL AMB + 2 µg/mL LF for Cryptococcus, and 0.03 µg/mL AMB + 2 µg/mL LF for 
Saccharomyces) and 50 µL was dispensed across separate rows of the microtitre plate. Additional 
rows included AMB alone at the FIC concentration (= 0.06 µg/mL for Cryptococcus and 0.03 µg/mL 
for Saccharomyces), LF alone at its MIC (as there is no inhibition at the LF FIC; = 64 µg/mL for 
Cryptococcus and 16 µg/mL for Saccharomyces). Growth (no antifungal agents) and sterility (no 
yeast) controls were also included. Fifty microlitres of iron (III) chloride solutions were added to the 
wells to give a final concentration of 2, 4, 6, 8 or 10 µg/mL across each row, and the process was 
repeated in a second plate for iron (II) sulphate. Incubation conditions and back plating were 
performed according to the CLSI M27-A3 protocol [146]. All tests were performed in triplicate on 
separate days. The effect of iron supplementation was assessed visually and by measuring the 
optical density at 560 nm with a spectrophotometer. 
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3.3. Results 
3.3.1. MICs of antifungal drugs and iron chelating agents 
The mode and range of MIC values for antifungal and iron chelators studied are shown in Table 3.2. 
All Cryptococcus strains were susceptible to AMB and the azole drugs according to Cryptococcus 
epidemiological cut off values (ECVs) but had CAS MICs of ш Ϯ µg/ŵL ;ƌaŶge ϭ–4 µg/mL) [30, 297, 
298]. S. cerevisiae strain S288C had low MICs for all drugs except ITC where the MIC was 2 (range 2–
4 µg/mL).  
Among the iron chelating agents, CPO had the greatest activity against Cryptococcus (MIC range 0.5–
2 µg/mL), followed by DSX (range 2–8 µg/mL), DFP (range 4–64 µg/mL), LF (32–64 µg/mL) and EDTA 
(64–128 µg/mL). For S. cerevisiae, CPO was most potent (1 µg/mL), followed by DSX (4 µg/mL), EDTA 
and LF (16 µg/mL) and DFP (64 µg/mL). DFO had no effect on any of the strains, even when the drug 
concentration was increased to 2,084 µg/mL (data not shown), and was therefore excluded from 
further testing.  
3.3.2. Assessment of drug-chelator interactions by FICI 
Antifungal drugs and iron chelators that produced achievable MICs were further tested in 
combination by checkerboard assay with each of the five initial test strains. The resulting FICI values 
for each combination are shown in Figure 3.3a (top row), with the data listed in Appendix 3.1. The 
combination of AMB and LF was synergistic across all of the five initial strains (FICI ч Ϭ.ϱͿ, aŶd this 
remained consistent when extended to the additional set of Cryptococcus strains (Fig. 3.3a bottom 
row). Most of the remaining drug-chelator combinations were indifferent, with FICI medians from 
0.53 – 3.25 (Appendix 3.1).  
Chelating agents EDTA, DFP and DSX demonstrated antagonism in vitro with ITC and VRC against C. 
neoformans stƌaiŶ KNϵϵα ;FICI > ϰ; Fig. ϯ.ϯa, top ƌoǁͿ ďut these ĐoŵďiŶatioŶs ǁeƌe iŶdiffeƌeŶt foƌ S. 
cerevisiae strain S288C and for the C. gattii strains. Testing of additional C. neoformans strains found 
antagonism for all C. neoformans var. grubii (VNI and VNII) strains, and this extended to FLC in some 
cases (Fig. 3.3a bottom row; Appendix 3.1), but this was not seen for C. neoformans var. neoformans 
(VNIV) strains JECϮϭα aŶd WMϲϮϵ, ǁheƌe interactions were indifferent. The MIC for VRC was 
consistently raised 4-fold when combined with EDTA, DFP and DSX for C. neoformans var. grubii, 
while for ITC and FLC interactions were strain-specific; for example in C. neoformans var. grubii VNI 
strain KNϵϵα the ĐoŵďiŶatioŶ of ITC+DFP gave an FICI value of 4.25 (antagonistic), while for the C. 
neoformans var. grubii VNI strain WM148 this was 1.25 (indifferent).  
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Table 3.2. MIC values for antifungal drugs and iron chelating agents: Mode (range) in µg/mL  
Fungal species, 
strain and 
genotype 
Antifungal Agent MIC (Range) 
 
Iron Chelator MIC (Range) 
AMB FLC VRC ITC CAS 
 
LF EDTA DFP DSX DFO CFO 
C. neoformans var. grubii 
   H99 (VNI) 0.25 2 0.007 0.03 4  
32 64 8 2 ND 1 
 
(0.25–0.5) (1-2) (0.0035-0.007) (0.015-0.06) (2-4) 
 
(16-64) (64-128) (2-8) (1-4) 
 
(1) 
   KNϵϵα ;VNIͿ 0.5 0.25 0.0035 0.015 2  64 64 16 4 >256 2 
 
(0.5-1) (0.25-0.5) (0.0035) (0.015-0.03) (2-4) 
 
(64-128) (64-128) (8-16) (4-32) 
 
(1-2) 
   WM148 (VNI) 0.5 4 0.03 0.25 2  
64 64 8 8 ND 1 
 
(0.25-1) (4) (0.015-0.03) (0.06-0.25) (2-4) 
 
(16-64) (64) (2-16) (2-16) 
 
(1) 
  WM626 (VNII) 0.5 4 0.03 0.125 2  
64 64 8 4 ND 1 
 
(0.25-1) (4) (0.015-0.06) (0.06-0.5) (2-4) 
 
(16-64) (32-64) (2-16) (2-16) 
 
(1) 
C. neoformans var. neoformans 
   WM629 (VNIV) 0.25 1 0.015 0.03 2  
64 128 4 4 ND 1 
 
(0.125-0.5) (1) (0.007-0.015) (0.03-0.06) (2-4) 
 
(16-64) (64-128) (1-8) (1-4) 
 
(1) 
   JECϮϭα ;VNIVͿ 0.25 0.5 0.007 0.03 2  64 64 8 2 ND 0.5 
 
(0.125-0.25) (0.5) (0.007) (0.007-0.06) (1-2) 
 
(16-64) (64-128) (1-16) (1-4) 
 
(0.25-1) 
C. gattii 
   R265 (VGIIa) 0.5 2 0.06 0.125 4  
64 128 32 4 >256 2 
 
(0.25-1) (1-4) (0.03-0.06) (0.125-0.25) (4) 
 
(64-128) (128-256) (8-32) (2-32) 
 
(1-2) 
   R272 (VGIIb) 0.5 2 0.06 0.06 4  
64 128 8 2 >256 1 
 
(0.25-1) (1-4) (0.06-0.125) (0.03-0.125) (2-4) 
 
(32-128) (128-256) (4-32) (2-4) 
 
(1-2) 
   97/170 (VGII) 0.5 64 0.5 0.5 4  
64 128 4 4 >256 1 
 
(0.25-1) (32-64) (0.5) (0.25-1) (2-4) 
 
(32-64) (128-256) (4-32) (1-8) 
 
(1-2) 
S. cerevisiae 
   S288C 0.125 4 0.125 2 0.06  
16 16 64 4 >256 1 
 
(0.06-0.25) (4) (0.125) (2-4) (0.06-0.125) 
 
(16-32) (8-32) (64-128) (1-8) 
 
(0.5-1) 
ND = not done 
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3.3.3. MacSynergy
TM 
II drug response curves 
Selected drug combinations were analysed in MacSynergy
TM 
II to visually analyse the dose-response 
surface of the antifungal-chelator interactions. Figure 3.3b shows a representative three dimensional 
drug response plot for C. neoformans straiŶ KNϵϵα ǁheŶ tƌeated ǁith AMB+LF. A sǇŶeƌgistiĐ ƌespoŶse is 
seen across a range of AMB+LF combinations, with a peak at 0.25 µg/mL AMB and 8 µg/mL LF, and a 
highly significant synergy volume of 902.22 µM
2
%. 
MacSynergy
TM 
II was also used to investigate the aŶtagoŶistiĐ iŶteƌaĐtioŶ seeŶ ǁheŶ KNϵϵα ǁas tƌeated 
with VRC+EDTA. Figure 3.3b shows this dose response curve, where there are clear troughs below the 
plane of additivity at concentrations of 0.0035 VRC + 16 µg/mL EDTA and 0.0018 VRC + 8 µg/mL EDTA. 
The overall antagonism volume was -32.76 µM
2
%, which is considered ͞significant but minor͟ based on 
the MacSynergy
TM 
II User Manual [167]. 
3.3.4. Fold-change in MIC for antifungals and iron chelators in combination 
The nature of the FICI calculation means both agents must reduce their MIC by at least 4-fold to produce 
aŶ FICI ч Ϭ.ϱ. However, as our main concern is with reducing the MIC of the antifungal agent rather than 
the chelator, we assessed fold changes for each antifungal across all drug-chelator combinations (Fig. 
3.3c; Appendix 3.1). The MICs for AMB in the presence of LF decreased at least 4-fold for all fungal 
strains, and the other chelators decreased the AMB MIC 2-fold for most strains. There was a substantial 
(8–32 fold) reduction in the MIC of LF in the presence of AMB, which was not seen when it was used in 
combination with other antifungal drugs. A number of combinations produced a 4-fold or greater 
reduction in the MIC for the antifungal agent, but as there was only small reduction in the MIC of the 
chelator these did Ŷot aĐhieǀe aŶ FICI of ч Ϭ.ϱ, however, these were strain-specific and no additional 
combinations that consistently reduced the MIC of the antifungal partner were revealed. The majority of 
the antagonistic combinations increased the MIC for the antifungal agent 4-fold. Most chelators 
increased in efficacy in the presence of antifungal agents, however, these changes were generally quite 
modest; the AMB+LF combination being an exception. 
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Figure 3.3. Interactions between antifungal drugs and iron chelators. (a) FICI values for antifungal agents 
combined with iron chelators. Top row: Combinations tested in an initial set of C. neoformans, C. gattii 
and S. cereviseae isolates; Bottom row: Selected drug-chelator combinations tested in an extended set 
of C. neoformans isolates. AMB+LF is ĐoŶsisteŶtlǇ sǇŶeƌgistiĐ ;FICI ч Ϭ.ϱͿ foƌ all isolates. IŶ ĐoŶtƌast, soŵe 
chelators are antagonist to the action of the azole drugs FLC, ITC and VRC for C. neoformans var. grubii 
strains (FICI > 4). (b) MacSynergy
TM 
II plots showing 3-dimensional dose response curves for C. 
neoformans strain H99 treated with AMB+LF (left) and VRC+EDTA (Right). (c) Fold change in MIC for 
antifungals in the presence of iron chelators (blue dots) and for iron chelators in the presence of 
antifungals (orange dots). 
(a) 
(b) 
(c) 
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3.3.5. Iron supplementation rescues AMB+LF synergy  
To assess the contribution of iron chelation to AMB+LF synergy, inhibitory concentrations of AMB, LF 
and AMB+LF were tested on Cryptococcus and Saccharomyces in the presence of increasing 
concentrations of iron (III) (FeCl3) and iron (II) (FeSO4) (Fig. 3.4). Iron addition in either form fully 
restored growth in the LF-treated wells but did not rescue growth in cultures treated with the FIC 
concentration of AMB+LF to that of cultures treated with the FIC of AMB alone. This indicates that 
synergy is not due primarily to the ability of LF to chelate iron, and may instead be due to other 
antifungal properties of the LF protein, which are significantly enhanced by the presence of AMB.  
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Figure 3.4. Iron rescue assays indicate synergy is not principally due to iron chelation in S. cerevisiae 
S288C and C. neoformans H99. The addition of exogenous ferric (Fe(III)) iron in (a) and (c) and 
ferrous (Fe (II)) iron in (b) and (d) completely rescued cells from MIC levels of LF but was unable to 
restore growth in the presence of AMB+LF to the level produced in the presence of AMB alone. LF 
(inverted green triangles) was tested at the MIC level; AMB alone (red squares) and AMB+LF (orange 
triangles) were tested at FIC levels. 
(a) (b) 
(c) (d) 
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3.4. Discussion  
Maintaining iron homeostasis is important for all organisms, and mammalian hosts use iron 
sequestration to limit the growth of pathogens. Cryptococcus strains defective in iron homeostasis are 
more susceptible to antifungal drugs, including miconazole, AMB and FLC [94, 116, 293], and in the 
current study, it was hypothesised that iron chelation would enhance the ability of antifungal agents to 
inhibit Cryptococcus. The aim of this study was to use a diverse range of chelating agents to disrupt iron 
homeostasis and to test whether this would alter antifungal susceptibility, with a longer-term intention 
of using this to develop novel antifungal treatments. There is some controversy over drug interaction 
models and their application to fungi, and we applied both Loewe͛s additivity using FICI and Bliss 
independence with 3-dimensional modelling using MacSynergy
TM
 II [299]. Good agreement was 
generally found with both models, which predicted synergy and antagonism resulting from some 
combinations.  
3.4.1. LF+AMB produces potent synergism that is independent of the chelation of iron 
The combination of LF+AMB was synergistic for all of the Cryptococcus species and strains as well as for 
S. cerevisiae strain S288C (Fig. 3.3a), with MacSynergy
TM 
II dose response curves showing positive 
interactions across all AMB and LF concentrations (Fig. 3.3b). However, while supplementation with iron 
completely rescued cells from the MIC of LF this had very little effect on cells treated with a much lower 
dose of LF combined with AMB (Fig. 3.4). In fact, the lowest molar concentration of iron supplemented 
(12.33 µM FeCl3 and 13.16 µM FeSO4) was enough to saturate the two iron binding sites in LF at the FIC 
at 2 µg/mL (26.32 nM) with the presence of AMB. This indicates that iron chelation is important for 
inhibition by LF alone but does not play the principal role in AMB+LF synergy, which appears to be 
mediated by other processes. 
Synergism between LF and AMB has been seen previously in C. albicans and A. fumigatus (Table 3.1) [9, 
235], indicating that this combination has broad antifungal activity. Although the C. albicans study did 
not perform an iron rescue assay, iron chelation was considered unlikely as the primary cause of the 
synergy as both apo-lactoferrin and iron-saturated LF have been reported to have similar anti-Candida 
activities [10]. LF is a multifunctional protein with antibacterial, antiviral, anti-parasitic and antifungal 
activities in addition to chelating properties. As a component of saliva, LF is at the frontline of innate 
immunity to Candida, and efforts to understand the mechanisms responsible for its anti-candidal activity 
have been the focus of recent research. Active peptides isolated from LF have been shown to interact 
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with the surface of Candida cells, causing pits on the exterior surface and a decrease in cytoplasmic 
membrane potential [228, 278]. LF also chelates other trace metals and binds to foreign DNA, 
lipopolysaccharides and carboxylates [219]. In S. cerevisiae, LF appears to induce cell death via the 
accumulation of reactive oxygen species (ROS) and mitochondrial dysfunction but it does not appear to 
disrupt cell membrane integrity [300]. In the current study we found LF alone had a modest effect on 
Cryptococcus Đells ďut this ǁas gƌeatlǇ augŵeŶted ďǇ the pƌeseŶĐe of AMB ;ш 16-fold enhancement). 
AMB binds ergosterol in the fungal cell membrane inducing cell leakage, and recent studies have shown 
that AMB also induces cellular oxidative stress [301-304]. Together, these data suggest that AMB and LF 
likely act on the surface of fungi and their combined effect accelerates fungal inhibition, perhaps via ROS 
and oxidative stress, however the mechanistic details of this interaction remain unknown. 
3.4.2. Iron chelation does not consistently produce a synergistic response with antifungal agents in 
Cryptococcus 
With the exception of DFO, all of the iron chelators tested in this study inhibited the growth of 
Cryptococcus and Saccharomyces, consistent with the essential role of iron for fungal growth. However, 
iron chelation could not consistently synergise the various different antifungal agents in vitro, and some 
chelators were in fact antagonistic to the action of the antifungal. As noted above, even the synergy that 
was exhibited by AMB+LF was independent of the iron chelating properties of LF. Previous studies have 
found synergy between FLC+DFP and AMB+EDTA in inhibiting Aspergillus [9, 284] and synergy between 
FLC and deoxycycline against C. albicans has been attributed to the iron chelating properties of 
deoxycycline [305]. Studies of the cellular response to iron limitation indicate that even closely related 
species may mediate iron homeostasis by quite different mechanisms [306, 307], and it appears that 
fungal species must be tested empirically to determine their response to antifungal-chelator 
combination.  
For drug synergy the dose of both agents must be reduced at least 4-fold to achieve an FICI value below 
the 0.5 threshold. However, in this study it was of greater interest to either reduce the need for 
antifungals or improve their efficacy, which might be overlooked if there were no significant reduction in 
the need for chelators. To explore this, we assessed each combination for changes in the requirement 
for the antifungal in the presence of the chelator (Fig. 3.3c; Appendix 3.1). LF consistently reduced the 
need for AMB at least 4-fold, and the other chelators reduced the MIC for AMB by 2-fold in most strains. 
As AMB is toxic, and less toxic formulations are very expensive, the general ability of chelators to 
enhance activity suggests therapies that target iron homeostasis might be a useful adjunct for AMB-
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based therapy, even if the combination is not actually synergistic. Ideally, these would disrupt iron 
regulation rather than directly remove iron by chelation, as anaemia is a common side-effect of AMB 
treatment [308]. 
Some chelator-antifungal combinations reduced the antifungal MIC by 4-fold or greater, despite having 
an FICI greater than 0.5, however, this was sporadic and generally strain-specific. One possible exception 
was the combination of VRC+EDTA in C. gattii where the three strains tested had a 4-16 fold reduction in 
the VRC MIC, however, more strains should be tested to determine if this combination consistently 
inhibits C. gattii.  
3.4.3. Species-specific antagonism is produced by some antifungal-chelator combinations  
A surprising result of this study was that certain antifungal-chelator combinations produced an 
antagonistic response with an FICI greater than 4 (Fig. 3.3a and b). This was particularly the case for the 
azole drugs when combined with EDTA, DFP and DSX, where the antifungal MIC was raised up to 8-fold 
in some strains (Fig. 3.3c; Appendix 3.1). EDTA is a polyaminocarboxylic acid and is thought to inhibit 
Cryptococcus by disrupting the assembly of the polysaccharide capsule through Mg
2+
 and Ca
2+
 chelation 
[283], while DFP and DSX are small lipophilic molecules that can penetrate the cell membrane [263] and 
are antimicrobial through intracellular chelation of iron [73, 155]. The iron chelating agent DFO has been 
reported to enhance the growth of Rhizopus and Aspergillus due to its action as a xenosiderophore, 
which increases intracellular iron in the pathogens [9, 259]. EDTA, DFP and DSX are not likely to be 
xenosiderophores [260], however, and how they specifically interfere with azole drugs is not known. 
DFP has previously been reported to synergise with FLC against A. fumigatus, however, only a single 
reference strain of A. fumigatus was tested [9].  
In the current study antagonism was highly species-specific and was confined to strains of C. neoformans 
var. grubii; the two strains of C. neoformans var. neoformans were not affected, and in C. gattii these 
chelators often reduced the requirement for the azole drugs. Species- and genotype-specific differences 
in antifungal susceptibility have been observed in Cryptococcus [21], and a C. gattii strain (97/170) that 
is hyper-resistant to azoles was included but no difference in its response to the addition of chelators 
was seen. C. neoformans var. grubii is by far the most prevalent agent of cryptococcosis globally and 
causes the vast majority of disease in HIV/AIDS, which is commonly treated with FLC. Although the 
current study was limited to analysing interactions in vitro that may not fully correlate to interactions in 
vivo, the results indicate a need for caution if using chelators as drug adjuvants for cryptococcosis and 
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recommend against the use of DFP and DSX in AIDS patients receiving azole drugs.  
3.4.4. Conclusions  
This study revealed considerable diversity in the interactions between antifungals and iron chelators in 
their ability to inhibit Cryptococcus. The only combination to consistently inhibit Cryptococcus strains 
was AMB+LF, however, all chelators produced a modest reduction in the need for AMB, and therapies 
aimed at disrupting iron homeostasis may potentiate the action of AMB and reduce the dose required 
for this toxic drug. There was considerable diversity in the reaction of different Cryptococcus strains to 
antifungal-chelator combinations, and the same combination could range from synergistic to 
antagonistic in different strains. Cryptococcus and Saccharomyces now join Candida and Aspergillus, 
where synergism between AMB and LF has previously been reported, and their fully sequenced strains 
with advanced genetic resources will provide excellent platforms where the molecular and cellular basis 
of synergy can be explored. This, together with in vivo testing, can be used to develop new, broadly 
active antifungal adjuvants.  
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CHAPTER 4: Transcriptomic analyses of synergy 
and antagonism between antifungal drugs and 
iron chelating agents 
 
This chapter focuses on using transcriptomics to analyse the synergistic and antagonistic responses to 
antifungals plus iron chelators that were found in Chapter 3. It first investigates how the addition of LF to 
AMB induces synergy in S. cerevisiae S288C by mapping a detailed transcriptome response to AMB and 
AMB+LF treatment. This was then used to guide the analysis of the synergistic response to AMB+LF that 
was also seen in C. neoformans H99, where detailed protein-protein interaction data and other systems 
biology tools are not yet available. A preliminary comparison of drug antagonism and additivity that had 
been observed in response to VRC+EDTA treatment by C. neoformans H99 and C. gattii 97/170 was 
undertaken.  
In this chapter, the results and discussions of each transcriptome analyses of AMB+LF synergy in S288C 
and H99 and VRC+EDTA antagonism/additivity in H99 and 97/170 are presented together.  
 
Two publications based on this chapter are currently in preparation. One manuscript is currently under 
review in Scientific Reports with the working title: 
Chi Nam Ignatius Pang, Yu-Wen Lai, Leona Campbell, Sharon C-A. Chen, Dee Carter, Marc R. Wilkins 
Transcriptomic and network analysis in Saccharomyces cerevisiae reveal that amphotericin B and 
lactoferrin synergy disrupt metal homeostasis and stress response.  
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4.1. Introduction 
4.1.1. The search for antifungal synergents and problems harnessing information for improved 
therapies  
The search for synergents to improve current antifungal therapies and discover new drugs has seen 
many screens of antifungal drugs with bioactive compounds and off-patent medications, including iron 
chelators [54, 55, 70, 153, 309, 310]. To further aid the discovery of synergents, bioinformatic models 
and drug combination databases have been developed to help predict and understand synergy with 
antifungal drugs [310-312]. The vast majority of drug screens have been performed with FLC, which is 
the most widely used antifungal and is off-patent, relatively cheap and widely available. However, this 
has meant most research to develop and understand drug synergy has been largely limited to azole 
drugs [54, 313-315].  
There are published approaches that attempt to predict the likelihood of synergy between combinations 
of compounds and antifungals that exert similar genome-wide effects [311], affect similar and 
topologically close genetic interactions [153, 310, 316] or have similar physiochemical properties [317]. 
However, these predictive models are reliant on prior knowledge of the physical and genome-wide 
effects that are exerted on cells by both drugs alone. Many bioactive compounds, especially natural 
products, have largely unknown antimicrobial mechanisms. Likewise, many repurposed medicines have 
unknown targets and inhibitory mechanisms in the new system in which they are employed, and even 
medicines that were designed to inhibit a specific target can exert additional, unknown effects [318, 
319]. Finally, these bioinformatic models adopt a reductionist approach to understanding synergy by 
combining individual phenotypic responses of knock-out mutants to pairs of drugs and finding cellular 
processes and pathways that are commonly affected. However, synergy can be more complex than just 
two drugs specifically disrupting common cellular targets. It can also occur through promiscuous 
mechanisms that generally disrupt the cell, particularly when these affect the cell membrane [320]. 
Most importantly, these approaches do not show the dynamic and complex changes that occur in cells 
as they respond to synergistic drug treatments, which are where the mechanistic details of synergy can 
be deduced.  
Despite numerous studies to find synergistic drug pairs and understand their mechanisms of synergy, 
there have been only three studies to date that have analysed the synergistic interaction of drugs in 
fungi using ͚omics͛ and systems biology approaches. The first of these used a 2D proteomic analysis to 
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analyse synergy between FLC and berberine (BBR), a plant alkaloid used in many traditional Chinese 
medicines. FLC+BBR treatment caused an up-regulation of tricarboxylic acid cycle -related proteins and a 
down-regulation of proteins involved in fermentation compared to FLC and BRR treatment alone, which 
suggested a shift from fermentation to mitochondrial respiration. This shift was experimentally tested in 
all drug treatments by measuring the cellular components that correlate to increased respiratory 
activity: mitochondrial membrane potential and intracellular ATP level, ROS levels and ATP synthase 
activity. Compared to FLC and BBR alone, FLC+BBR treatment increased mitochondrial membrane 
potential, decreased ATP levels and inhibited ATP synthase activity. All of these processes increase 
endogenous ROS production, which was also detected at higher concentrations in FLC+BBR treatment 
compared to single treatments. Based on these changes, synergy was suggested to result from a shift in 
mitochondrial aerobic activity and an increase in endogenous ROS production, resulting in oxidative 
damage and cell death [6].  
The second study of synergy also used a 2D proteomics approach, and analysed synergy between FLC 
and the calcium channel blocker tetrandine (TET) in C. albicans. In this study, only six differentially 
expressed proteins were identified in the combined treatment, while three and five proteins 
respectively were differentially expressed in response to FLC and TET alone. Adh1, an alcohol 
dehydrogenase involved in energy metabolism, was up-regulated when FLC and TET were used alone 
but was down-regulated in the combined treatment. As Adh1 has been reported to contribute to FLC 
resistance in C. albicans, its down-regulation was suggested to be responsible for the synergistic 
response. However, there were some issues with this study; most notably the concentration of FLC that 
was used to treat the cells (750 µg/mL for 6 hrs), which well exceeded the strain͛s FLC MIC ;ч ϴ µg/ŵLͿ 
[7].  
Most recently, Li et al. (2015) repeated the previous proteomic analysis of FLC+BBR synergy using B-7b, 
a less toxic derivative of BBR, in a different FLC-resistant strain of C. albicans. Instead of the changes to 
mitochondrial function and ROS production that were observed in their previous study, FLC+B-7b 
treatment was associated with increased protein processing and a down-regulation of stress response 
regulators. This suggested the previous responses were more likely due to a toxic response to BBR, and 
that a disruption to protein processing and stress responses was the more likely cause of synergy [321]. 
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4.1.2. Systems biology tools and resources   
The availability of genome sequences and the ability to analyse genome-wide gene expression using 
systems biology has revolutionised our knowledge of the effect of antifungal drugs. In turn, 
understanding these effects has aided drug discovery and development by finding newer antifungal 
targets and designing drugs that disrupt them.  
Transcriptomics, like all system biology approaches, generate enormous datasets that are daunting and 
complex to analyse. A number of tools have been developed to manage and contextualise these large 
volumes of information in an interpretable and visual manner.  
4.1.3.1. Gene ontology terms  
As fully sequenced genomes became available, gene ontology (GO) terms were introduced to provide 
consistent descriptions of gene products so that they can be compared across databases of different 
organisms. Genes and proteins are characterised and annotated based on their roles in biological 
processes (BP), molecular function (MF) and the cellular component (CC) where they are found. 
Hierarchical structures were also assigned to describe the relationship of gene products to one another, 
such as between mother processes, which provides broader and more general descriptions, and child 
processes that provides more specific descriptions that are either a part of or occur as a result of the 
parent [322]. With the vast amount of data produced by systems biology studies, GO terms allow the 
data to be analysed in manageable sizes by enabling enrichment analyses on gene sets that have the 
same annotations. Enrichment analyses show the most over and/or under-represented GO terms in a 
dataset, the frequency of the number of annotated genes appearing in a GO term, and the significance 
of a GO term being associated with a group of genes [323]. Using GO terms, the most significant changes 
seen in an experimental condition are observed. The biggest limitation in using GO terms to characterise 
data into functional categories is its reliance on annotation, as outside model organisms many genes and 
products in sequenced genomes are poorly annotated.  
4.1.3.2. Self organising maps  
Self organising maps (SOMs) were developed by Kohonen [324] as a type of artificial neural network that 
identifies similar data in multidimensional datasets and clusters these together. Clustering reduces the 
space in the datasets into lower dimensions where the data can be visualised as a map, allowing trends 
in the data to be easily observed and interpreted. As this clustering is performed using an unsupervised 
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algorithm, it avoids the introduction of bias based on prior knowledge or assumptions [325]. One of the 
first uses of SOMs was the analysis of gene expression in hematopoietic differentiation. SOMs was able 
to find patterns in the data by clustering characterised and unknown genes involved in the different 
stages of cell differentiation together [326]. By revealing relationships between these, genes that were 
not known to have functions in cell differentiation could be found. SOMs can also identify co-expressed 
and co-regulated genes that may participate in a common pathway or be controlled under the same 
regulatory element [327].  
4.1.3.3. Cytoscape  
Cytoscape is an open source software platform that was designed to visualise molecular interaction 
networks, such as protein-protein, protein-DNA and genetic interactions. It is also an interactive 
platform where generated networks can be integrated with annotations, gene expression profiles and 
other state data (http://www.cytoscape.org/what_is_cytoscape.html). Cytoscape can create very large 
networks with nodes representing objects (e.g. genes or proteins) and edges showing the relationships 
between nodes. Experimental data, known as attributes, and annotations like GO terms can be 
incorporated with the nodes and edges. Visual cues, such as shapes and colours, can also be added to 
networks to allow for ease of viewing. Cytoscape has many features that enable networks to be 
managed and analysed, including different map layouts, scaling, construction, editing and the filtering of 
attributes and annotations to reduce network complexity. Additionally, Cytoscape incorporates 
statistical analysis and supports many file formats and extensions to provide different ways of analysing 
networks [328, 329]. These features enable the exploration of complex holistic data. The main 
limitation, however, is that Cytoscape requires well characterised pathways and interaction data to build 
and visualise networks, and is therefore most useful in model organisms.  
4.1.3.4. S. cerevisiae as a model organism and reference genome strain S288C 
S. cerevisiae has long been studied and used as a model organism in molecular and cell biology [330, 
331]. Many of its genes and pathways are conserved across higher order organism [332], thus, S. 
cerevisiae has also been used to model and study a variety of processes and diseases such as cell cycle 
progression, aging and neurology disorders [333-335].  
There are various commonly used laboratory strains of S. cerevisiae, all of which have different genetic 
backgrounds and are used for different biochemical studies [336]. One of the commonly used laboratory 
strains is S288C, which was genetically bred by Mortimer et al. (1986) for biochemical studies and was 
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designed to be non-flocculent under minimal nutrient conditions. The genealogy of this strain is 
complex, with approximately 88% of the S288C genome derived from strain EM93, which was isolated 
from a rotting fig. The rest of the S288C genome was derived from strains found from rotting fruits: 
EM126 and NRRL-210, and commercial strains of baking yeasts: FLD, LF and Yeast Foam [337].  
In 1996, S288C was the first eukaryotic organism to have its genome sequenced [338], which was then 
updated in 2010 [339]. Shortly after the genome was published, a gene knock-out library of all known 
open reading frames in the S288C genome was generated to understand the biological function of each 
gene [340, 341]. Nearly 20 years later with 6,604 open reading frames reported in the S288C genome, 
78% of the genes have been functionally characterised, while 10% remain unknown and 12% are have 
dubious gene assignments (http://www.yeastgenome.org/genomesnapshot). Technologies that 
investigate the interactions between proteins and genes, such as epitope tagging and synthetic gene 
arrays, were also developed using S288C [342]. These techniques have expanded the knowledge of 
individual protein functions to their functional relationships with other proteins and genes and their 
contributions to particular cellular processes such as filamentation, stress responses and DNA damage 
checkpoint signalling [343, 344]. This makes the S288C genome arguably the best annotated and 
functionally characterised in all eukaryotes [342]. Additionally, up-to-date genome browsers and 
integrative databases like the Saccharomcyes Genome Database (SGD) and YeastMine provide 
information including GO annotations, mutant phenotypes and biochemical pathways that aid 
experimental design and analysis [332, 345]. Hence, many pioneering systems-level studies have been 
performed in S288C where the analysis of genome wide responses can be used to its full potential [346-
348].  
4.1.3. The C. neoformans var. grubii reference strain H99 and systems biology resources  
Globally, more than 95% of cryptococcosis is caused by C. neoformans var. grubii [349]. In order to gain 
a better understanding of Cryptococcus as a pathogen, nearly all recent genetic, molecular, phenotypic 
and virulence studies have been performed in var. grubii strain H99. In this project, C. neoformans var. 
grubii stƌaiŶ KNϵϵα, which was derived from H99 by backcrossing [350] and has a congenic a mating 
type partner (KN99a), was initially intended for the transcriptome analysis of drug synergy. However, as 
there have been some issues raised with the genome of KN99α (James Fraser, personal communication) 
a switch to reference strain H99 was made, which also enabled better compatibility with the majority of 
Cryptococcus studies.  
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H99 was isolated in 1978 from a 30 year-old male patient with Hodgkin͛s lymphoma at Duke University 
Medical Centre [351]. Its genome was sequenced by the Broad Institute and comprises 14 chromosomes 
with an overall size of 18.89 Mb, excluding the rDNA locus with an approximate size of 1 Mb, with 6,962 
genes predicted to encode proteins (http://www. broadinstitute.org/annotation/genome/cryptococcus_ 
neoformans/GenomeStats.html). A majority of annotations in the H99 genome have not been 
functionally characterised but have been predicted bioinformatically and from sequence homology to 
other fungi [141]. Many resources and technologies that were developed for S288C have been partially 
generated in H99, including a gene knock-out library of around 2,000 strains and a transcription factor 
knock-out library of 155 strains [310, 352, 353]. Essential Cryptococcus genes that lack mammalian 
homologues have also been identified for drug targeting [354]. A probabilisit co-functional gene network 
for Cryptococcus, CryptoNet (www.inetbio.org/cryptonet/), was developed by Kim et al. (2015) to 
predict novel genes involved in certain biological processes, such as virulence and drug response [355]. 
The interactions between genes and proteins, such as transcription factors and signalling proteins, are 
progressively being studied to understand their functions in Cryptococcus-specific processes like capsule 
production and pathogenicity [111, 355].  
In Cryptococcus, holistic studies using transcriptomics and proteomics have focused on different 
approaches to finding alternative therapies, from understanding the inhibitory actions of antifungals and 
the development of resistance to finding pathways and proteins affected by antifungal treatment in 
order to target them as potential means of augmenting current antifungals [137, 356, 357]. However, no 
system biology studies published to date have investigated the genome-wide changes caused by drug 
interactions that are synergistic in Cryptococcus.  
4.1.4. Aims and hypothesis  
Drug interactions are complex and can differ with the combination of agents used and the organism in 
which they are tested. A number of studies have investigated the effects of single drugs on fungal cells 
in order to understand their mechanism of antifungal activity [135], the development of resistance [137, 
358, 359] and to identify pathways that can be targeted to augment antifungal therapy [356]. However, 
the molecular and cellular basis of synergistic drug combinations has not been systematically studied or 
investigated as a source of potential new therapies.  
The original aim of this chapter was to analyse gene expression in fungal cells exposed to combinations 
of antifungals and iron chelators that were found to act synergistically in Chapter 3, in order to find 
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pathways and processes that were similarly perturbed by different drug-chelator pairs that could then 
be tested as new therapeutic targets. Unexpectedly, however, only one antifungal-chelator combination 
was synergistic, and some antagonistic combinations were found. Based on this, the aims in this chapter 
refocused to conducting a detailed analysis of the synergy found between AMB+LF, and to investigating 
the species-specific antagonism seen between VRC+EDTA.  
The hypothesis underlying this chapter was that changes to gene expression in a fungal cell exposed to 
antifungal-chelator combinations could be identified using a systems biology approach, and that these 
changes would help elucidate the molecular mechanisms behind synergy and antagonism.  
The specific aims of this chapter were therefore: 
1. To understand the effect of AMB+LF synergy on the transcriptome of S. cerevisiae S288C and C. 
neoformans H99.  
This was achieved by: 
a. characterising the growth of S288C and H99 cells treated with AMB and AMB+LF to 
determine optimal time points for RNA extraction; 
b. performing RNA-Seq, assembling the transcriptomes and analysing these by 
i. identifying differentially expressed genes and grouping these into functional 
groups via GO term analysis; and 
ii. contextualising and visualising the transcriptomic data using SOMs and 
Cytoscape. 
2. To identify genes in altered pathways or processes that may be suitable for targeting by novel 
antifungal drugs.  
This was achieved by 
a. comparing the transcriptomes generated above and using the S288C transcriptome as a 
scaffold for missing transcriptome data in H99;  
b. validating the transcriptome analysis using gene knock-outs and phenotypic testing, to 
find targets in S288C and H99 that may induce synergy with AMB. 
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3. To understand how VRC+EDTA induces antagonism in C. neoforman H99 and additivity in C. 
gattii 97/170.  
This was achieved by  
a. characterising the effect of VRC+EDTA on the growth of H99 and 97/170 to determine 
the time point to extract RNA;  
b. performing RNA-Seq, assembling the transcriptomes and comparing the response of 
H99 and 97/170 to VRC+EDTA by 
i. identifying reciprocally orthologous transcripts present in H99 and 97/170; and 
ii. identifying differentially expressed genes for each treatment type and grouping 
these into functional groups via GO term analysis. 
 
 
62 
 
4.2. Methods and materials 
4.2.1. Preparation of chemical agents and stock concentrations  
4.2.1.1. Stock concentration of stressing agents 
AMB and FLC stocks were prepared as outlined in Section 2.2.3. Stock concentrations of calcofluor white 
(blankaphor) and congo red were made at 10 mg/mL in Milli Q water. 10% (w/v) SDS, 5 M NaCl, 1 M 
sodium nitrite were made in Milli Q water. 500 mM caffeine was dissolved in Milli Q water with heat. All 
stressing agents were filter sterilised.  
4.2.1.2. Stock preparations of rescue agents 
Iron chloride stocks were prepared as outlined in Section 3.2.6. Stock concentrations of zinc chloride and 
ĐalĐiuŵ Đhloƌide ǁeƌe ŵade iŶ Milli Q ǁateƌ at ϰ,Ϭϵϲ μg/ŵL aŶd ϯϮ ŵg/ŵL, ƌespeĐtiǀelǇ. BAPTA ǁas 
dissolved in RPMI-1640 media at 8 mg/mL and all chemicals were filter sterilised.  
4.2.1.3. Preparation of chemicals and reagents for transformation 
Salmon sperm DNA (SS-DNA) was dissolved in TE buffer overnight at 4 °C to make a stock concentration 
of 4 mg/mL and frozen at – 20 °C until use. Stock concentrations of 1 M LiAc and 50% (w/v) PEG 
(molecular weight 3350) were made in Milli Q water and heat sterilised. 50 mg/mL of hygromycin B was 
purchased from GibcoBRL. Kanamycin and nourseothricin were made in Milli Q water at 50 mg/mL and 
filter sterilised. The drugs were kept frozen at – 20 °C unless otherwise specified by manufacturer's 
instructions. 
4.2.1.4. Genomic DNA extraction 
Genomic DNA was extracted from Cryptococcus and Saccharomcyes cultures by mechanical breakage 
with glass beads. Approximately 20 µL of cells cultured on SDA were harvested and vortexed in 500 µL 
extraction buffer and 500 µL of 0.5 mm glass beads for 10 min. The mixture was incubated at 70 °C for 
10 min and briefly vortexed. 200 µL of both 5 M potassium acetate and 5 M sodium chloride were added 
and mixed by inversion. After 5 min incubation in ice, the mixture was centrifuged for 10 min at 14,000 
rpm.  
The upper aqueous phase was transferred to a new eppendorf tube and mixed with 500 µL of 5:1 
phenol/chloroform before another round of centrifugation for 5 min. The aqueous phase was 
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transferred into a new tube, 500 µL of chloroform was added, mixed by inversion and further 
centrifuged for 5 min. The aqueous layer was once again removed into a fresh tube and one volume of 
isopropanol was added, mixed and incubated at room temperature for 20 min. The precipitated DNA 
was pelleted by centrifugation at the maximum speed and washed with 75% isopropanol before the 
DNA was dissolved in 100 µL of TE.  
4.2.2. Illumina sequencing and de novo assembly of the C. gattii strain 97/170 genome  
The genome sequence of 97/170 was compiled by Dr Nandan Deshpande from the University of New 
South Wales, Australia.  
Following extraction as outline above, DNA from strain 97/170 was purified of RNA using the moBIO 
UltraClean® microbial DNA isolation kit. Twenty micrograms of 97/170 DNA dissolved in 100 µL TE was 
mixed with 450 µL of MD3 buffer and centrifuged through the supplied column at 10,000 g for 30 sec. 
300 µL of solution MD4 was then added to the column and the flow through discarded before 
centrifuging for 1 min at 10,000 g. The spin filter was then transferred into the supplied collection tube 
and the purified DNA was eluted through the column with 50 µL nuclease free water at 10,000 g for 30 
sec.  
The OD260/280 and OD260/230 ratios of the extracted 97/170 genomic DNA were assessed using a NanoDrop 
1000 (ver. 3.6.0, Thermo Scientific). DNA quantity was assessed using a Qubit® dsDNA HS assay kit and 
Qubit® 2.0 fluorometer (ver. 2, Invitrogen) as specified by the manufacturer͛s instructions. The grade 
and purity of the DNA were checked on a 1% agarose gel. At least 5 µg of DNA in 25 µL of nuclease free 
water, with optical density (OD) ratios from 1.8 – 2, was sent to the Ramaciotti Centre, UNSW, Australia 
for Illumina genomic sequencing, using the MiSeq sequencing platform.  
Genomic read-data were generated in a single lane on an Illumina MiSeq sequencing platform. DNA 
libraries were prepared with the TruSeq DNA LT Sample prep kit (Illumina), according to the 
manufacturer͛s instructions. Chromosomal DNA was chemically fragmented to generate blunt ended, 
double stranded sequences of less than 800 bp. ͚A͛ bases were then attached to the 3͛ ends for ligation 
of index adapters, which contain sequencing primer hybridisation sites. As the genome DNA of 97/170 
was sequenced along with 4 other strains (not included in this thesis), the DNA fragments were 
multiplexed, which involves adding ͚barcode͛ sequences onto the fragments of each sample. This allows 
for faster sorting, sequencing and assembly of each sample. The library fragments were then attached to 
a flow cell channel, where 250 bp paired-end reads with inset sizes between 500 – 600 bp were enriched 
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by bridge amplification using 500 cycles of PCR and sequenced using the MiSeq Reagent Kit v2. PhiX 
Control v3 was spiked in the runs at 1% and the data were demultiplexed using Casava (ver. 1.8.3).  
Prior to assembly, low quality bases in sequence reads were trimmed using SolexaQA (ver. 2.2). De novo 
assembly of reads was performed using the genome assembly tool Assembly By Short Sequences 
(ABySS; ver. 1.3.4) [360], using the default parameters. ABySS uses de Bruijn graphs, which breaks reads 
into smaller sequences of DNA called k-mers where k denotes the length in bases. Directed graphs are 
then constructed by connecting pairs of k-mers with overlapping nucleotides [361]. These parameters 
yielded an optimised genome assembly of 17.45 Mb with 364 contigs and a N50 parameter of 85,384 
bp. N50 indicates the median contig size and gives an indication of the quality of assembly with respect 
to all the generated contigs [362]. A total of 7,315 genes were predicted from the assembly using 
Augustus (ver. 2.7), a tool for ab initio gene prediction in eukaryotic genomic sequences [363].  
4.2.3. Transcriptome analysis  
4.2.3.1. Characterising the effect of the AMB+LF combination in S. cerevisiae S288C and C. neoformans 
H99 for RNA isolation 
To understand the mechanism of drug synergy, the transcriptome of cells treated with the synergistic 
combination AMB+LF was examined. The ID20 time point (= the time taken for drug exposures to inhibit 
20% of growth in drug treated versus untreated cells) was chosen to extract RNA for RNA-Seq, as at this 
point the effect of the drugs would be evident without a dominant apoptotic response.  
C. neoformans strain H99 and S. cerevisiae strain S288C were streaked from glycerol stocks onto SDA as 
detailed previously (Section 2.2.1). For broth cultures, H99 was grown in YNB at 37 °C and S288C in 
RPMI-1640 at 30 °C in a shaking incubator at 180 rpm. S288C was incubated at ϯϬ ˚C as it eǆhiďited 
difficulty in budding at 37 °C, suggesting the yeast was under stress. (Note: Results from the AMB+LF 
checkerboard assay at 30 °C aŶd ϯϳ˚ C ǁeƌe ideŶtiĐal; data Ŷot shoǁŶͿ. ϭϬϬ ŵL Đultuƌes of Hϵϵ aŶd 
S288C were grown overnight and the exponential phase culture was subcultured into fresh media in a 
final volume of 150 mL at a starting concentration of 1 x 10
7
 cells/mL and grown to the start of log phase 
(3 hrs).  
To determine ID20 for RNA isolation, the inoculum was divided into four cultures, with two cultures 
treated with AMB and AMB+LF, and the remaining two cultures serving as untreated controls for AMB 
treatment (CA) and AMB+LF treatment (CAL). AMB+LF treatment used the concentrations of AMB and 
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LF that achieved drug synergy in H99 and S288C, i.e. 0.06 µg/mL AMB + 2 µg/mL LF and 0.03 µg/mL AMB 
+ 2 µg/mL LF, respectively. For AMB treatment, the concentration of AMB was 0.06 µg/mL for H99 and 
0.03 µg/mL for S288C. Growth curves for AMB and AMB+LF-treated cultures were established by 
sampling 500 µL of the drug-treated and corresponding untreated cultures every 15 min following drug 
inoculation and performing serial dilutions from 10
-1
 to 10
-6
 in Milli Q water. Aliquots of 100 µL were 
plated in duplicate on Sabouraud dextrose agar (SDA) to obtain countable plates (30 – 300 cfu) following 
48 hr of incubation at 30 °C.  
4.2.3.2. Sample preparation for RNA isolation in AMB+LF synergy experiments 
For RNA isolation, 300 mL overnight cultures of S288C and H99 were grown and subcultured into 700 mL 
fresh media as detailed previously (Section 4.2.3.1). To prevent RNA degradation during harvesting of 
the cells for RNA extraction, the cultures of each organism were divided into four 50 mL volumes for 
each drug treatment and corresponding controls, giving a total of twelve 50 mL cultures. The addition of 
drugs to the AMB and AMB+LF treatments were staggered by 10 min to allow time for harvesting the 
cells by centrifugation and back plating.  
At the ID20 timepoints determined above (1 hr for AMB and 50 min for AMB+LF, in S288C and H99), 
three 15 mL aliquots of each treatment and its corresponding control were harvested and pelleted in 
falcon tubes for 30 sec at 4,000 rpm at 4 °C. The supernatant was decanted and the cells were snap 
frozen in liquid nitrogen, lyophilised, and kept at – 80 °C until RNA extraction. Non-lyophilised samples 
were also kept in – 80 °C storage before freeze drying. To confirm ID20 time points, 500 µL samples from 
drug treated and corresponding untreated control cultures were serially diluted and back plated onto 
SDA as detailed previously (Section 4.2.3.1).  
For the AMB+LF synergy experiments, the entire RNA isolation procedure, beginning with the growth of 
cells, was repeated on three separate occasions to give three independent biological replicates. Three 
technical replicates were performed for each sample, so that for the four treatments there was a total 
number of 36 samples each for S288C and H99.  
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4.2.3.3. Characterising the effect of VRC+EDTA in C. neoformans H99 and C. gattii 97/170 and sample 
preparation for RNA isolation 
Similar to characterising the effect of AMB+LF on the growth of S288C and H99, the effects of VRC and 
VRC+EDTA treatments were characterised in comparison to untreated controls (C). This was done in H99 
(antagonistic; 4-fold increase in requirement for VRC in the presence of EDTA) and C. gattii 97/170 
(additive; 16-fold decrease in requirement for VRC in combinations with EDTA; Appendix 3.1). Unlike 
AMB+LF synergy where an ID20 between drug treated cells versus untreated cells was used to extract 
RNA, the timepoint where a 20% increase in growth of VRC+EDTA versus VRC treated cells in H99 was 
used to extract RNA. This timepoint was also used to extract RNA from H99 and 97/170 following C, VRC 
and VRC+EDTA treatments to provide a comparable analysis of the drug treatments and of antagonism 
and additivity between the two Cryptococcus strains. 
Growth curves were performed as described in Section 4.2.3.1 but at a lower starting concentration of 1 
x 10
6
 cells/mL as preliminary analyses indicated the effect of VRC was cell concentration-dependant. 
H99 was treated with 0.03 µg/mL VRC alone and in combination with 8 µg/mL EDTA, while 97/170 was 
treated with 0.03 µg/mL VRC alone and in combination with 64 µg/mL EDTA (Appendix 3.1). Three 
independent biological replicates were performed for the three drug treatments, with three technical 
replicates performed for each sample. Altogether, H99 and had a total 27 samples each for RNA 
isolation.  
For RNA isolation, 100 mL overnight cultures of H99 and 97/170 were grown and the exponential phase 
cultures were subcultured into fresh media to a starting concentration of 1 x 10
6
 cells/mL in a final 
volume of 200 mL and grown for 3 hours. These were then divided into three 50 mL volumes for C, VRC 
and VRC+EDTA treatments. The addition of the drugs to VRC and VRC+EDTA treatments were staggered 
at 3 min to allow time for harvesting the cells by centrifugation and back plating. Cell harvesting and 
lyophilisation were performed as detailed in Section 4.2.3.2.  
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4.2.3.4. RNA extraction from S. cerevisiae S288C and C. neoformans H99 
To ensure uniformity across RNA extractions, lyophilised S288C, H99 and 97/170 samples were 
randomised to twelve isolations at a time. Labels were assigned by grouping the 12 samples numerically, 
with the twelve individual samples labelled alphabetically. This labelling was kept for Illumina 
sequencing and data sorting and is presented in Appendix 4.1.  
Approximately 200 µL of freeze-dried cells prepared above were transferred to a cryogenic storage tube 
and mechanically broken with ~ 200 – 250 µL RNAse Zap-treated 0.5 mm glass beads using a Minilys 
tissue homogeniser at 5,000 rpm. The cells were beaten for a total of 2 min and cooled on ice after 
every 1 min of beating.  
Total RNA was extracted from the disrupted yeast cells using the Qiagen RNA isolation kit with some 
modifications. Firstly, 700 µL of lysis buffer was added to each tube and the debris and beads were 
removed by centrifugation at maximum speed in a desktop centrifuge at 4 °C for 3 min. The supernatant 
was transferred to a new tube and mixed with an equal volume of 70% ethanol, and this was then 
centrifuged through the Qiagen RNA spin-through column for 30 sec at 10,000 g. The column was 
washed once with 700 µL RW1 buffer and twice with 500 µL of RPE buffer by centrifugation for 30 sec at 
10,000 g for each wash, and the flow through was discarded. The column was then transferred to a new 
collection tube and spun dry for 2 min at 10,000 g before the RNA was eluted by centrifuging at 10,000 g 
for 1 min with 50 µL of RNAse free water (supplied in the Qiagen kit).  
Aliquots of 10 µL of the eluted RNA were used to assess quantity and quality. OD260/280 and OD260/230 
were assessed using a NanoDrop 1000 (ver. 3.6.0, Thermo Scientific). RNA integrity number (RIN)/RNA 
quality index (RQI) was assessed using Experion std Sen RNA chips and reagents and Experion
TM
 
software (ver. 3.2, Bio-Rad). RNA quantity was assessed using a Qubit® RNA BR assay kit and Qubit® 2.0 
fluorometer (ver. 2, Invitrogen). Total RNA with OD ratios between 1.8 – 2, a RIN/RQI of at least 8 and a 
yield of at least 5 µg in a minimum concentration of 200 µg/mL was sent to the Ramaciotti Centre, 
UNSW, Australia, for Illumina RNA sequencing.  
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4.2.4. Illumina RNA-Seq and data processing 
The following sections were undertaken with assistance from Dr Igy Pang, a bioinformatician employed 
on the grant that funded this work. 
4.2.4.1. RNA-Seq library preparation and sequencing  
One technical replicate from each biological replicate was selected for RNA-sequencing, giving 12 
samples each for S288C and H99 for synergy experiments, and 9 samples each for H99 and 97/170 for 
antagonism experiments. The RNA samples were prepared using an Illumina TruSeq RNA sample prep kit 
(ver. 2) to generate DNA libraries, according to manufacturer͛s instructions. Briefly, mRNA was purified 
fƌoŵ Ϯ μg of total RNA usiŶg polǇA seleĐtioŶ ďefoƌe the ŶuĐleiĐ aĐids ǁeƌe chemically fragmented and 
converted into single-stranded cDNA by random hexamer priming. The second strand of cDNA was 
synthesised, and double-stranded cDNAs were created with blunt ends. ͚A͛ bases were then attached to 
the blunt ends for the ligation of index adapters, which contain sequencing primer hybridisation sites for 
selected reads, such as single, paired-end or multiplexed reads [364]. Paired end reads were chosen to 
improve the discovery of novel transcripts and increases the total read length per library fragment. 
Multiplexing was also applied.   
The library fragments were then attached to a flow cell channel, which is a planar surface fixed with 
complementary adapter sequences and primers that hybridise to the ends of the added DNA fragments. 
Libraries were constructed with insert sizes between 80 – 330 bp and were enriched by bridge 
amplification using 15 cycles of PCR. Complementary fragments were removed, and libraries were 
randomised onto two separate lanes for RNA-Seq using the HiSeq2000 platform to generate 100 bp 
paired-end reads. The TruSeq v3 SBS kit was used to fluorescently label nucleotides in each library for 
sequencing by capturing the emitted fluorescence of different bases. The data were demultiplexed using 
Casava (ver. 1.8.2). An overview of this process is shown in Figure 4.1. 
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(a) Library preparation 
 
(b) Cluster amplification 
 
(c) Sequencing 
 
(d) Alignment and data analysis 
 
 
Figure 4.1. An overview of RNA-Seq library preparation and sequencing. (a) mRNA was chemically 
fragmented and converted to cDNA, where DNA libraries were prepared by ligating specialised adapters 
to both ends of DNA fragments. (b) Libraries were loaded to the surface of a flow cell channel and DNA 
fragments hybridised to complementary adapter sequences present on the channel. Each bound 
fragment was enriched through bridge amplification and complementary fragments were removed after 
amplification. (c) Amplified fragments were sequenced by adding fluorescently labelled nucleotides and 
sequencing reagents. The flow cell was imaged and sequence data were generated by capturing the 
emitted fluroresence of incorporated bases. (d) Sequenced reads were then aligned bioinformatically to 
a reference sequence. Taken from http://www.illumina.com/content/dam/illumina-marketing/ 
documents/products/illumina_sequencing_introduction.pdf  
mRNA  
cDNA  
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4.2.4.2. Processing of RNA-Seq data 
FastQC (ver. 0.10.1) was used to assess the accuracy of sequence reads. Phred quality scores (Q scores) 
are defined by the equation Q = -10 log10 P and indicate the accuracy of a sequencing platform by 
calculating the probability (P) of a given base being called incorrectly [365]. All RNA samples achieved an 
average Phred score of at least 30, indicating a base call accuracy of 99.9% where the probability of an 
incorrect base call was 1 in 1000 bp.  
The quality of generated sequences was checked using SolexaQA (ver. 2.2). This program extracts the 
longest contiguous sequence where all bases have high Phred scores by trimming off bases with low 
Phred scores [366]. A median of 93.26% of high quality paired-end reads across all samples was achieved 
by trimming paired end sequences with the cut-off p-value of < 0.05, and read lengths of at least 25 
nucleotides was generated.  
The reads were then mapped against the reference genomes using TopHat (ver. 2.0.4), a fast short read 
mapping program for RNA-Seq that aligns sequences to a reference genome and identifies exon-exon 
splice junctions [367]. The parameter ͚-N 3 -library-type-fr-unstranded͛ was selected to map reads from 
the left most end of the nucleotide fragment to the transcript strand and the right most end to the 
opposite strand. Aligned reads with three or more mismatches were discarded and S288C sequences 
were mapped to the genome reference R64-1-1 from the Saccharomyces genome database (SGD) [332]. 
H99 sequences were mapped to the C. neoformans var. grubii H99 CNA3 and mitochondrial reference 
genomes (Assembly 2, ver. 29/07/2013) from the Broad institute of Harvard and MIT 
(http://www.broadinstitute.org/). 97/170 sequences were mapped to the 97/170 genome, which was 
sequenced.  
HTSeq (ver. 0.5.3p9) was used to count the number of reads that mapped to a gene on the reference 
genome. This program pre-processes RNA-Seq data for differential expression analysis by counting the 
overlap of aligned reads on exons of a gene [368]. The general feature format (GFF) that contains the 
coordinates of each gene on each chromosome of the S. cerevisiae genome was downloaded from SGD 
and converted to the gene transfer format (GTF) using a custom Perl scripts for HTSeq. For Cryptococcus, 
transcripts.fasta and transcripts.gtf files, which contain the position of the genes on each chromosome, 
were used. The parameters ͚-s no –m union –t CDS –i gene_id͛ were used, where reads were mapped to 
the coding sequence (CDS) regardless of the strand and only counted if they aligned unambiguously to a 
CDS. Genes with low raw read counts were removed and only genes with seven counts per million for at 
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least six samples were kept for analysis. For S288C, H99 and 97/170 sequences, a 99% median 
correlation was observed for counts per gene between biological triplicates, indicating high 
reproducibility. The counts were then used for gene level differential expression analysis using the 
Empirical analysis of digital gene expression data in R (EdgeR; ver. 3.2.8) software.  
To correct for technical biases introduced during the RNA-Seq procedure and to allow for accurate 
estimation and detection of differential gene expressions and analysis, normalisation was applied. Each 
sample was first normalised to the size of the library with the statistical package in EdgeR using the 
͚cpm͛ (counts per million) function, such that the expected size of each count is the product of the 
library size and the relative abundance of that gene in an analysed sample. The RNA-Seq lane effect was 
normalised as part of the generalised linear model parameter. Negative binomial distribution was used 
to model transcript counts by distinguishing biological (due to expression levels between experimental 
samples) and technical (associated with sequencing technology) variance across the samples. This was 
then used to infer the biological coefficient variance (BCV), which is estimated by the square-root of the 
dispersion parameter for the negative binomial distribution [369]. The similarity of biological replicates 
for each treatment was analysed by multiple dimension scaling (MDS), where the distances between 
samples correspond to the average of the largest absolute log fold change between each pair of 
samples.  
4.2.4.3. Generating differentially expressed transcripts from the effects of synergistic and antagonistic 
drug treatments 
To determine the effect of drug synergy and antagonism on the yeast transcriptome, the averaged 
differential gene expression of untreated controls were subtracted from their respective drug 
treatments. These were labelled TA (treatment with AMB only; AMB – CA) and TAL (treatment with 
AMB+LF; AMB+LF – CAL) in synergy, and TV (treatment with VRC only; VRC-C) and TVE (treatment with 
VRC+EDTA; VRC+EDTA – C) in antagonism experiments. The Benjamini-Hochberg algorithm [370] was 
applied to filter out genes falsely differentially expressed, using the cut-off p-value of < 0.05.   
4.2.4.4. Self-organising maps (SOMs) 
The differentially expressed genes in TA and TAL were analysed independantly using two SOMs, (Kohonen 
package, ver. 2.0.15) which uses an unsupervised learning algorithm to group similar data points from 
high dimensional data sets and visualises it in lower dimensional representations. This type of artificial 
neural network (also known as Kohonen maps or networks) clusters genes with close expression profiles 
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into individual cells, and then organises the cells across the map based on cell-to-cell similarity [371, 
372].  
The log normalised read counts from EdgeR were further scaled to log reads per kilobase per million 
(rpkm) by subtracting the log of the gene length. The log rpkm values across the 12 samples per gene 
were transformed to a mean of 0 and standard deviation of 1 across all samples with Pareto scaling from 
the ͚genefilter͛ library (ver. 1.46.1). Each SOMs was generated using the R statistical computing 
environment (ver. 3.1.1) [373] and the normalised data were clustered into a 5 x 5 grid using the ͚som͛ 
function. The groups converged after 100 iterations of the learning algorithm. The maps were then 
visualised using custom R scripts and the ͚lattice͛ package, and the clusters were labelled numerically 
starting from the bottom left to the top right cluster. A heat map was generated for each SOMs to 
present the average expression pattern for each cluster to provide an overview of the SOMs. 
4.2.4.5. Gene ontology (GO) enrichment analysis  
Significantly up and down-regulated genes in each treatment and model were analysed for enrichment 
of GO terms. Co-expressed genes within each of the SOMs cells were likewise analysed. The analysis of 
differentially expressed S288C and H99 genes was performed with the GOstats package (ver. 2.30.0) 
from the R statistical computing software (ver. 3.1.1) [373]. The GO annotations used for S288C were 
from org.Sc.sgd.db (ver. 2.14.0) and GO.db (ver. 2.14.0) package. For H99, GO annotations were 
compiled from multiple sources to improve GO coverage and quality. 97/170 GO annotations were 
reciprocal blasted against the improved H99 GO annotations to identify homologous proteins with one-
to-one sequence matches using custom scripts to run BLAST+ [374], using the Blastp option. Statistics 
for GO enrichments were calculated in R using a ͚GOstats͛ library (ver. 2.29.2) [375]. GO terms for S288C 
were biased for child terms to enable detailed analyses, and were retrieved by Fisher͛s exact test at a p-
value < 0.05. Significant child GO terms that appeared with their significant parent term were filtered 
out to ensure the significance of child terms was not biasing the parent GO terms. For H99 and 97/170, 
only the parent GO terms were used. The Benjamini-Hochberg algorithm [370] from the multtest 
package (ver. 2.19.2) [376] was then used to adjust for false discovery rates and significance of GO terms 
were considered at a p-value < 0.01. GO terms containing only one gene were removed from the 
analysis. GO analysis was also cross-checked with YeastMine [345] using Benjamini-Hochberg at a p-
value of < 0.05.   
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To improve the coverage and quality of GO annotations from the C. neoformans genome, UNSW 
colleagues Igy Pang and Nandan Deshpande compiled GO annotations from Uniprot (accessed 
09/02/2015) [377] and QuickGO [378] (unpublished). OrthoMCL [379] was used to find orthologous C. 
neoformans proteins with one-to-one sequence matches in other fungal species, including S. cerevisiae, 
Aspergillus fumigatus, Schizasaccharomyces pombe and Agaricus bisporus. Blast2GO (ver. 3, database 
ver. B2g_sept2014) [380] was also used to search for homologous C. neoformans proteins from the 
Broad Institute against the NCBI non redundant (NR) sequence database using the Blastp option [374]. 
GO terms that were not previously found in the databases of fungal species mentioned above, including 
C. neoformans, were removed from the Blast2GO output. All GO term annotations from Uniprot, 
QuickGO, OrthoMCL and Blast2GO were merged into a single table. Duplicated protein entries were 
removed and the resulting list was used for GO enrichment analysis. All analyses were performed using 
custom Python scripts. The databases used for each organism, websites and dates accessed are listed 
below: 
 C. neoformans protein sequences (accessed 03/2014):   
https://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiDownloa
ds.html     
 Uniprot C. neoformans GO annotations (accessed 09/02/2015): 
http://www.uniprot.org/uniprot/?query=taxonomy:235443  
 QuickGO (accessed 07/05/2015): 
QuickGO: http://www.ebi.ac.uk/QuickGO/GAnnotation?tax=235443  
 S. cerevisiae GO annotations (accessed 06/05/2015): 
http://downloads.yeastgenome.org/curation/literature/gene_association.sgd.gz  
 S. pombe GO annotations (accessed 06/05/2015): http://www.pombase.org/downloads/go-
associations  
 A. fumigatus GO annotations (accessed 06/05/2015):  
http://www.aspergillusgenome.org/download/go/  
 A. bisporus GO annotations (accessed 06/05/2015): http://genome.jgi-psf.org/cgi-
bin/ToGo?accession=all&species=Agabi_varbisH97_2&batchId=Agabi_varbisH97_2-159  
Non-redundant (NR) protein sequences were from GenPept, Swissprot, PIR, PDF, PDB and NCBI RefSeq 
(accessed 21/01/2015):  ftp://ftp.ncbi.nlm.nih.gov/blast/db/   
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4.2.4.6. Analysis of biological networks  
For network analysis, selected pathways were mapped and visualised in the open source software 
Cytoscape (ver. 3.1.1) [381]. Regulatory data for transcription factors and target genes, which were 
identified from ChIP-Seq studies or from transcript changes in gene deletion studies, were downloaded 
from Yeastract (accessed 27/09/2013) and the ranking of transcription factors based on their 
connectivity to differentially expressed genes was performed using TFRank with a heat diffusion 
coefficient of 0.25 [382]. Protein-protein interactions were obtained from Pang et al. (2012) [383] and 
genes in selected pathways were further curated with literature searches and in the Kyoto Encyclopedia 
of Gene and Genomes (KEGG) and YeastCyc biochemical pathway databases [332, 384]. Log fold-
changes from the differential expression analysis were co-visualised as node colours.  
4.2.5. Validation of transcriptomic data in S. cerevisiae   
To validate the transcriptomic data in S288C, knock-out mutants of chosen genes were obtained from 
the Yeast Deletion Project collection [341], which was provided by the Wilkins Lab in UNSW. This 
collection contains a near complete set of deletion strains and allows the functions of characterised 
genes and many uncharacterised ORFs in the S288C genome to be analysed through phenotypic 
characterisation of the knock-out mutants. The knock-out collection was generated in the background 
strain BY4741 with the genotype MATa uraϯΔϬ leuϮΔϬ hisϯΔϭ ŵetϭϱΔϬ. 
4.2.5.1. PCR confirmation of knock-out mutants 
Knock-out mutants were confirmed with PCR primers using primer combinations A-B, A-KanB, A-NatB, 
KanC-D, NatC-D and A-D that were designed for each selected gene (Fig. 4.2; Appendix 4.2). KanB and 
KanC are primers designed from the kanamycin selection marker and NatC and NatD were designed 
from the nourseothricin marker. Amplification of bands using primers A-KanB and KanC-D was required 
for knock-out confirmation. Where bands were not amplified with either of primer A-KanB or KanC-D 
combinations, amplification of expected band sizes from primers A-D served as knock-out confirmation. 
Additionally, primers A-B were used to amplify DNA sequences from the wild type strain BY4741 to 
confirm gene identity [341]. PCR conditions were performed as specified in the Yeast Deletion Project, 
where reaction mixtures contained 10 x Taq reaction buffer, 2.5 U Taq polymerase, 0.2 mM of mixed 
dNTPs, aŶd ϱ μL geŶoŵiĐ DNA ;ϭ Ŷg – ϭ μgͿ iŶ a fiŶal ǀoluŵe of ϱϬ μL. Foƌǁaƌd ;A, KaŶC oƌ NatCͿ aŶd 
ƌeǀeƌse ;B, KaŶB, NatB oƌ DͿ pƌiŵeƌs ǁeƌe added at a fiŶal ĐoŶĐeŶtƌatioŶ of ϭ μM to the ƌeaĐtioŶ 
mixture for the region of amplification desired. Amplifications were performed by an initial denaturation 
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of 94 °C for 3 min, followed by 35 cycles of 94 °C for 15 sec, 57 °C for 15 sec and 72 °C for 60 sec, with a 
final extension of 72 °C for 3 min. For ĐĐhϭ∆, the annealing temperature in the 35 cycles was lowered to 
50 °C, with an extension time of 7 min. 
4.2.5.2. Knock-out cassette construction 
As one of the chosen genes, YOR387C, was not present in the Saccharomyces gene deletion library, gene 
deletion was performed by homologous recombination in the wild type strain BY4741 using a modified 
protocol from Janke et al. (2004) [385]. A double deletion of YOR387C in the vel1Δ mutant was also 
created as VEL1 shares 93% homology with YOR387C. The plasmid cassette pFA6a-natNT2 with a 
selection marker for nourseothricin was provided by the Wilkins Lab. PCR primers were designed to 
encompass 45-55 bp before and after the YOR387C ORF, inclusive of the start and stop codons. Each 
primer contained a sequence at the 3͛ end that was homologous to the selection marker cassette within 
the plasmid (see Fig. 4.3). The primers were designated yor387c_S1 and yor387c_S2, with the sequences 
outlined in Appendix 4.2.  
The YOR387C geŶe deletioŶ ĐoŶstƌuĐt ǁas ŵade iŶ a ϱϬ μL ƌeaĐtioŶ ŵiǆtuƌe ĐoŶtaiŶiŶg LoŶgAŵpTM Taq 
Ϯ X ŵasteƌ ŵiǆ, ϭϬ μM of eaĐh yor387c_S1 and ǇoƌϯϴϳĐ_SϮ pƌiŵeƌ, aŶd ϭ μL ;ϭϬϬ ŶgͿ of the selected 
plasmid cassette DNA. Amplification conditions were performed with an initial denaturation of 94 °C for 
3 min, followed by 30 cycles of 94 °C for 30 sec, 54 °C for 30 sec and 65 °C for 4 min, with a final 
extension of 65 °C for 10 min.  
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Figure 4.2. Primers designed to confirm gene deletions. Primers A and D were designed from sequences 
200 – 400 bp before and after the yeast ORF or selection marker. Primers B, C, KanB, KanC, NatB and 
NatC were designed from sequences 100-200 bp from the ends of the yeast ORF and selection marker, 
to amplify with primers A and D. (a) Primer sets A-B, C-D and A-D will amplify bands in the DNA of wild-
type cells while A-KanB/NatB and KanC/NatC-D will not. (b) DNA of mutants with successful gene 
deletions by replacement with the selection marker will have amplification bands from primer sets A-
KanB/NatB and KanC/NatC-D, but not with A-B and C-D. Adapted from Kelly et al. (2001) [341]. 
 
 
Figure 4.3. Primer design for cassette construction and gene deletion. Primers were designed to stitch 
the selection marker from the plasmid cassette with homologous sequences upstream and downstream 
from the ORF of interest. From 5͛ to 3͛ direction, primers included sequences 45-55 bp upstream of the 
start/stop codon, plus the start/stop codon and the sequence of the selection marker as indicated in the 
diagram. Adapted from Janke et al. (2004) [385]. 
 
(a) 
(b) 
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4.2.5.3. Transformation of S. cerevisiae with knock-out constructs 
Five micolitres of the constructed plasmid cassette DNA was transformed into the S. cerevisiae wild type 
BY4741 and velϭ∆ (KanMX4 marker, BY4741 background) strains using a LiAc/SS-DNA transformation 
protocol [386] with slight modifications. Briefly, a 5 mL culture of BY4741 was grown overnight in 
Sabouraud dextrose broth (SDB) at 30 °C, with shaking at 180 rpm. The overnight yeast culture was used 
to inoculate 50 mL of pre-warmed SDB at a starting concentration of 5 x 10
6 
cells/mL. The culture was 
grown at 30 °C, 200 rpm, until it reached 2 x 10
7
 cells/mL indicating at least two rounds of cell division. 
10 mL of the culture was pelleted at 4,000 rpm for 5 min, washed with 25 mL of sterile water and re-
centrifuged. The pelleted cells were resuspended in 1 mL of sterile 100 mM LiAc, centrifuged again at 
top speed for 40 sec and resuspended in 100 mM LiAc, giving a final cell concentration of approximately 
2 x 10
9
 Đells/ŵL iŶ a fiŶal ǀoluŵe of ϱϬϬ μL. ϱϬ μL of the Đell suspeŶsioŶ ǁas aliƋuoted iŶto fouƌ sepaƌate 
eppendorf tubes (for the three replicates and one control), pelleted and the LiAc solution removed. 
Transformation reagents were then added in the following order to a total volume of 360 µL: 240 µL of 
PEG (50% w/v), 36 µL of 1 M LiAc, 25 µL of pre-boiled and chilled SS-DNA (4 mg/mL), plasmid DNA (100 
ng – 1 µg, volume not to exceed 10% of total volume) and sterile distilled water. Water was added in 
place of plasmid DNA as a negative control.  
Each tube was vortexed until the cell pellets were resuspended, before incubation at 30 °C for 30 min. 
Cells were then heat shocked for 30 min at 42 °C and centrifuged at 7,000 rpm for 90 sec. The 
transformation mix was removed and transformed cells were incubated overnight at room temperature 
in 200 µL SDB before selecting mutants on SDA plates supplemented with 100 µg/mL nourseothricin. 
Plates were incubated at 30 °C for up to 5 days. Knock-out mutants were confirmed using the primers 
outlined above (Section 4.2.5.1; Fig. 4.2, Appendix 4.2).   
4.2.6. Spot plate assays  
To test the phenotype of the knock-out mutants, spot plate assays were performed on synthetic 
complete (SC) media with a variety of stressing agents. Overnight broth cultures of knock-out mutants 
were grown in 5 mL SC broth in a shaking incubator at 30 °C, 180 rpm. Cell concentrations were 
standardised at 1 x 10
6
 cells/mL with a haemocytometer and dilutions were made from 10
6
 to 10 
cells/mL. Five microlitre aliquots of each dilution were spotted onto 25 mL SC plates supplemented with 
stressing agents at the following concentration ranges: AMB from 0.25 – ϭ μg/ŵL, FLC fƌoŵ ϭϲ – 64 
μg/ŵL, ĐalĐofluoƌ ǁhite fƌoŵ ϭϬϬ – ϮϬϬ μg/ŵL, ĐoŶgo ƌed fƌoŵ ϭϬϬ – ϯϬϬ μg/ŵL, SDS fƌom 0.005 – 
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0.02% (w/v), salt (NaCl) at 1 M, sodium nitrite (NaNO2) from 1 – 3 mM, hydrogen peroxide (H2O2) from 1 
– 3 mM, caffeine from 10 – 15 mM. Plates were left to dry and were incubated at 30 °C. Growth was 
checked every day until the 5
th
 day.  
4.2.7. Rescue assays 
Rescue iron assays performed in Chapter 3 (3.2.6) showed that low concentrations of iron did not 
disrupt AMB+LF synergy and were unable to rescue cell growth (Fig. 3.4). To understand the effect of 
iron addition at higher concentrations, rescue assays were once again performed, along with zinc, 
calcium, and BAPTA, in the presence of different concentrations of AMB+LF. The concentrations tested 
were determined by preliminary screens, unless specified. Iron (III) chloride and iron (II) sulphate were 
tested from 0.3 – ϴϬ μg/ŵL, ziŶĐ Đhloƌide fƌoŵ Ϭ.Ϯϱ – ϲϰ μg/ŵL, ĐalĐiuŵ Đhloƌide fƌoŵ ϭ.ϱ – ϰϬϬ μg/ŵL, 
BAPTA from 1.5 – ϰϬϬ μg/ŵL. The ĐoŶĐeŶtƌatioŶs of AMB aŶd LF tested eŶĐoŵpassed the FIC ǁith the 
following combinations (AMB, LF): (0.015, 0.5), (0.015, 1), (0.03, 2; the FIC), (0.06, 4) and (0.06, 8) 
μg/ŵL. AMB+LF ĐoŵďiŶatioŶs ǁeƌe ŵade togetheƌ at ϰ ǆ the fiŶal ĐoŶĐeŶtƌatioŶ. SiŵilaƌlǇ, AMB aŶd LF 
were prepared separately at 4 x their MIC, and each rescue agent was prepared at 4 x the final 
concentration.  
Rescue assay plates were set up as follows: serial doubling dilutions of the rescue agent were aliquoted 
from columns 11 to 3 in 50 µL volumes. Column 12 was designated as the positive growth control and 
column 1 was the negative growth control. Row A tested the effect of the rescue agent alone on yeast 
growth, and included 50 µL of media in the place of 50 µL of AMB+LF. 50 µL of each of the AMB+LF 
concentrations was aliquoted into each well from row B to F, from column 11 to 2. Column 2 tested the 
individual effects of the different concentrations of AMB+LF as well as AMB and LF alone on growth and 
included 50 µL of media in place of rescue agents. Row G and H contained 50 µL of MIC levels of AMB 
alone and LF alone, respectively.  
Cell inoculations were performed as outlined in the MIC protocols (Section 3.2.3). Assays were 
incubated for 48 hr and growth or no growth was recorded by visual observation.  
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4.3. Results  
4.3.1 Effect of AMB, LF and AMB+LF on the growth of S. cerevisiae S288C and C. neoformans H99 
Growth curves of S288C and H99 treated with AMB+LF at concentrations causing synergy, and with AMB 
or LF alone at their respective FIC concentrations, were performed to determine the ID20 for RNA 
extraction and sequencing (Fig. 4.4). Growth curves clearly differed between the cultures treated with 
AMB+LF and AMB alone after three hours of drug exposure (Fig 4.4a and 4.4c). Treatment with LF at 2 
μg/ŵL did Ŷot iŶhiďit the gƌoǁth of SϮϴϴC oƌ Hϵϵ, aŶd aŶ ID20 could not be determined even when LF 
treatment was extended to 24 hrs (Fig. 4.4b and 4.4d). Note that these assays were more favourable for 
fungal growth than the plates used for MIC testing as they were performed in large culture volumes with 
shaking, and the level of inhibition therefore differs somewhat to what was seen in the checkerboard 
assays.  
In S288C, the ID20 for AMB+LF occurred between 45 min and 1 hr, and the ID20 for AMB was at 1 hr (Fig. 
4.4a). With increasing time of exposure, the drug treatments progressively inhibited cell growth, with 
AMB+LF inhibiting growth to a significantly greater extent than AMB (Table 4.1, Fig. 4.4b). In H99, a 
similar ID20 was seen in the AMB+LF and AMB treatments (Fig. 4.4.c), however, the extended growth 
curve was quite different with inhibition by AMB essentially lost at 24 hr (Table 4.1, Fig. 4.4d). AMB+LF 
continued to inhibit growth to a greater extent than AMB alone but did not inhibit H99 to the extent 
seen in S288C (Fig. 4.4b and 4.4d). For RNA-sequencing, RNA was extracted at 50 min for AMB+LF 
treatment (along with the untreated control at the same timepoint) and 1 hr for AMB treatment (with 
an untreated 1 hr control) for both S288C and H99.  
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Figure 4.4. The effect of AMB+LF, AMB, and LF on the growth of S. cerevisiae S288C and C. neoformans 
H99. (a) and (c) First 3 hours of drug treatment. ID20 occurred at 50 min for AMB+LF and 1 hr for AMB 
treatment. (b) and (d) Growth curves extended for 24 hr. LF at 2 µg/mL did not inhibit S288C or H99 
growth throughout 24 hr of treatment, while AMB and AMB+LF provided sustained inhibition, 
particularly of S288C. Data is shown as mean +/- standard error of the mean (SEM). 
 
Table 4.1. Percent reduction in growth relative to untreated controls at selected timepoints for AMB 
and AMB+LF treatment in S. cerevisiae S288C and C. neoformans H99  
Organism  Treatments  30 min 45 min 1 hr 2 hr 3 hr 6 hr 9 hr 
S288C  AMB 11% 12% 20% 28% 36% 38% 46% 
 AMB+LF 15% 18% 26% 35% 40% 65% 67% 
H99 AMB 7% 12% 20% 27% 24% 26% 24% 
 AMB+LF 10% 17% 28% 37% 47% 36% 47% 
 
(d) 
ID20 of 
AMB + LF 
    ↓ 
↑ 
ID20 of AMB 
ID20 of 
AMB + LF 
    ↓ 
↑ 
ID20 of AMB 
(b) (a) 
(c) 
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4.3.2. Analysis of RNA-Seq data 
4.3.2.1. Data quality control for RNA-Seq analysis 
The accuracy and quality of RNA-Seq reads were analysed with FastQC (ver. 0.10.1) and SolexaQA (ver. 
2.2). There were on average 9.95 million reads per sample with a coverage of approximately 80x. 
Sequences had a median Spearman correlation of 0.99 for raw gene counts between biological 
replicates, indicating high experimental reproducibility. A total of 5,456 transcripts were identified in 
S288C, while 6,810 transcripts were identified in H99.  
For S288C samples in synergy experiments, the average biological coefficient variance (BCV) was 0.0987 
(about 10%) (Fig. 4.5b), indicating low variability between biological replicates, which is normally 
observed in model organisms [387]. Biological replicates of each drug treatment grouped together in 
MDS, indicating similar gene expression profiles (Fig. 4.5a). However, sample 1B from the AMB control 
(CA) clustered with the AMB+LF control (CAL) samples, and vice versa for sample 8A. To determine if 
samples 1B and 8A should be swapped to where they should cluster, i.e. corrected, kept without 
swapping, or deleted, a list of differentially expressed transcripts was first generated to then compare 
the number of differentially expressed genes for each drug treatment (detailed in Section 4.3.2.2). Not 
swapping the positions of 1B and 8A caused a drastic reduction in the gene counts for both drug 
treatments, while deletion of both samples caused a minor increase in the gene counts in AMB treated 
cells and a decrease in AMB+LF treated cells (Table 4.2). Based on these results it was assumed that 
these samples had been inadvertently mixed up and they were swapped to be where they clustered by 
MDS.  
For AMB and AMB+LF treatment, the log-fold changes of individual genes relative to their expression in 
their respective controls (CA and CAL) were plotted against their log-concentrations, to give a ratio of 
expression levels against the overall averaged expression level (Fig. 4.5c – d). Genes with low counts are 
shown in black and differentially expressed genes are in red. Comparison of genes expressed following 
AMB (Fig. 4.5c) and AMB+LF treatment (Fig. 4.5d) shows that differential expression was greater 
following AMB+LF treatment.  
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Figure 4.5. RNA-Seq analyses of S. cerevisiae S288C samples. (a) MDS plot of all RNA-Seq samples after 
normalisation with EdgeR. Biological replicates of each drug treatment have similar gene expression 
profiles and cluster together as outlined, except for samples 1B and 8A. (b) BCV versus average log2 
counts per million (CPM) of RNA-Seq samples. The red line represents the common dispersion of all 
genes while the blue line represents the trended dispersion of all genes. Each dot is a data point that 
represents the tag-wise dispersion of each gene. (c) Smear plot of log2 fold change (FC) versus the 
average log2 CPM values of genes in the AMB treatment. (d) Smear plot of log2 FC versus the average 
log2 CPM values of genes in the AMB+LF treatment. For (c) and (d), differentially expressed genes are 
represented in red and the blue lines are drawn at 2-fold changes in expression. 
 
 
(a) 
(c) (d) 
(b) 
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Table 4.2. Comparison of gene counts when S. cerevisiae S288C RNA samples 1B and 8A were swapped, 
not swapped or deleted  
 Gene expression 1B and 8A with 
swapping 
1B and 8A with no 
swapping 
1B and 8A deletion 
TA Up-regulated 907 474 946 
No fold change  3628 4613 3600 
Down-regulated  921 369 897 
TAL Up-regulated  748 302 675 
No fold change  4019 4961 4308 
Down-regulated  689 193 460 
 
Although treatment with LF alone did not cause growth inhibition (Fig. 4.4), RNA-Seq analysis was 
subsequently performed to investigate whether the FIC of LF caused changes to the yeast transcriptome 
(Fig. 4.6). Three separate clusters are seen in the MDS plot (Fig. 4.6a), which represent the three 
biological replicates of LF treatment and the untreated control. The smear plot in Figure 4.6b shows that 
no genes were differentially expressed between LF and the untreated control. The BCV of LF samples are 
presented in Appendix 4.3. As there was no apparent transcriptional response to LF alone, the analysis 
of synergy between AMB+LF was restricted to the comparison between AMB and AMB+LF treatment.  
 
  
Figure 4.6. RNA-Seq analysis of LF treatment only. (a) MDS plot of LF treatment and its untreated 
control. Biological replicates of treatments and control samples grouped together. (b) Smear plot of log2 
fold change (FC) versus the average log2 CPM values of genes in the LF treatment. An absence of red 
dots indicates there was no change in log-fold expression of any genes. 
(a) (b) 
D 
D 
D 
D 
D 
D 
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For H99, PCA plots clustered the samples better than MDS and identified sample 5A as an outlier (Fig. 
4.7a). The effects of deleting 5A on the counts of differentially expressed genes in AMB and AMB+LF 
treatment was investigated. Deletion of this sample increased the number of genes in AMB treatment, 
while little change was observed in AMB+LF treatment (Table 4.3). The averaged BCV improved from 
0.2179 to 0.1511 with 5A deletion (Fig. 4.7b, Appendix 4.4) and subsequent analyses were performed 
without this sample. The plots of gene fold-changes of AMB and AMB+LF treatment were highly similar, 
with AMB+LF treatment having more differentially expressed genes at log fold changes above six (Fig. 
4.7c and d).  
4.3.2.2. Comparison of differentially expressed genes in S. cerevisiae S288C and C. neoformans H99  
AMB and AMB+LF treatment affected the growth of cells differently and cultures reached ID20 at 
different timepoints (Fig. 4.4). As ID20 was used for RNA-Seq, the differences in the time of RNA isolation 
is likely to result in changes in the transcriptomes between AMB and AMB+LF treatment that are due to 
factors other than drug treatment. Each single and combined drug treatment therefore needed its own 
control, i.e., CA and CAL, respectively, to allow a comparable analysis. A list of transcripts that were 
differentially regulated due to AMB and AMB+LF treatment was then generated by subtracting genes 
that were expressed under AMB with those expressed in its control CA (defined as TA, where T stands for 
transcripts), and AMB+LF with CAL (defined as TAL).  
A comparison of the number of differentially expressed genes from the two yeast species is shown in 
Table 4.4. In S288C, TA had 906 and 921 up- and down-regulated genes, respectively, while TAL had 748 
up-regulated genes and 689 down-regulated genes. In H99, TA had 1677 and 1615 up- and down-
regulated genes, respectively and TAL had 1678 up-regulated genes and 1474 down-regulated genes. In 
S288C around 15% of genes encoded putative proteins or proteins with unknown function, whereas 
about a third of the transcripts in H99 encoded uncharacterised proteins, even when annotations were 
taken from other fungal species. This likely reflects differences in annotation between the two yeast 
genomes. Approximately 50% and 60% of genes were differentially expressed from the total number of 
transcripts identified for S288C and H99, respectively.  
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Figure 4.7. RNA-Seq analyses of C. neoformans H99 samples. (a) PCA plot of all RNA-Seq samples after 
normalisation with EdgeR. Biological replicates clustered together as circled, showing 5A as an outlier. 
(b) BCV versus average log2 CPM with 5A deletion. The red line represents the common dispersion of all 
genes while the blue line represents the trended dispersion of all genes. Each dot is a data point that 
represents the tag-wise dispersion of each gene. (c) Smear plot of log2 fold change (FC) versus the 
average log2 CPM values of genes in AMB treatment with 5A deletion. (d) Smear plot of log2 FC versus 
the average log2 CPM values of genes in AMB+LF treatment with 5A deletion. For (c) and (d), 
differentially expressed genes are represented in red and the blue lines are drawn at 2-fold changes in 
expression.  
 
 
(d) 
(b) (a) 
(c) 
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Table 4.3. C. neoformans H99 gene count comparison with and without RNA sample 5A 
 Gene expression With 5A Without 5A 
TA Up-regulated  1103 1677 
No fold change  4894 3517 
Down-regulated  819 1615 
TAL Up-regulated  1694 1678 
No fold change 3576 3658 
Down-regulated 1546 1474 
 
 
Table 4.4. Comparison of differentially expressed genes in S. cerevisiae S288C and C. neoformans H99 in 
response to the two drug treatments 
Differentially expressed genes  TA TAL 
S288C H99 S288C H99 
Total number  1828 3293 1437 3152 
Up-regulated 907 1677 748 1678 
Down-regulated 921 1615 689 1474 
Protein of unknown function 97 – 63 – 
Putative protein 192 – 163 – 
Uncharacterised protein – 1430 – 1350 
Unique to treatment – Up-regulated 532 244 320 241 
Unique to treatment – Down-regulated  630 331 451 192 
 
A 
B 
c 
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4.4. Results – Analysis of the transcriptome of drug synergy in S. cerevisiae S288C  
4.4.1. GO enrichments of differentially expressed S288C genes in TA and TAL 
GO enrichment was performed to analyse the changes in transcript expression induced in synergy by 
comparing the expressions caused by AMB+LF treatment to the expressions observed in AMB treatment 
alone. As seen in Table 4.5, the GO enrichments between the two drug treatments were distinctly 
different. Treatment with AMB down-regulated GO terms related to DNA synthesis, RNA processes and 
cellular component biogenesis, and up-regulated GO terms involved energy production-related 
processes such as the tricarboxylic acid (TCA) cycle, electron transport and redox. Other up-regulated 
GO terms include degradation processes including mitophagy and the cytoplasm to vacuole transport 
(CVT) pathway, processes related to metal ion homeostasis, especially iron homeostasis, and stress such 
as trehalose biosynthesis [388] and hydrogen peroxide catabolism. These enrichments suggest a 
reduction in DNA replication and protein production, and an increased requirement for energy, possibly 
for the degradation of intracellular organelles to survive AMB treatment [389].  
For TAL, down-regulated GO terms were related to post-translational modifications like ubiquitination 
and lipid biosynthesis. Stress related processes such as endoplasmic reticulum (ER) and oxidative stress 
were also down-regulated, in contrast to TA. Amino acid synthesis, translation and ribosome biogenesis 
GO terms were up-regulated in AMB+LF treatment, suggesting the cells are not sensing and responding 
to the toxic stress of AMB when LF is present and are continuing to switch on growth-related terms. 
Despite the chelating properties of LF, terms related to metal ion homeostasis were not enriched.  
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Table 4.5. Selected gene ontology term enrichments of differentially expressed transcripts in S. cerevisiae S288C for TA and TAL  
GO Terms  
Transcriptome responses to drug treatments and odds ratio
a
 
TA Genes in enrichment TAL Genes in enrichment 
DNA synthesis related     
Nucleobase metabolic process 5.68 AAH1, ADE2, ADE4, ADE5,7, ADE8, APT1, 
MTD1, URA1, URA3, URA4, URA5, URA6, 
URA7, URA8, XPT1 
  
Positive regulation of transcription from RNA 
polymerase I promoter  
4.38 CDC37, NAN1, UTP10, UTP15, UTP4, UTP5, 
UTP8, UTP9 
  
Purine ribonucleoside monophosphate 
biosynthetic process  
3.18 AAH1, ADE1, ADE17, ADE2, ADE4, ADE5,7, 
ADE6, ADE8, ADK2, PMA1, XPT1 
  
Pyrimidine ribonucleoside monophosphate 
biosynthetic process  
9.02 DAS2, FUR1, URA1, URA3, URA4, URA5   
Amino acid related     
Cellular amino acid metabolic process 3.69 69 genes 8.44 51 genes 
Positive regulation of cellular amino acid metabolic 
process 
  10.32 DAL81, LEU3, LYS14, PUT3 
Amino acid transmembrane transport 6.25 AGP1, AGP2, ALP1, ATG22, AVT4, AVT6, 
BAP2, BAP3, BIO5, CAN1, DIP5, GAP1, 
GNP1, PUT4, RTC2, TAT2 
11.83 AGP1, ALP1, AVT1, BAP2, BAP3, CAN1, 
DIP5, GAP1, GNP1, HNM1, LYP1, PUT4, 
TAT1, TAT2, UGA4 
Protein  related     
Regulation of translation fidelity    7.81 CDC60, ILS1, RPL31A, RPL31B, RPS23A, 
RPS23B, RPS5, VAS2, YHR202W 
Regulation of translation initiation 4.83 FUN12, GCD1, GCD10, GCN3, MPT5, NIP1, 
PAB1, TIF1, TIF2, TIF34, TIF35, TIF5 
  
Cytoplasmic translation   19.11 116 genes 
Negative regulation of protein modification 
process 
3.24 BMH2, CDC20, CDH1, LAG2, LRE1, LSP1, 
NCE102, PIL1, PTP2, SDP1, SPL2, STP22 
  
Ribosome biogenesis 5.36 BCD1, RPA12, RPA135, RPA190, RPA34, 
RPA43, RPA49, RPB5, RPB8, RPC10, RPC40, 
RPO26, RPS26B, TMA20 
3.88 BRX1, RPA12, RPA14, RPA49, RPC10, 
RPC40, RPL10, RPL11A, RPL11B, RPL12A, 
RPL12B, RPL25, RPL3, RPL34A, RPL5, 
RPL6A, RPL6B, RPP0, TOR1, TOR2 
Protein folding 2.18 AHA1, CCT2, CCT3, CCT5, CIN4, CNE5, 
CNS1, CPR7, CUR1, EMC5, FLC1, FPR4, 
GIM4, GIM5, GSF2, HCH1, HSP26, HSP82, 
PAC2, SIS1, SLP1, SSA2, SSA4, SSB1, SSB2, 
3.77 AHA1, BTN2, CNE1, CPR1, CPR2, CUR1, 
ERJ5, EUG1, FLC1, FMO1, FPR1, FPR2, 
GSF2, HCH1, HSP26, JAC1, MPD1, MPD2, 
PDI1, PLP1, SIS1, SSA4, STI1, TAH1 
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SSE1, STI1, TAH1, YDJ1 
Post-translational protein targeting to membrane    16.65 KAR2, LHS1, SBH1, SEC61, SEC62, SEC72 
SRP-dependant co-translational protein targeting 
to membrane, translocation  
  10.39 KAR2, SBH1, SEC61, SIL1, SSA4 
Retrograde protein transport, ER to cytosol   24.98 DER1, HRD1, HRD3, NPL4, SEC61, UFD1 
ER associated misfolded protein catabolic process   32.21 NPL4, PMT1, PMT2, UFD1 
ER asssociated ubiquitin dependent protein 
catabolic process 
  6.65 ADD37, ATG19, CNE1, DER1, DFM1, 
HRD1, HRD3, JEM1, KAR2, LCL2, MNS1, 
POF1, SCJ1, SEC61, UBC7, UBX2, UBX4, 
YDJ1 
Lipid related     
Ergosterol biosynthesis  4.03 ERG11, ERG2, ERG24, ERG26, ERG27, ERG3, 
ERG5, ERG6, ERG7, ERG8, MOT3, NCP1 
4.84 ERG10, ERG12, ERG20, ERG26, ERG27, 
ERG28, ERG5, ERG6, ERG8, MCR1, NCP1 
Steroid biosynthetic process 3.25 CYB5, ERG11, ERG2, ERG24, ERG26, ERG27, 
ERG3, ERG5, ERG6, ERG7, ERG8, MOT3, 
MVD2, NCP1 
4.03 CYB5, ERG10, ERG12, ERG20, ERG26, 
ERG27, ERG28, ERG5, ERG6, ERG8, MCR1, 
MVD1, NCP1 
Phospholipid biosynthetic process   2.52 CKI1, CSR1, DPM1, EPT1, ERG12, ERG20, 
ERG8, GAB1, GPI16, GPI17, GPI2, GWT1, 
ICT1, MCD4, MVD1, OPI3, PIK1, SCS22, 
SCS3, SEC14, URA8, YDR018C, YFT2 
Energy generation related     
ATP synthesis coupled electron transport 3.8 COX5B, CYC7, CYT1, NDI1, QCR10, QCR2, 
QCR6, RIP1, SDH1, SDH2, YLR164W 
  
Energy reserve metabolic process 7.05 AAP1, BMH2, GAC1, GDB1, GIP2, GLC3, 
GLG1, GLG2, GPH1, GSY1, GSY2, IDG1, 
PCL8, PGM2, PIG2, PSK1, SGA1, UGP1 
  
Glycogen biosynthetic process 10.14 GAC1, GDB1, GLC3, GLG1, GLG2, GSY1, 
GSY2, IGD1, PCL8, PGM2, PIG2, PSK1, UGP1 
  
Mitochondrial electron transport 7.43 CYC7, CYT1, QCR10, QCR2, QCR6, RIP1   
Oxidation reduction process 2.31 101 genes 2.09 84 genes 
TCA cycle 3.27 ACO2, CIT1, DAL7, FUM1, IDP1, IDP2, LSC2, 
SDH1, SDH2, YMR31 
  
Degradation and recycling related     
CVT pathway 3.11 ATG1, ATG13, ATG14, ATG19, ATG2, 
ATG20, ATG4, ATG7, ATG8, COG1, COG6, 
TLG2, VSP30 
  
Eisosome assembly 10.32 EIS1, NCE102, PIL1, SLM1, YPK2   
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Mitochondrion degradation  5.86 ATG1, ATG13, ATG2, ATG20, ATG29, 
ATG32, ATG33, ATG4, ATG7, ATG8, ICY2, 
RTG3, WHI2, YIL165C, YOR019W 
  
Stress related     
Hydrogen peroxide catabolic process Inf* CCP1, CTA1, CTT1   
Trehalose biosynthetic process 37.19 PGM2, TPS1, TPS2, TPS3, TSL1, UGP1   
Trehalose catabolism  Inf* NTH1, NTH2, ATH1   
Cellular response to oxidative stress   2.26 AHP1, GCY1, GPX1, GRE3, GRX1, GRX3, 
GRX7, HSP12, HYR1, LOT6, MCR1, MHR1, 
MXR1, MXR2, PRX1, SNT2, TSA1, TSA2, 
YDL124W, YJR096W, YKL069W 
Response to misfolded protein    9.99 FES1, NPL4, PMT1, PMT2, SIS1, UFD1 
Others     
Cellular metal ion homeostasis 2.48 ARN2, COT1, CTH1, CTR2, ERV1, FET3, 
FRE3, GGC1, GRX4, ISU1, IZH3, MDM38, 
PGM2, PHO80, PIC2, PPZ1, SCO1, SCO2, 
SIT1, SMF3, SOD1, SSQ1, TIS11 
  
Cellular iron ion homeostasis  3.24 ARN2, CTH1, ERV1, FET3, FRE3, GGC1, 
GRX4, ISU1, SIT1, SMF3, SSQ1, TIS1 
  
Siderophore transport 18.59 ARN1, ARN2, FIT2, FIT3, FRE3   
Iron-sulphur cluster assembly    5 CFD1, DRE2, ISA1, IBA57, ISU1, NAR1, 
TAH18, YAH1, YHR122W  
a
Odds ratios for each GO term are included, with regulation of GO terms colour coded. Red: up-regulated. Green: down-regulated. *Inf = all 
genes contributing to enrichment of this GO term are present. 
 
91 
 
4.4.2. SOMs analyses of TA and TAL in S. cerevisiae S288C  
Independent SOMs analyses were performed on the genes differentially expressed in TA and TAL. SOMs 
groups together genes with a similar pattern of expression across the different treatments with the 
assumption that these are co-expressed or co-regulated, to allow a visual analysis of trends in the 
regulation of a group of genes. This provides more interpretive power to what and how transcripts 
change in response to different conditions. The SOMs maps are generated from the read counts of all 
experimental conditions (AMB, CA, AMB+LF, CAL), with a focus on genes differentially expressed in 
either TA or TAL, where TA and TAL each have different sets of genes. Each gene is represented by a line 
and their log fold changes are normalised to reach a maximum expression level of +/- 3 in each SOMs 
cell. The overall SOMs results are presented in Figures 4.8a and 4.8b along with their associated heat 
maps in Figures 4.8c and d. The heat maps were generated from the SOMs clusters and show the 
averaged expressions of genes present in each cluster for each drug treatment. The dendrogram on the 
left of each heat map separates the clusters into two groups based on up or down-regulation of co-
expressed genes. In TA (Fig. 4.8c), more SOMs clusters were down-regulated as indicated in blue in the 
AMB experiments (clusters 1 – 15), whereas the converse was observed for TAL in the AMB+LF 
experiments (clusters 11 – 25) (Fig. 4.8d). GO enrichments for each SOMs cluster for TA and TAL were 
analysed and clusters of interest are presented in the following sections.  
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Figure 4.8. Independent SOMs of differentially expressed genes in S. cerevisiae S288C (a) TA and (b) TAL, 
and the heat maps of averaged gene expressions of each SOMs cluster for (c) TA and (d) TAL. In the SOMs 
clusters, each gene is represented by a line and the y-axis denotes scaled expression levels across the 12 
experimental samples along the x-axis. These are: Experiments 1-3: the three biological replicates of the 
control for AMB treatment (CA1 – CA3); Experiments 4-6: AMB treatment (A1 – A3, where A is AMB); 
Experiments 7-9: the control for AMB+LF treatment (CAL1 – CAL3); and Experiments 10-12: AMB+LF 
treatment (AL1 – AL3, where A is AMB and L is LF). The clusters are numbered from bottom left to top 
right. Empty clusters have no genes. The heat maps of average gene expressions (c) and (d) are 
represented by rpkm values scaled to standard normal per gene using Pareto scaling. The x-axis 
represents the 12 experimental samples with each biological replicate numbered 1 – 3. The y-axis shows 
the 25 SOMs clusters and the dendrogram on the left separates the SOMs clusters into up- or down-
regulated groups, exclusively. For TA (c), up-regulated genes were found in clusters 16 – 25 while clusters 
1 – 15 mapped down-regulated genes. In TAL (d), up-regulated genes were found in clusters 11 – 25 and 
down-regulated genes in clusters 1 – 10. 
(a) (b) 
(c) (d) 
1 1 5 5 
25 25 20 20 
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4.4.2.1. Metal ion transport and homeostasis are enriched but oppositely regulated in TA and TAL 
In TA, GO enrichments for metal ion homeostasis and siderophore transport were up-regulated in cluster 
17 (Fig. 4.9a(i)). The genes contributing to these enrichments are mainly related to iron homeostasis and 
encode siderophore uptake proteins Arn1, Arn2, Fit2, and Fit3 and the cell wall ferric reductases Fre2, 
and Fre3 [390], similar to what was seen under metal ion homeostasis and siderophore transport in the 
overall GO terms in Table 4.5. Other co-regulated metal-related proteins in the same cluster were Cot1, 
encoding vacuolar zinc transport, and Sco2, encoding thioredoxin like copper binding protein involved in 
cytochrome c oxidase activity (Fig. 4.9a(i)) [391, 392]. Enrichment for copper ion homeostasis was seen 
in cluster 22 and consisted of the genes encoding Sco1, a homologue of Sco2, a vacuolar transporter 
Ctr2, and a mitochondrial copper transporter Pic2 (Fig. 4.9a(ii)) [392-394].  
As the enrichment of metal ion homeostasis in Table 4.5 lists metal-related genes that were not 
observed in the TA SOMs enrichments, a manual search was performed to observe where these genes 
clustered. Metal-related genes, including iron-related genes, were found in cluster 24 and included SIT1, 
FET3 and PHO80, in cluster 21 with TIS11, in cluster 22 with PGM2, in cluster 25 with CTH1, IZH3, 
MDM38 and SOD1, and in cluster 19 with SSQ1 and ENB1 (not shown). Cluster 20 was enriched for iron-
sulphur (Fe-S) cluster assembly proteins Isa1, Isu1, Nar1, Cia2, and Erv1, Ggc1 and Grx4 (not shown), and 
the iron-regulating transcription factor Aft1 mapped to cluster 19 (not shown) [395]. The presence of 
iron-related genes in different SOMs clusters suggests different levels of gene regulation and differing 
co-expression.  
In TAL, genes encoding zinc ion transport were enriched and down-regulated in cluster 9 (Fig. 4.9b(i)). 
These included genes encoding Fet4, a low affinity plasma membrane iron transporter, Msc2, a 
transporter located in the ER, and Zrt3, a vacuolar membrane zinc transporter [396]. The zinc-regulating 
transcription factor Zap1 was also co-expressed in this cluster (not shown) [397]. Similar to the overall 
GO enrichments seen in Table 4.5, Fe-S cluster assembly was enriched and up-regulated, and was 
induced in cluster 23 with the assembly proteins Dre2, Tah18 and Yah1 (Fig. 4.9b(ii)). 
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(a) SOMs clusters in TA Details 
(i) 
 
Cluster: 17 
 
Gene expression: Up-regulated 
 
Siderophore transport:  ARN1, ARN2, FIT2, FIT3, FRE3 
Metal ion homeostasis: ARN1, ARN2, FIT2, FIT3, FRE3, FRE2, 
COT1, SCO2 
Proteolysis: ASI2, CUE5, HUL5, NAR2, UBP11, UBP15, UBP2, 
UBX5, YKL100C, VID28, VID30 
(ii) 
 
Cluster: 22 
 
Gene expression: Up-regulated  
 
Trehalose biosynthesis: PGM2, TPS1, TPS2, UGP1 
Protein kinase A signalling:  TPK1, TPK2 
Copper uptake: CTR2, PIC2, SCO1 
 
(iii) 
 
Cluster:  14 
 
Gene expression: Down-regulated  
 
Oxidative stress: GPX2, TMA19, URM1 
 
(iv) 
 
Cluster: 21 
 
Gene expression: Up-regulated 
 
Protein targeting to vacuole: ATG34, ATG8 
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(b) SOMs cluster in TAL Details 
(i) 
 
Cluster: 9 
 
Expression level: Down-regulated 
 
Zinc transport: FET4, MSC2, ZRT3 
 
ZAP1 co-expressed in cluster 9 (not shown)  
(ii) 
 
Cluster: 23 
 
Expression level: Up-regulated 
 
Iron-sulphur assembly: DRE2, TAH18, YAH1 
 
(iii) 
 
Cluster: 4 
 
Expression level: Down-regulated 
 
ER ubitquitin dependant catabolism: DER1, DFM1, JEM1, LCL2, 
UBC7 
Sulphur assimilation: MET16, MET3 
 
MET2 and MET32 also mapped to cluster 4 (not shown) 
(iv) 
 
Cluster: 24 
 
Expression level: Up-regulated 
 
Threonine biosynthetic process: HOM2, HOM3, THR4 
Methionine biosynthetic process: ARO8, ARO9, HOM2, HOM3, 
SAM4 
Sulphur compound biosynthetic process: ARO8, ARO9, BIO4, 
HOM2, HOM3, SAM4 
 
 
96 
 
(v) 
 
Cluster: 8 
 
Expression level: Down-regulated 
 
Proteolysis: DDI1, FIN1, PRE1, RPN10, RPN12, RPT3, RPT6, 
UBC4, UBP16  UBX4, VPS25, CUZ1  
(vi) 
 
Cluster: 10 
 
Expression level: Down-regulated 
 
ER ubiquitin dependant catabolism: ADD37, ATG19, HRD1, 
HRD3 
Late nucleophagy: ATG23, ATG31, ATG9 
CVT pathway: ATG19, ATG23, ATG9, SNX4 
 
(vii) 
 
Cluster: 3 
 
Expression level: Down-regulated 
 
Protein exit from ER: PMT1 and PMT2  
ER misfolded protein catabolism: PMT1 and PMT2 
Figure 4.9. SOMs of interest and their enriched GO terms in S. cerevisiae S288C TA (a) and TAL (b). The 
average expression level of all co-expressed genes in each cluster is indicated by a black line, with each 
coloured line representing a single gene. Genes included in a GO enrichment are labelled with the same 
colour. The y-axis gives the normalised expression levels of genes in response to AMB and AMB+LF 
treatment. Drug treatments are boxed for visual clarity. Genes that make up the GO enrichments in each 
cluster are listed, along with other genes of interest. 
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4.4.2.2. Addition of LF causes changes to the regulation of cellular stress responses  
In the overall enrichments for TA, hydrogen peroxide catabolism and trehalose biosynthesis and 
catabolism were up-regulated (Table 4.5). In SOMs, enrichments related to stress were expressed in 
cluster 22, involving genes encoding for protein kinase A (PKA) signalling TPK1 and TPK2, and trehalose 
biosynthesis processes PGM2, TPS1, TPS2 and UGP1 (Fig. 4.9a(ii)). Activation of the protein kinase 
signalling pathway increases the production of reactive oxygen species (ROS) in the mitochondria [398, 
399]. Transcriptional evidence of mitochondrial ROS production is supported by the enrichment of 
mitophagy in the overall GO enrichments (Table 4.5), which is a selective autophagic process that 
prevents cellular damage from defective mitochondria [400]. Trehalose, peroxidases and catalases are 
most likely induced to protect the cell from ROS damage [401]. However, cellular responses to oxidative 
stress were down-regulated in cluster 14, which includes the genes GPX2, TMA19 and URM1 (Fig. 
4.9a(iii)). As the proteins translated from these genes are localised to the cytosol 
(www.yeastgenome.org/), this suggests stress responses may be regulated by intracellular location.  
While stress related enrichments were up-regulated in TA, a down-regulation in these terms was 
observed in TAL (Table 4.5). Although stress-related terms were not enriched in SOMs in TAL, enrichments 
relating to sulphur metabolism were observed, which are required for many cellular functions including 
stress responses, where sulphur in amino acids like cysteine is required for the secondary structure of 
antioxidants like peroxiredoxins and glutathione [402]. Sulphur metabolising pathways were mapped to 
different clusters and included sulphate assimilation, which has been shown by Wu et al. (2009) to be 
involved in oxidative stress [403]. Sulphate assimilation mapped to cluster 4, which was down-regulated 
with Met3, an ATP sulfurylase that reduces assimilated sulphate into sulphide [404], and Met16, an 
enzyme that reduces 3͛-phosphoadenylsulfate to produce free sulphites for downstream sulphur 
processes [405] (Fig. 4.9b(iii)). Other sulphur related genes in the same cluster but not under an 
enriched GO term include Met2, a L-homoserine-O-acetyltransferase that acts as the first step of the 
methionine biosynthesis pathway [406], and Met32, a transcription factor that regulates methionine 
biosynthetic genes [407] (not shown). 
In contrast to the down-regulation of Met32 in cluster 4, methionine and sulphur compound 
biosynthesis were up-regulated in TAL and enriched in cluster 24, which includes ARO8, ARO9, HOM2, 
HOM3, SAM4 and BIO4 (Fig. 4.9b(iv)). ARO8 and ARO9 encode aromatic aminotransferases that 
catabolise amino acids that can then be used to synthesise methionine via an alternative route from the 
sulphur assimilation pathway [408]. HOM2 and HOM3 are part of the threonine biosynthesis pathway 
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that can branch into the methionine biosynthetic pathway via MET2. However, while threonine 
biosynthesis was induced and also enriched in SOMs cluster 24 (Fig. 4.9b(iv)), the conversion of 
homoserine to homocysteine by MET2 was shut down.  
To understand the regulation of sulphur metabolism in TAL, all of the pathways mentioned above, as well 
as downstream sulphur metabolising pathways including the S-adenosylmethionine (SAM) cycle and 
glutathione biosynthesis, were mapped along with the expression of their constituent genes. Figure 4.10 
shows the control of sulphur metabolism in TAL, where the regulation of sulphur-related pathways 
indicates that the generation and supply of precursors leading to the production of homocysteine is 
limited. This involves the expression of Ssu1, which exports sulphites out of the cell [409], the down-
regulation of MET17, which converts sulphides into homocysteine at later steps in the sulphur 
assimilation pathway (blue-coloured pathway) and the repression of MET2 from the threonine 
biosynthetic pathway (purple-coloured pathway). Pathways that use homocysteine as a starting 
substrate such as the SAM cycle (pink-coloured pathway) and the glutathione biosynthetic pathway 
(yellow-coloured pathway), which is involved in stress responses, were also repressed. 
The down-regulation of glutathione biosynthesis also affects the production of cysteine, which is a 
precursor to many proteins and enzymes including Fe-S clusters and antioxidants like superoxide 
dismustases, and this in turn affects the cellular response to oxidative stress [77, 410]. However, 
cysteine can be acquired by the degradation of glutathione, through the induction of ECM38, or by 
importing extracellular cysteine using the transport protein Yct1 [411], which were induced (Fig. 4.10). 
The overall regulation of sulphur metabolic pathways in TAL points to the limitation of homocysteine 
production, which in turn affects cysteine and glutathione synthesis that is required for stress responses.   
Sulphur metabolism is indirectly regulated by Met32, an auxiliary transcription factor that targets the 
transcriptional activator Met4 to the promoters of sulphur metabolic genes [412]. It is interesting to 
note that Met32 is also regulated by Zap1, which mapped to SOMs cluster 9 (not shown), hence, zinc 
homeostasis is important for stress responses through the regulation of sulphur metabolism as reported 
by Wu et al. (2009) [403].  
Together, the transcriptome results for S. cerevisiae S288C suggest that AMB treatment induces stress in 
the mitochondria, and mitophagy is activated to avoid cellular damage. In contrast to TA, the addition of 
LF to AMB treatment causes a down-regulation of stress responses. This may occur by the repression of 
sulphur assimilation, which is affected by zinc homeostasis that is also repressed in TAL. Repressing 
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sulphur assimilation may in turn down-regulate the expression of genes in downstream pathways, 
including the production of glutathione and cysteine that are needed for detoxification of stress-
inducing oxidants. 
 
 
Figure 4.10. Mapping of sulphur metabolism pathways suggests in AMB+LF synergy there is a shutdown 
of homocysteine production by alterations in sulphur assimilation, threonine biosynthesis and 
glutathione biosynthesis pathways. Blue arrows indicate steps in the sulphur assimilation pathway, 
yellow arrows the glutathione biosynthetic pathway, purple arrows the threonine biosynthetic pathway, 
pink arrows the S-adenosylmethionine cycle and grey arrows indicate the substrates that feed into or 
out of the pathways. Genes induced in TAL are shown in red, genes down-regulated are in green and 
those with no change in expression are black. Diagram based on pathway.yeastgenome.org  
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4.4.2.3. Protein degradation is regulated differently in TA and TAL  
In TA, proteolysis-related terms were enriched and induced in SOMs cluster 17, including vacuolar 
import and degradation with Vid28 and Vid30, and ubiquitin related processes Ubx5, Ubp2, Ubp11, 
Upb15, Hul5, and Cue5 (Fig. 4.9a(i)). Protein targeting to the vacuole was enriched in cluster 21 with 
Atg34 and Atg8, which are part of the cytoplasm to vacuole targeting (CVT) pathway that delivers 
hydrolases to the vacuole (Fig. 4.9a(iv)) [413]. Proteasome-related enrichments were not seen in either 
the overall GO terms in Table 4.5 or SOMs, implying that protein degradation occurred through the 
vacuole in TA.  
In TAL, proteolysis was repressed and mapped to cluster 8 with genes mostly associated with 
ubiquitination (UBC4, UFD1, VPS25, UBX4, CUZ1, UBP16) and the proteasome (PRE1, RPN10, RPN12, 
RPT3, RPT6, CUZ1) (Fig. 4.9b(v)). Other enrichments mapped to cluster 8 included the SNARE complex 
assembly involved in vesicle fusion with Sly1 and Vsp45 (not shown) [414]. While the CVT pathway was 
not observed in the overall TAL GO enrichments (Table 4.5), transcripts making up this enrichment were 
down-regulated in cluster 10 and included ATG19, ATG23, ATG9 and SNX4. ATG23 and ATG9 also 
contributed to the enrichment of nucleophagy, the selective degradation of the nucleus [415], in the 
same cluster (Fig. 4.9b(vi)). Other enrichments involving protein degradation include endoplasmic 
reticulum (ER)-associated terms encompassing the ER-associated protein degradation (ERAD) process, 
which is an ER stress response involving the ubiquitination of misfolded proteins and their 
retrotranslocation to the cytosol for proteasomal degradation [416]. The terms that were enriched 
involved misfolded protein catabolism and exit from the ER in cluster 3 with protein O-
mannosyltransferases Pmt1 and Pmt2, which are involved in glycosylation [417] (Fig. 4.9b(vii)), and 
ubiquitin-dependant catabolism which was mapped to clusters 4 and 10. The transcripts present in 
these clusters have functions in protein folding, ubiquitin tagging and lumen-to-cytosol signalling, with 
DER1, DFM1, JEM1, LCL2 and UBC7 mapping to cluster 4 (Fig. 4.9b(iii)), and ADD37, HRD3, HRD1 and 
ATG19 mapping to cluster 10 (Fig. 4.9b(vi)). Overall, this suggests the additional of LF in TAL suppresses 
selective proteolytic pathways.  
Interestingly, while co-translation translocation and retrograde transport from ER to the cytosol were 
repressed in TAL, the expression of ribosome biogenesis and cytoplasmic translation were induced (Table 
4.5). Another interesting finding was the co-expression of ER-associated ubiquitin protein catabolism 
with sulphate assimilation in cluster 4 (Fig. 4.9b(iii)). Eug1, Mpd1 and Ero1, which are protein disulfide 
isomerases and ER oxidoreductases involved in protein folding, also mapped to SOMs cluster 4 (not 
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shown), which altogether suggests ER function is repressed and that there is a dependency of ER 
function on sulphur metabolism.  
In summary, vacuole mediated proteolysis was induced in TA, while this was repressed in TAL. Although 
protein synthesis was induced in TAL, protein processing, which occurs in the ER, was repressed, 
suggesting disruptions in ER function.  
4.4.3. Network analysis reveals metal ion regulation differs in TA and TAL  
GO enrichments associated with iron and zinc import were observed in SOMs (Fig. 4.9a(i) and 4.9b(i)), 
but the up-regulation of iron uptake genes in TA and down-regulation of zinc uptake genes in TAL were 
unexpected in the context of the metal ion-chelating ability of LF. The expression of transcription factors 
Aft1, which regulates iron, and Zap1, which regulates zinc, were identified in TA and TAL respectively. 
Networks were drawn to investigate how these transcription factors interact with their target genes 
under the two drug treatments (Fig. 4.11). These have been co-visualised with the log fold-changes for 
each gene, with gene targets grouped according to biological functions for better interpretation.  
To construct the regulatory network for Aft1 and iron homeostasis, binding targets of Aft1 and known 
iron uptake genes were curated from Yeastract and from Philpott and Protchenko (2008) [82]. The iron-
related networks for TA and TAL are shown in Figures 4.11a and b. The localisation of Aft1 is controlled by 
the Grx3/Grx4/Fra1/Fra2 complex, which binds to Aft1 and prevents its entry into the nucleus to 
activate the iron regulon [91, 418]. In TA, transcripts of GRX3 and FRA2 were down-regulated, while 
AFT1, FRA1, GRX4 and YAP5 (which induces GRX4 expression) were up-regulated [90]. Twelve out of 
nineteen iron-associated genes with functions in iron uptake, storage and transport were also induced, 
which together suggest nuclear localisation of Aft1 and active transcription of the iron regulon. Two 
transcription factors regulated by Aft1, Cad1 and Yap5, share iron uptake-related gene targets with Aft1 
and were also induced. In addition to iron transport, Aft1 also induces the expression of zinc and copper 
transport genes, showing that it can regulate other metals. Other processes unrelated to metal ion 
homeostasis but requiring metal ions were also seen and mostly induced, including vitamin and amino 
acid metabolism, response to stress and protein processing and degradation (Fig. 4.11a).   
In TAL, AFT1 was not differentially regulated compared to the untreated control and expression fold-
changes for genes controlling Aft1 localisation were only observed for GRX3 and GRX4, which were 
down- and up-regulated, respectively. Only a subset of iron uptake transcripts in the iron regulon were 
significantly expressed, including the up-regulation of FET3, SIT1, MRS4 and SMF3, and down-regulation 
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of FIT3, FRE1, FRE4, FET4, and FTH1. This implies that the addition of LF to the AMB treatment shuts 
down the iron regulon. Disrupting iron homeostasis also affects the uptake and storage of other metals, 
stress responses and protein processing, the transcripts of which were mostly repressed or not 
significantly expressed (Fig. 4.11b).  
Zap1 regulates zinc homeostasis and metabolic responses to zinc deficiency [397, 419] and its target 
genes were curated from Wu et al. (2008), Wu et al. (2009) and Eide (2009) [403, 419, 420] and 
Yeastract. As Yeastract found more than 70 Zap1 target genes, only a subset of these were used to build 
the regulatory networks, based on their biological functions in YeastMine (yeastmine. 
yeastgenome.org/). The networks for TA and TAL are presented in Figures 4.11c and d, respectively. In TA, 
the ZAP1 transcript was not differentially expressed and direct Zap1 targets involved in zinc homeostasis 
and other processes were also not expressed (Fig. 4.11c). Genes that were differentially regulated are 
possibly under the control of other regulatory factors, such as the iron uptake genes that are under the 
control of Aft1 (Fig. 4.11a). 
In contrast to TA, ZAP1 was repressed in TAL. The expression of genes involved in zinc uptake (FET4), ER 
import (MSC2 and ZRG17), and storage (ZRT3) were all repressed, which is consistent with observations 
in zinc-replete conditions (Fig. 4.11d) [419, 421]. Alcohol dehydrogenases, which are abundant zinc 
binding enzymes, are differentially regulated by Zap1 during zinc limitation to conserve zinc, with ADH1 
and ADH3 repressed by Zap1 while ADH4 is induced [93]. However, an opposite expression of these 
genes in the Figure 4.11d network suggests the cell senses an abundance of intracellular zinc in TAL. 
Similar to Aft1, the network shows that Zap1 regulates the homeostasis of other metal ions and its 
repression down-regulates iron and copper related genes. Additionally, genes involved in stress 
responses, sulphur metabolism, cell wall function, lipid synthesis and protein processing are repressed, 
corresponding to the regulation of similar GO enrichments in Table 4.5 and the SOMs analyses (Fig. 4.9). 
Overall, the networks show that LF dysregulates zinc homeostasis, which in turn affects a broad range of 
cellular functions. 
In summary, these networks show that, contrary to expected cellular responses in the presence of a 
metal ion chelator, the addition of LF causes an overall decrease in the transcription of iron and zinc 
regulatory elements, including gene targets that are involved in other cellular processes. This is in 
contrast to treatment with AMB alone, where the iron regulon was induced and the zinc network was 
largely unaffected.  
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(a) TA 
(b) TAL 
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Figure legend on the next page. 
(c) TA 
(d) TAL 
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Figure 4.11. Regulatory networks of the transcription factors Aft1 and its gene targets in (a) TA and (b) 
TAL, and Zap1 and its gene targets in (c) TA and (d) TAL. Each node represents a gene and the arrows show 
the direction of regulation. Transcription factors are shown in octagonal nodes. Log fold-changes of 
genes are coloured red for up-regulation, green for down-regulation and white for no expression 
relative to the control, with intensity of change indicated by the scale bar. Blue lines indicate direct 
protein-protein interactions. 
 
4.4.4. Biological validation of transcriptome analysis  
4.4.4.1. Rescue assays  
As detailed in the previous chapter, LF is a metal ion chelator with the greatest binding affinity to iron 
(Section 3.1.3.2). However, LF did not cause synergy with AMB via iron chelation, as supplementation 
with iron at levels calculated to saturate the binding sites of LF neutralised growth inhibition in cells 
treated with LF alone but not when LF was combined with AMB (Fig. 3.4). In addition, the network 
analyses showed that the iron regulon was induced in TA and repressed in the presence of LF, that zinc 
homeostasis was repressed in TAL, and that Aft1 and Zap1 regulate the homeostasis of other metals (Fig. 
4.11). Rescue assays were therefore performed, testing broad concentrations of selected rescue agents 
in the presence of different AMB+LF concentrations, to determine if and at what concentrations these 
might disrupt drug synergy.   
Iron, zinc, calcium and the calcium chelator BAPTA were used. A summary detailing why these rescue 
agents were chosen and how they were hypothesised to rescue AMB+LF synergy is presented in Table 
4.6. Iron rescue assays were first performed in this chapter to determine the concentration of iron 
required to rescue cells from AMB+LF synergy, before a modified version using lower concentrations of 
iron was tested in Chapter 3 (Section 3.2.6).  
The following results are preliminary observations, as there was insufficient time to refine the rescue 
experiments using more appropriate levels of rescue agents as had been done for iron in Chapter 3. In 
addition batch-to-batch variation in LF sometimes changed the AMB+LF FIC between biological 
replicates, and toward the end of this study LF was discontinued from the original supplier (MP 
Biomedical) and LF from a new supplier, although still synergistic with AMB, gave quite different FIC 
results.   
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Table 4.6. Agents used for rescue assays in S. cerevisiae S288C  
Rescue agent Observations/Reasons  Hypothesis  
Iron Strongly chelated by LF (Fig. 3.4). 
Iron homeostasis and iron responsive 
genes in various biological pathways 
were altered in TAL (Fig. 4.11.b) 
Saturating iron binding by LF will prevent 
antifungal action caused by iron 
limitation and disrupt AMB+LF synergy. 
 
Zinc Can be chelated by LF [219].  
Zinc homeostasis and zinc responsive 
genes in various biological pathways 
were  altered in TAL (Fig. 4.11.d).  
Saturating zinc binding by LF will prevent 
antifungal action caused by zinc 
limitation and this will partially disrupt 
AMB+LF synergy. 
 
Calcium Weakly chelated by LF [219].  
Calcium is essential for signalling, 
membrane fusion and ER regulation 
[422-424], and ER function was 
observed to be disrupted in TAL (Fig. 
4.11.d). 
Addition will over-ride any limitation 
caused by LF chelation and will partially 
disrupt AMB+LF synergy 
  
BAPTA (Calcium 
chelator) 
Calcium is essential for signalling and 
regulation of cellular responses [422]. 
Test the effect of intracellular calcium 
depletion in AMB+LF synergy.  
Chelation of calcium will do the opposite 
of calcium addition and enhance AMB+LF 
synergy  
 
AMB+LF was previously found to be synergistic at 0.03 µg/mL AMB and 2 µg/mL LF (Fig. 3.3, Appendix 
3.1). At this concentration, none of the agents apart from iron were able to rescue growth (Fig. 4.12a 
and b). Iron supplementation was only able to rescue growth when supplied at excess levels; more 
appropriate lower iron concentrations that were sufficient to saturate iron binding by LF did not rescue 
synergy (Fig. 3.4). Only iron rescued the inhibition caused by LF alone at its MIC (Fig. 4.12a and b) and 
none of the agents were able to rescue inhibition by AMB alone at its MIC. As suggested in the previous 
iron rescue assay in Chapter 3, iron is not critical for synergy between AMB+LF, however iron is 
important for the inhibitory effect of LF alone. Growth at high concentrations of iron suggests 
oversaturation causes exuberant growth and interferes with the synergistic effect of AMB+LF. Over-
supplementation with the other rescue agents was toxic to the cells and growth was inhibited at the 
highest concentrations (Fig. 4.12c – e). 
Surprisingly, growth inhibition was observed at concentrations of the antifungal drug and iron chelator 
that were lower than the usual FIC levels (0.015 µg/mL AMB + 1 µg/mL LF), which may be due to the 
batch-to-batch variation in LF as noted above. At this concentration, all agents interfered with growth 
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inhibition as shown by the presence of growth in wells where rescue agents were added, even at the 
lowest concentrations tested. It is possible that at this very low FIC level synergy was borderline and 
rescue was more achievable. These experiments need to be repeated to fully understand the role of 
metal ions in synergy, however based on the inability to rescue synergy with iron supplementation seen 
in Chapter 3, and the general down-regulation of metal ion homeostasis seen in this chapter, it seems 
unlikely that chelation plays a primary role in AMB+LF synergy.   
 
 
 
(a) 
(b) 
108 
 
 
 
 
 
Figure legend on the next page. 
(c) 
(d) 
(e) 
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Figure 4.12. Saccharomyces rescue assays in RPMI-1640 medium supplemented with (a) Iron (III) (b) Iron 
(II) (c) Zinc (d) Calcium and (e) BAPTA. Rescue agents were added to AMB and LF alone at their MICs, 
and to different concentrations of AMB+LF, including the established FIC concentration of AMB 0.03 
µg/mL + LF 2 µg/mL. Yeast growth in the wells indicates rescue from the antifungal agents. Note that 
only iron could rescue cells from LF, and no agents rescued cells from AMB. In (d), high concentrations 
of calcium have precipitated out into the medium.   
 
4.4.4.2. Validation of selected target genes using spot plate assays of gene knock-out mutants 
To validate the GO terms and network analyses obtained from the transcriptomic data, and to further 
investigate the roles of differentially regulated proteins in the response to AMB and other stressors, a 
list of criteria was drawn to select genes of interest for mutant generation and phenotype 
characterisation. The aim of testing each mutant was to determine if disruption would increase 
susceptibility to AMB without the addition of LF, and to determine if this was due to alterations in cell or 
membrane integrity or due to oxidative or nitrosative stress. The criteria selected the genes based on 
their:  
- log fold expression  
- co-expression with other genes 
- involvement in a significant pathway  
- type of protein when translated and effects on other proteins, i.e., kinases, transcription factors, 
part of a protein complex 
- fungal orthologues  
- mutant phenotypes compiled in SGD (www.yeastgenome.org/)  
A summary of the list of potential and chosen genes using the above criteria is presented in Table 4.7 
and the genes of interest and their hypothesised phenotypes in relation to AMB sensitivity are discussed 
below.  
AFT1: encodes the iron regulating transcription factor Aft1 that also plays a role in chromosome 
maintenance [395, 425]. aft1Δ mutants have decreased accumulation and use of iron, decreased 
resistance to DFP, DFO, oxidative stress and a decreased rate of respiratory growth. Mutants also have 
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abnormal vacuole morphologies. In TA, but not TAL, biological networks predict the nucleolar localisation 
of Aft1 and its activation of the iron regulon (Fig. 4.11a). Iron is important for many cellular processes 
and supplementation with ferrous and ferric iron at high concentrations was able to rescue AMB+LF 
synergy (Fig. 4.12a and b), although this was not seen at lower concentrations, even though there was 
enough iron to saturate the binding sites of LF and prevent its antifungal activity (Fig. 3.4). The deletion 
of AFT1 was hypothesised to increase inhibition by AMB through inactivation of the iron regulon, as was 
seen in TAL (Fig. 4.11b).  
ATG1: encodes a protein serine/threonine kinase and is part of the core machinery of autophagy and 
the CVT pathway [426]. Atg1 forms the first signal that activates autophagy and the CVT pathway and 
mutants are defective in progression of these processes. This is because activation becomes a cascade, 
where Atg1 binds to Atg13 and Atg17 and this complex then interacts with other proteins and targets 
them to the phagophore assembly site (PAS). The PAS isolates the cargo for degradation in a membrane 
vesicle, which is then delivered to the vacuole [427]. Autophagy and related processes are important to 
the cell as they serve to degrade old and defective organelles that can damage the cell; mutants 
defective in autophagy and the CVT pathway have decreased lifespans and increased ROS accumulation. 
ATG1 was induced in TA (not shown) and deletion of ATG1 is hypothesised to increase AMB susceptibility 
through the impaired delivery of cargo to the vacuole for degradation, as this process is repressed in TAL 
(Fig. 4.9b(vi)).  
CCH1: encodes a voltage gated calcium channel that associates with the transmembrane proteins Mid1 
and Ecm7 [93]. This complex imports extracellular calcium with high affinity but at low capacity under 
environmental stresses and perturbations to the membrane [428, 429]. Other stresses that induce CCH1 
expression include compromised vesicle mediated transport in the protein secretory pathway and ER 
stress from the accumulation of unfolded proteins [430, 431]. The influx of extracellular calcium 
activates calcineurin-dependent signalling [430, 432], which exerts control on many cellular functions 
including ion homeostasis, cell wall and lipid synthesis, autophagy, vesicle transport and protein 
degradation [422, 433]. However, while CCH1 was induced in TAL, possibly from the disrupting effect of 
AMB and LF on the cell membrane, the majority of genes involved in the calcineurin pathway were not 
significantly expressed. Additionally, ER protein processing and response to misfolded proteins, which 
are also regulated by calcineurin signalling and induce CCH1 expression, were repressed (Table 4.5). 
Targeting extracellular calcium uptake by knocking out CCH1 may increase sensitivity to AMB and may 
be a potential antifungal drug target, as suggested by other studies [434].  
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TPK2: encodes a subunit of the Ras/cAMP-dependent PKA [435]. PKA regulates cell metabolism and 
growth according to available carbon sources, and Tpk2 is involved in the negative regulation of iron 
uptake as well as the induction of trehalose degradation [436]. PKA also negatively regulates autophagy 
by directly modifying Atg1 and alters its intracellular localisation such that it is not targeted to the PAS 
and halts the delivery of cargo to the vacuole for degradation [426]. TPK2 was induced in TA (Fig. 
4.9a(ii)), which has also been reported by Belenky et al. (2013) [398]. Knock-out mutants were predicted 
to de-repress the iron regulon, reduce trehalose degradation needed to counter ROS production [401], 
dysregulate autophagy and increase susceptibility to AMB.  
YAP5: is a basic leucine zipper iron-sensing transcription factor that controls iron overload [89]. It 
directly regulates GRX4 that forms a complex with Grx3, Fra1 and Fra2 and controls the localisation of 
Aft1 [90]. Yap5 also regulates vacuolar iron storage through activation of CCC1, which sequesters 
cytosolic iron into the vacuole [89]. Knock-out mutants of this transcription factor have abnormal 
vacuoles. YAP5 was induced in TA along with the iron regulon (Fig. 4.11a), and the deletion of this gene 
was predicted to increase susceptibility to AMB by an unregulated importation of iron, resulting in 
increased oxidative damage in the cell.  
YCT1: encodes a high affinity cysteine-specific transporter that is fungal-specific and localised to the ER 
[411]. Cysteines can be used for glutathione biosynthesis or broken down to homocysteine to generate 
amino acids. Cells may prefer to import extracellular cysteine as this takes less energy than its 
biosynthesis, and cysteine may be required in TA where energy production is induced, possibly for the 
induction of stress responses, or alternatively in TAL where energy needs to be conserved as its 
production is not induced (Table 4.5). YCT1 was induced in TA, where the need for extracellular cysteine 
was suggested by the activation of the iron regulon (Fig. 4.11a), an observation also reported by Philpott 
et al. (2012) who found that amino acid transporters were induced in iron starvation conditions [92]. 
YCT1 was also induced in TAL where the glutathione biosynthetic pathway was repressed, suggesting 
they may have an increased need for cysteine as a precursor for glutathione (Fig. 4.10). Deletion of this 
transporter is hypothesised to decrease the levels of cysteine available for glutathione biosynthesis and 
detoxification, leading to an increased susceptibility to AMB due to an inability to mount a full stress 
response to AMB exposure.    
YOR387C and VEL1: encode uncharacterised proteins that are paralogous and have 93% similarity in 
gene sequence. YOR387C is located on chromosome XV, in proximity to FIT2, FIT3 and FRE3 that are 
regulated by AFT1 in the iron regulon (SGD; www.yeastgenome.org/). In TAL, VEL1 is the most highly 
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repressed gene and is controlled by ZAP1 and IZH2 [437], while YOR387C is the next most repressed 
gene and is controlled by both AFT1 and ZAP1 (Fig. 4.11). Both VEL1 and YOR387C are highly induced in 
zinc-depleted conditions [438] and encode soluble putative glycoproteins [439, 440]. Knock-out mutants 
of either or both genes are hypothesised to be disrupted in iron and zinc regulation and to have 
increased cell stress in response to AMB, leading to increased AMB susceptibility.  
ZAP1: encodes transcription factor Zap1 that controls zinc homeostasis as well a range of other 
biological processes. These include response to stress, lipid biosynthesis, amino acid metabolism and 
protein processing [403, 419, 420, 441]. zap1Δ mutants have decreased resistance to oxidative stress, 
BAPTA, EDTA, decreased use of iron and abnormal vacuole morphologies. ZAP1 transcription was 
repressed in TAL but not differentially expressed in TA. As Zap1 target genes were also repressed in TAL 
(Fig. 4.11d), its deletion is predicted to mimic the AMB susceptibility seen following AMB+LF treatment.  
The following genes were potential candidates for knock-out testing based on the selected criteria, but 
were not tested as they have been tested in other studies in Saccharomyces and/or Cryptococcus:  
FET3: encodes a multicopper oxidase that oxidises ferrous iron to ferric iron for import by the 
transmembrane permease Ftr1 [442]. Orthologues of Fet3 have been identified in other fungi [116, 443] 
and fet3Δ mutants are defective in iron accumulation, respiration, and resistance to transition metals. 
FET3 was a knock-out candidate as the protein imports iron with high affinity and was induced in both TA 
and TAL (Fig. 4.11), even though the iron regulon was differentially expressed in the two treatments. 
There has been evidence that some fungi are able to utilise transferrin and/or LF as a source of iron via 
the Fet3/Ftr1 iron uptake system [94, 444]. Therefore, this gene was chosen for deletion to rule out the 
possibility of LF acting as a siderophore with the prediction that the mutant will become more 
susceptible to AMB. However, literature searches found knock-outs of Fet3 orthologues were reported 
to be sensitive to AMB in Cryptococcus and Candida and Fet3 was therefore removed from the 
candidate list [116, 445].  
IZH2: encodes a plasma membrane receptor homologous to mammalian adiponectin receptors that 
regulate sugar and lipid metabolism [446]. Izh2 has been proposed as a potential antifungal drug target 
as its binding to the antifungal plant protein osmotin mediates apoptosis [446, 447]. Omsotin-bound 
Izh2 also activates PKA via the cAMP pathway and suppresses stress responses by modulating the 
expression of transcription factors NRG1/NRG2 and MSN2/MSN4 [448, 449]. Additionally, Izh2 is 
involved in iron homeostasis, through the repression of FET3 via TPK2, and zinc homeostasis, by the 
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repression of ZAP1 and ZRT1 [437, 450, 451]. Overexpression of IZH2 has been shown to increase levels 
of phytosphingosine (PHS) [450], which is a bioactive lipid required for sphingolipid biosynthesis, and 
PHS play important roles in cell signalling, regulation and intracellular trafficking [452]. Sphingolipids, 
together with ergosterol, constitute lipid rafts that deliver secretary proteins to their correct locations 
and have been observed to deliver virulence factors like phospholipase B and Cu/Zn sulperoxide 
dismutase in Cryptococcus [452, 453]. This suggests a possible mechanism of AMB+LF synergy through 
Izh2-mediated membrane disruption. Although IZH2 was repressed in TA (Table 4.7) and its deletion was 
hypothesised to cause an increased sensitivity to AMB by disrupting sphingolipid production, mutants 
have been observed to be resistant to AMB [447, 451] and IZH2 was removed from the candidate list. 
THR1: is a homoserine kinase that is required for threonine biosynthesis [454]. Disruption of THR1 
causes threonine auxotrophy as well as decreased resistance to oxidative stress, fluconazole, ionic stress 
and changes in pH. Knock-out mutants also accumulate homoserine from the threonine pathway, which 
replaces threonine as a toxic analogue and disrupts protein degradation [455]. THR1 was up-regulated in 
TA and the knock-out mutant was predicted to become more susceptible to AMB from defective 
proteolytic pathways that are induced in TA (Table 4.5). Alternatively, aspartate metabolism would be 
directed into the sulphur assimilation pathway through MET6 and lead to an overaccumulation of 
homocysteine (Fig. 4.10), and increased susceptibility to AMB might occur via dual oxidative damage 
from homocysteine and AMB. THR1 has been suggested as an antifungal drug target, however, as thr1Δ 
mutants have already been reported to be sensitive to AMB in Saccharomyces and lethal in 
Cryptococcus [456-458], the gene was removed from the candidate gene list.   
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Table 4.7. Candidate genes for knock-out mutant generation and their selection criteria  
Gene 
name 
TA log2 
FC
a
 
TAL log2 
FC 
Orthologues in fungal 
pathogens
b
 
Pathway Knock-out Phenotypes
c
  Description of gene type 
AFT1* 0.34  C. glabrata (CAGL0H03487g) Iron 
homeostasis 
 
Decreased iron accumulation 
Decreased resistance to DFO and DFP 
Increased protein accumulation 
Transcription factor involved in 
regulation of iron homeostasis  
ATG1* 1.30 0.43 C. neoformans (CNAG_05005) 
C. albicans (orf19.3841) 
C. glabrata (CAGL0L06006g) 
A. fumigatus (Afu4g09050) 
Autophagy 
and CVT 
Absence of autophagy and mitophagy  
Increased accumulation of ROS 
Decreased respiratory growth 
Protein serine/threonine kinase 
required for vesicle formation in 
autophagy and CVT pathway 
CCH1*  0.31 C. neoformans (CNAG_01208) 
C. albicans (orf19.3298) 
C. glabrata (CAGL0B02211g) 
A. fumigatus (Afu1g11110) 
Calcium 
homeostasis 
Cell signalling 
Decreased resistance to iron 
Abnormal vacuole morphology 
Decreased stress resistance 
Decreased calcium accumulation 
Regulation of transmembrane 
transport 
FET3 0.60 0.69 C. neoformans (CNAG_02958/ 
CNAG_06241) 
C. albicans 
(Orf19.4211/Orf19.4212/ 
Orf19.4213/Orf19.4215/ 
Orf19.943) 
C. glabrata (CAGL0F06413g) 
A. fumigatus 
(Afu4g14490/Afu5g03790) 
Iron regulon Decreased oxidative stress resistance  
Decreased resistance to CPO and DSX 
Abnormal vacuole morphology 
Decreased respiratory growth  
Decreased resistance to metals 
Complex with Ftr1 involved in 
high affinity iron uptake  
IZH2 -0.36  C. neoformans (CNAG_05370) 
C. glabrata (CAGL0G04631g) 
A. fumigatus (Afu3g10570) 
Zinc/lipid 
homeostasis 
Absence of apoptosis 
Decreased accumulation of ROS 
Decreased resistance to CPO 
Abnormal vacuole morphology 
Increased resistance to polyenes [447] 
Plasma membrane receptor for 
plant antifungal osmotin 
THR1 0.32 0.55 C. neoformans (CNAG_04156) 
C. albicans (orf19.923) 
C. glabrata (CAGL0J00649g) 
A. fumigatus (Afu5g05820) 
Threonine 
synthesis  
Auxotrophy  
Decreased resistance to FLC 
Decreased resistance to oxidative 
stress 
Susceptible to AMB [457] 
Homoserine kinase required for 
threonine biosynthesis   
TPK2* 0.43  C. neoformans 
(CNAG_00396/CNAG_04162) 
C. albicans 
(orf19.2277/orf19.4892) 
cAMP 
pathway 
Abnormal vacuole morphology Protein kinase A subunit 
involved in repression of iron 
uptake genes 
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C. glabrata (CAGL0G09020g/ 
CAGL0M08404g) 
A. fumigatus  
(Afu2g12200/Afu5g08570) 
VEL1*
#
  -5.51 None Iron/zinc 
homeostasis 
Decreased invasive growth Putative cell surface 
glycoprotein [439] 
YAP5* 0.31  C. glabrata (CAGL0K08756g) Iron 
homeostasis 
Abnormal vacuole morphology  
 
Transcription factor involved in 
regulation of iron homeostasis 
YCT1* 0.66 0.65 A. fumigatus (Afu7g06790) Sulphur 
assimilation, 
stress 
response 
Absent utilisation of sulphur source 
Abnormal vacuole morphology 
Transporter involved in cysteine 
import and sulphur assimilation  
YOR387C*  -4.91 None Iron/zinc 
homeostasis 
Decreased invasive growth  Putative cell surface 
glycoprotein [439] 
ZAP1*  -2.22 C. neoformans (CNAG_05392) 
C. albicans (orf19.3794) 
C. glabrata (CAGL0J05060g) 
Zinc 
homeostasis 
Decreased oxidative stress resistance 
Decreased resistance to BAPTA, EDTA 
Decreased use of iron source 
Abnormal vacuole morphology 
Transcription factor involved in 
regulation of zinc homeostasis 
*Genes selected for knock-out mutant analysis. 
#
 Used for double knock-out with YOR387C 
a
Fold-change  
b
Whether an orthologue of the S. cerevisiae gene is present in the genomes of C. neoformans, C. albicans and A. fumigatus using OrthoMCL [379] 
c
Phenotypes were according to SGD unless referenced with specific study (www.yeastgenome.org/) 
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Knock-out mutants obtained from the Yeast Deletion Project collection [341] were screened by PCR 
using the primers listed in Appendix 4.2 to confirm that the genes of interest were deleted. Each primer 
set used to confirm gene deletions amplified the expected band sizes from the DNA of wild type strains 
and knock-out mutants (Appendix 4.6 and 4.7). The knock-out mutants were tested for susceptibility to 
AMB, FLC, heat (37 °C), cell wall inhibitors (calcofluor white (CW), salt (NaCl), caffeine, and SDS), 
oxidative stress (hydrogen peroxide; H2O2) and nitrosative stress; NaNO2). With the exception of zapϭ∆, 
all knock-out mutants grew to a similar extent as the wild type strain on the control plates. Of the knock-
out mutants tested (Fig. 4.13), only aft1∆ was susceptible to AMB and all other stressing agents. zap1∆ 
had increased susceptibility to AMB and other stressors except NaCl, NaNO2 and 0.005% SDS; and was 
susceptible to 0.01% SDS (not shown). These results confirm the importance of Aft1 and Zap1 in cell wall 
and membrane maintenance, and for AMB and general stress survival, as predicted by the regulatory 
networks (Fig. 4.11). The lack of susceptibility to stressors by other mutants suggests that the yeast cell 
has redundant pathways that compensate for the deletion of the other target genes.  
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Figure 4.13. Spot plate assays of knock-out mutants 
grown (a) on plates containing antifungal agents, 
oxidative and nitrosative stressors; (b) on plates 
containing cell wall stressing agents; and (c) at 37 °C. 
10-fold serial dilutions of cultures were plated on 
synthetic complete agar from left to right starting at 10
6
 
cells/mL. ͚D͛ indicates the days of growth. #Calcofluor 
white (CW) was tested at 200 µg/mL except with vel1∆, 
yor387c∆ and vel1∆/yorϯϴϳĐ∆ where it was accidentally 
tested at 300 µg/mL. In (a) and (b) cch1∆ was tested 
later with only selected stressing agents. 
(a) 
(b) 
(c) 
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4.4.4.3. Testing downstream binding targets of Aft1 and Zap1 as possible drug targets 
Iron and zinc are essential trace elements and the direct disruption of their regulation through AFT1 and 
ZAP1 deletion confirms their necessity in cellular functions (Fig. 4.13). While targeting zinc and iron 
homeostasis through disrupting AFT1 and ZAP1 might be considered a promising approach for 
enhancing current antifungal drugs (AMB and FLC), AFT1 is not widely conserved across pathogenic 
fungal species, while ZAP1 is conserved between fungi and mammals, although it does has druggable 
domains (from OrthoMCL [92, 379]). Given that iron and zinc are important in humans, any disruption to 
their regulation in the human host could cause the same problems with side effects as the iron chelating 
drugs (Sections 3.1.3.1 – 3.1.3.6), hence less conserved targets were sought.  
Targets that require metal ions but are not involved in their uptake may be better choices as potential 
antifungal targets. To investigate this, mutants with disruptions to genes encoding mutual targets of 
Aft1 and Zap1 were targeted. As above, a set of criteria was implemented to choose the best candidate 
genes. The genes selected were:  
 binding targets of Zap1 and Aft1 transcription factors 
 differentially expressed in TA or TAL  
 associated with a list of manually curated enriched GO terms from SOMs analysis 
 not homologous with human genes, based on the OrthoMCL database [379] 
 homologous to genes in C. neoformans, C. albicans, C. glabrata and A. fumigatus based on the 
OrthoMCL database [379] 
 ͚druggable͛ based on DrugBank (ver. 4.1) (http://www.drugbank.ca/) [459], from common 
domains in their protein sequences based on Pfam (ver. 27.0) [460] 
These criteria narrowed down the target to two genes: MET32 and MTD1. Met32 is an auxillary 
transcription factor involved in targeting Met4 to sulphur metabolism genes as previously mentioned 
(4.4.2.2). MTD1 is an NAD-dependant methylenetetrahydrofolate dehydrogenase involved in folate 
biosynthesis [461] and was down-regulated in TA and up-regulated in TAL.(not shown). Knock-outs of 
these genes were tested for their response to AMB, FLC, oxidative and cell wall stress. Unfortunately, 
neither of the knock-out mutants were susceptible to any of the stressing agents tested and grew to the 
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same extent as the wild type strain (Fig.4.14). This suggests that direct disruption of iron and zinc 
regulation at the level of overall control, i.e., Aft1 and Zap1 as seen in Figure 4.13, is needed to increase 
susceptibility to antifungal drugs. 
 
 
Figure 4.14. Knock-out mutants of ͚druggable͛ targets tested on various stressors. aft1∆ was included as 
a susceptible control. 10-fold serial dilutions of cells starting at 10
6
 cell/mL from left to right were plated 
onto synthetic complete agar. ͚D͛ indicates the number of days grown at 30 °C.  
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4.5. Discussion – AMB+LF synergy in S. cerevisiae S288C  
4.5.1. Exploring the molecular mechanisms of synergy between antifungals and iron chelators for 
novel antifungal therapies  
There is increased interest in synergising compounds that potentiate current antifungal drugs [69, 70, 
462]. The use of iron chelators as synergents is rationalised by the fact that iron is a critical growth 
factor for fungal pathogens during host infection. In vitro, some iron chelators have been found to 
synergise the activity of antifungal drugs against fungal pathogens [9, 10], and in animal infection 
studies iron chelation has been seen to potentiate antifungal treatment, reducing fungal dissemination 
and organ burden and increasing survival [73, 74].  
A range of iron chelating agents and antifungal drugs were screened in Saccharomyces and Cryptococcus 
(in Chapter 3) with the expectation of finding a number of synergistic combinations for transcriptomic 
analysis. However, the only synergistic combination was AMB and LF, and the focus then became 
understanding this synergy. As supplementation with iron did not rescue AMB+LF synergy (Fig. 3.4) and 
other iron chelating agents were not synergistic, it appeared that iron chelation was not the primary 
cause of synergy with AMB.  
To understand how LF potentiates AMB, yeast cells were treated at the fractional inhibitory 
concentrations (FIC) of each agent alone and in combination to find the ID20 timepoint, when cells were 
harvested for RNA-sequencing. LF is only weakly antifungal toward Cryptococcus and Saccharomyces 
;Taďle ϯ.ϮͿ, aŶd at the FIC ;Ϯ μg/ŵLͿ it did Ŷot iŶhiďit gƌoǁth oƌ pƌoduĐe aŶ ID20 (Fig. 4.4). Futhermore, 
the transcriptome of S. cerevisiae tƌeated ǁith Ϯ μg/ŵL LF had Ŷo ĐhaŶges iŶ geŶe eǆpƌessioŶ Đoŵpaƌed 
to the untreated control (Fig. 4.6). Hence, this chapter focuses on understanding the response to 
AMB+LF treatment by analysing the yeast transcriptome when treated with AMB treatment alone and 
comparing this to the response to AMB+LF.  
4.5.2. The addition of LF to AMB caused unexpected changes in the transcriptomic response by S. 
cerevisiae that appear contrary to enhanced growth inhibition  
With AMB treatment, Saccharomyces cells mounted a response fairly typical to the environmental stress 
response (ESR), which is a set of differentially regulated responses that are common to a variety of 
suboptimal environmental conditions including heat and osmotic shock, oxidative stress and nutrient 
starvation [347]. Responses seen in the analysis of TA that were similar to the ESR included the up-
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regulation of the cellular responses to stress, mitochondrial processes and carbohydrate metabolism for 
the generation of energy, metabolite and metal ion transport and autophagy (Table 4.5). Responses that 
were down-regulated were associated with cell growth, such as DNA, ribosome and protein synthesis 
(Table 4.5). Exceptions to the ESR were the down-regulation of ergosterol biosynthesis and protein 
folding, which have been reported in microarray studies in AMB-treated Saccharomyces and Candida 
cells (Table 4.5) [346, 463].  
In contrast, gene expression in TAL was more indicative of an absence of cellular stress. In addition, and 
contrary to expectations in the presence of an iron chelator, cells did not appear to have an increased 
requirement for iron and other trace metals as there was an absence of enrichments relating to iron 
homeostasis and down-regulation in zinc uptake (Table 4.5 and Fig. 4.9b(i)). Finally, an up-regulation of 
transcripts related to amino acid and protein synthesis suggested active growth. Given the more rapid 
and severe growth inhibition caused by AMB+LF compared to AMB treatment (Fig. 4.4), the observed 
responses were surprising and contrary to expected cell stress and death responses. Down-regulation of 
responses associated with stress does not correspond to the growth inhibition mechanism reported for 
AMB and LF when used independently, which both involve an increased production of endogenous ROS 
[303]. LF also inhibits growth through the chelation of iron and other metals and through perturbations 
to the cell membrane and cell wall [464-467]. While it was established in Chapter 3 that iron chelation 
by LF was not the cause of synergy when combined with AMB (Fig. 3.4), LF is nonetheless a chelator, and 
the down-regulation of metal uptake genes (Fig. 4.11b and d) is difficult to explain.  
The cellular response to AMB and AMB+LF are summarised in the model presented in Figure 4.15 and 
are discussed in the following sections.  
4.5.2.1. The presence of LF down-regulated stress-associated responses that were induced by AMB  
TA showed an up-regulation of antioxidant responses related to hydrogen peroxide catabolism and 
trehalose metabolism [401] (Table 4.5), which suggested the induction of oxidative stress. This is 
consistent with many studies that have shown that AMB induces the accumulation of ROS in fungi and 
that antioxidants are produced as a mechanism to protect cells from ROS damage [303, 468-471]. In the 
current study, SOMs analysis suggested an increase in mitochondrial stress with the induction of PKA 
signalling (Fig. 4.9a(ii)), which increases the production of ROS in the mitochondria through increased 
respiratory function [398]. Additionally, mitophagy, which prevents apoptosis by degrading damaged 
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mitochondria [400], was up-regulated (Table 4.5) and suggested oxidative stress was induced following 
AMB treatment.  
In contrast to TA, the synergistic response seen in TAL was characterised by a down-regulation in 
responses associated with stress (Fig. 4.15). This was seen by the down-regulation of transcripts 
involved in glutathione biosynthesis and the shutdown of GO terms related to ER processes that are 
typical of ERAD, which suggests either the cells fail to sense oxidative damage or are unable to mount an 
appropriate response. Glutathione is a major antioxidant involved in oxidative stress responses [472]. 
Down-regulation of glutathione biosynthesis may be a secondary effect resulting from the down-
regulation of sulphur metabolic pathways that in turn limit homocysteine production (Fig. 4.10). 
Although contrary to an expected increase in antioxidant production in response to AMB+LF, the down-
regulation of homocysteine production may be a mechanism to avoid homocysteine toxicity as this can 
cause oxidative stress, alter purine biosynthesis, and inhibit transmethylation reactions [473, 474].  
In TAL, there was a down-regulation of protein sorting processes while enrichments for protein synthesis 
were up-regulated, suggesting disruption to protein turnover (Table 4.5), which would be expected to 
activate ERAD. Contrary to this, however, the processes involved in ERAD were down-regulated in TAL 
(Fig. 4.9b(iii), (v) – (vii)), which may be linked to the decrease in glutathione production noted above 
(Fig. 4.15). The ER lumen is highly oxidising as the process of protein folding generates ROS [475] and 
glutathiones are present in the ER as a net reductant to maintain redox balance [476]. Protein folding 
activities in the ER have been shown to be suppressed when glutathione is depleted, indicating a 
dependency between these processes [477]. In TAL, down-regulation of ERAD processes and the 
repression of glutathione production from the down-regulation of sulphur metabolising pathways may 
be a response to minimise oxidative damage in the ER, which can induce apoptosis. The ER stores 
calcium, which has a major role in signalling and is maintained at low cytosolic concentrations [93]. One 
of the consequences of oxidative stress in the ER is the leakage of calcium ions into the cytosol where 
they can come into contact with the mitochondria and induce apoptosis [424].  
4.5.2.2. The addition of LF decreased the need for trace metals that was required with AMB treatment  
In TA, network analysis suggested activation of the iron regulon through the up-regulation of AFT1 and 
increased iron uptake processes (Fig. 4.11a). A similar response was reported by Zhang et al. (2002) and 
Agarwal et al. (2003) with up-regulation of genes involved in metal uptake and transport seen in their 
microarray analysis of AMB-treated Saccharomyces and Candida cells [346, 463]. Iron is required for 
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many cellular processes and is co-regulated with processes involved in oxygen metabolism, such as 
respiration and lipid biosynthesis [109]. Iron is also required as a catalytic cofactor in catalases and 
peroxidises that are part of the response to oxidative stress [77]. Up-regulation of iron homeostasis by 
AMB correlates with the induction of mitochondrial stress that was suggested by SOMs analysis (Fig. 
4.9a(ii)). The importance of iron regulation to AMB susceptibility was further shown by the increased 
susceptibility of the aftϭ∆ strain to AMB and other stressors (Fig. 4.13).  
In contrast to this, the addition of LF shut down the activated iron regulon in TA and caused a repression 
of genes involved in iron uptake (Fig. 4.11b and 4.15). This was unexpected as iron should be limited by 
LF chelation. Furthermore, the enrichment for Fe-S assembly, which requires iron and sulphur, was 
induced (Fig. 4.9b(ii)). Repression of the iron regulon may be associated with the down-regulation of 
stress responses as these are co-regulated, as mentioned previously. The presence of LF also caused zinc 
transport and the expression of the zinc-controlling transcription factor Zap1 to be down-regulated (Fig. 
4.9b(i)), suggesting the cell was either not sensing or not responding appropriately to zinc depletion. 
Zinc is another essential metal that is needed as a structural and catalytic cofactor in many proteins and 
its depletion induces the production of oxidants [478]. Zinc deficiency usually up-regulates the 
expression of oxidative stress response genes through the activity of Zap1 [419], and the repression of 
oxidative stress responses observed in TAL is consistent with ZAP1 down-regulation. Interestingly, 
network analysis suggested that the down-regulation of ZAP1 in TAL was also associated with the 
repression of genes involved in protein processing and sulphur metabolism (Fig. 4.11d). This finding 
suggests that the down-regulation of oxidative stress and ER function may be linked to zinc regulation. 
Similar to iron, zap1Δ showed increased susceptibility to AMB (Fig. 4.13), which suggests zinc regulation 
is also important for AMB susceptibility.   
In summary, the transcriptome analysis suggests the addition of LF caused a dysregulation of responses 
to stress and metal regulation (Fig. 4.15). AMB alone caused up-regulation of oxidative stress responses 
and increased stress in the mitochondria as suggested by the activation of PKA signalling, along with an 
increased need for iron through the activation of the iron regulon. In the synergistic response to 
AMB+LF, however, the coordinated stress responses of glutathione biosynthesis and ERAD were down-
regulated, along with metal ion regulation. These stress-associated responses may be linked to the 
regulation of zinc via ZAP1, which is important in AMB susceptibility, but was repressed with the 
addition of LF.  
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Figure 4.15. Model of the transcriptome response to AMB+LF synergy in S. cerevisiae S288C. (a) In TA, a 
range of stress responses were induced, metal transport was up-regulated via the transcription factor 
AFT1 and cell growth was shut down. (b) In TAL, there was down-regulation of stress responses and of 
iron and zinc metal ion uptake mediated by AFT1 and ZAP1. Proteolysis was repressed while protein and 
ribosome production, which are indicative of cell growth, were induced. This paradoxical response 
suggests a general dysfunction of the appropriate cellular stress response and metal ion homeostasis, 
resulting in enhanced cell death. Red arrows and text: up-regulated processes; green arrows and text: 
down-regulated processes. Black arrows: observed effect of processes on other cellular functions in drug 
treatments. Asterisks: gene knock-out mutants that have increased susceptibility to AMB treatment.  
(a) TA  
(b) TAL  
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4.5.3. Appropriate regulation of stress responses is required for survival against combinatorial stresses  
Although the down-regulation of stress-associated responses seen in TAL appeared paradoxical, other 
studies examining the enhanced antifungal activity of combined drug treatments or chemical stressors 
have reported similar effects. Proteomic analysis of synergy between FLC and the BBR derivative B-7b in 
Candida albicans also found GO enrichments related to protein folding and regulation of stress defences 
were down-regulated by FLC+B-7b compared to FLC treatment alone. Interaction network analysis of 
the differentially expressed proteins found those regulating stress were highly connected, indicating 
that the regulation of stress responses had a major role in FLC+B-7b synergy. Interesting, FLC+B-7b 
treatment did not augment ROS production and was only synergistic in FLC-resistant C. albicans strains, 
suggesting FLC+B-7b inhibits cellular mechanisms that cause resistance to FLC [321].  
A combined exposure to cationic and oxidative stresses has also been seen to reduce stress responses 
but enhance cell death in Candida [479, 480]. Comparison of the transcriptome response to NaCl and 
H2O2 treatments alone and in combination found stress responses were up-regulated with each 
individual agent, but were not enriched in NaCl+H2O2. Cationic and oxidative stresses activate Hog1 and 
Cap1, which are regulatory proteins involved in different stress signalling pathways that mediate osmo-
adaptative responses and antioxidant gene expressions in Candida. Expression analysis of Hog1 and 
Cap1 and their respective gene targets following NaCl+H2O2 treatment found that while Hog1 was 
activated, some of its downstream cationic stress targets were not expressed. Cap1 was not activated 
following NaCl+H2O2 treatment, and Cap1-dependent genes, such as catalases and thioredoxin 
reductases, were not up-regulated. This reduced activity of catalase was correlated with an increased 
accumulation of ROS and increased anti-Candida activity by NaCl+H2O2 treatment. Overall, this showed 
that the stress response to NaCl impaired the appropriate response to oxidative stress by disrupting the 
expression of catalase, which was required to neutralise ROS induced by H2O2 [479]. The disruption of 
one stress signalling pathway by the activity of another was termed ͚stress pathway interference͛ and 
was suggested as a new target for antifungal development.  
While stress pathway interference cannot be deduced in the current study as stress pathways were not 
activated by LF alone, this does illustrate how a paradoxical down-regulation of stress responses can 
contribute to enhanced cell death. Cross talk exists between the many stress signalling pathways in a 
cell, such as between calcineurin and Rim101 signalling pathways, which both mediate adaptive 
responses to pH and cell wall perturbations [481]. In response to combinatorial stresses, stress signalling 
pathways can either act cooperatively or antagonistically with one another, resulting in either stress 
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adaptation and survival, or cell death [480]. Therefore, while the down-regulation of stress responses 
during AMB+LF synergy suggested an avoidance of oxidative stress, this may instead imply a disruption 
to the appropriate regulation or activation of stress-associated responses.   
4.5.3.1. Dysregulation of stress responses in AMB+LF synergy is associated with metal ion homeostasis  
Aft1 and Zap1 were suggested to play critical roles in AMB+LF synergy. Network analysis suggested Aft1 
was involved in various cellular functions in TA including stress responses and nutrient metabolism (Fig. 
4.11a and 4.11b), which is consistent with iron being essential for various homeostatic processes [77, 
307]. In contrast, absence of AFT1 expression and shut down of the iron regulon in TAL were associated 
with down-regulation of cellular stress responses (Fig. 4.11b), which together with the increased 
susceptibility of aft1Δ to AMB (Fig. 4.13) suggested AFT1 is needed to maintain an appropriate 
regulation of stress responses to survive AMB+LF inhibition. 
Zap1 had a profound effect in AMB+LF synergy. Analysis of differential expression in TAL suggested 
down-regulation of many genes regulated by Zap1. A subset of Zap1-regulated genes is shown in the 
network analysis, which illustrates the central role of ZAP1 in functions performed in the ER, sulphur 
metabolic pathways and response to stress (Fig. 4.11d). This, together with the increased susceptibility 
of the zapϭ∆ mutant to AMB and other stressors, suggests that ZAP1 may have a central role in LF-
mediated drug synergy (Fig. 4.13). 
Sulphur metabolism is involved in glutathione biosynthesis and is coordinated with zinc homeostasis 
through the activity of Zap1. Under zinc deficiency, Zap1 is activated and down-regulates sulphur 
metabolism by increasing the expression of the MET30 [403]. Met30 is associated with a SCF ubiquitin 
ligase complex and binds to and inhibits the activity of transcriptional activator Met4 [482]. This 
prevents the interaction of Met4, which does not have DNA binding activity, with DNA binding cofactors 
Met31 and/or Met32 that then regulate sulphur metabolic genes [412]. As Zap1 activity and sulphur 
metabolism are normally negatively correlated, the down-regulation of both processes seen in TAL 
suggests that cross talk between them was disrupted. This in turn may have affected stress responses, 
such as by decreasing production of the antioxidant glutathione. Zap1 also controls the activity of 
MET32, which was the only gene encoding a transcription factor involved in sulphur metabolism to be 
differentially regulated in TAL (Fig. 4.9b(iii)). However, knocking out MET32 did not increase susceptibility 
to AMB (Fig. 4.14), which suggests that cross-communication between zinc homeostasis and the 
regulation of sulphur pathways is complex and that redundant processes probably occur.  
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Similar to sulphur metabolism, Zap1 regulates the expression of genes involved in ER function and 
homeostasis, such as protein sorting and degradation and lipid metabolism [420]. In TAL, network 
analysis of suggested Zap1 caused the regulation of ER-related stress responses to be suppressed (Fig. 
4.11d). Among the genes under the regulation of Zap1, KAR2, which encodes an ATPase/chaperone and 
is integral to ER stress tolerance [483, 484], was down-regulated (Fig. 4.11d). Kar2 is an essential protein 
that has a basal level of expression and is usually bound to Ire1 under normal ER conditions [485, 486]. 
Ire1 is a kinase/endoribonuclease that is required for the synthesis of the ER stress-specific transcription 
factor Hac1 [487]. Under ER stress, Kar2 disassociates from Ire1, which in turn induces the ER stress 
response through the synthesis and activity of Hac1 [486, 487]. As both IRE1 and HAC1 were not 
observed in TAL (not shown) and KAR2, which is normally constitutively expressed, was down-regulated 
by Zap1 (Fig. 4.11d), this suggests that Zap1 affects the regulation of the ER stress response.  
The ER requires zinc ions for function and homeostasis, and disruption to ER zinc concentration, such as 
through deletion of ER zinc transporters Zrg17 and Msc2, induces ER stress [421, 488]. However, the 
induction of ER stress responses including ERAD also requires cytsolic zinc as msc2Δ mutants are 
defective in ERAD induction under zinc deficient conditions [488]. In TAL, where ERAD processes were 
down-regulated (Fig. 4.9b(iii), (v) – (vii)), network analysis indicated that Zap1 suppressed extracellular 
and ER zinc uptake by down-regulating MSC2 and ZRG17 (Fig. 4.11d). This suggested that the down-
regulation of overall zinc homeostasis by Zap1 repression also affected induction of ERAD due to lack of 
ER zinc that is required for this stress response. 
Zap1 also plays a role in oxidative stress responses as it controls the expression of antioxidants like TSA1 
and CTT1 [420, 489]. Down-regulation of target genes involved in oxidative stress in the Zap1 regulatory 
network (Fig. 4.11d) and the susceptibility of zapϭΔ to hydrogen peroxide showed the importance of 
Zap1 for surviving oxidative stress (Fig. 4.13).  
Overall in TAL, Zap1 and Aft1 are suggested to be important for cellular stress responses as these metal-
controlling transcription factors directly and indirectly affected stress regulation. Compared to Aft1, 
Zap1 appeared to have a more pronounced impact on the dysregulation of stress responses in AMB+LF 
synergy. This included the disrupted cross talk between Zap1 and sulphur metabolism, where regulation 
by Zap1 on sulphur metabolic pathways affected the expression of stress defence responses such as 
glutathione biosynthesis. Additionally, the repression of Zap1 seen in TAL may have disrupted the 
induction of ER stress responses such as ERAD through down-regulation of KAR2, which is needed to 
express the ER stress transcription factor Hac1. As zinc ions are required for ER homeostasis, down-
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regulation of Zap1 may have also disrupted ER stress tolerance through an overall decrease in zinc ion 
uptake. Together, this suggests that disruption of stress-associated responses via metal regulation and 
homeostasis may be a mechanism of synergy in AMB+LF.  
4.5.4. LF enhances disruption in membrane-mediated trafficking that is associated with AMB 
treatment  
Enriched processes that were not related to the dysregulation of stress-associated responses were also 
seen. These included down-regulation of ergosterol biosynthesis over that seen in response to AMB 
treatment (Table 4.5), and repression of vacuole-mediated degradation processes like the CVT pathway 
and nucleophagy (Fig. 4.9b(vi)). Disruptions to ergosterol biosynthesis affect vacuole function and 
membrane fusion and trafficking [490, 491], which were down-regulated in TAL (Fig. 4.9b(vi – vii)). While 
these processes were not observed when AMB was used alone at sub-inhibitory concentrations, lethal 
concentrations of AMB have been shown to disrupt membrane-mediated trafficking such as cargo 
delivery to the vacuole [492]. As the addition of LF to sub-inhibitory concentrations of AMB caused a 
similar disruption in membrane-mediated trafficking that is seen at higher concentrations of AMB, this 
suggests that LF may enhance activities of AMB that would normally be sub-inhibitory. This may 
therefore be another mechanism whereby LF mediates synergy with AMB, in addition to the 
dysregulation of stress responses.  
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4.6. Results – Analysis of AMB+LF synergy in C. neoformans H99 
4.6.1. GO enrichments of differentially expressed H99 genes in TA and TAL 
GO enrichments analyses in TA and TAL for C. neoformans H99 are shown in Table 4.8. This also includes 
the GO terms enriched in response to each drug treatment in S. cerevisiae S288C for comparison. 
Enriched GO terms in TA and TAL had the same direction of expression in H99, which is unlike S288C 
where the regulation of some GO enrichments changed in direction with the addition of LF. Overall, the 
transcriptional responses between TA and TAL in H99 were similar: nucleic acid metabolism, replication, 
cell organisation, transcription, translation and lipid biosynthesis were suppressed, and terms related to 
energy production and lipid catabolism were induced. GO enrichments unique to either drug treatment 
include protein folding, which was suppressed in TA, and actin polymerisation, responses to oxidative 
stress and autophagy, which were induced in TAL. Overall, AMB inhibited all aspects of cell function in 
H99, except for processes required for the production of energy, and lipid catabolism. The addition of LF 
to AMB treatment caused similar dysfunctions to the cell, but additionally induced autophagy and cell 
stress.  
 
Table 4.8. Major GO enrichments in TA and TAL for C. neoformans H99 and S. cerevisiae S288C 
GO term enrichments  
H99 S288C 
GO ID TA TAL TA TAL 
Nucleic acid and amino acid related 
Nitrogen compound metabolic process GO:0006807 1.65 1.71 0 4.88 
Nucleic acid metabolic process GO:0090304 2.07 2.07 2.01  
Nucleobase-containing compound catabolic process GO:0034655 0 0 1.88 0 
Purine-containing compound metabolic process GO:0072521 0 0 1.86 0 
Pyridine-containing compound metabolic process GO:0072524 2.76 0 2.47 0 
Cellular amino acid metabolic process GO:0006520 0 0 3.69 8.44 
Cell organisation and replication related 
Cellular component biogenesis GO:0044085 2.55 2.65 2.69 0 
DNA replication GO:0006260 4.09 4.91   
Cell division GO:0051301 2.26 2.6   
Microtubule-based process GO:0007017 5.53 6.33   
Actin polymerisation or depolymerisation GO:0008154 0 4.44   
Energy related 
Tricarboxylic acid cycle GO:0006099 9.69 11.67 3.27 0 
Mitochondrial electron transport, ubiquinol to cytochrome c GO:0006122 0 0 7.43 0 
Generation of precursor metabolites and energy GO:0006091 0 0 2.06 0 
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Oxidation-reduction process GO:0055114 2.23 1.98 2.31 2.09 
Carbohydrate catabolic process GO:0016052 3.2 2.45   
Transcription and translation related 
Ribonucleoprotein complex biogenesis GO:0022613 4.57 4.36   
Ribosome biogenesis GO:0042254 6.61 6.96 5.36 3.88 
RNA processing GO:0006396 2.05 1.51 2.71 0 
Translational initiation GO:0006413 1.92 0   
Regulation of translational initiation GO:0006446 0 0 4.83  
Transcription of nuclear large rRNA transcript from RNA 
polymerase I promoter 
GO:0042790 8.43 6.63 5.42  
Protein related 
Cellular protein metabolic process GO:0044267 1.38 0   
Protein folding GO:0006457 2.54 0 2.18 3.77 
Post-translational protein targeting to membrane, 
translocation 
GO:0031204 0 0 0 16.65 
Ubiquitin-dependent protein catabolic process GO:0006511 0 0 0 2.51 
ER-associated ubiquitin-dependent protein catabolic process GO:0030433 0 0 0 6.65 
Lipid related 
Ergosterol biosynthetic process GO:0006696 3.03 4.16 4.03 4.84 
Cellular lipid catabolic process GO:0044242 4.22 3.41 0 0 
Phospholipid biosynthetic process GO:0008654 0 0 0 2.52 
Fatty acid catabolic process GO:0009062 5.77 0   
Stress related 
Hydrogen peroxide catabolic process GO:0042744 0 16.98 Inf*  
Response to oxidative stress GO:0006979 0 2.04   
Cellular response to oxidative stress GO:0034599 0 0  2.26 
Cellular response to DNA damage stimulus GO:0006974 1.9 2.39  0 
Response to misfolded protein GO:0051788 0 0  9.99 
ER-associated misfolded protein catabolic process GO:0071712 0 0  33.21 
Metal related 
Cellular iron ion homeostasis GO:0006879 0 0 3.24 0 
Iron-sulphur cluster assembly GO:0016226 0 0 0 5 
Siderophore transport GO:0015891 0 0 18.59 0 
Cellular metal ion homeostasis GO:0006875 0 0 2.48 0 
Autophagy related 
CVT pathway GO:0032258 0 0 3.11 0 
Autophagy GO:0006914 0 2.13 0 0 
Mitochondrion degradation GO:0000422 0 0 5.86 0 
Odds ratios for each GO term are included, with regulation of GO terms colour coded. Red: up-regulated. Green: down-
regulated. *Inf = all genes contributing to enrichment of this GO term are present.  
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4.6.2. SOMs enrichment analyses of C. neoformans H99 transcripts in TA and TAL  
SOMs analyses were performed on the H99 transcriptomic data, with the results presented in Figure 
4.16. As one outlier from the AMB+LF treatment had been removed (Fig. 4.7), transcript expressions in 
each SOMs cluster (Fig. 4.16a and b) and the heat maps showing the averaged gene expressions for each 
SOMs cluster (Fig. 4.16c and d) were mapped across a total of 11 experiments along the x-axis. 
Dendrograms from the heat maps once again separated the SOMs clusters for TA and TAL by the 
differential expression of co-regulated genes mapped to each cluster. In TA, transcripts with up-
regulated expression were mapped to clusters 1 – 3, 6 – 8, 11 – 12, 16 – 17 and 21 – 22, while clusters 4 
– 5, 9 – 10, 14 – 15, 20, 24 – 25 mapped down-regulated genes. In TAL, up-regulated genes were found in 
clusters 11 – 25 and down-regulated genes in clusters 1 – 10. SOMs of interest are presented in Figure 
4.17 and are discussed in the following sections. As in Table 4.8, similar GO enrichments in some of the 
SOMs clusters were observed between the drug treatments and these SOMs clusters are placed 
adjacent to each other in Figure 4.17 (a(i) – (iii) and b(i) – (iii)) for comparison. Other SOMs clusters of 
interest are presented in Figures 4.17c(i) – (iv).  
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Figure 4.16. Independent SOMs of C. neoformans H99 genes differentially expressed in (a) TA and (b) TAL, 
and the heat maps of average gene expressions of each SOMs cluster for (c) TA and (d) TAL. For each 
SOMs cluster shown in (a) and (b), the y-axis denotes the scaled gene expression levels and the x-axis 
represents the 11 experimental samples, arranged from left to right. These are the three biological 
replicates of the control for AMB treatment (CA1 – CA3), AMB treatment (A4 – A6), the control for 
AMB+LF treatment (CAL7 – CAL9), and AMB+LF treatment (with one biological replicate removed; AL10 
– AL11). The clusters are numbered from bottom left to top right. Empty clusters have no genes. The 
heat maps for average gene expressions (c) and (d) are represented by rpkm values scaled to standard 
normal per gene using Pareto scaling. The x-axis represents the 11 experimental samples with each 
biological replicate numbered. The y-axis shows the 25 SOMs clusters and the dendogram on the left 
separates the SOMs clusters into up- or down-regulated groups, exclusively. For TA (c), down-regulated 
genes were found in clusters 4 – 5, 9 – 10, 14 – 15, 20, 24 – 25 while the remaining clusters mapped up-
regulated genes. In TAL (d), up-regulated genes were found in clusters 11 – 25 and down-regulated genes 
in clusters 1 – 10.  
 
(a) (b) 
(c) (d) 
1 1 
25 25 20 20 
5 5 
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4.6.2.1. Metal homeostasis is affected in AMB and AMB+LF drug treatments  
No enrichment of metal ion homeostasis was observed in the overall H99 transcripts presented in Table 
4.8. However, the analysis of gene co-expressions by SOMs mapped enrichments associated with copper 
transport to cluster 1 in TA with CNAG_05626, Ctr4 and Ctr1 (CNAG_07701, formally named Ctr2 [493]), 
which were induced (Fig. 4.17a(i)). Iron transporters including Cft1, Cfo1, CNAG_05640 and 
CNAG_05154 were also enriched in TA, but were repressed and mapped to cluster 5 (Fig. 4.17a(ii)). 
CNAG_05640 and CNAG_05154 also contribute to the enrichment for manganese transport. However, 
the functions of CNAG_05640 and CNAG_05154 as iron and manganese transporters are tentative as 
they were based on homology and have not been experimentally validated.  
In TAL, SOMs analysis found metal homeostasis enriched and up-regulated in cluster 14, with genes 
related to iron, manganese, zinc, and copper transport and homeostasis (Fig. 4.17b(i)). For iron, these 
included the Fe-S cluster assembly proteins Isa1, CNAG_03589, CNAG_03395 and CNAG_03226, and a 
copper exporting ATPase Ccc2 [494]. For zinc, the transporters CNAG_02993 and CNAG_02806, which 
are homologous to the Saccharomcyes zinc transporters Yke4 and Zrc1 (from FungiDB; 
http://fungidb.org/fungidb/), respectively, were identified. For copper transport, Ccc2, Ctr1 and the 
cytochrome c oxidase assembly protein subunit CNAG_05573 [495] contributed to metal homeostasis 
enrichment.  
As was done for S288C transcripts, a manual search for other iron, copper and zinc related transcripts 
was performed. All metal-related genes, including those mentioned previously, are listed in Table 4.9 
with the SOMs clusters they were mapped to and their differential expression levels. In addition to ferric 
reductases and siderophore transporters, a haem transporter Cig1 [100] was induced in both TA and TAL, 
which implies that under drug exposure H99 sequesters inorganic (e.g. iron chloride) and organic (e.g. 
haem) sources of iron. While iron and manganese uptake were down-regulated in TA, the expression of 
mitochondrial manganese superoxide dismutase (Sod2), which detoxifies superoxides [496], was up-
regulated. A similar finding was observed in TAL where transcripts for zinc and copper uptake were 
induced, but the chaperone that transfers copper ions to Sod1 (CNAG_02292) was repressed and the 
expression of Sod1 itself was absent.  
Transcription factors regulating iron, copper and zinc were also observed in SOMs, but these had 
different expression patterns as each mapped to different clusters, as summarised in Table 4.10. The 
copper transcription factor Cuf1 was expressed in TAL only (cluster 21), while the zinc regulatory factor 
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Zap104 mapped to clusters 6 in TA and 20 in TAL. Iron homeostasis in Cryptococcus is mainly regulated by 
Cir1 and HapX, however, other regulatory factors also play a part (reviewed in Ding et al. (2014)) [106]. 
CIR1 is constitutively regulated [107] and its transcript was not detected in TA or TAL. HapX is part of a 
CCAAT motif binding complex that associates with other Hap proteins [497] and induces siderophore 
transport while suppressing mitochondrial functions such as respiratory and TCA functions in low iron 
conditions [103]. However, while HapX mapped to cluster 2 in TA and 20 in TAL, Hap2 and Hap3 mapped 
to different clusters suggesting differences in the regulation of the Hap complex under the different 
experimental conditions (Table 4.9 and 4.10). Other iron-regulating transcription factors included the 
pH-responsive transcription factor Rim101 [111], which was induced in clusters 1 and 19 in TA and TAL, 
respectively, and Nrg1, which is involved in the cAMP signalling pathway [110] and was repressed in 
clusters 15 in TA and 2 in TAL (not shown). 
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Table 4.9. Iron-, copper- and zinc-related transcripts identified in SOMs analysis of C. neoformans H99 in TA and TAL   
C. neoformans gene 
name (ID)* 
 Description  
SOMs cluster 
in TA 
SOMs 
cluster in TAL 
S. cerevisiae 
homologue 
Description  
Iron related genes 
HAP3 (CNAG_02215) CCAAT-binding transcription factor 3 - HAP3 (YBL021C) 
Subunit of the haem activated, glucose repressed 
Hap2/3/4/5 CCAAT-binding complex 
SRE1 (CNAG_04804) 
Sterol regulatory element binding 
protein 
22 - - - 
CCC2 (CNAG_06415) Copper-exporting P-type ATPase - 14 CCC2 (YDR270W) Copper transporting P-type ATPase  
CNAG_03589 Adrenodoxin-type ferredoxin 1 14 YAH1 (YPL252C)  
Ferredoxin of the mitochondrial matrix required for 
cellular Fe-S protein formation 
CNAG_06524 Uncharacterised protein  1 14 
FRE2 (YKL220C) 
FRE3 (YOR381W) 
FRE4 (YNR060W) 
FRE5 (YOR384W) 
FRE6 (YLL051C) 
Metalloreductase  
ISA1 (CNAG_02131) Fe-S cluster assembly protein 17 14 ISA1 (YLL027W)  
Protein required for maturation of mitochondrial 
Fe-S proteins 
CNAG_03395 NifU-like protein c - 14 NFU1 (YKL040C)  Protein required for maturation of Fe-S clusters  
CNAG_03226 
Succinate dyhydrogenase 
[ubiquinone] Fe-S subunit, 
mitochondria 
- 14 SDH2 (YLL041C)  Fe-S protein subunit of succinate dehydrogenases 
CNAG_04202 
Cytosolic Fe-S cluster assembly factor 
NAR1 
21 17 NAR1 (YNL240C)  
Component of cytosolic Fe-S protein assembly 
machinery, required for normal resistance to 
oxidative stress  
HAP2 (CNAG_07435) CCAAT-binding transcription factor 11 18 HAP2 (YGL237C)  
Subunit of the haem activated, glucose repressed 
Hap2/3/4/5/ CCAAT binding complex 
CNAG_00491 Uncharacterised protein - 18 ISA2 (YPR067W)  
Required for maturation of mitochondrial Fe-S 
proteins, functions in a complex with Isa1 
CNAG_05058 GTPase  - 18 MTG2 (YHR168W)  
Putative GPTase, peripheral protein of the 
mitochondrial inner membrane  
RIM101 (CNAG_05431) pH-response transcription factor  1 19 RIM101 (YHL027W) 
Transcription repressor involved in adaptation to 
alkaline conditions  
FRE7 (CNAG_00876) Ferric reductase 12 19 FRE7 (YOL152W)  Putative ferric reductase  
HAPX  (CNAG_01242) CCAAT-binding transcription factor 2 20 - - 
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CIG1 (CNAG_01653) Cytokine inducing-glycoprotein 2 20 - - 
CNAG_00727 
Mitochondrial protein with role in 
iron accumulation  
21 22 
MMT2 (YPL224C)  
MMT1(YMR177W)  
Putative metal transporter involved in 
mitochondrial iron accumulation  
CNAG_07316 
Hydroxyacid-oxoacid 
transhydrogenase  
6 24 ADH4 (YGL256W)  Alcohol dehydrogenase  
CNAG_05737 Oligopeptide transporter 8  11 24 YGL114W Oligopeptide transporter 
SOD2 (CNAG_04388) 
Mitochondrial manganese superoxide 
dismutase 
16 24 SOD2 (YHR008C)  Mitochondrial manganese superoxide dismutase  
CNAG_00638 GTPase 17 24 MSS1 (YMR023C)  
Mitochondrial protein; involved in the modification 
of mitochondrial tRNAs  
CNAG_04039 
Fe-S cluster assembly protein 2, 
mitochondrial 
17 24 
ISU1 (YPL135W)  
ISU2 (YOR226C)  
Protein required for synthesis of Fe-S proteins 
ZIP2 (CNAG_03398) 
Solute carrier family 39 (Zinc 
transporter), member 1/2/3 
6 25 
ZRT1 (YGL255W)  
ZRT2 (YLR130C)  
High affinity zinc transporter (Zrt1), Low affinity 
zinc transporter (Zrt2) 
FRE4 (CNAG_07334) Ferric reductase 6 25 FRE5 (YOR384W)  Putative ferric reductase with similarity to Fre2 
SIT1 (CNAG_00815) Siderophore iron transporter  12 25 
SIT1 (YEL065W)  
ARN1 (YHL040C)  
 ARN2 (YHL047C)  
 GEX1 (YCL073C)  
 GEX2 (YKR106W)  
Glutathione antiporter (Gex1, Gex2), ferrioxamine 
B transporter (Sit1), ARN family transporter for 
siderophore iron chelates (Arn1, Arn2) 
SIT2 (CNAG_02083) Siderochrome iron transporter - 1 - - 
NRG1 (CNAG_05222) Transcriptional regulator  15 2 NRG1 (YDR043C) 
Transcriptional repressor involved in glucose, 
filamentation and alkaline adaptation  
CNAG_01608 Nuclear GTP-binding protein 15 2 NUG1 (YER006W)  
GTPase that associates with nuclear 60S pre-
ribosomes 
CNAG_04872 Mitochondrial protein 24 2 FSF1 (YOR271C)  
Predicted alpha-isopropylmalate carrier, likely to 
play a role in iron homeostasis  
CNAG_01634 Large subunit GTPase 1 24 4 LSG1 (YGL099W)  
Putative GTPase involved in 60S ribosomal subunit 
biogenesis  
CFT1 (CNAG_06242) Major iron permease 5 7 FTR1 (YER145C)  High affinity iron permease (Ftr1) 
CFO1 (CNAG_06241) Ferroxidase/lacase 5 7 FET3 (YMR058W)  Multicopper oxidase  
CNAG_05640 
Metal iron and manganese 
transporter 
5 7 
SMF1 (YOL122C)  
SMF3 (YLR034C)  
Putative divalent metal ion transporter (Smf3), 
divalent metal ion transporter (Smf1) 
CNAG_05154 
Membrane fraction protein. 
Transports iron and manganese ions  
5 9 CCC1 (YLR220W)  Putative vacuolar iron/manganese transporter 
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CFO2 (CNAG_02958) Ferroxidase - 8 FET5 (YFL041W)  Multicopper oxidase  
FRE201 (CNAG_03498) Ferric reductase - 10 - - 
Copper related genes 
CUF1 (CNAG_07724) 
Ligand-regulated, copper-sensing 
transcription factor 
- 21 HAA1 (YPR008W) 
Transcriptional activator involved in adaptation to 
weak acid stress  
CNAG_05626 Uncharacterised 1 25 
SCO1 (YBR037C)  
SCO2 (YBR024W)  
Copper binding protein, required for cytochrome c 
oxidase activity and respiration  
CTR4 (CNAG_00979) 
High affinity copper uptake 
transporter  
1 25 CTR2 (YHR175W)  Low affinity vacuolar copper transporter 
CCC2 (CNAG_06415) Copper-exporting P-type ATPase  - 14 CCC2 (YDR270W)  Copper transporter P-type ATPase  
CTR1 (CNAG_07701) 
Copper transporter (formerly named 
CTR2 [493]) 
1 14 CTR1 (YPR124W)  - 
CNAG_05573 
Cytochrome c oxidase assembly 
protein subunit 17 
12 14 COX17 (YLL009C)  
Copper metallochaperone, transfers copper to 
Sco1 and Cox1, to cytochrome c oxidase  
CMT2 (CNAG_00306) Copper metallothionein 10 3 - - 
CNAG_02292 
Superoxide dismutase copper 
chaperone 
20 3 CCS1 (YMR038C)  Copper chaperone for superoxide dismutase Sod1 
CNAG_06414 
Cytochrome c oxidase-assembly 
factor COX23, mitochondrial  
24 4 COX23 (YHR116W)  Cytochrome oxidase function  
LAC2 (CNAG_03464) Cu-oxidase, laccase 20 6 
FET3 (YMR058W)  
FET5 (YFL041W)  
Multicopper oxidase  
CNAG_02157 Hypothetical protein 20 6 - - 
CFO1 (CNAG_06241) Ferrioxidase/laccase 5 7 
FET5 (YFL041W)  
FET3 (YMR058W)  
Multicopper oxidase  
CFO2 (CNAG_02958) Ferrioxidase  - 8 
FET5 (YFL041W)  
FET3 (YMR058W)  
Iron transporter  
CTR2 (CNAG_01872) 
Solute carrier family 31 (copper 
vacuole transporter)  
4 - 
CTR2 (YHR175W)  
CTR3 (YLR411W)  
Putative low affinity copper transporter (Ctr2), 
High affinity copper transporter (Ctr3) 
Zinc related genes 
CNAG_02993 
Solute carrier family 39 (zinc 
transporter), member 7 
16 14 YKE4 (YIL023C)  ER zinc transporter  
CNAG_02806 
Solute carrier family 30 (zinc 
transporter), member 1 
16 14 
COT1 (YOR316C)  
ZRC1 (YMR243C)  
Vacuole membrane zinc transporter 
CNAG_07728 Solute carrier family 39 (zinc 3 19 - - 
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transporter), member 1/2/3 
ZAP104 (CNAG_05392) 
Putative zinc finger transcription 
factor 
6 20 ZAP1 (YJL056C)  Zinc regulating transcription factor 
ZIP2 (CNAG_03398) Zinc ion transporter 6 25 
ZRT1 (YGL255W)  
ZRT2 (YLR130C)  
High affinity zinc transporter (Zrt1), low affinity zinc 
transporter (Zrt2) 
CNAG_04524 Zinc metalloprotease 16 14 - - 
CNAG_01969 Zinc metalloprotease - 17 - - 
CNAG_01016 Vacuolar membrane protein 11 18 MTC5 (YDR128W)  Subunit of SEA (Seh1-associated) complex 
CNAG_00505 Uncharacterised protein 1 25 - - 
CNAG_05394 Cation:cation antiporter 24 8 MSC2 (YDR205W)  ER zinc transporter  
CNAG_00837 Uncharacterised protein  - 7 ZRG17 (YNR039C)  ER zinc transporter  
*Expression of genes colour-coded red = up-regulated; green = down-regulated. - = not present. 
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4.6.2.2. Co-expression of stress and ER-related enrichments suggests that ER stress is repressed in TA 
and induced in TAL  
Stress responses were enriched in different SOMs clusters for both TA and TAL, suggesting stress terms 
were related to co-expressed GO enrichments present in the different clusters. In TA, response to 
oxidative stress was up-regulated and enriched in cluster 17, along with genes encoding antioxidants 
such as catalases (Cat1 and Cat4), sulfiredoxins (Srx1) and flavoproteins (CNAG_01846). Oxidative stress 
was co-enriched with protein maturation by Fe-S cluster transfer, with the Fe-S assembly proteins Isa1 
and CNAG_04039 (Fig. 4.17a(iii)). These co-enrichments reflect the requirement of Fe-S clusters for the 
catalytic activity of antioxidant proteins [77]. Although these transcripts can be associated with 
mitochondrial processes, enrichments of cellular components in cluster 17 did not return any terms 
associated with the mitochondrion. cAMP signalling, which causes mitochondrial stress by stimulating 
ROS production when induced [399] was down-regulated (cluster 15; Fig. 4.17c(i)). Together these 
results suggest that oxidative stress was not occurring in mitochondria. 
Response to stress was also enriched in cluster 9 in TA but was down-regulated. Many of the transcripts 
in this GO term encode for chaperones and heat shock proteins and contribute to the enrichments 
associated with protein folding (CNAG_00305, CNAG_03892), response to topologically incorrect 
proteins (CNAG_01185, CNAG_02500) and apoptosis (CNAG_06150, CNAG_02500) (Fig. 4.17c(ii)). Most 
of these terms relate to functions of the ER and suggest that within the ER there is a repression of stress 
responses, possibly by repressing functions that increase ROS production like protein folding [475] to 
avoid apoptosis. Other stress-related enrichments were found in cluster 24 with cell cycle regulation and 
transcription (not shown), which was also repressed.  
In TAL, stress-related enrichments were all induced. In cluster 24, oxidative stress was co-enriched with 
membrane fusion and trehalose biosynthesis, where genes with functions in oxidative stress were also 
involved in membrane fusion and trehalose biosyntheses. These include CNAG_00816, CNAG_03796, 
and CNAG_02895 for membrane fusion, and Tps2 for trehalose biosynthesis (Fig. 4.17b(iii)). Enrichments 
of cellular components in cluster 24 returned lipid, ER and vacuole terms (not shown), suggesting that 
oxidative stress could be occurring in the ER through the protein secretory process. The induction of 
oxidative stress promotes membrane fusion via actin polymerisation [498] and although actin-related 
enrichments were not co-expressed in cluster 24, they were enriched in SOMs clusters 16 (not shown) 
and 21 (Fig. 4.17c(iv)), and were also observed in the overall enrichments for TAL (Table 4.8). 
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In TAL, stress responses were co-enriched with protein folding as was seen in TA (Fig. 4.17c(ii)), however, 
these terms were up-regulated and mapped to cluster 11 (Fig. 4.17c(iii)), further suggesting that the ER 
is under stress in AMB+LF treatment. Other enrichments for stress and related terms mapped to clusters 
4 and 10 with cell cycle and maintenance-related processes (not shown), and cluster 18 with 
mitochondrion degradation (i.e. mitophagy) and nucleophagy (Fig. 4.17c(v)).  
4.6.2.3. Repression of protein sorting and lipid biosynthesis in TA and TAL suggests disruptions in ER 
functions such as transport protein synthesis  
In TA, protein retention in the ER and glycophosphatidylinositol (GPI) anchor biosynthesis were 
repressed and co-regulated with iron and manganese transport in cluster 5 (Fig. 4.17a(ii)). Lipid 
biosynthesis was also enriched in this cluster. Protein retention in the ER describes the transport of 
correctly synthesised and folded proteins in the ER to the Golgi apparatus (http://www.yeastgenome. 
org/go/GO:0006621/overview). GPI anchors are synthesised in the ER lumen and are required for the 
localisation of proteins processed through the ER [499]. As transport proteins like iron transporters are 
made in the ER, all the enriched terms in cluster 5 suggest the down-regulation of protein sorting in the 
ER. 
Protein-, lipid- and transport-related enrichments were also observed in TAL. These were repressed and 
co-enriched in SOMs cluster 7, with a wider range of transport proteins affected by repression of ER 
function (Fig. 4.17b(ii)). These included transport proteins for iron (CNAG_05640 and Cft1), zinc 
(CNAG_00837, homologous to Zrg17 in Saccharomcyes), carbohydrates (Hxs1, Itr4, CNAG_05867 and 
CNAG_05387), salts (CNAG_04038 and CNAG_04142), vitamins (CNAG_00598), and multidrug resistance 
transporters (Fnx1). Interestingly, while ER processes were repressed in TAL, protein targeting to the ER 
was induced in cluster 11 (Fig. 4.17c(iii)), as were terms related to protein exit through the Golgi 
apparatus in cluster 21 (discussed below, Section 4.6.2.4).  
4.6.2.4. Enrichments related to vesicle-mediated transport are induced in TAL 
The addition of LF to AMB treatment induced transcripts involved with the SNARE complex assembly, 
which mediates membrane fusion [500], endocytosis, Golgi to endosome transport, endosome to 
vacuole transport, and ubiquitin-dependent protein catabolism. These terms were all co-enriched in 
cluster 21 (Fig. 4.17c(iv)) and describe the journey of cargo from the Golgi apparatus to the vacuole, 
possibly for degradation or storage. Actin polymerisation, which is required to aid membrane fusion and 
trafficking [501], was also enriched in this cluster. Similar to this process, autophagy, which requires 
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membrane organisation and mediates protein degradation through the vacuole [426], was observed in 
the overall GO enrichments in TAL (Table 4.8). Apart from vesicle fusion, where enrichments were 
repressed in TA in cluster 4 (not shown), the enrichments related to vesicle-mediated transport were 
unique to TAL. This suggests that one of the ways through which LF causes synergy with AMB in H99 
could be by affecting processes related to membrane fusion and trafficking.  
4.6.2.5. Addition of LF to AMB treatment may repress cellular processes regulated by the activity of 
kinases  
The regulation of kinase activity was enriched and repressed in TAL in clusters 3, 5 and 8 (not shown) but 
was absent in TA. Kinase activity is important for many cellular functions, ranging from metabolism, 
signalling and transport. The GO terms co-enriched with kinase regulation in clusters 3, 5 and 8 included 
processes related to cell cycle and replication, signal transduction, RNA metabolism and protein 
modification, suggesting the repression of kinase activity may have down-regulated these processes.  
 
SOMs clusters with similar profiles and enrichments in (a) TA and (b) TAL 
(a) TA SOMs clusters (b) TAL SOMs clusters 
(i) 
 
Cluster: 1 
 
Gene expression: Up-regulated 
 
Copper ion transport: CTR4 (CNAG_00979), CTR1 
(CNAG_07701), CNAG_05626 
 
RIM101 (CNAG_05431) expressed in this cluster (not 
shown) 
(i) 
  
Cluster: 14 
 
Gene expression: Up-regulated 
 
Fe-S assembly: ISA1 (CNAG_02131), CNAG_03395, 
CNAG_03589 
Iron ion homeostasis: CCC2 (CNAG_06415), 
CNAG_03589, CNAG_02131, CNAG_03395, 
CNAG_03226 
Copper ion transport: CCC2 (CNAG_06415), CTR1 
(CNAG_07701), CNAG_05573 
Cellular zinc ion homeostasis: YKE4 (CNAG_02993), 
ZRC1 (CNAG_02806)  
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(ii) 
 
 
Cluster: 5 
 
Gene expression: Down-regulated 
 
Cellular lipid biosynthetic process: ERG20 
(CNAG_02084), ERG28 (CNAG_03009), ERG26 
(CNAG_04605), CNAG_05125, ERG27 (CNAG_07437), 
CNAG_07510 
Protein retention in ER lumen: CNAG_00319, 
CNAG_04671 
GPI anchor biosynthetic process: CNAG_00420, 
CNAG_03753, CNAG_03855, CNAG_06647 
Iron ion transport: CFT1 (CNAG_06242), CFO1 
(CNAG_06241), CNAG_05640, CNAG_05154 
Manganese ion transport: SMF1/SMF3 
(CNAG_05640), CCC1 (CNAG_05154) 
 
Post-translational modifications enriched (not shown) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued on the next page.  
 
(ii) 
 
Cluster: 7 
 
Gene expression: Down-regulated 
 
Transition metal ion transport: CNAG_05640, CFT1 
(CNAG_06242), ZRG17 (CNAG_00837) 
Protein glycosylation: CNAG_00473, CNAG_03014, 
CNAG_03855, CNAG_04671 
Cellular lipid biosynthetic process: ERG20 
(CNAG_02084), ERG26 (CNAG_04605), ERG27 
(CNAG_07437) 
Protein retention in ER lumen: CNAG_00319, 
CNAG_04671 
Transmembrane transport: CNAG_05640, CFT1 
(CNAG_06242), ZRG17 (CNAG_00837), HXS1 
(CNAG_03772), ITR4 (CNAG_05662), CNAG_05867, 
CNAG_05387, CNAG_04038, CNAG_04142, 
CNAG_00598, CNAG_06186, CNAG_07869, 
CNAG_03605, FNX1 (CNAG_03845) 
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(iii) 
 
 
Cluster: 17 
 
Gene expression: Up-regulated 
 
Protein maturation by Fe-S cluster transfer: ISA1 
(CNAG_02131), CNAG_04039 
Response to oxidative stress: AOX1 (CNAG_00162), 
RCK2 (CNAG_00130), SRX1 (CNAG_00654), 
CNAG_01686, CNAG_01846, CNAG_03143, ATF1 
(CNAG_04090), CNAG_04268, CNAG_04466, CAT1 
(CNAG_04981), CAT4 (CNAG_05015), CNAG_05260, 
PIM1 (CNAG_01266), TPS2 (CNAG_03765) 
(iii) 
 
Cluster: 24 
  
Gene expression: Up-regulated 
 
Response to oxidative stress: RCK2 (CNAG_00130), 
SRX1 (CNAG_00654), CNAG_00816, PIM1 
(CNAG_01266), CNAG_01686, CNAG_01846, 
CNAG_02431, CNAG_02895, ZWF1 (CNAG_03245), TPS2 
(CNAG_03765), CNAG_03796, ATF1 (CNAG_04090), 
CNAG_04268, SOD2 (CNAG_04388), CNAG_04466, CAT1 
(CNAG_04981), CNAG_05260, YPD1 (CNAG_06151), 
CNAG_07032 
Membrane fusion: CNAG_00582, CNAG_00816, 
CNAG_01412, CNAG_02895, CNAG_03796, 
CNAG_04270, CNAG_04401, CNAG_04959, 
CNAG_05410, CNAG_06021, CNAG_06625, 
CNAG_06737 
Trehalose biosynthetic process: TPS2 (CNAG_03765), 
CNAG_05292, CNAG_06313 
 
ER-, lipid- and vacuole- associated enrichments were 
observed in cellular component analysis (not shown) 
 
(c) SOMs clusters with no similarity in TA and TAL 
(i) 
 
Experiment: TA 
 
Cluster: 15 
 
Gene expression: Down-regulated 
 
cAMP-mediated signalling: CNAG_01203, PDE1 (CNAG_05081), 
CNAG_06401 
 
NRG1 (CNAG_05222) expressed in this cluster (not shown) 
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(ii) 
 
Experiment: TA 
 
Cluster: 9 
 
Differential expression: Down-regulated 
 
Apoptotic process: CNAG_02500, CNAG_06150 
Misfolded or incompletely synthesised protein catabolic process: 
CNAG_01185, CNAG_02500 
Cellular response to stress: CNAG_00305, CNAG_01185, CNAG_01391, 
CNAG_01727, CNAG_02500, CNAG_03892, CNAG_06150 
Protein folding: CNAG_00100, CNAG_00305, CNAG_01391, CNAG_02500, 
CNAG_03176, CNAG_03892, CNAG_06150 
 
(iii) 
 
Experiment: TAL 
 
Cluster: 11 
 
Gene expression: Up-regulated 
 
Protein targeting to ER: CNAG_00287, CNAG_03899 
Response to stress: CNAG_00287, CNAG_01727, CNAG_02674, 
CNAG_03347, CNAG_03899, CNAG_06106 
Protein folding: CNAG_03899, CNAG_06106, CNAG_07558 
 
 
(iv) 
 
Experiment: TAL 
 
Cluster: 21 
 
Gene expression: Up-regulated 
 
Regulation of SNARE complex assembly: CNAG_01610, CNAG_03628, 
CNAG_06376 
Proteolysis: DOA4 (CNAG_00757), UFD4 (CNAG_01251), CNAG_01561, 
CNAG_01732, CNAG_02167, CNAG_02543, ATG4 (CNAG_02662), 
CNAG_02873, CNAG_03376, CNAG_04636, CNAG_05195, CNAG_05308, 
HSE102 (CNAG_05882), CNAG_06423 
Actin filament polymerisation: WSP1 (CNAG_02029), CNAG_02201, 
CNAG_03900, CNAG_04765, CNAG_05878 
Vacuolar transport: CNAG_00787, CNAG_01610, CNAG_02167, ATG4 
(CNAG_02662), CNAG_03628, VTA1 (CNAG_05747), HSE102 
(CNAG_05882), CNAG_06376 
Endocytosis: DOA4 (CNAG_00757), CNAG_00787, WSP1 (CNAG_02029), 
CNAG_02167, CNAG_02201, CNAG_02568, CNAG_03155, CNAG_04765, 
CNAG_05878, CNAG_06423, CNAG_07571 
 
Golgi to endosome transport, endosome to vacuole transport and 
ubiquitin dependant protein catabolism were also enriched in this cluster 
(not shown) 
CUF1 (CNAG_07724) mapped to this cluster (not shown) 
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(v) 
 
Experiment: TAL 
 
Cluster: 18 
 
Gene expression: Up-regulated  
 
Mitochondrion degradation: CNAG_00778, APG9 (CNAG_01445), 
CNAG_05005 
Nucleophagy: CNAG_00778, APG9 (CNAG_01445), CNAG_01601, HSV2 
(CNAG_04371), CNAG_05005 
 
Figure 4.17. SOMs of interest and their enriched GO terms in C. neoformans H99. Adjacent clusters (ai – iii) and (bi 
– iii) have similar GO term enrichments and differential expression profiles in TA and TAL. SOMs clusters (ci – v) 
contain GO terms in TA or TAL that are not present in the other treatment. Each coloured line represents a gene, 
with colour determined by the associated GO term. The averaged expression level of all co-expressed genes in 
each cluster is drawn in black. Normalised expression levels of genes in response to AMB and AMB+LF treatment 
(boxed for visual clarity) are depicted by the y-axis. Genes that make up the GO enrichments in each cluster are 
listed.  
 
 
In summary, both treatments repressed the transcription of genes related to protein processing and 
metal transport proteins. The presence of LF in AMB treatment repressed the synthesis of additional 
transport proteins that mobilise substrates like sugars, salts and drugs. While protein transfer between 
the ER and Golgi appeared to be down-regulated in AMB treatment, LF with AMB induced the 
expression of genes related to membrane fusion and transport, through the up-regulation of terms 
related to the protein secretory pathway in the ER and Golgi apparatus, and autophagy-related 
processes. Responses to stress were enriched in both drug treatments. However, terms related to ER 
stress were down-regulated in TA while mitophagy was induced in TAL. Finally, the addition of LF to AMB 
appeared to down-regulate the regulation of kinase activity.  
4.6.3. Comparison of the response to AMB and AMB+LF treatment by S. cerevisiae S288C and C. 
neoformans H99   
Similarities and differences in the transcriptional response to AMB and AMB+LF treatments by S288C 
and H99 are summarised in this section.  
The overall GO enrichments indicated that the FIC concentration of AMB repressed cellular metabolism 
in both S288C and H99. These terms included nucleic acid metabolism, RNA and protein processing, 
ergosterol biosynthesis and the response to DNA damage. Conversely, processes involved in energy 
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generation like the TCA cycle and redox were induced (Table 4.8). Additional GO enrichments induced in 
S288C were hydrogen peroxide catabolism, autophagy and metal ion homeostasis, while in H99 fatty 
acid catabolism was induced. The differential expression of these GO enrichments, apart from protein 
folding which is part of protein processing, response to DNA damage and metal ion homeostasis, are 
typical of an environmental stress response [347].  
In TAL, a stark contrast between the transcriptomes of S288C and H99 was observed. In H99 GO 
enrichments continued to resemble the environmental stress response seen with AMB treatment, while 
in S288C the reverse was seen, with amino acid metabolism and ribosome biogenesis induced and redox 
processes and oxidative stress repressed following the addition of LF (Table 4.8).   
SOMs analyses further highlighted similarities and differences between the transcriptomes of H99 and 
S288C cells treated with AMB and AMB+LF. These involved metal ion homeostasis, responses to stress, 
protein translation, and disruption of the protein secretory pathway and membrane-mediated 
processes.  
Metal ion homeostasis was enriched in both drug treatments in S288C and H99. However, the regulation 
of iron and zinc differed between the drug treatments and the two yeasts. While iron homeostasis was 
induced in TA in S288C (Fig. 4.9a(i)), iron uptake transcripts were repressed in H99 (Fig. 4.17a(ii)). 
Similarly in TAL, zinc homeostasis was repressed in S288C (Fig. 4.9b(i)) but induced in H99 (Fig. 4.17b(i)). 
Copper was the only metal that was commonly regulated, with copper transport genes induced in TA in 
both S288C and H99 (Fig. 4.9a(ii) and Fig. 4.17a(i)). However, while copper transport was enriched and 
up-regulated in TAL in H99 (Fig. 4.17b(i)), it was not enriched in S288C. 
The SOMs analysis suggested that responses to stress localised to different organelles in S288C and H99. 
In TA, mitochondrial stress was observed in S288C (Fig. 4.9a(ii)) while ER stress was repressed in H99 (Fig. 
4.17c(ii)). Oxidative stress was enriched in both species, but this was repressed in S288C (Fig. 4.9a(iii)) 
and induced in H99 (Fig. 4.17a(iii)). There were no clear indications of where oxidative stress was 
located in both organisms. In TAL, oxidative stress was down-regulated and was associated with the 
repression of sulphur assimilation and ER function in S288C (Fig. 4.9b(iii)). In contrast, ER stress was 
induced in H99 (Fig. 4.17b(iii)).  
Protein translation was affected by the addition of LF. AMB treatment repressed terms related to 
cytoplasmic translation in S288C and H99 (not shown), while AMB+LF treatment induced this process in 
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S288C (Table 4.5). With LF addition, protein targeting to the ER showed opposite differential regulation, 
where it was down- and up-regulated in S288C (Table 4.5) and H99 (Fig. 4.17c(iii)), respectively.  
One common effect of AMB and AMB+LF treatment was the disruption of the protein secretory 
pathway, which was seen in both H99 and S288C. This was observed through the repression of GO terms 
related to ER function, which involved protein processing and lipid biosynthesis (Table 4.8). An exception 
was protein folding in H99, which was induced in AMB+LF treatment (Fig. 4.17c(iii)). With LF, the GO 
term relating to protein exit from the ER was repressed in S288C (Fig. 4.9b(vii)), whereas protein 
transfer from the Golgi to the endosome was induced in H99 (Fig. 4.17c(iv)).  
AMB and AMB+LF treatment disrupted terms related to vesicle-mediated processes in both organisms, 
including membrane fusion, endocytosis, vacuole mediated proteolysis and transport. In TA, the CVT 
pathway was induced in S288C (Table 4.5), while membrane fusion was repressed in H99 (not shown). In 
TAL, membrane fusion and autophagy-related processes were repressed in S288C (Fig. 4.9b(vi)) and 
induced in H99 (Fig. 4.17b(iii) and c(iv)).  
4.6.4. Dysregulation of metal homeostasis increases susceptibility to stress and antifungal drugs in C. 
neoformans H99  
Disruptions to metal ion homeostasis were seen in both S288C and H99 TA and TAL transcripts. However, 
as noted above transcripts for iron uptake proteins were induced in TA in S288C but repressed in H99. 
Similarly, transcripts for zinc uptake were repressed in S288C TAL but induced in H99.  
Disruption of iron and zinc homeostasis in S288C increased susceptibility to AMB and other cell stressors 
(Fig. 4.13), indicating the importance of metal regulation and its requirement to mount an appropriate 
stress response against antifungal exposure. Knock-out mutants in H99 with phenotypic 
characterisations have been reported by Jung et al. (2006), Jung et al. (2015), Kim et al. (2012) and 
Geddes (2015) [104, 293, 353, 502]. These data were used to assess the phenotypes of metal ion 
transcription factors present in TA and TAL and are summarised in Table 4.10. Cir1 was also included as it 
is the main regulator of iron homeostasis in C. neoformans, even though it was not differentially 
expressed in the drug treatments.  
Where the phenotypes were known, a majority of iron controlling transcription factors exhibited 
increased susceptibility to AMB, except for hap2∆ and sre1∆. Hap2 is a subunit of the CCAAT motif 
binding Hap complex that, together with HapX, controls iron dependant pathways like haem 
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biosynthesis [503]. Sre1 senses oxygen and regulates sterol homeostasis and iron uptake proteins [109]. 
The knock-out mutants sre1∆ and rim101∆ additionally had increased susceptibility to FLC. Knock-out 
mutants of iron-controlling transcription factors were defective in response to various stressors. 
Dysregulation of copper and zinc homeostasis by knocking out CUF1 and ZAP104 also increased 
susceptibility to AMB, but caused a decrease and no change in susceptibility to FLC, respectively. Proper 
copper regulation was required for survival against cell wall and oxidative stressors, whereas disrupting 
zinc homeostasis did not appear to affect the cellular response to the various stressors. Overall, these 
results indicate that disrupting the homeostasis of different metals affects cell responses and survival 
against antifungal agents in C. neoformans in different ways.  
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Table 4.10. Phenotypes of C. neoformans mutants with disrupted iron, copper and zinc transcription factors that were differentially expressed in 
TA and TAL  
Transcription factor knock-out mutants Transcript data* Susceptibility to stressors
#
 
Log Fold 
Change  
SOMs cluster 
number 
Antifungal 
drugs 
Oxidative 
stress 
ER stress Cell wall and 
membrane stress 
°C 
Metal Gene name Gene ID TA TAL TA TAL AMB FLC H2O2 DTT TUN SDS CW NaCl 37 °C 
Iron cir1∆ [104, 502, 
504]
 
CNAG_04864 - - NA NA + - ND ND ND + ND ND + 
hapX∆ [293] CNAG_01242 0.77 0.76 2 20 ND - ND ND ND ND ND ND ND 
hap3∆ [293] CNAG_02215 0.57 - 3 - ND - ND ND ND ND ND ND ND 
hap2∆ [353] CNAG_07435 0.79 0.92 11 18 0 - 0 + - + + 0 0 
nrg1∆ [353] CNAG_05222 -0.34 -0.48 15 2 + - + 0 - + + 0 + 
rim101∆ [353] CNAG_05431 1.12 1.07 1 19 + + + 0 + 0 + + 0 
sre1∆ [353] CNAG_04804 0.92 - 22 - - + + + 0 + 0 0 0 
Copper cuf1∆ [353] CNAG_07724 - 0.48 - 21 + - + + - + 0 0 + 
Zinc zap104∆ [353] CNAG_05392 0.35 0.65 6 20 + 0 0 0 0 0 0 0 0 
*- = No change in expression. NA = not applicable  
#
 DTT = dithiothreitol. TUN = tunicamycin. + = increased susceptibility, 0 = no difference to wild type, - = decreased susceptibility, ND = not done. 
 
 
A 
B 
c 
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4.7. Discussion –AMB+LF synergy in C. neoformans H99 
4.7.1. Transcriptomic analysis of synergy in C. neoformans H99 revealed a completely different 
response to AMB+LF compared to S. cerevisiae S288C  
The transcriptome response to AMB treatment was similar overall in H99 and S288C, apart from an 
absence of enrichments relating to stress response and metal homeostasis in H99 (Table 4.8), which 
suggests that Cryptococcus may tolerate the stress induced by AMB better than Saccharomcyes 
(discussed Section 4.7.2). However, the addition of LF to AMB elicited responses in H99 that were 
completely different to the responses seen in S288C (Table 4.8). A schematic model of the overall 
responses to AMB and AMB+LF synergy in H99 is presented in Figure 4.18 (see Figure 4.15 for a 
direct comparison of these in S288C). While TAL in S288C indicated an up-regulation of responses 
such as protein synthesis and nucleic acid metabolism that indicated cell growth, repression of these 
responses indicating a decrease in cell growth was seen in H99. Additionally, response to stress and 
metal ion uptake that were down-regulated in S288C were up-regulated in H99, including up-
regulation of oxidative stress (Fig. 4.17b(iii) and Table 4.8) and iron, copper and zinc transport (Fig. 
4.17b(i)). Unlike in S288C, the responses in H99 are more in line with what might be expected 
following AMB+LF treatment as they are consistent with the increased inhibition of H99 growth (Fig. 
4.4), the ROS-inducing properties of AMB and LF, and the metal chelating activity of LF [219, 303, 
465].  
The different responses seen in TAL in H99 and S288C suggest that the mechanisms responsible for 
synergy are different in H99, and that despite a similar outcome to treatment, diverse cellular 
responses may be elicited in different fungi. However, analysis of differential gene expression 
patterns and validation by gene deletion revealed metal ion homeostasis as a critical point in 
AMB+LF synergy in both S288C and H99. These results suggest transcription factors controlling metal 
ions may be putative targets to enhance susceptibility to AMB.  
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Figure 4.18. A model of the transcriptome response to AMB+LF synergy in C. neoformans H99. 
Cellular responses to AMB and AMB+LF treatments had many similarities including down-regulation 
of cell growth processes and up-regulation of stress responses, which may be associated with 
disruption to metal regulation and transmembrane transport synthesis. (a) TA showed minimal 
induction in stress responses, which may be due to the up-regulation of antioxidants that rapidly 
neutralise ROS induced by AMB. (b) TAL indicated that the cell experienced similar but higher levels 
of stress in the presence of AMB+LF, which may be due to stress in the ER and an increased 
dysregulation of metal homeostasis from the destabilisation of Fe-S clusters. This accumulation of 
cell stress then resulted in enhanced cell death. Red arrows and text: up-regulated processes; green 
arrows and text: down-regulated processes. Black arrows: observed effect of processes on other 
cellular functions in drug treatments. Asterisks: gene knock-out mutants that have increased 
susceptibility to AMB treatment.   
(a) TA  
(b) TAL  
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4.7.2. Up-regulation of antioxidant genes may lower the overall stress response to AMB in C. 
neoformans H99  
In H99, an absence of stress defence responses in the overall enrichments in TA (Table 4.8) suggested 
it had a higher capacity to tolerate and adapt to the stresses induced by AMB treatment than S288C. 
In the SOMs analysis, up-regulation of the response to oxidative stress also encompassed 
antioxidant genes including catalases Cat1 and Cat4, and sulfiredoxin (CNAG_00654) (Fig. 4.17a(iii)), 
which suggested the presence of ROS that is consistent with AMB exposure [303, 469]. In TA, CAT1, 
CAT4 and sulfiredoxin were highly induced with 3.6, 1.3 and 2.29 log fold-changes in expression, 
respectively (not shown). This is consistent with studies in Candida tropicalis, which found increased 
activity of catalases and minimal ROS accumulation correlated with the increased capacity for AMB 
tolerance in AMB-resistant strains [303]. Similarly, analysis of the transcriptomic response to H2O2 -
induced oxidative stress in Cryptococcus found the expression of catalases and sulfiredoxin to be 
highly induced, and this was associated with the ability to rapidly detoxify H2O2 [505]. Altogether, 
the minimal induction of stress responses in TA suggested minimal oxidative damage following AMB 
treatment due to highly induced expression of antioxidants that contributed to rapid clearance of 
oxidants (Fig. 4.18).  
4.7.3. Disruption to transmembrane transport synthesis may be associated with ER stress and 
enhanced growth inhibition in AMB+LF synergy 
The most significant responses that were seen in AMB+LF synergy in H99 were the up-regulation of 
stress in the ER and vesicle mediated trafficking (Fig. 4.17b(iii), c(iii) and c(iv)), which were down-
regulated and absent in TA, respectively (Fig. 4.17c(ii)). A more pronounced disruption to 
transmembrane transport synthesis was also seen in TAL compared to TA (Section 4.6.2.3), which 
suggested that this and ER stress may have worked together to enhance cell inhibition following 
AMB+LF treatment (Fig. 4.18).  
ER stress induces the unfolded protein response (UPR) which regulates a number of cellular 
responses to restore the folding capacity of the ER and maintain homeostasis. These include a 
decrease in translation activity to limit protein synthesis, an increase in ER protein folding and 
proteolysis, and the retrotranslocation of unfolded and misfolded proteins from the ER into the 
cytoplasm for degradation via ERAD [506]. These responses were observed in TAL (Fig. 4.17b(iii), c(iii), 
c(iv) and Table 4.8). The exceptions were down-regulation of ER functions relating to the 
biosynthesis of lipids and protein processing activities like glycosylation. These were co-regulated 
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with transmembrane transporters, suggesting a disruption in the synthesis of transporter proteins 
(Fig. 4.17b(ii)).  
Transmembrane transport proteins are post-translationally modified in order to traverse through 
the secretory pathway and localise to their required cellular destinations [507, 508]. Inadequate 
processing, such as by disrupted glycosylation, causes the proteins to be retained or mobilised back 
into the ER where they are either degraded or accumulate and cause ER stress [507, 509]. 
Disruptions to transmembrane transporters also cause stress as they serve important functions in 
cellular homeostasis by maintaining the balance of ions in the cytosol, which are involved in osmo-
regulation (K
+
/Na
+
), signalling (Ca
2+
) and act as enzyme cofactors (Fe
3+
/Fe
2+
 and Zn
2+
) [93, 510]. 
Transporters also enable the fast mobilisation of specific substrates like vitamins and amino acids to 
meet cellular requirements [511]. Additionally, they control the transport of ions and substrates into 
cellular organelles, such as the transport of calcium and iron into the mitochondria, which helps 
prevent organelle damage [512, 513]. Ions and substrates can also play a role in maintaining 
organelle homeostasis, and disruption of their transport affects organelle function.  
Disruptions to processes involving transmembrane transporters may also cause alterations in ER 
function. In TAL, the expression of cryptococcal orthologues of MSC2 (CNAG_05394) and ZRG17 
(CNAG_00873), which encode ER zinc transporters, was down-regulated and ZRG17 was observed in 
the enrichment for transmembrane transport (Table 4.9 and Fig. 4.17b(ii)). As mentioned in Section 
4.5.3.1, zinc is needed for the protein-sorting and secretory processes performed in the ER, and 
disruption of ER zinc uptake induces ER stress [421, 488]. Repression of MSC2 and ZRG17 would be 
expected to cause a decrease in zinc uptake and influence the down-regulation of ER protein and 
lipid processing that was seen in TAL (Fig. 4.17b(ii)). Down-regulation of ER zinc uptake and transport 
proteins was also seen in TA (Table 4.9 and Fig. 4.17a(ii)) but to a lesser extent (Fig. 4.17b(ii)). This 
suggested that AMB disrupts the synthesis of transmembrane proteins in Cryptococcus and that the 
addition of LF enhances these disruptions that possibly resulted in ER stress.  
In summary, it is suggested that in H99 the addition of LF to AMB enhanced disruption of 
transmembrane transport synthesis in the ER with subsequent disruption of the ionic balance, and 
these caused an accumulation of stress resulting in an increase in cell inhibition (Fig. 4.18).  
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4.7.4. Increased dysregulation of metal homeostasis in AMB+LF synergy may be mediated by 
destabilisation of Fe-S clusters and contribute to cell stress  
Analysis of TA and TAL showed that enrichments involved in metal ion uptake were both up and 
down-regulated despite the induction of the metal ion-controlling transcription factors (HapX, Hap2, 
Rim101 and Zap104) in both treatments (Fig. 4.17a(i – ii), b(i – ii) and Table 4.10)). Although metal 
regulation in Cryptococcus is less well characterised than in Saccharomyces, the opposing 
enrichments of metal uptake seen in both TA and TAL suggested that the way the metal ion-
controlling transcription factors control their gene targets was disrupted. This may be associated 
with the disrupted synthesis of transmembrane transport proteins in the ER (Section 4.7.3), which 
included down-regulated iron (Cft1 and CNAG_05640) and zinc (CNAG_00837) transporters (Fig. 
4.17a(ii) and b(ii)).  
In addition to the disrupted synthesis of metal transporters, the dysregulation of metal ions in 
AMB+LF synergy may also be mediated by the destabilisation of Fe-S clusters, which can contribute 
to increased stress. Fe-S cluster assembly was co-regulated with iron, zinc and copper transport (Fig. 
4.17b(i)), but while iron and zinc are required for the synthesis and structural stability of Fe-S 
clusters [514], copper has been shown to target and destabilise Fe-S clusters [515]. Iron 
homeostasis, especially iron uptake, is regulated by sensing the level of Fe-S clusters, and in 
Saccharomyces decreased Fe-S clusters levels activate the iron regulon through Aft1 [86, 88]. Fe-S 
clusters are also present in proteins and their destabilisation causes a loss in their activity, which can 
be detrimental to the cell as they have functions in important cellular homeostatic processes as well 
as stress responses like oxidation-reduction and catalase activity [77, 516]. 
Copper mediated destabilisation of Fe-S structures in proteins is an antimicrobial mechanism of the 
ionophore zinc pyrithione, which causes an increase in copper influx across the cell membrane [517]. 
Additionally, in Saccharomyces zinc pyrithione has been found to induce metal starvation, increasing 
iron uptake through AFT1 up-regulation and zinc uptake through Zap1 activation [517, 518]. LF has 
not been shown to have ionophoric activity. However, the up-regulation of metal ion-controlling 
transcription factors and co-enrichment of Fe-S cluster synthesis and copper transport during 
AMB+LF treatment suggest the inappropriate induction of metal ion-regulating transcription factors 
may occur through a mechanism similar to that seen in zinc pyrithione. Disrupted regulation of 
metal ions can catalyse the formation of oxidants and cause cell stress [93]. This, together with the 
induction of stress responses associated with the disruption in ER functions described previously, 
suggest that in H99 LF produces an increase in cellular stress that overwhelms the capacity of the 
cell to cope, resulting in inhibition and death.   
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4.7.5. Avenues for future work  
Transcriptome analysis of AMB+LF treatment and knock-out data in both Saccharomyces and 
Cryptococcus suggested that disruptions to metal regulation involving iron and zinc homeostasis via 
Aft1, Zap1, Cir1 and Zap104 were critical to AMB+LF synergy (Fig. 4.13 and Table 4.10). In 
Cryptococcus, the copper regulating transcription factor Cuf1 was also important for AMB survival 
(Table 4.10). Additionally, the disruption of metal homeostasis was suggested to cause either a 
dysregulated stress responses (in S288C) or an accumulation of stress (in H99), in each case resulting 
in drug synergy (Fig. 4.15 and Fig. 4.18). However, transcriptomic data can only provide indirect 
evidence of cellular responses and validation and future work are needed to confirm these 
observations.  
Of most interest is validating the differential expressions of AFT1 and ZAP1 in S288C and HAPX and 
ZAP104 in H99, and the effects of their regulatory activities on stress responses. This can be 
confirmed by qPCR on the transcription factors and their gene targets, including Zap1 targets ZRG17, 
YHB1, KAR2 and Aft1 targets FIT3, GRX4 and CAD1 in S288C (Fig. 4.11). In H99, HapX targets SIT1 and 
RIM101 [103], and Zap104 target ZIP2 [519] could be tested. The expression of genes that are not 
targets of these transcription factors but encode functions related to stress responses should also be 
confirmed, such as TPK2, which encodes a subunit of the Ras/cAMP-dependant PKA in S288C, and 
the copper regulating transcription factor CUF1, which was expressed only in H99.  
In addition to confirming their differential expression, the dynamic response of these genes during 
treatment can be monitored by qPCR. Chong et al. (2012) assessed the response of Cryptococcus to 
FLC over 6 hrs and revealed substantial changes in the level of various proteins [356]. In the current 
study, RNA samples from AMB and AMB+LF treatments were extracted before and after the ID20, 
which will enable this analysis. Examining the expression dynamics of the chosen genes at these 
additional time points will help unravel how the changes in cellular function that occur in response 
to AMB+LF eventually lead to enhanced cell death.  
Other avenues for understanding AMB+LF synergy include assessing the physical interaction of LF 
with the cell and determining the intracellular concentrations of metal ions during treatment. While 
LF has been shown to bind to and cause alterations to the cell surface [464-467], it is not known if LF 
can enter the cell. AMB create pores in the cell membrane and can enter the cell [520], and it is 
possible that this facilitates LF entry and subsequent disruption of intracellular targets. To assess 
this, LF could be tagged with a fluorescent protein or radiolabel and tracked during AMB+LF 
treatment [521].  
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The transcriptomic observations and the results of the iron rescue assay in Chapter 3 (Fig. 3.4) 
suggested that the dysregulation of metal homeostasis was not a direct result of metal chelation by 
LF but was due to the shutdown of Aft1 activity and repression of Zap1. However, Aft1 and Zap1 
expression is normally regulated by internal metal concentrations [87, 522] and it is not known if LF 
directly disrupts intracellular metal concentrations, which then affect the regulation of metal-
controlling transcription factors, as has been observed for zinc pyrithione [517]. Inductively coupled 
plasma mass spectrometry (ICP-MS) is a sensitive technique that detects elements at low 
concentrations by converting the atoms of elements into ions and separating them for detection by 
mass spectrometry, and was used by Chillappagari et al. (2010) to show that cells treated with zinc 
pyrithione had an increased concentration of copper compared to untreated controls [515]. This 
method could similarly be employed in AMB+LF treated H99 and S288C cells to establish if changes 
in intracellular metal ion concentrations affect the regulation of metal-regulating transcription 
factors.  
The effect of synergy on oxidative stress could also be further explored. The inability to clear ROS 
could be confirmed via fluorescence using fluorogenic dye 2͛, 7͛-dichlorofluorescin diacetate, which 
is oxidised in the presence of ROS and converts into a fluorescent substrate. Glutathione, a major 
antioxidant, has previously been found to rescue C. albicans from BBR+FLC synergy by neutralising 
the accumulation of ROS [6], and was down-regulated in S288C by AMB+LF (Fig. 4.10). 
Supplementing AMB+LF treated S288C with glutathione would determine whether the disruption of 
glutathione biosynthesis or if the inhibition of other antioxidants contributes to enhanced cell death. 
Although the response to AMB+LF synergy in S288C differed to H99, it might be applicable to other 
more closely related ascomycete pathogens. Additionally, developing drug strategies aimed at 
inhibiting appropriate stress responses would be a novel and beneficial approach to therapy as this 
should be less likely to induce toxic damage to the host cells than agents that induce stress. 
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4.8. Results – Analysis of VRC+EDTA antagonism and additivity in C. neoformans H99 and C. gattii 
97/170 
4.8.1. Effect of VRC and VRC+EDTA on the growth of C. neoformans H99 and C. gattii 97/170  
Growth curves were established to choose the optimal time point for RNA extraction from C. 
neoformans H99 and C. gattii 97/170 cells, where treatment with VRC+EDTA resulted in antagonism 
and additivity, respectively (Fig. 4.19). Both strains were treated at the FIC for VRC+EDTA, which was 
0.03 µg/mL VRC + 8 µg/mL EDTA for H99, and 0.03 µg/mL VRC + 64 µg/mL EDTA for 97/170. Growth 
curves were also established for both strains with VRC alone at the FIC (0.03 µg/mL). For 97/170, the 
additive effect of EDTA to the activity of VRC was evident from the 5
th
 hr of treatment, where growth 
decreased compared to treatment with VRC alone. Significant inhibition of growth by VRC was not 
seen until 8 hrs, which was three hours later than was observed for VRC+EDTA (Fig. 4.19a). In 
contrast, in H99 the addition of EDTA antagonised the inhibitory activity of VRC, which was evident 
from the 5
th
 hr and persisted throughout treatment (Fig. 4.19b). Note that VRC inhibited the growth 
of H99 to a greater extent than 97/170 as the concentration of VRC used was 4-fold higher than the 
MIC for H99 (MIC = 0.007 µg/mL) but 16-fold lower than the MIC for 97/170 (MIC = 0.5 µg/mL; Table 
3.2). In H99, VRC+EDTA caused a 20% increase in growth compared to VRC at the 7
th
 hour of 
treatment, and this timepoint was chosen for RNA-Seq. The same timepoint was used to extract RNA 
from 97/170 treated with VRC and VRC+EDTA (shown by arrows on Fig. 4.19).  
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Figure 4.19. The effect of VRC and VRC+EDTA on the growth of C. gattii 97/170 and C. neoformans 
H99. (a) Treatment of C. gattii 97/170 with 0.03 µg/mL VRC had a limited effect on growth, and 
activity was enhanced by the addition of 64 µg/mL EDTA. (b) In contrast, 0.03 µg/mL VRC inhibited 
the growth of C. neoformans H99, and the addition of EDTA was antagonistic to this treatment. 
Arrows indicate the timepoints chosen for RNA-Seq, based on a 20% increase in growth of H99 with 
VRC+EDTA compared to VRC only treatment at 7 hrs. Data are shown as mean +/- SEM.  
(b) 
↓ ↓ 
(a) 
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4.8.2. Analysis of RNA-Seq data from VRC and VRC+EDTA treatments  
4.8.2.1. RNA-Seq data quality  
As all RNA samples were sequenced together, the drug antagonism experiments had the same 
number of reads per sample and coverage as the synergy experiments (Section 4.3.2.1). Similarity 
between the biological replicates of H99 and 97/170 RNA samples was examined on MDS plots (Fig. 
4.20). In H99, sample 7J was an outlier in the VRC treatment (Fig. 4.20a) while all biological replicates 
of the same drug treatments clustered together in 97/170 (Fig. 4.20e). To determine whether or not 
to delete 7J, a list of differentially expressed transcripts induced or repressed in H99 due to VRC and 
VRC+EDTA treatment was generated by subtracting the fold-change expressions of genes under the 
drug treatments with those expressed in the control, i.e. TV and TVE, where ͚T͛ stands for transcripts. 
Deletion of 7J from the H99 dataset improved the BCV from 0.267 to 0.237 (Fig. 4.20b; Appendix 
4.8), and mostly increased the counts of differentially expressed genes in both VRC and VRC+EDTA 
treatment (Table 4.11). Subsequent analyses of H99 transcripts for antagonism experiments were 
therefore performed without sample 7J.  
   
Table 4.11. C. neoformans H99 gene count comparison with and without RNA sample 7J 
 Gene fold expression With 7J Without 7J 
TV 
Up-regulated 79 62 
No fold change 6391 6909 
Down-regulated 1 4 
TVE 
Up-regulated 148 208 
No fold change 6240 6632 
Down-regulated 83 135 
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Figure 4.20. Quality analysis of RNA-Seq data from drug antagonism experiments in C. neoformans 
H99 (a) – (d) and C. gattii 97/170 (e) – (h). (a) and (e) MDS plot of RNA-Seq samples after 
normalisation with EdgeR. In H99, biological replicates clustered together except for H99 sample 7J, 
which was excluded from all subsequent analyses. (b) and (f) BCV versus average log2 CPM. The red 
line represents the common dispersion of all genes and the blue line represents their trended 
dispersion. Each dot is a data point that represents tag-wise dispersion of each gene. (c) and (g) 
Smear plot of log2 FC versus the average log2 CPM values of genes in response to VRC treatment. (d) 
and (h) Smear plot of log2 FC versus the average log2 CPM values of genes in response to VRC+EDTA 
treatment. Differentially expressed genes in (c) – (d) and (g) – (h) are represented in red. Blue lines 
are drawn at 2-fold changes in expression. Black dots above the blue lines are genes not counted in 
the analysis due to high a signal-to-noise ratio between biological replicates.  
 
4.8.3. Analysis of gene expression in C. neoformans H99 and C. gattii 97/170 in response to VRC 
and VRC+EDTA  
Due to time constraints, the following section is a preliminary analysis of the transcriptome data and 
awaits further validation. 
4.8.3.1. Analysis of orthology between genes expressed in C. neoformans H99 and C. gattii 97/170 
RNA-Seq results identified transcripts for a total of 6,975 genes in H99 and 6,932 genes in 97/170 
that were expressed in response to the single or the combined drug treatment or were in the 
untreated controls. Although C. neoformans and C. gattii are closely related they are different 
species estimated to have diverged between 16 – 160 million years ago [28]. Therefore, in order to 
compare their response to the drug treatments, genes that were common to the transcriptomes of 
both were first identified by reciprocal BLAST to find orthologues. BLAST returned 5,935 orthologous 
(g) (h)
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genes between H99 and 97/170, and 1,040 and 977 non-orthologous genes in H99 and 97/170, 
respectively.  
4.8.3.2. Analysis of differentially expressed genes in response to drug treatments  
A list of transcripts that were differentially expressed in response to VRC and VRC+EDTA treatment 
were generated as described in Section 4.3.2.2. Two datasets are presented for subsequent 
comparison: the total number of genes differentially expressed in each organism, and the total 
number of orthologous genes differentially expressed in each organism.  
For clarity, the number of orthologous and non-orthologous transcripts identified from BLAST 
(Section 4.8.3.1) and the gene sets that were used to analyse the two datasets of differentially 
expressed genes are presented in the Venn diagram shown in Figure 4.21. The yellow circle includes 
all 6,975 genes expressed in H99, including genes with orthologues in 97/170 that were either 
expressed only in H99 (A) or were also expressed in 97/170 (B), and genes without orthologues in 
97/170 (D: 1,040 genes). Similarly, the purple circle includes the 6,932 genes expressed in 97/170, 
which comprises (B) as above, along with genes with orthologues that were not expressed in H99 (C) 
and genes without orthologues in H99 (E). The blue circle (A+B+C) comprises all 5,935 transcribed 
genes in H99 and 97/170 with orthologues in both strains. The total set of differentially expressed 
genes was analysed from A+B+D for H99, where 138, 171 and 37 genes were differentially 
expressed, respectively. Similarly in 97/170, the total set of differentially expressed genes was 
analysed from B+C+E, where C and E contained 825 and 46 differentially expressed genes, 
respectively. The differentially expressed orthologous genes were analysed from A+B for H99 and 
B+C for 97/170.  
Table 4.12 shows the gene counts for the total number of genes differentially expressed in each 
organism (Fig. 4.21; A+B+D for H99, B+C+E for 97/170) and the total number of orthologous genes 
differentially expressed in each organism (Fig. 4.21; A+B for H99, C+B for 97/170). Of the total genes 
differentially expressed in H99 in TV, 62 were up-regulated while 4 were down-regulated. In TVE, 208 
and 124 genes were up and down-regulated, respectively. Substantially more genes were 
differentially expressed in 97/170, with 168 genes up-regulated and 8 genes down-regulated in TV, 
and 560 genes up-regulated and 473 down-regulated in TVE (Table 4.12). The majority of genes that 
were differentially expressed in both H99 and 97/170 were orthologous. Overall, the combined drug 
treatment resulted in more genes being differentially expressed and up-regulated in both species 
compared to VRC treatment only. About 5% and 15% of genes were differentially expressed from 
the total number of transcripts identified for H99 and 97/170, respectively. 
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Among the orthologous gene set, H99 had 58 up-regulated and 4 down-regulated genes in TV, and 
184 and 124 up and down-regulated genes in TVE. In 97/170, there were 161 up-regulated and 8 
down-regulated genes in TV and 531 up-regulated and 458 genes down-regulated in TVE, (Table 4.12). 
There were 171 orthologous genes that were expressed in both in H99 and 97/170, (represented by 
B in Fig. 4.21). The direction of fold-change of these genes in H99 and 97/170 were plotted against 
each other for TV and TVE (Fig. 4.22), which revealed that all but five genes in TVE presented in Table 
4.12 had the same direction of fold-change. These five genes are listed in Table 4.13. 
 
 
Figure 4.21. Venn diagram of differentially genes in C. neoformans H99 and C. gattii 97/170 divided 
according to whether or not orthologues were identified in one or both strains. The total number of 
differentially expressed genes for H99 is A+B+D (346) and for 97/170 is B+C+E (1,042). The blue circle 
(A+B+C) encompasses reciprocally orthologous genes expressed in both H99 and 97/170 (1,134 
genes). B includes orthologous genes that were expressed in both H99 and 97/170 (171 genes); A 
and C include orthologous genes that were exclusively expressed in H99 (138 genes) or 97/170 (825 
genes), respectively; D and E include non-orthologous genes that were expressed in H99 (37 genes) 
and 97/170 (46 genes), respectively. Bolded numbers indicate differentially expressed genes relative 
to the untreated controls; bracketed numbers indicate identified transcripts. 
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Table 4.12. Number of genes differentially expressed in C. neoformans H99 and C. gattii 97/170 in 
each drug treatment compared to untreated controls: orthologous genes* (total gene count
#
) 
Differentially expressed genes TV  TVE 
H99 97/170  H99 97/170  
Total number 62 (66) 169 (176) 308 (343) 989 (1,033) 
Up-regulated 58 (62) 161 (168) 184 (208) 531 (560) 
Down-regulated 4 (4) 8 (8) 124 (135) 458 (473) 
Uncharacterised/hypothetical 24 (28) 53 (77) 115 (139) 350 (393) 
Unique to treatment – Up-regulated 1 (2) 1 (1) 129 (148) 371 (393) 
Unique to treatment – Down-
regulated  
0 (1) 2 (2) 121 (132) 452 (467) 
*Gene set A+B for H99 and B+C for 97/170 in Figure 4.21. 
# 
Gene set A+B+D for H99 and B+C+E for 97/170 in Figure 4.21.  
 
 
  
 
Figure 4.22. Comparison of the direction of expression of orthologous genes (B in Fig. 4.21) in C. 
neoformans H99 and C. gattii 97/170 following (a) VRC treatment and (b) VRC+EDTA treatment. 
Axes show fold-change in expression of genes present in H99 (x-axis) and 97/170 (y-axis) compared 
to untreated controls. Five orthologous genes had opposing fold change expression following 
VRC+EDTA treatment and are boxed in red. These genes and their functions are presented in Table 
4.13.  
 
 
 
 
(a) (b) 
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Table 4.13. Orthologous genes in C. neoformans H99 and C. gattii 97/170 with opposing directions of 
expression 
97/170 contig TV* TVE H99 Gene ID TV TVE Gene description 
g1778 – -0.98 CNAG_01980 – 2.42 Uncharacterised protein 
g2974 1.07 1.28 CNAG_02000 – -1.74 Short-chain dehydrogenase 
g3042 – -0.73 CNAG_00537 – 1.20 Carnitine O-acetyltransferase  
g3228 – 0.62 CNAG_02387 – -1.24 Uncharacterised protein 
g4485 – 2.02 CNAG_03663 – -1.40 L-lactate dehydrogenase 
* Fold-change in expression relative to untreated control; – = No change 
 
4.8.4. GO term enrichments for C. neoformans H99 and C. gattii 97/170 in TV and TVE  
GO terms were enriched from the total set of differentially expressed genes to investigate the 
overall response by H99 and 97/170 to VRC and VRC+EDTA (Table 4.14; genes included in A, B, C, D 
and E in Fig. 4.21). These results are presented below in Section 4.8.4.1. The analysis was then 
restricted to just orthologous transcripts that were exclusively expressed in one or other organism to 
compare the antagonism produced by VRC+EDTA in H99 with the additive interaction seen in 97/170 
(Table 4.15; A and C in Fig. 4.21); presented in Section 4.8.4.2.   
4.8.4.1. GO term analysis of total differentially expressed genes to assess the individual responses 
by H99 and 97/170 to treatment 
Among the GO terms enriched from the total transcripts in H99 (Table 4.14) only ergosterol 
biosynthesis, which is targeted by azoles including VRC, was enriched and up-regulated in TV, with 
thirteen genes present under this term (not shown). There were no enrichments that were down-
regulated in TV as only four unrelated genes, an oxidoreductase (CNAG_01878), nitric oxide 
dioxygenase (CNAG_01464) and two uncharacterised proteins (CNAG_03454 and CNAG_07765) 
were present. With the addition of EDTA to VRC treatment, ergosterol biosynthesis remained 
enriched and up-regulated in TVE and included fourteen genes (not shown). However, the odds ratio 
for ergosterol biosynthesis was much higher in TV than in TVE as it represents a greater proportion of 
all expressed genes (Table 4.12). EDTA+VRC in H99 affected additional cellular processes with GO 
enrichments involved in mitochondrial ATP synthesis, redox, energy generation and purine 
metabolism, which were all repressed. 
Genes where log-fold changes in differential expression exceeded 2 were examined further. As 
expected with VRC treatment in H99, the majority of up-regulated genes were involved in lipid 
biosynthesis and energy generation, with the most up-regulated gene encoding a methylsterol 
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monooxygenase (CNAG_01737) involved in steroid biosynthesis. Other highly expressed transcripts 
that are not involved in lipid synthesis or energy generation and have known functions included a 
sodium dependant phosphate transporter (CNAG_05075) and β-glucan synthesis-associated protein 
(CNAG_06031).  
The most highly induced transcript in TVE in H99 encodes a cytokine-inducing glycoprotein 
(CNAG_01653). Other induced transcripts encode a number of transporters, including zinc 
transporters (CNAG_03398, CNAG_00895 and CNAG_07728) and an ATP binding cassette 
transporter (CNAG_00869). The same β-glucan synthesis-associated protein (CNAG_06031) noted 
above was also highly induced. Highly repressed genes included antioxidants including catalases 
(CNAG_ 00575 and CNAG_04981), flavoprotein (CNAG_01846) and a nitric oxide dioxygenase 
(CNAG_01464). 3-isopropylmalate dehydratase, which is involved in leucine biosynthesis, was also 
repressed (CNAG_00237).  
In 97/170, transcripts involved in ergosterol biosynthesis were enriched and up-regulated with VRC 
treatment as was seen in H99. Unlike H99, however, protein insertion into membrane rafts was also 
induced. There were no down-regulated enrichments as the eight genes that were repressed in TV 
were involved in a variety of functions including redox, stress, assembly of the nuclear pore complex 
and copper transport. The addition of EDTA to VRC, which produces an additive effect in 97/170, 
also affected DNA, amino acid and mitochondrial-related processes as was seen in H99. Other 
enrichments in TVE in 97/170 included translation, and protein folding and localisation, which were 
repressed, while metal and vacuolar transport were induced.  
The most up-regulated transcript in 97/170 with VRC treatment was a hypothetical protein (g1817) 
at a fold change of 6.36. Most of the up-regulated genes with more than 2-log fold changes in 
differential expression in TV were hypothetical proteins, genes related to lipid biosynthesis and genes 
involved in mitochondrial processes. The exceptions were transport-related proteins, such as a 
vacuolar iron transporter (g3364), an ATP binding cassette transporter (g6492), a membrane 
transporter (g5603) and Grg1, a regulator of G protein signalling (g2446).  
The most down-regulated 97/170 transcripts following VRC+EDTA treatment had log fold changes 
less than 2 and were involved in cell stress, including a heat shock protein (g141) and a 
flavohemoprotein (g6989). The most highly up-regulated gene was a hypothetical protein (g7205) 
with a log fold change of 9.14. Other genes up-regulated more than 2-log fold with predicted 
functions were involved in signalling and included Crg1 (g2446), a cytokine inducing glycoprotein 
(g3268) and a receptor (g6793). Transporters mobilising zinc (g4019 and g762), iron (g1505, g2180, 
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g3364 and g1996), dityrosine (g822), oligopeptide (g564), and ATP binding cassette transporters 
(g6492 and Pdr11; g5852) were also induced. A metalloreductase (g3415) and a homologue of 
Zap104 (g3530), which is a zinc-controlling transcription factor, were also highly up-regulated in 
97/170. 
In summary, relatively few GO terms were enriched in response to VRC and VRC+EDTA treatments in 
both Cryptococcus species when all differentially expressed genes were considered. Ergosterol 
biosynthesis was induced by both drug treatments in both organisms, as would be expected in 
response to azole drugs. Little changes to cellular processes were observed with VRC treatment, 
while the addition of EDTA to VRC treatment turned off transcripts involved in mitochondrial 
functions in both organisms. In 97/170, however, protein-related processes were additionally 
repressed by VRC+EDTA treatment.  
4.8.4.2. GO analysis of differentially expressed orthologous genes to compare the antagonistic 
(H99) versus additive (97/170) interaction of VRC+EDTA  
Orthologous genes that were expressed in both H99 and 97/170 (Fig. 4.21, set B) were removed to 
focus on the genes unique to each organism. Most of the genes in this set that were up-regulated in 
both H99 and 97/170 compared to the untreated controls encode functions involved in lipid 
biosynthesis, including ergosterol biosynthesis, and these were seen in both VRC and VRC+EDTA 
treatments. Genes involved in metal transport were also up-regulated by VRC+EDTA, while genes 
involved in energy generation, oxidation-reduction, TCA cycle and Fe-S cluster assembly were down-
regulated (not shown).  
Restricting the analysis to orthologous genes expressed only in one organism (Fig. 4.21; A and C) 
changed the types of GO terms enriched by VRC and VRC+EDTA treatment in H99 (Table 4.15). In TV, 
proteolysis and oxidation-reduction processes were enriched and up-regulated, as were 
phospholipid and phosphatidylinositol biosynthesis. In the H99 response to VRC+EDTA, oxidation-
reduction was shut down and GO enrichments including transmembrane and transition metal ion 
transporters were induced. More than half of the genes involved in transmembrane transport 
encode proteins that are involved in transporting drugs (CNAG_06348, CNAG_04616, CNAG_04546, 
CNAG_02336), which have been observed in response to azole drugs in other studies [523], while 
other transporters mobilise substrates such as sugar (CNAG_02586) and inorganic phosphate 
(CNAG_02777). The transition metal transporters transport iron (Cft3; CNAG_03694) and copper 
(Ctr4; CNAG_00970).  
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C. gattii strain 97/170 had substantially more differentially expressed genes in response to both VRC 
and VRC+EDTA than C. neoformans H99. In TV, GO enrichments for redox, lipid metabolism, 
transport including transmembrane and metal ion transporters, and cell stress responses such as 
response to hydrogen peroxide and osmotic stress were up-regulated. Genes that were enriched in 
transmembrane transport encode proteins that mobilise drugs (g4255, g6793, g3132, g3248). Other 
up-regulated GO enrichments included amino acid import, regulation of actin organisation, and 
osmosensory signalling.  
A more dynamic response was seen in 97/170 upon the addition of EDTA to VRC treatment, where 
enrichments related to translation, protein folding and the regulation of translation in response to 
stress were repressed. Mitochondrial functions were also repressed, and redox, which was induced 
in VRC treatment, was shut down. GO enrichments that were induced included amino acid import, 
lipid metabolism, vesicle mediated transport and signalling. The enrichment of GO terms related to 
drug mobilisation found in TV was no longer seen in TVE. Stress responses differed between the single 
and combined drug treatments in 97/170. While autophagy and cellular responses to pH were also 
induced, the response to hydrogen peroxide that was observed in TV was no longer seen.   
To understand how EDTA represses the inhibitory action of VRC in H99, the response to treatment 
was compared to that seen for 97/170. The most striking difference in enrichment in TVE was the 
induced expression of transmembrane transport genes, most of which were drug transporters 
(CNAG_06348, CNAG_04616, CNAG_04546, CNAG_02336), which occurred in H99 but not in 97/170. 
Transition metal ion transporters were also induced in H99 but not in 97/170 and included Cft3 and 
Ctr4, which transport iron and copper, respectively. Additional GO terms in 97/170 that were not 
enriched in H99 included the induction of lipid metabolism, response to pH, mitophagy and cytolysis. 
Protein-related processes such as translation and folding, and terms associated with transport such 
as tubulin complex assembly and protein localisation to the mitochondria were repressed in 97/170, 
suggesting a decrease in active growth. The only enrichment common to the two species was the 
shutdown of oxidation-reduction, and DNA metabolism was generally repressed in both organisms. 
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Table 4.14. Selected GO term enrichments for all differentially expressed transcripts in C. 
neoformans H99 and C. gattii 97/170 in TV and TVE  
GO term   H99 97/170 
 GO ID TV TVE TV TVE 
DNA and amino acid related 
Cellular amino acid metabolic process GO:0006520    2.46 
Purine nucleoside triphosphate metabolic 
process 
GO:0009144  11.82  11.5 
Mitochondria and energy related 
Haem biosynthetic process GO:0006783    9.9 
Mitochondrial ATP synthesis coupled 
electron transport 
GO:0042775  41.19  142.54 
Oxidation-reduction process GO:0055114  7.16  2.46 
Generation of precursor metabolites and 
energy 
GO:0006091  9.66  5.69 
Mitochondrial membrane organisation GO:0007006    4.66 
Lipid related
#
 
Cellular lipid biosynthetic process GO:0097384 176.2 40.35 97.69 26.14 
Ergosterol biosynthetic process GO:0006696 176.2 40.35 97.69 26.14 
Protein related 
Protein insertion into membrane raft GO:0071210 5.23  Inf*  
Protein folding GO:0006457    3.87 
Translation related 
Translation GO:0006412    4.46 
Cytoplasmic translation GO:0002181    5.56 
Transport, cell organisation  and regulation related 
Metal ion transport GO:0030001  2.14  3 
Vacuolar transport GO:0007034   4.58 2.8 
Tubulin complex assembly GO:0007021    7.02 
Protein localisation to mitochondrion  GO:0070585    7.08 
Odds ratios for each GO term are included, with regulation of GO terms colour coded. Red: up-regulated. 
Green: down-regulated. *Inf = all genes contributing to enrichment of this GO term are present. 
#
 Ergosterol 
biosynthesis is a child GO term of lipid biosynthesis and both terms have the same odds ratios.  
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Table 4.15. Selected GO term enrichments for transcripts of orthologous genes in C. neoformans 
H99 and C. gattii 97/170 in TV and TVE 
GO term  H99 97/170 
 GO ID TV TVE TV TVE 
DNA and amino acid related 
Cellular amino acid metabolic process GO:0006520    2.44 
Purine nucleobase biosynthetic process  GO:0009113    5.71 
Pyridine nucleotide biosynthetic process GO:0019363  19.46   
Pyrimidine nucleobase metabolic process GO:0006206    17.15 
Amino acid import  GO:0043090   22.01 13.78 
Mitochondria and energy related 
Haem biosynthetic process GO:0006783    4.58 
Mitochondrial ATP synthesis coupled 
electron transport 
GO:0042775    10.15 
Oxidation-reduction process GO:0055114 Inf* 2.99 2.13 1.62 
Generation of precursor metabolites and 
energy 
GO:0006091    3.01 
Mitochondrial membrane organisation GO:0007006    4.49 
Lipid related 
Phosphatidylinositol  biosynthetic process GO:0006661 20.51    
Phospholipid biosynthetic process GO:0008654 8.94    
Lipid metabolic process GO:0006629   3.10 1.75 
Fatty acid biosynthetic process GO:0006633   10.63  
Protein related 
Proteolysis GO:0006508 5.23    
Protein folding GO:0006457    4.23 
Translation related 
Posttranscriptional regulation of gene 
expression 
GO:0010608    2.32 
Translation GO:0006412    5.18 
Cytoplasmic translation GO:0002181    6.21 
Response to stress 
Regulation of translation in response to 
stress 
GO:0043555    8.57 
Positive regulation of autophagy GO:0010508    13.72 
Response to hydrogen peroxide GO:0042542   8.78  
Cellular response to hydrogen peroxide GO:0070301   10.99  
Cellular response to osmotic stress  GO:0071470   4.02  
Cellular response to pH GO:0071467    3.67 
Cytolysis GO:0019835    Inf* 
Mitochondrion degradation GO:0000422    5.89 
Transport, cell organisation and regulation related 
Transmembrane transport GO:0055085  2.14 2.47  
Regulation of actin cytoskeleton organisation GO:0032956   4.58  
Tubulin complex assembly GO:0007021    8.22 
Protein localisation to mitochondrion  GO:0070585    7.33 
Golgi vesicle transport GO:0048193    2.14 
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Endosomal transport GO:0016197    3.30 
Activation of MAPKKK activity GO:0000185    27.45 
Signal transduction by phosphorylation  GO:0023014    3.14 
Osmosensory signalling pathway GO:0007231   12.56 6.88 
Metal related
#
 
Transition metal ion transport GO:0000041  6.59   
Metal ion transport GO:0030001   3.50  
Odds ratios for each GO term are included, with regulation of GO terms colour coded. Red: up-regulated. 
Green: down-regulated. *Inf = all genes in this GO enrichment are present. 
#
Metal ion transport also includes 
transition metal ion transport.  
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4.9. Discussion – VRC+EDTA antagonism and additivity in C. neoformans H99 and C. gattii 97/170  
Antagonistic drug interactions occur when the efficacy of the drugs when combined is less than the 
most effective drug when used alone [148]. Drug prediction databases can identify some 
antagonistic drug pairs but investigations into the mechanistic understanding of antagonistic drug 
combinations have not garnered as much attention as drug synergy.  
Certain iron chelators can act as antagonists in combination with antifungal treatments. An in vivo 
study of Rhizopus-infected guinea pigs found the addition of DFO to AMB treatment abolished the 
prolonged survival produced by the antifungal alone. It appeared that DFO antagonised AMB activity 
by behaving as a siderophore and stimulating Rhizopus growth by providing iron [294]. Antagonistic 
interactions between antifungals and iron chelators have also been observed in vitro in other fungi, 
with AMB+DFP and FLC+LF producing antagonism in A. fumigatus, and FLC+LF in C. albicans [9, 235]. 
Minor antagonism was also seen when LF was combined with FLC, AMB and 5-FC in Candida species 
but only at the lower range of concentrations tested for both agents [10]. None of these studies 
investigated or discussed how the tested iron chelators might antagonise the activity of antifungal 
drugs. In the current study AMB+DFP and FLC+LF produced an additive interaction in Saccharomyces 
and Cryptococcus while AMB+LF was synergistic (Fig. 3.3a), indicating the complexity and species-
specific nature of drug interactions.  
In this thesis, antagonism occurred when FLC, ITC and VRC were combined with DFP, DSX and EDTA, 
but this occurred in C. neoformans var. grubii only and was not seen in closely related C. neoformans 
var. neoformans and C. gattii strains (Fig. 3.3a). The most extreme difference was where VRC+EDTA 
was antagonistic in H99, raising the requirement for VRC 4-fold yet, this same combination was 
almost synergistic in 97/170 and reduced the requirement for VRC 16-fold (Section 3.4.2; Appendix 
3.1). Understanding how this difference occurred became the focus of the analysis presented in this 
chapter.  
As using cells that are inhibited but not killed is essential for transcriptomic analysis of drug 
inhibition, considerable effort went into determining a suitable timepoint to analyse the 
transcriptome of VRC+EDTA antagonism in H99 and additivity in 97/170. In the synergy experiments 
(Section 4.2.3.1), RNA-Seq was performed when AMB and AMB+LF treatments caused a 20% 
decrease in growth compared to the untreated control (i.e. at ID20). It was therefore decided to use 
the point where VRC+EDTA treatment caused a 20% increase in the growth of H99 compared to VRC 
treatment alone, which was at the 7
th
 hour of treatment (Fig. 4.19), to extract RNA across all 
VRC+EDTA experiments in H99 and 97/170. This caused some challenges in choosing a comparable 
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time for RNA-Seq during treatment with VRC alone. Most importantly, the concentrations of VRC 
and EDTA used to treat H99 and 97/170, which was included to investigate how VRC+EDTA could be 
additive in one species but antagonistic in another, caused different effects on the growth of both 
organisms (Fig. 4.19) as the MICs of VRC and EDTA were different in the two strains (Table 3.2). At 
the 7
th
 hour of treatment, H99 was significantly inhibited by the FIC for VRC treatment (which was 
four times higher than its MIC), while the growth of VRC-treated 97/170 cells resembled that of its 
untreated control (Fig. 4.19). Therefore, the transcriptome analysis of VRC treatment in H99 may be 
confounded by the presence of apoptotic responses, while 97/170 may lack a sufficiently strong 
response to VRC. 
In 97/170 at the 7
th
 hour of drug treatment, VRC+EDTA had inhibited growth by 27% relative to the 
untreated control, while VRC had only inhibited growth by 4% (Fig. 4.19a). This may affect the 
comparison between the two treatments by RNA-Seq, compared to performing it at a common 
inhibitory point like ID20, as used in Section 4.2.3.1. In addition, due to cost the transcriptome 
responses to EDTA alone in H99 and 97/170 was not assessed and this is therefore not available for 
comparison. These issues need to be considered in the comparative analysis of VRC and VRC+EDTA 
treatments in H99 and 97/170, which are also limited by a lack of validation. Nevertheless, the 
transcriptomic data revealed interesting insights into antagonism and highlight species-specific 
differences in how cells respond to the same drug combination.  
4.9.1. Up-regulation of efflux pumps as a mechanism of VRC+EDTA antagonism in C. neoformans 
H99 
In H99, ergosterol biosynthesis and oxidation-reduction processes, which were up-regulated in TV, 
(Table 4.14 and 4.15) reflect a subset of cellular responses that have been reported in FLC-treated 
Cryptococcus cells. In contrast the up-regulation in proteolysis (Table 4.15) has not been previously 
observed as a response to azole treatment [137, 356]. This may be due to the high concentration of 
VRC used here, which was 4 x MIC for VRC compared to 0.5 and 2 x MIC of FLC used in the two other 
Cryptococcus studies [137, 356]. Alternatively, it may be due to different effects of VRC on the cell 
compared to FLC.  
With the addition of EDTA, the most striking enrichment in H99 was the induction of transmembrane 
transport, where genes encoding drug efflux pumps were observed (Table 4.15). These included the 
ATP-binding cassette (ABC) transporter Pmr5 (CNAG_06348), major facilitator superfamily (MFS) 
transporters (CNAG_04616 and CNAG_00433), a multidrug transporter (CNAG_04546) and a 
multidrug resistance protein (CNAG_02336). Of these, only PMR5 was up-regulated following VRC 
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treatment in H99 (not shown). While some genes encoding drug transporters were also seen in TVE in 
97/170, none of drug transport genes listed above were seen.  
The expression of efflux transporters that remove drugs from the cell is a major mechanism of 
decreasing azole susceptibility in fungi and has been extensively reviewed [523, 524]. ABC and MFS 
transporters are the main classes of drug translocators that cause multidrug resistance. ABC 
transporters hydrolyse ATP to move substrates across membranes and include pleiotrophic drug 
resistance (PDR), multidrug resistance (MDR) and multidrug resistance-associated proteins (MRP). 
MFS transporters use proton motive force and include drug:H
+
 antiporters, symporters and 
uniporters [523]. Up-regulation of these suggested that EDTA may antagonise the inhibitory effect of 
VRC in H99 by enhancing the removal of VRC from the cell. This would explain the substantially 
lower transcriptomic response to VRC+EDTA treatment seen in H99 compared to 97/170, as the 
intracellular concentration of VRC may not be harmful enough to elicit changes in cellular 
homeostasis and cause cell stress. This is in contrast to 97/170, where efflux genes were seen TV but 
became absent in TVE, and suggests that the lack of differentially expressed drug efflux genes may be 
one of the mechanisms that augmented the inhibitory activity of VRC in 97/170 (Table 4.15).  
Interestingly, MDR1 and AFR1, which encode the most characterised drug efflux transporters in C. 
neoformans [523], were not observed in H99 in TV or TVE. However, PDR11, a C. gattii orthologue of 
AFR1 [525], was up-regulated by both drug treatments in 97/170 with fold changes of 1.69 in 
response to VRC, and 2.69 in response to VRC+EDTA (Section 4.8.4.1, not shown). AFR1 
overexpression is associated with FLC resistance and increased virulence [523]. In C. neoformans, 
azole treatment can cause heteroresistance, which appears in part due to duplication of the 
chromosome containing the AFR1 locus [185]. MDR1 overexpression is also associated with 
decreased FLC susceptibility and heteroresistance, but this is not as well characterised as the Afr1 
response [523, 526]. The absence of AFR1 and MDR1 expression in C. neoformans strain H99 
suggests that these transporters may not have a major role in VRC efflux and that other drug 
transporters may have higher specificity for VRC. In contrast to H99, up-regulation of PDR11 in C. 
gattii strain 97/170 suggests that PDR11 may have a role in VRC survival. However, PDR11 
expression may not contribute to VRC+EDTA survival, even at a higher fold-change in expression, as 
this drug combination may have caused cellular damage that was irreversible by drug efflux.  
The induction of efflux proteins has been implicated as a mechanism of antagonism in other 
organisms. In gram negative bacteria, addition of the analgesic salicylate to chloramphenicol or 
tetracycline induced antagonism through the induction of the marRAB operon, which encodes 
transcriptional activators that increase the production of various drug efflux mechanisms [527]. The 
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role of drug efflux proteins in drug antagonism was clearly demonstrated when the deletion of a 
central efflux protein, TolC, abolished antagonism between salicylate combinations with 
chloramphenical and tetracycline in E. coli [528]. This suggests that non-antimicrobial medicines, 
which are not thought to induce drug resistance mechanisms, can have unexpected consequences 
on the activities of antimicrobial drugs.  
Increased expression of drug efflux pumps has also been observed in Candida petite mutants, which 
are deficient in mitochondrial DNA and have decreased susceptibility to azole drugs [529-531]. In 
Cryptococcus, mutants that are disrupted in mitochondrial function have decreased susceptibility to 
azoles, which suggests azole sensitivity can be dependent on mitochondrial function [532]. This may 
be relevant to the antagonistic effect of VRC+EDTA on H99, as the addition of EDTA had a 
suppressive effect on enrichments relevant to mitochondrial activity and to the targeting of protein 
to the mitochondrion (Table 4.14). Additionally, transition metal ion transport was enriched and up-
regulated in TVE in H99 (Table 4.15) but not in TV. While this coincides with the metal chelating ability 
of EDTA, it also corresponds to the accumulation of metals and the activation of metal uptake 
responses exhibited by cells with dysfunctional mitochondria [533, 534]. Therefore, an additional 
way in which EDTA is antagonistic to VRC in H99 may be by causing mitochondria to mis-function in 
ways similar to those seen in petite mutants, which may in turn cause the up-regulation of drug 
efflux genes and decrease susceptibility to azole drugs.  
Interestingly, certain disruptions of mitochondrial functions including electron transport chain 
complexes and mitochondrial biogenesis can increase susceptibility to azoles [534, 535], and this 
may have occurred in 97/170, where EDTA increased VRC inhibition and enrichments for 
mitochondrial processes were suppressed (Table 4.14).  
4.9.2. EDTA may potentiate VRC activity in C. gattii 97/170 by alterations to the stress response  
With VRC treatment, 97/170 exhibited responses that are commonly seen in response to azole 
drugs, with up-regulation of enrichments relating to ergosterol biosynthesis, mitochondrial and 
energy generation, response to stress and transmembrane transport that included some drug efflux 
transporters (Table 4.14 and 4.15) [137, 356, 359, 463]. Additional responses that have been 
reported in other azole-treated yeast cells included the up-regulation of metal transport, signal 
transduction and cell wall maintenance (Table 4.15) [137, 359, 463]. Altogether, this suggested that 
the effect of VRC on 97/170 was typical for azoles.  
EDTA altered the stress responses seen in TV, where the enrichments for oxidative and osmotic 
stress responses became absent. Additionally, the GO term transmembrane transport, which was 
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induced in TV, became absent with the addition of EDTA. In contrast, activation of mitogen protein 
kinase kinase kinase (MAPKKK), mitophagy, response to pH and cytolysis, which were not observed 
TV, were induced (Table 4.15).  
These enrichments suggest that EDTA may have potentiated the effect of VRC in 97/170 by 
disrupting antioxidant production and inducing more rapid cytolysis. EDTA disrupts membrane 
integrity by binding to the membrane and increases its permeability [536], which can lead to cellular 
osmotic imbalance. The high-osmolarity glycerol (HOG) response pathway may be activated in 
response, as SSK2, an upstream MAPKKK activator in the HOG pathway that is the main regulator of 
stress responses, cell differentiation and virulence factor production, was up-regulated in TVE [537]. 
However, target genes of Ssk1 were not differentially expressed (not shown). This suggests an 
incomplete activation of the stress adaptation response and inability of the cells to respond 
appropriately.  
EDTA causes Mg
2+
 efflux from the mitochondrial matrix, which can disrupt mitochondrial function by 
affecting mitochondrial RNA metabolism and ATP synthesis [538]. This effect, in addition to the 
antifungal activity of VRC, may lead to increased mitochondrial stress and mitophagy in 97/170 
(Table 4.15). Additionally, EDTA has been shown to affect vesicle mediated trafficking, which is 
required for the localisation of transport proteins [283]. Interestingly, mitochondrial dysfunction also 
disrupts HOG stress signalling and affects the localisation of drug efflux transporters [534], which 
were all suggested in TVE in 97/170. This may explain why in 97/170 the enrichments for metal ion 
and transmembrane transport, which included drug efflux transporters, were seen in VRC treatment 
but became absent in the presence of EDTA (Table 4.15).  
A comparison of the transcriptomic data produced by H99 and 97/170 showed a number of 
differences that may determine their responses to VRC+EDTA. Up-regulation of transmembrane 
transporters including drug efflux proteins was implicated as a mechanism of VRC+EDTA antagonism 
in H99 (Table 4.15). However, although some genes associated with drug transporters were up-
regulated, the absence of enrichments related to drug efflux proteins in 97/170 suggested that the 
expression of more drug transport encoding genes may be associated with increased survival to 
VRC+EDTA. This was because enrichments for drug efflux were up-regulated in VRC where growth 
was less inhibited than VRC+EDTA treatment (Fig. 4.19 and Table 4.15). Dysregulation of 
mitochondrial responses was also observed in both H99 and 97/170, however in 97/170 many more 
mitochondrial-related enrichments were observed, including haem and ATP synthesis and 
mitophagy, suggesting a more severe disruption to mitochondrial function (Table 4.15). Finally, 
dysregulation of stress responses was implicated in 97/170 but not in H99, suggesting that the 
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disruption in mitochondrial function caused by the addition of EDTA to VRC in 97/710 may have 
affected the appropriate induction of stress responses. Interestingly, this dysregulation of stress 
responses was similar to that seen in the synergistic interaction of AMB+LF in S288C (Section 4.5.3.1) 
and to the synergy of FLC+B-7b and NaCl+H2O2 reported in C. albicans [321, 479], suggesting a 
common mechanism of synergy is the disruption of stress related responses. This will be further 
discussed in Section 5.2.  
4.9.3. Species-specific responses to drugs and to drug combinations  
Transcriptome analyses of EDTA+VRC treatment in C. neoformans H99 and C. gattii 97/170 revealed 
species-specific differences in their cellular response. Different fungal organisms can vary 
substantially in their intrinsic susceptibility to antifungal drugs; for example, FLC is active against a 
range of fungal organisms but has no activity against Aspergillus and some species of Candida [181]. 
Differences in drug susceptibility are also seen between closely related fungal species. In 
Cryptococcus, C. gattii isolates are generally less susceptible to azoles than C. neoformans isolates 
and between cryptococcal genotypes, C. gattii VGII strains have been shown to be less susceptible to 
FLC than VGI and VGIII strains [21]. Additionally, the development of heteroresistance is more 
prevalent in C. gattii than C. neoformans strains [32]. However, how and why closely related fungal 
species respond differently to drug treatments is often poorly understood.  
The response to drug combinations can also differ substantially among closely related species, as 
seen in Chapter 3 in this thesis. Azole combinations with EDTA, DFP and DSX were antagonistic only 
in C. neoformans var. grubii strains (genotypes VNI and VNII) and not in C. neoformans var. 
neoformans (VNIV) or C. gattii strains (Fig. 3.3a). However, while VRC was consistently antagonistic 
with EDTA, DFP and DSX in all C. neoformans var. grubii strains, other azole-chelator combinations 
like FLC+EDTA were not (Fig. 3.3a). In the C. gattii strains tested most of the additive and synergistic 
drug combinations produced consistent 2- to 4-fold reductions in the requirement for the antifungal, 
however for strain R272 treated with AMB+LF, and strain 97/170 treated with VRC+EDTA, the 
presence of chelators caused a 16-fold reduction in antifungal requirement (Appendix 3.1).  
C. gattii strain 97/170 has been of interest to our laboratory as it is a VGII isolate with no apparent 
previous exposure to FLC, yet it is inherently very resistant to FLC with an MIC of 64 µg/mL (Table 
3.2). Of the VGII strains tested, 97/170 exhibited the highest MIC to VRC and other azoles and it also 
had the greatest reduction for VRC in presence of EDTA (Table 3.2, Appendix 3.1). Based on its highly 
resistant phenotype, our laboratory undertook a comparative analysis of the genomic sequence of 
97/170 and other C. gattii VGII strains with wild-type and elevated resistance but found minimal 
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differences (not shown) and none appeared to account for how the strains differed in their 
responses to azoles. Similarly, comparative studies of the genomes of C. neoformans and C. gattii 
strains did not find a genetic basis for the difference in drug susceptibilities between the two species 
[141, 539].   
97/170 is closely related to H99 and shares 83% genome identity, which is consistent with the 
genomic differences reported between C. gattii and C. neoformans [539]. In hindsight, however, 
investigating the antagonistic interaction of VRC+EDTA in H99 may have been better with a more 
closely related strain where VRC+EDTA was not antagonistic, such as C. neoformans var. neoformans 
stƌaiŶ JECϮϭα ;Fig. ϯ.ϯaͿ. StƌaiŶs ǁithiŶ the saŵe speĐies geŶeƌallǇ haǀe higheƌ sǇŶteŶǇ aŶd 
orthology [141, 539] making it easier to find specific differences in genome content that cause 
differences in drug responses. However, as only the variety grubii in C. neoformans exhibited 
antagonism in Chapter 3, this suggested that the different drug interactions seen between the 
varieties and species of Cryptococcus may be influenced by other factors that make these organisms 
distinct.  
C. neoformans var. grubii is the most common Cryptococcus species isolated from HIV/AIDS and 
other immunosuppressed patients [540] and latent clinical isolates may be exposed to azoles during 
prophylactic treatment prior to being isolated during active infection. C. gattii, on the other hand, is 
a primary pathogen and exposure to clinical azoles is unlikely. Such prior exposure could increase the 
expression resistance mechanisms like drug transporters [541], and this may contribute to the 
difference in drug interactions observed between H99 and 97/170. Adaptive responses to host 
infection may also contribute to differences in drug response. Analysis of the transcriptome profiles 
of C. neoformans var. grubii strains isolated from the cerebral spinal fluid of AIDs patients before 
antifungal treatment showed that genes encoding drug efflux transporters were commonly up-
regulated during host infection [542]. While transcriptome profiles of host adaptation during 
infection by other varieties have yet to be reported, it is possible that extended infection during 
latency and HIV/AIDS and/or a greater exposure to azoles may cause C. neoformans var. grubii 
strains to have a higher propensity for drug efflux expression during stress, which may influence 
responses to drug interactions in a different manner to other cryptococcal varieties. 
Overall, this study shows that a drug combination that inhibits the growth of one fungal organism 
may not always be suitable to inhibit the growth of another due to potential differences in their 
responses to the drug combination, which can be difficult to predict, and extensive testing across a 
wide variety of different strains is advisable.  
178 
 
4.9.4. Future avenues for understanding the mechanisms of azole-chelator interactions   
Drug efflux transporters and disruption of stress responses were strongly implied by the 
transcriptomic data as mechanisms of VRC+EDTA antagonism in H99 and additivity in 97/170. In 
order to validate these, qPCR using primers specific for the H99 multidrug transporter CNAG_004546 
and the 97/170 MAPKKK associated kinase STE11 (g3399), which were only expressed in TVE, can be 
monitored during VRC+EDTA treatment, as previously mentioned for AMB+LF synergy experiments 
(Section 4.7.5). Monitoring of genes expressed in both TV and TVE, such as the H99 β-glycan 
associated protein CNAG_00869 and the 97/170 ABC transporter PDR11 (g8582), should also be 
done. As well as validating the current data, qPCR of efflux transporter genes would also be useful 
for understanding the species-specific nature of drug interactions with VRC+EDTA and other 
antagonistic azole-chelator combinations like ITC+DFP and FLC+DSX (Fig. 3.3) in different 
Cryptcococcus species and strains.  
Due to time constraints, SOMs analyses of the transcriptome data produced by H99 and 97/170 
were not performed. As SOMs analysis in the synergy experiments provided a more detailed 
understanding of AMB+LF mechanisms in S288C and H99. SOMs should also be applied to the 
antagonism experiments. This would enable further understanding of the functional processes that 
are co-regulated following VRC+EDTA treatment and contribute to antagonism in H99 and additivity 
in 97/170.  
As noted above, disruption of mitochondrial function can cause increased expression of drug efflux 
pumps [529-531]. However, while enrichment analysis of TVE in H99 and 97/170 both suggested 
alterations in the mitochondria (Table 4.15), the increased expression of efflux transporters seen 
only in H99 suggested that the disruptive effect of VRC+EDTA on the mitochondria may differ 
between H99 and 97/170. Disruptions to the mitochondria can range from changes in physiological 
functions such as ATP synthesis, to apoptotic processes, changes mitochondrial ion homeostasis and 
the generation and neutralisation of ROS [543]. These could be assessed in VRC+EDTA-treated H99 
and 97/170 cells such as by assaying changes in mitochondrial membrane potential, ATPase activity 
and intracellular ATP and ROS concentrations, as were performed in the study of BBR+FLC synergy 
[6]. Release of cytochrome c, which is a pre-apoptotic indicator and is indicative of disruptions in the 
electron transport chain and the generation of superoxides [544], could also be tested. Differences 
in how mitochondria were disrupted in H99 and 97/170 may indicate how VRC+EDTA disrupted 
stress responses in 97/170 but up-regulated drug efflux proteins in H99.  
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4.10. Additional observations in the transcriptomes of drug synergy and antagonism  
4.10.1. Differences in RNA-Seq data between synergy and antagonism experiments reflect the 
different cellular effects of polyenes and azoles  
One of the intriguing observations in this analysis was the difference in the number of genes 
differentially expressed in response to azole treatments (TV and TVE) compared to polyene 
treatments (TA and TAL), as well as the difference in the number of genes differentially expressed in 
H99 AMB+LF synergy versus those expressed in 97/170 VRC+EDTA additivity/H99 VRC+EDTA 
antagonism. Previous microarray studies have reported more differentially regulated genes in 
response to polyenes than azoles. In Saccharomcyes, 44 genes were up-regulated and 7 were down-
regulated in response to ketaconazole treatment compared to 185 up- and 80 down-regulated genes 
with AMB treatment [463]. Similarly in Candida, 60 genes were up-regulated and 22 were down-
regulated in response to ketaconazole, while 87 were up- and 169 genes were down-regulated in 
response to AMB [359, 463]. These differences may reflect different inhibitory mechanisms and a 
wider range of effects exerted on cells by polyenes compared to azoles. The higher percentage of 
genes differentially expressed from the total number of identified transcripts in AMB+LF 
experiments (50% in S288C and 60% in H99) compared to VRC+EDTA experiments (5% in H99 and 
15% in 97/170) appears to reflect this.  
The fewer number of genes in both TV and TVE in H99 compared to 97/170 (Table 4.12) is surprising 
given that level of inhibition of H99 caused by both drug treatments in relation to the untreated 
controls was greater at the time of RNA-sequencing (Fig. 4.19). In H99, the minimal changes in the 
transcriptome during VRC+EDTA treatment may be due to the negating effect of EDTA inducing VRC 
efflux out of the cell. However, the lack of differentially expressed genes in H99 during treatment 
with VRC alone, which was used at 4 x MIC and caused significant growth inhibition of H99, is 
difficult to explain. It is possible that at the concentration used, VRC overwhelmed the cell making it 
unable to mount an appropriate transcriptional response, or that by the time of extraction (7 hr), the 
response had been missed. Conversely, the higher number of genes that were differentially 
expressed by H99 and S288C during AMB+LF synergy and by 97/170 during VRC+EDTA additivity 
(Table 4.4 and 4.12) may be a result of the cell rewiring its metabolic pathways and processes to 
survive the drug treatments that were at a more sub-lethal level. 
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4.10.2. Problems and limitations in transcriptome analyses of drug synergy and antagonism  
A major limitation to the transcriptome analysis of synergy and antagonism was the level of genome 
annotation available for Cryptococcus strains H99 and 97/170, which affected the depth of analysis 
of the drug interactions. Although genome annotations were improved by pooling functional 
annotations of orthologous genes from other fungal species such as Saccharomyces, Aspergillus, 
Candida and Agaricus, about 30% of the genes differentially expressed in AMB+LF synergy and 40% 
of those seen in VRC+EDTA antagonism were uncharacterised with no known functions (Tables 4.4 
and 4.12). This in turn affected network analysis, as the mapping of cellular processes and pathways 
relies on genes or proteins that have been characterised in terms of functions and interactions or 
have orthology to Saccharomcyes.  
Another problem observed in the RNA-Seq analysis was the presence of outlier RNA samples (Fig. 
4.7a and 4.20a). As RNA-Seq is a sensitive technique that can detect low abundance transcripts 
[127], drug synergy and antagonism treatments and sequencing of RNA samples were performed in 
a way to minimise technical and biological variations. This involved performing drug treatments and 
RNA harvesting in the same way, randomising the extraction of RNA from all samples across 
different drug treatments and their placements across sequencing lanes, and normalising the 
generated data. Outliers in RNA-Seq data are more often found in studies that process and analyse 
many RNA samples [545] and the current drug synergy and antagonism transcriptome studies had a 
total of 42 RNA samples that were sequenced together. The presence of outliers suggested that 
variation in stages of the RNA processing may have occurred, which can invariably occur with larger 
RNA sample sizes. Additionally, biological variation between Cryptococcus RNA samples was higher 
than between Saccharomcyes RNA samples (Fig. 4.5b, 4.7b, 4.20b and 4.20f). However, this is 
consistent with the low variability of biological replicates observed in model organisms such as 
Saccharomcyes versus non model organisms like Cryptococcus [387]. 
 
181 
 
 
CHAPTER 5: Final discussion and conclusions  
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5.1. The value of holistic analysis  
Significant advances in next generation sequencing technologies and reducing costs have led to their 
increased application in systems biology, which adopts a holistic approach to understanding cellular 
responses. This contrasts with the reductionist approach of molecular biology, which studies 
complex systems by analysing their simpler components. Systems biology also differs from molecular 
biology and other more traditional sciences where hypotheses are formed from observations and/or 
prior knowledge, which is then proven or refuted from the generation and analysis of experimental 
results. In contrast, systems biology uses a reverse hypothesis approach, where the analysis of 
experimental data is used to generate hypotheses. This type of unbiased approach has been 
advantageous in understanding poorly characterised and complex events. An example is 
understanding the process of pathogenicity in host-pathogen interactions, which involves the 
expression of gene sets with distinct functions at different stages of infection, which would have 
been challenging to decipher using molecular biological approaches alone [546].  
Holistic analyses have also unveiled additional functions of characterised proteins, such as the 
collagen tyrosine kinase receptor Drd2, which besides regulating cell proliferation, adhesion, 
migration and extracellular collagen remodelling, has an unexpected role in regulating ovarian 
function [547]. Sometimes unexpected or contrary findings have been observed via holistic studies. 
For example, transcriptomics has been used to study how calcification and skeletal formation in 
corals is disrupted by ocean acidification. One proposed mechanism of coral calcification involves 
the uptake and transport of extracellular ions involved in the chemical production of calcium 
carbonate in the space where skeletal formation occurs. Acidification was thought to disturb this 
process, but contrary to expectations, transcriptomic analysis found the expression of ion 
transporters was relatively unaffected by the decrease in pH. Instead, genes associated with the 
skeletal organic matrix, which mediates the controlled deposition of the calcium carbonate skeleton, 
were shown to be enriched and up-regulated following acidification [548].  
In this thesis, the transcriptomic analysis of antifungal-iron chelator interactions revealed 
unexpected mechanisms of synergy and antagonism. The comparison of transcriptome data 
produced by different yeast species further revealed complex and diverse species-specific responses 
to the same synergistic and antagonistic drug pair. Visualisation of the dynamic changes to cellular 
pathways caused by the presence of iron chelators aided the discovery of targets that, when 
disrupted, perpetuated synergy with AMB.  
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5.2. Disruption of stress-related responses as an antifungal strategy  
Stress is an adaptive response that is activated to survive changes in the external and internal 
cellular environment. An inability to adapt to change inhibits the restoration of cellular homeostasis 
and eventually results in cell death. The transcriptomic analysis of AMB+LF and VRC+EDTA presented 
in this thesis, and the proteomic analyses of synergy induced by NaCl+H2O2 and FLC+B-7b in C. 
albicans by Kaloriti et al. (2014) and Li et al. (2015) [321, 479] suggest that alteration in stress-
related responses is a common mechanism of enhanced fungal death.  
Stress related responses can be perturbed in a number of ways. In the synergy experiments with 
AMB+LF, AMB alone caused a relatively typical toxin-induced ESR in S288C and H99 (Sections 4.5.2 
and 4.7.2). However, the addition of LF disrupted this response differently in the two species. In H99, 
LF caused an increase in cell stress that was suggested to overwhelm the ESR and prevent the 
restoration of cellular homeostasis (Section 4.7.3 and 4.7.4, Fig. 4.18). In S288C, however, LF 
disrupted the stress response to AMB causing the inappropriate sensing of stress and/or 
dysregulation of stress-related pathways, which were repressed (Section 4.5.3.1, Fig. 4.15). This 
disruption appeared paradoxical and contrary to expectations but is similar to the mechanism of 
synergy between FLC+B-7b, where regulation of stress defences were down-regulated compared to 
FLC alone, which weakened the cell defence response to drugs and inhibited growth [321].  
In the additive interaction between VRC+EDTA in 97/170, dysregulation of stress responses were 
also observed, but this was mediated via a disrupted activation of stress-related pathways. With VRC 
alone, oxidative and osmotic stress responses were induced, but these became absent with the 
addition of EDTA. Interestingly, SSK1, an upstream activator and regulator of stress responses in the 
HOG signalling pathway was up-regulated by VRC+EDTA. However, Ssk1 target genes were not 
differentially expressed, suggesting that EDTA caused an incomplete activation of the HOG pathway 
and impaired the appropriate cellular response to stress (Section 4.9.2). Impairment of stress 
signalling pathways was also observed in the synergy induced by NaCl+H2O2, where target genes of 
Cap1 and Hog1, which are activated in response to cationic and oxidative stresses, respectively, were 
not differentially expressed by the combined treatment, resulting in cell death via ROS accumulation 
[479]. 
Stress adaptation responses are crucial for survival and are ideal sources of antifungal targets. 
Examples include calcineurin and the heat shock protein Hsp90, which are inhibited by the drugs 
FK506 and geldanamycin, respectively. Interestingly, while these drugs inhibit fungi on their own 
they also induce synergy with some antifungal drugs [170, 549, 550]. In this thesis, the different 
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alterations of stress responses observed in synergistic and additive antifungal-chelator combinations 
suggest different avenues for targeting fungal stress responses as an antifungal strategy that warrant 
further investigation.  
5.3. The potential of metal homeostasis as an antifungal target  
Although the regulation of copper, iron and zinc in response to AMB and AMB+LF treatments 
differed in S. cerevisiae and C. neoformans (Section 4.6.3), disruption of metal ion homeostasis by 
knocking out controlling transcription factors increased the susceptibility to AMB in both fungal 
species. For Zap1, Aft1, Rim101 and Sre1, antifungal susceptibility extended to FLC, suggesting metal 
homeostasis could be targeted as an antifungal strategy (Fig. 4.13 and Table 4.10).  
Metal ions have important functions in biological systems as they take part in many catalytic, 
homeostatic and signalling roles. While important for cellular functions, metal ions are tightly 
regulated as they can also cause the production of ROS and mediate apoptosis [93]. Additionally, the 
dysregulation of the homeostasis of one metal often affects the regulation of another; for example 
high zinc levels decrease the intracellular content of iron [551] and elevated concentrations of 
cytosolic calcium cause zinc release from storage organelles [552]. Due to its importance, metal 
homeostasis has been explored as a potential source of antifungal targets [553-555]. Furthermore, 
disruption of metal homeostasis has been suggested as an inhibitory mechanism for existing 
antifungal drugs and bioactive compounds, including amiodorane, an anti-arrhythmic drug that 
causes the hyper-accumulation of cytosolic calcium and has a broad spectrum of antifungal activity, 
and zinc pyrithione, which inhibits the scalp fungus Malassezia globasa [517, 556]. 
In S. cerevisiae, disrupting iron homeostasis by deleting AFT1, which is the dominant iron-controlling 
transcription factor, rendered the cell susceptible to a range of oxidative, nitrosative, cell wall and 
membrane stressors (Fig. 4.13). Similarly, disrupting zinc homeostasis by deleting ZAP1 increased 
susceptibility to most of the tested stressors (Fig. 4.13), suggesting that the regulation of iron and 
zinc are required for various cellular functions and processes including stress response and 
maintenance of the cell wall and membrane.  
To narrow down potential drug targets involved in metal homeostasis, knock-out mutants of known 
upstream regulators of Aft1 and Zap1 and their downstream gene targets were investigated for 
increased susceptibility to antifungal drugs. However, knock-out mutants of the kinase Tpk2 and the 
transcription factor Yap5, which control Aft1 activity and Aft1 localisation to the nucleus, 
respectively, did not result in altered susceptibility to AMB compared to wild type cells (Fig. 4.13). 
For zinc homeostasis, a knock-out mutant of Izh2, which influences Zap1 activity, was previously 
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shown to have decreased susceptibility to AMB [447, 451]. Knock-out mutants of YOR387C and VEL1, 
which are downstream targets of both Aft1 and Zap1, also had no change in susceptibility to AMB 
compared to the wild type strain (Fig. 4.13). Mutants of two other Aft1 and Zap1 targets, MET32 and 
MTD1, which are regulated by both Aft1 and Zap1 and encode proteins with ͚druggable͛ domains, 
did not exhibit increased susceptibility to AMB or FLC (Fig. 4.14). From this it appeared that only 
targeting the transcription factors that directly regulate iron and zinc homeostasis, i.e. Aft1 and 
Zap1, would augment antifungal activity in S. cerevisiae.  
Similarly in Cryptococcus, knock-out mutants of metal-controlling transcription factors generated by 
Kim et al. (2015), including ĐirϭΔ, ŶrgϭΔ, riŵϭϬϭΔ, zapϭϬϰΔ and ĐufϭΔ, showed increased 
susceptibility to AMB ([353]; Table 4.10), which suggested that iron-, zinc- and copper-regulating 
transcription factors might be potential antifungal targets. In contrast to S. cerevisiae, however, 
disruption of the cryptococcal iron uptake proteins Cfo1 and Cft1 has been observed to increase 
susceptibility to AMB and FLC [94, 116, 557], suggesting these may also be potential antifungal 
targets. In Cryptococcus, zinc uptake genes under the control of transcription factors Zap103 and 
Zap104 have been identified [558] but have not been tested as potential antifungal targets. It would 
be interesting to test whether these, like Cfo1 and Cft1, increase susceptibility to AMB and FLC.  
5.4. Potential of Zap1 and Zap104 transcription factors as antifungal drug targets  
Transcription factors have been suggested as antifungal drug targets as their disruption can render 
mutants avirulent in infection models, dysregulate cellular stress responses and increase antifungal 
drug susceptibility [353]. One transcription factor from the analysis of AMB+LF synergy in S288C and 
H99 that emerged as a potential, broad-spectrum antifungal target was Zap1. While Aft1 was also a 
potential target, it is only conserved in the pathogen C. glabrata [92]. In contrast, Zap1 is widely 
conserved and orthologues in Cryptococcus and Aspergillus have been identified [353, 555], with an 
increase in AMB susceptibility of the C. neoformans Zap104 knock-out mutant already reported 
[353].  
One difference observed following Zap1 and Zap104 deletion was that zapϭΔ (in S. cerevisiae) had a 
sickly phenotype and was susceptible to many stressors (Fig. 4.13), whereas zapϭϬϰΔ (in 
Cryptococcus) grew robustly and was only susceptible to AMB (Table 4.10). C. neoformans has a 
paralogue of Zap104 named Zap103, however deletion of ZAP103 does not confer susceptibility to 
antifungal drugs [353]. This suggests that the different phenotypes observed between zapϭΔ and 
zapϭϬϰΔ are not due to functional redundancy and rewiring of Zap103/Zap104-controlling pathways 
in C. neoformans, and points to a difference in functions governed by Zap1 in S. cerevisiae and 
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Zap104 in C. neoformans. Despite potentially different functions, both Zap1 and Zap104 contain a 
C2H2 zinc finger domain that is druggable [459] and can be inhibited by small molecules that are 
designed or modified to bind to it. However, Zap1 is also conserved in humans and drugs targeting 
fungal Zap1 could inadvertently cause toxicity in humans. Further study of the structural similarities 
between yeast and human Zap1 is required to determine if there are drug binding sites that are 
either specific to fungal Zap1 or will not affect the function of the human orthologue.  
5.5. Iron chelators as therapeutic agents for antifungal treatment  
In Chapter 3, the search for iron chelators that synergised with antifungal drugs found that only LF 
potentiated AMB activity (Fig. 3.3). Unlike the general metal chelator EDTA, or the clinically 
approved iron chelators DFO, DFP, DSX and CPO, LF is a natural and multifunctional glycoprotein that 
increases in concentration during host infection and inflammation. The activities of LF, its peptides 
and derivatives have been investigated in various fields of research, as has their therapeutic 
potential as adjuvants in chemotherapies and treatments of severe and chronic infections such as 
sepsis and hepatitis C infection [559-561].   
Interestingly, besides the prophylactic use of LF to prevent invasive fungal infections in neonates 
[562], there are no studies that have investigated its use as a therapeutic agent for invasive fungal 
diseases. This contrasts with DSX which is employed in last resort adjuvant therapies against 
mucormycoses [57, 154]. Although the aim of this thesis was to understand the molecular basis of 
synergy to discover alternative antifungal strategies, the therapeutic potential of LF in treating 
invasive fungal diseases is worth exploring as LF appears to have broad-spectrum synergistic activity 
against fungal pathogens when combined with AMB. To date, AMB+LF has been tested and reported 
to produce synergy in Cryptococcus, Saccharomyces, Candida and Aspergillus [9, 10, 72]. Further 
work is required to determine the spectrum of synergistic activity in a wider range of pathogenic 
fungi, and to test whether interactions other than synergy can occur.  
Published studies on the effects of iron chelators on fungi are limited, and most are pilot studies that 
have used a small number of fungal strains (see Table 3.1). It is possible that chelators possess 
additional properties that cause unknown outcomes in fungi, especially when combined with 
antifungal drugs, which can be complicated by species-specific responses. Caution should therefore 
be observed when using iron chelating agents during antifungal therapy.  
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5.6. Diversity of fungal responses to drug treatment and implications for studying drug responses 
in model organisms  
Although the combination of AMB+LF was synergistic in both S288C and H99, their different 
transcriptional responses demonstrate that diverse responses can be elicited by the same drug 
combination (Fig. 4.15 and 4.18). This may be due to the physiological differences between 
Saccharomcyes and Cryptococcus, which may in turn be influenced by the transcription factors 
present in their genomes. 
S. cerevisiae and C. neoformans belong to different phyla where the former is ascomycete and the 
latter is a basidiomycete. Analysis of transcription factors in sequenced genomes of ascomycetes and 
basidiomycetes found different classes dominated in the two phyla, with Zn2Cys6 regulators more 
abundant in ascomycetes, and C2H2 dominating in basidiomycetes. Basidiomycetes also had fewer 
transcription factors for which an ascomycete orthologue could be found, compared to the number 
of ascomycete transcription factors that had orthologues in basidiomycetes. This suggests that some 
components of the regulatory systems in the two phyla evolved after their divergence [563]. 
Additionally, orthologous transcription factors between the phyla may not always have conserved 
functions; for example Nrg1 plays an important role in filamentation in Saccharomcyes but does not 
in Cryptococcus, where it mediates pathogenesis, capsule formation and stress responses [110].  
Fungal species are also known to exhibit different susceptibility to different types of stresses, such as 
oxidative, osmotic and cell wall stress. A comparative bioinformatic analysis of regulatory proteins 
involved in stress-related pathways across the genomes of fungi from different environmental 
niches, including Cryptococcus and Saccharomyces, showed that the upstream sensory proteins and 
downstream transcription factors in stress signalling pathways were generally less evolutionarily 
conserved compared to those that were central to a pathway. This study also found a correlation 
between susceptibility to stressors and environmental niche. For example, Debaryomyces hansenii is 
isolated from saline environments and was resistant to NaCl, and the human pathogens A. 
fumigatus, C. albicans and C. glabrata were highly resistant to oxidative stress compared to plant 
pathogens Magnaporthe grisea, Fusarium graminearum, Ashbya gossypii and Ustilago maydis, 
which may have evolved to survive encounters with phagocytes and phagocytic microbes like 
amoeba that kill cells using oxidative bursts. This suggests that up- and downstream transcriptional 
regulators in stress signalling pathways are diverse to enable fungi to adapt to their different 
environmental niches [564].  
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While the specific niche of S. cerevisiae is unknown, it is mostly found in controlled or stable 
environments with limited exposure to stresses and it has a long history of domestication in the 
production of fermented foods and beverages [565]. In addition, as a laboratory strain used for 
biochemical studies, S288C was developed to have minimal nutritional requirements [337]. 
Furthermore, although it can grow at 37 °C S. cerevisiae cannot naturally infect mammals except in 
cases of extreme immunocompromise. In contrast, C. neoformans is a cosmopolitan yeast that has 
to adapt to a range of stresses including changes in temperature and nutrient availability. 
Pathogenic strains such as H99 are exposed to harsh stresses including elevated temperature, 
oxidative stress and nutrient limitation. These different environmental pressures influence how 
Saccharomyces and Cryptococcus have evolved to respond to stress, which may explain their 
divergent responses to AMB+LF synergy (Fig. 4.15 and 4.18).   
S. cerevisiae is a widely used model organism as its genome is well annotated and many of its genes 
and pathways are highly conserved [332]. However, the different transcriptomic response seen for 
S288C and H99 under AMB and AMB+LF treatment suggest that S. cerevisiae may not be a good 
platform for modelling drug responses in Cryptococcus as initially intended. It may, however, still be 
suitable for modelling and understanding fungal responses in ascomycete pathogens such as 
Candida and Aspergillus.  
5.7. Implications of drug antagonism for antifungal therapy  
Up-regulation of drug efflux pumps as a mechanism of drug antagonism is unusual compared to the 
inhibition of metabolic and homeostatic functions that have been found to be associated with many 
other antagonistic drug combinations. In fungi, azoles are thought to be antagonistic with polyenes 
as they both target ergosterol but in ways that reduces the efficacy of the other, i.e. azoles inhibit 
the biosynthesis of ergosterol which is required for polyenes to bind to in order to exert their 
fungicidal activity. In other drug combinations, antagonism can occur by the competitive binding of 
drugs to the same target, which inhibits the effects of one of the agents [320]. Drugs that impede 
cellular metabolism, such as bromopyruvate which inhibits glycolysis, have also been found to act as 
antagonists and prevent the optimal activity of a second drug [320]. Additionally, drugs can interact 
directly with each other and cause a reduction in their efficacies, such as the antileishmania drug 
miltefosine, which binds to AMB and decreases the uptake of both drugs into the cell [566]. 
An aspect of drug efflux as a mode of antagonism is its role in drug resistance, as combination 
therapies are often employed to reduce the rate of development of drug resistance. In fitness trade-
off studies in bacteria, synergistic drug pairs are thought to inhibit drug-resistant strains by 
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exploiting the fitness costs associated with drug resistance and associated changes in cellular 
functions, resulting in metabolic burden. For example, resistance to aminoglycosides is mediated by 
decreased proton motive force activity, which is required for aminoglycoside uptake and the 
activities of drug efflux pumps. However, this change in function reduces cellular fitness in 
aminoglycoside-resistant bacteria when exposed to other antibiotics that require active efflux 
pumps to expel drugs from the cell [567]. In fungi, acquired resistance to drug pairs such as FLC 
combined with the Hsp90 inhibitor GdA, and FLC with the calcineurin inhibitor FK506, were also 
resistant to FLC alone but imposed a fitness costs in the absence of both drugs or when exposed to 
different types of stresses. These experiments implied that the cost of resistance that developed to 
the drug combination during therapy would reduce the population of drug-resistant pathogens in 
the host once drug selection was removed [568].  
However, fitness trade-offs associated with increased drug efflux transport in response to VRC+EDTA 
are not obvious in H99, as resistance to VRC+EDTA was not induced in this strain and it grew better 
with no inhibition in the absence of both agents (Fig. 4.19b). Additionally, in the absence of 
antifungal selection, induced expression of drug efflux transporters is commonly observed in human 
infections and has been shown to contribute to fungal virulence in mice [542, 569]. This questions 
whether a fitness cost is involved with efflux transporters as a mechanims of resistance to drug 
combinations and as a mechanism of antagonism. In contrast, inhibition of drug efflux has an 
obvious effect on fitness cost and is considered a potential antifungal strategy [523]. It has also been 
proposed to be a mechanism of synergy in FLC resistant Candida strains, where FLC combined with 
thyme oil extracts thymol and carvacrol caused a decrease in efflux pump activity compared to FLC 
treatment alone [570]. 
Overall, drug antagonism via induction of efflux pumps has significant implications for combination 
therapies. A better understanding of what drugs and agents can induce the expression of efflux 
pumps and how this occurs is needed in order to consider what drugs and other agents can be co-
administered and which combinations should be avoided. 
5.8. Conclusions  
In summary, the major findings of this study are that antifungal-iron chelator combinations exhibit a 
diverse range of interactions in Cryptococcus species, where synergy was observed with AMB+LF and 
antagonism was seen between azoles and EDTA, DFP and DSX. Iron rescue assays with AMB+LF 
showed that synergy is not due to iron chelation and that additional properties of LF enhanced the 
activity of AMB.  
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Transcriptomic analysis of AMB+LF synergy in S. cerevisiae S288C and C. neoformans H99 showed 
that LF caused complex changes in the transcriptomic response to AMB, which differed between 
S288C and H99. As S288C was included to guide the understanding and validation of AMB+LF 
synergy in H99 and find potential antifungal targets, the different transcriptome responses to 
AMB+LF highlighted issues with using S288C to model drug responses for distantly related 
organisms. Nevertheless, metal regulation was found to be important in AMB+LF synergy as knock-
out mutants of iron- and zinc-controlling transcription factors in both yeasts showed similar 
susceptibilities to AMB 
The comparative analysis of how VRC+EDTA is antagonistic in C. neoformans H99 but additive in C. 
gattii 97/170 revealed an unexpected but simple mechanism of antagonism, which involved the up-
regulation of drug efflux transporters. Although VRC+EDTA caused similar disruptions to 
mitochondrial function in both Cryptococcus species, the different outcomes to VRC+EDTA, with 
antagonism in C. neoformans and additivity in C. gattii, highlighted the complexity of species-specific 
responses to the same drug combination, which requires further analysis. 
The analysis of AMB+LF synergy and VRC+EDTA additivity suggested that the dysregulation of metals 
ions by iron chelators enhances cell inhibition by disrupting stress-related responses and stress 
signalling pathways. Stress responses can be disrupted by overwhelming the stress adaptation 
response, or by dysregulating appropriate stress associated responses via inactivation or down-
regulation of stress-associated pathways. Metal homeostasis and its importance for proper stress 
regulation provide multiple avenues for developing antifungal strategies. A potential antifungal 
target that disrupts stress responses and perpetuates synergy with antifungal drugs is the zinc 
controlling transcription factor Zap1, which is conserved across fungal species and contains domains 
that can be targeted by drugs.  
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Chapter 3 Appendix  
 Appendix 3.1. MIC of antifungal drugs (A) and iron chelators (ICͿ aloŶe aŶd iŶ ĐoŵďiŶatioŶ ;μg/ŵLͿ, ǁith fold ĐhaŶges ;FCͿ  
   
Iron chelating agent (IC) 
 
  
  LACTOFERRIN EDTA DFP DSX CPO 
Species 
Strain / 
Genotype MIC of A 
MIC of A 
in 
presence 
of IC (FC) 
MIC of 
IC  
MIC of 
IC in 
presence 
of A (FC) FICI 
MIC of A 
in 
presence 
of IC (FC) 
MIC of 
IC  
MIC of IC 
in 
presence 
of A (FC) FICI 
MIC of A in 
presence 
of IC (FC) 
MIC of 
IC  
MIC of 
IC in 
presence 
of A (FC) FICI 
MIC of A 
in 
presence 
of IC (FC) 
MIC of 
IC  
MIC of 
IC in 
presence 
of A (FC) FICI 
MIC of A 
in 
presence 
of IC (FC) 
MIC of 
IC  
MIC of 
IC in 
presence 
of A (FC) FICI 
AMPHOTERICIN 
B 
 
AMB MIC                     
C. neoformans 
var. grubii 
KN99α / VNI 0.5 0.125 (- 4) 64 4 (-16) 0.31 0.125 (- 4) 64 32 (-2) 1 0.25 (- 2) 8 8 (0) 1 0.25 (- 2) 2 2 (0) 0.625 0.5 (0) 1 1 0.84 
H99 / VNI 0.25 0.06 (- 4) 64 2 (-32) 0.28 - 64 - - - 16 - - - 4 - - - 2 - - 
WM148 / VNI 0.5 0.125 (- 4) 64 4 (-16) 0.31 - 64 - - - 8 - - - 4 - - - 1 - - 
WM626 / VNII 0.5 0.125 (- 4) 64 2 (-32) 0.31 - 64 - - - 8 - - - 8 - - - 1 - - 
C. neoformans 
var. neoformans 
WM629 / VNIV 0.25 0.06 (- 4) 64 2 (-32) 0.28 - 128 - - - 4 - - - 4 - - - 1 - - 
JEC21α / VNIV 0.125 0.03 (- 4) 64 2 (-32) 0.31 - 64 - - - 8 - - - 2 - - - 0.5 - - 
C. gattii 
R265 / VGIIa 0.5 0.125 (- 4) 64 4 (-16) 0.25 0.25 (- 2) 128 32 (-4) 0.75 0.25 (- 2) 32 4 (-8) 0.56 0.125 (- 4) 4 4 (0) 0.56 0.25 (- 2) 2 0.25 (-8) 0.78 
R272 / VGIIb 0.5 0.03 (-16) 64 4 (-16) 0.29 0.25 (- 2) 128 32 (-4) 0.75 0.25 (- 2) 8 4 (-2) 1 0.25 (- 2) 2 4 (+2) 0.75 0.25 (- 2) 1 0.5 (-2) 0.87 
97/170 / VGII 0.5 0.125 (- 4) 64 2 (-32) 0.41 0.25 (- 2) 128 32 (-4) 1 0.25 (- 2) 4 4 (0) 1.75 0.25 (- 2) 4 4 (0) 0.81 0.25 (- 2) 1 0.25 (-4) 0.87 
S. cerevisiae S288C 0.125 0.03 (- 4) 16 2 (-8) 0.37 0.06 (- 2) 16 4 (-4) 0.625 0.125 (0) 64 64 (0) 2 0.06 (- 2) 4 4 (0) 1 0.06 (- 2) 1 0.125(-8) 0.75 
FLUCONAZOLE 
 
FLC MIC 
                    
C. neoformans 
var. grubii 
KN99α / VNI 0.25 0.25 (0) 64 64 (0) 2 0.25 (0) 128 64 (-2) 1.12 0.25 (0) 8 4 (-2) 1.625 0.25 (0) 8 4 (-2) 1.75 0.25 (0) 2 2 (0) 1.5 
H99 / VNI 1 - - - - 1 (0) 64 64 (0) 2 4 (+ 4) 4 1 (-4) 3.25 4 (+ 4) 2 0.5 (-4) 3.25 - - - - 
WM148 / VNI 4 - - - - 16 (+ 4) 64 8 (-8) 4.125 16 (+ 4) 8 2 (-4) 4.19 16 (+ 4) 8 1 (-8) 4.31 - - - - 
WM626 / VNII 4 - - - - 8 (+ 2) 64 8 (-8) 2.125 16 (+ 4) 8 4 (-2) 4.19 16 (+ 4) 4 1 (-4) 4.25 - - - - 
C. neoformans 
var. neoformans 
WM629 / VNIV 1 - - - - 1 (0) 64 4 (-16) 0.84 2 (+ 2) 4 1 (-4) 2.25 1 (0) 4 4 (0) 2.125 - - - - 
JEC21α / VNIV 0.5 - - - - 0.5 (0) 64 16 (-4) 1.125 0.5 (0) 8 4 (-2) 1.5 0.5 (0) 2 1 (-2) 1.75 - - - - 
C. gattii 
R265 / VGIIa 2 1 (- 2) 128 128 (0) 1.5 2 (0) 128 64 (-2) 1.5 1 (- 2) 32 16 (-2) 1 2 (0) 4 4 (0) 2 1 (- 2) 2 1 (-2) 1 
R272 / VGIIb 2 2 (0) 64 16 (-4) 1.12 2 (0) 128 128 (0) 1.5 1 (- 2) 8 4 (-2) 1.25 2 (0) 2 1 (-2) 1 2 (0) 1 0.5 (-2) 1.25 
97/170 / VGII 64 64 (0) 128 128 (0) 1 16 (- 4) 128 64 (-2) 0.75 32 ( - 2) 4 2 (-2) 1.5 64 (0) 4 2 (-2) 2 64 (0) 2 1 (-2) 1.5 
S. cerevisiae S288C 4 2 (-2) 16 8 (-2) 1 2 (-2) 16 16 (0) 1.5 2 (-2) 64 32 (-2) 1.5 2 (-2) 4 2 (-2) 1 4 (0) 1 0.5 (-2) 1.5 
ITRACONAZOLE 
 
ITR MIC 
                    
C. neoformans 
var. grubii 
KN99α / VNI 0.015 0.007 (- 2) 64 32 (-2) 1 0.06 (+ 4) 64 8 (-8) 4.38 0.06 (+ 4) 16 4 (-4) 4.25 0.06 (+ 4) 4 0.5 (-8) 4.25 0.007 (- 2) 2 1 (-2) 1 
H99 / VNI 0.03 - - - - 0.25 (+ 8) 64 16 (-4) 4.125 0.125 (+ 4) 8 1 (-8) 4.125 0.125 (+ 4) 2 0.5 (-4) 4.25 - - - - 
WM148 / VNI 0.25 - - - - 0.25 (0) 64 8 (-8) 1.08 0.25 (0) 8 4 (-2) 1.25 0.25 (0) 4 1 (-4) 1.5 - - - - 
WM626 / VNII 0.125 - - - - 0.5 (+ 4) 64 8 (-8) 4.06 0.25 (+ 2) 8 4 (-2) 2.81 0.25 (+ 2) 4 2 (-2)  2.25 - - - - 
C. neoformans 
var. neoformans 
WM629 / VNIV 0.03 - - - - 0.015 (- 2) 128 32 (-4) 0.75 0.03 (0) 4 0.5 (-8) 1.88 0.03 (0) 4 2 (-2) 1.81 - - - - 
JEC21α / VNIV 0.03 - - - - 0.015 (- 2) 64 16 (-4) 0.64 0.015 (- 2) 64 16 (-4) 0.88 0.03 (0) 4 1 (-4) 0.81 - - - - 
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C. gattii 
R265 / VGIIa 0.125 0.06 (- 2) 128 32 (-4) 0.75 0.06 (- 2) 128 32 (-4) 0.625 0.06 (- 2) 32 8 (-4) 0.625 0.06 (- 2) 2 1 (-2) 1 0.06 (- 2) 2 1 (-2) 1 
R272 / VGIIb 0.06 0.03 (- 2) 64 32 (-2) 1 0.03 (- 2) 128 32 (-4) 0.75 0.015 (- 4) 8 4 (-2) 0.75 0.015 (- 4) 2 1 (-2) 0.75 0.015 (- 4) 2 1 (-2) 0.75 
97/170 / VGII 0.5 0.5 (0) 64 32 (-2) 1.5 0.25 (- 2) 128 32 (-4) 0.75 0.5 (0) 4 4 (0) 2 0.5 (0) 2 1 (-2) 1.5 0.5 (0) 2 2 (0) 2 
S. cerevisiae S288C 2 1 (- 2) 16 8 (-2) 1 0.5 (- 4) 8 4 (-2) 0.66 1 (- 2) 64 16 (-4) 0.81 1 (- 2) 1 1 (0) 1 1 (- 2) 1 0.5 (-2) 0.88 
VORICONAZOLE 
 
VRC MIC 
                    
C. neoformans 
var. grubii 
KN99α / VNI 0.0035 0.0035 (0) 64 32 (-2) 1.56 0.015 (+4) 64 16 (-4) 4.5 0.015 (+ 4) 16 2 (-8) 4.25 0.015 (+ 4) 4 0.5 (-8) 4.25 0.0035 (0) 2 2 (0) 2 
H99 / VNI 0.007 - - - - 0.03 (+ 4) 64 8 (-8) 4.125 0.03 (+ 4) 8 1 (-8) 4.25 0.03 (+ 4) 4 1 (-4) 4.25 - - - - 
WM148 / VNI 0.03 - - - - 0.125 (+4) 64 8 (-8) 4.125 0.125 (+ 4) 8 2 (-4) 4.25 0.125 (+ 4) 8 2 (-4) 4.19 - - - - 
WM626 / VNII 0.03 - - - - 0.125 (+4) 32 8 (-4) 4.16 0.125 (+ 4) 16 2 (-8) 4.125 0.125 (+ 4) 4 1 (-4) 4.125 - - - - 
C. neoformans 
var. neoformans 
WM629 / VNIV 0.015 - - - - 0.015 (0) 128 16 (-8) 1 0.03 (+2) 8 4 (-2) 2.63 0.015 (0) 2 1 (-2) 1.63 - - - - 
JEC21α / VNIV 0.007 - - - - 0.0035(-2) 128 16 (-8) 0.69 0.0035 (-2) 4 2 (-2) 0.84 0.007 (0) 2 1 (-2) 1.5 - - - - 
C. gattii 
R265 / VGIIa 0.06 0.03 (-2) 128 64 (-2) 1.5 0.015 (-4) 128 64 (-2) 0.65 0.03 (-2) 32 16 (-2) 1.25 0.06 (0) 4 2 (-2) 1.25 0.06 (0) 2 2 (0) 2 
R272 / VGIIb 0.06 0.06 (0) 64 64 (0) 2 0.015 (-4) 128 64 (-2) 0.75 0.03 (- 2) 8 4 (-2) 1 0.06 (0) 2 1 (-2) 1.25 0.06 (0) 1 1 (0) 2 
97/170 / VGII 0.5 0.5 (0) 64 64 (0) 1.5 0.03 (-16) 128 64 (-2) 0.56 0.5 (0) 4 1 (-4) 1.57 0.25 (- 2) 1 1 (0) 1.5 0.5 (0) 2 2 (0) 2 
S. cerevisiae S288C 0.125 0.125 (0) 16 16 (0) 2 0.06 (- 2) 16 8 (-2)  1 0.06 (-2) 64 64 (0) 1.5 0.06 (- 2) 2 1 (-2) 1 0.125 (0) 0.5 0.5 (0) 2 
CASPOFUNGIN 
 
CAS MIC 
                    
C. neoformans 
var. grubii KN99α / VNI 2 1 (- 2) 64 64 (0) 1.5 2 (0) 64 64 (0) 2 1 (- 2) 16 4 (-4) 0.64 1 (- 2) 8 0.5 (-16) 0.59 2 (0) 2 2 (0) 2 
C. gattii 
R265 / VGIIa 4 2 (- 2) 64 64 (0) 1.37 1 (- 4) 128 64 (-2) 0.68 2 (- 2) 32 2 (-16) 0.53 2 (- 2) 4 0.5 (-8) 0.625 4 (0) 2 2 (0) 2 
R272 / VGIIb 2 1 (- 2) 128 64 (-2) 1.27 0.5 (- 4) 128 64 (-2) 0.75 1 (- 2) 32 32 (0) 0.87 1 (- 2) 2 1 (-2) 1 2 (0) 1 1 (0) 2 
97/170 / VGII 4 4 (0) 64 64 (0) 2 2 (- 2) 128 64 (-2) 0.87 2 (- 2) 8 2 (-4) 0.75 2 (- 2) 2 0.5 (-4) 0.65 4 (0) 1 1 (0) 2 
S. cerevisiae S288C 0.06 0.03 (- 2) 16 4 (-4) 0.63 0.03 (- 2) 8 8 (0) 1.75 0.06 (0) 64 64 (0) 1.5 0.06 (0) 4 2 (-2)  1.5 0.06 (0) 1 0.5 (-2) 1.125 
- = Not done.  
Bold deŶotes sigŶifiĐaŶt sǇŶeƌgǇ ;ч Ϭ.ϱͿ oƌ aŶtagoŶisŵ ;> ϰͿ.  
Green = decreased requirement for A in presence of IC; yellow = increased requirement for A in presence of IC. 
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Chapter 4 Appendix 
Appendix 4.1. S. cerevisiae S288C, C. neoformans  H99 and C. gattii 97/170 RNA samples 
Experiment  Organism  Labelling  Sample name Illumina Lane 
AMB+LF Synergy S288C 1B CAL L1 
S288C 2F AMB+LF L1 
S288C 2I AMB L1 
S288C 3F CA L1 
S288C 3G CAL L1 
S288C 4E AMB L1 
S288C 4I CAL L1 
S288C 5C AMB+LF L2 
S288C 5G CA L2 
S288C 8A CA L2 
S288C 9D AMB+LF L2 
S288C 9E AMB L2 
H99 1C AMB L1 
H99 2G AMB+LF L1 
H99 2K CA L1 
H99 3D CAL L1 
H99 4A AMB L1 
H99 5A AMB+LF L1 
H99 5F AMB L2 
H99 5L CA L2 
H99 6F CAL L2 
H99 7B CAL L2 
H99 8G CA L2 
H99 8H AMB+LF L2 
LF only*  S288C 10B LF -  
 S288C 10D LF - 
 S288C 10F LF - 
 S288C 10G CLF - 
 S288C 10H CLF - 
 S288C 10I CLF - 
VRC+EDTA 
Antagonism  
H99 1H VRC L1 
H99 2J VRC+EDTA L1 
H99 3E C L1 
H99 4F VRC+EDTA L1 
H99 5E VRC+EDTA L2 
H99 5I C L2 
H99 6G C L2 
H99 7J VRC L2 
H99 8B VRC L2 
97/170 1I C L1 
97/170 2B VRC L1 
97/170 3J VRC+EDTA L1 
97/170 4C VRC L1 
97/170 5J VRC+EDTA L2 
97/170 6E VRC+EDTA L2 
97/170 7D C L2 
97/170 8K C L2 
97/170 9F VRC L2 
*LF only samples were sequenced using Next-Seq.  
CA = corresponding control for AMB treatment. CAL = corresponding control for AMB+LF treatment. CLF = corresponding 
control for LF treatment. C = corresponding control for VRC and VRC+EDTA treatments, 
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Appendix 4.2. List of primers designed in this study that were used to construct and confirm knock-out 
mutants in S. cerevisiae S288C  
Primer type  5͛ – 3͛ sequence  
KanB CTGCAGCGAGGAGCCGTAAT 
KanC TGATTTTGATGACGAGCGTAAT 
NatB* ATTCGTCGTCCGATTCGTC 
NatC* TACATGAGCATGCCCTGC 
aft1_A AGCAGAAACAGAATTCGCATATTAC      
aft1_B CTTATCTTCAAAGTTGGGTACTGGA 
aft1_D CAAAATTAATGACAGAGGGAGAGAA 
atg1_A AAGTTAAGTACCAAGGCCATCTTTT      
atg1_B TAAAATGGGTAAGTTGTAGATCCCA      
atg1_D TATAGCCAAAGGCAAGTACTAAACG      
cch1_A AGAAAATGTAATTTGGCATGTCATT      
cch1_B GCTATAACTACTGAAGCTACGCCTG      
cch1_D AATTCCCTTCTAATGGGTACTCTTG      
grx4_A CCAAAATTGAAGTTGTTTGGAATAC      
grx4_B CATCTATTGATAAAAACCGGACATC      
grx4_C ATATGAAAGAAATGTGATGATGGCT      
met32_A CGCTTAGTACGCCACAGTTTATATT      
met32_B GCGTTTTCCTTTTTAACCTTTATGT      
met32_D CCAAGAACTTGAGTATTTGACAGGT      
mtd1_A TATTCTTTTCCTAGTCCAAGTCCTG      
mtd1_B CTATGCATTTCTTCCCATACAGTCT      
mtd1_D GATATCATGGGTGATAAATTGGGTA      
tpk2_A TACAATTCTGGCCTTCTTACCTAAA      
tpk2_B TTGCTACAGGATTAGGAAATCTTTG      
tpk2_D TAATTTTTGCACTGAGATCATGAGA      
yap5_A GTATTTTAGTTTACCTATTGGGCCG      
yap5_B ATCTGTTTCCAGTTCTTTACAAACG      
yap5_D TATAGGCATAGTAAGCGGTACCTTG   
yct1_A CAATAGTGTTCGAAGTTCTTCCATT      
yct1_B GTGAATATTTTCCATAACGAAATGC      
yct1_D AGGCTAGAGGGGTTACTAGTCTCTG 
yor387c_A* TTCGGATCTTTCCTAAACGG 
yor387c_C* ACTCTTGGGCAGACACCG  
yor387c_D* TGACAAGAAAACCATCTGCG  
vel1_A AAGGTAGTAATTTCATGCATTCTCG      
vel1_C ATCTTCACCACCAATATCAACACTT      
vel1_D TTACTTTTATCTTGTAGGCAAACCG      
zap1_A CTGCGATTTACTCTAGGGATCTTC       
zap1_B CTCAGATATGTCTTTCTTTGTCGGT      
zap1_D CTTCGGTTACCTAGTTGTCACTCAT      
yor387c_S1*
#
 TTCTGATAGATTGTACAATCTCAAGAAATCAAGAACAACAACCATACCATGcgtacgctgcaggtcgac 
yor387c_S2*
#
 TAAAAAATATACTTAAAATATGTCTACAGATTATGCAGCTGGAAAAAATCAatcgatgaattcgagctcg 
*Primers for other genes analysed in this study were obtained from the Yeast Deletion Project [341]. 
#
Sequences from 
the plasmid cassette are in lower case. 
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Appendix. 4.3. BCV of LF only transcripts.  
 
BCV = 0.1869.  
 
 
 
 
Appendix 4.4. BCV of C. neoformans H99 transcripts in AMB+LF synergy. 
  
BCV = 0.2179 before sample 5A deletion BCV = 0.1511 after 5A deletion 
 
 
(b) (a) 
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Appendix 4.5. Plasmid cassette construct for YOR387C deletion  
 
 
 
 
L1: 1 Kb ladder (Bioline). L2: yor387c_S1 and yor387c_S2 
primers stitched to pFA6a-natNT2 plasmid cassette using 
LongAmp® Taq 2 X master mix. Expected band size is 1460 bp. 
L3: Negative control (no DNA template). L4: Blue juice loading 
dye.    
 
 
 
 
 
 
 
Appendix 4.6. Expected amplification band sizes (base pairs) of gene knock-out confirmation primer sets 
in S. cerevisiae BY4741 
  Primer combinations 
Gene ID Mutant A-B A-KanB C-D C-KanD A-D K.O.
a
 A-D W.T.
b
 
YGL071W aftϭΔ 689 658 ND 985 2031 2790 
YGL180W atgϭΔ 865 546 ND 946 2150 3260 
YGR217W ĐĐhϭΔ 702 551 ND 936 2148 6681 
YDR253C ŵetϯϮΔ 557 638 ND 870 2166 1158 
YKR080W ŵtdϭΔ 882 640 ND 1015 2313 1692 
YPL203W tpkϮΔ 875 655 ND 1021 2344 1903 
YIR018W yapϱΔ 834 551 ND 910 2119 1273 
YLL55W yctϭΔ 936 576 ND 988 2222 2234 
YOR387C* yorϯϴϳĐΔ ND 1010 499 632 1989 1260 
YGL258W velϭΔ ND 616 624 928 2202 1239 
YJL056C zapϭΔ 945 560 ND 886 2104 3163 
a
knock-out. 
b
 wild type. *ORF replaced with CloNAT resistance marker.  
ND = not done. 
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Appendix 4.7. PCR confirmations of gene knock-outs in S. cerevisiae BY4741 
 
 
 
 
(a) (b) 
(c) (d) 
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PCR confirmations of (a) aft1Δ and tpk2Δ, (b) vel1Δ and velϭΔ in the yor387cΔ/vel1Δ double mutant, (c) 
atg1Δ and yap5Δ, (d) yor387cΔ aŶd yor387cΔ in the yor387cΔ/vel1Δ double mutant, (e) ŵetϯϮΔ and 
ŵtdϭΔ, (f) yct1Δ and zap1Δ and (g) ĐĐhϭΔ. Expected band sizes are present in Appendix 4.6.  
 
 
 
 
(e) (f) 
(g) 
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Appendix 4.8. BCV of C. neoformans H99 transcripts in VRC+EDTA antagonism.  
  
BCV = 0.2666 before sample 7J deletion BCV = 0.2373 after 7J deletion.  
 
 
(b) (a) 
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